MeSH term
Frequency | Condition_Probility | Female | 2204 | 2.0 |
Humans | 7150 | 3.0 |
Pregnancy | 152 | 2.0 |
Pregnancy Outcome | 6 | 2.0 |
Randomized Controlled Trials | 19 | 4.0 |
Acute Disease | 114 | 4.0 |
Adult | 1566 | 2.0 |
Bone Marrow Transplantation/*statistics & numerical data | 3 | 3.0 |
Comparative Study | 761 | 2.0 |
Cord Blood Stem Cell Transplantation/*statistics & numerical data | 3 | 3.0 |
Fetal Blood/transplantation | 3 | 3.0 |
Leukemia/*therapy | 4 | 3.0 |
Patient Selection | 6 | 3.0 |
Adolescent | 428 | 2.0 |
Male | 2158 | 2.0 |
Mycobacterium tuberculosis/isolation & purification | 2 | 9.0 |
Tomography, X-Ray Computed | 4 | 0.0 |
Influenza A virus | 2 | 6.0 |
United States/epidemiology | 5 | 1.0 |
Albumins/metabolism | 3 | 2.0 |
Albuminuria/*prevention & control | 2 | 2.0 |
Antihypertensive Agents/*therapeutic use | 2 | 0.0 |
Diabetes Mellitus, Type 2/complications/*drug therapy | 2 | 2.0 |
Hypertension/complications/*drug therapy | 2 | 1.0 |
Indoles/*therapeutic use | 4 | 3.0 |
Renin-Angiotensin System/*drug effects | 2 | 1.0 |
Aged | 806 | 2.0 |
English Abstract | 307 | 2.0 |
*Laparoscopy | 2 | 11.0 |
Length of Stay | 4 | 5.0 |
Middle Aged | 1353 | 2.0 |
Risk | 12 | 1.0 |
Time Factors | 439 | 4.0 |
Animals | 2322 | 3.0 |
*Colorectal Neoplasms/diagnosis/metabolism/pathology/therapy | 2 | 3.0 |
*Education, Medical, Graduate | 2 | 6.0 |
*Educational Status | 2 | 6.0 |
*Students, Medical | 2 | 5.0 |
Surgery/*education | 2 | 5.0 |
Antibodies/*therapeutic use | 6 | 31.0 |
Arthritis, Rheumatoid/*drug therapy | 30 | 63.0 |
Tumor Necrosis Factor-alpha/*antagonists & inhibitors/*immunology | 2 | 66.0 |
Amino Acid Sequence | 294 | 1.0 |
Carrier Proteins/*biosynthesis/genetics | 2 | 3.0 |
Immunohistochemistry | 173 | 1.0 |
Immunoprecipitation | 4 | 1.0 |
Lung/*metabolism | 10 | 11.0 |
Molecular Sequence Data | 566 | 1.0 |
Organ Specificity | 21 | 1.0 |
RNA, Messenger/biosynthesis | 117 | 6.0 |
Rats | 361 | 2.0 |
Rats, Wistar | 40 | 3.0 |
Research Support, Non-U.S. Gov't | 4332 | 3.0 |
Reverse Transcriptase Polymerase Chain Reaction | 154 | 2.0 |
Sequence Alignment | 45 | 1.0 |
Staining and Labeling | 7 | 1.0 |
Alleles | 144 | 1.0 |
Pharmacogenetics | 3 | 2.0 |
Variation (Genetics) | 17 | 1.0 |
African Continental Ancestry Group | 6 | 2.0 |
History, 20th Century | 4 | 2.0 |
United States | 17 | 2.0 |
Antibodies, Monoclonal/immunology/pharmacology | 5 | 5.0 |
Apoptosis | 105 | 6.0 |
Clinical Trials | 54 | 5.0 |
Crohn Disease/*drug therapy/*immunology | 2 | 66.0 |
Models, Biological | 110 | 3.0 |
Treatment Outcome | 152 | 4.0 |
Tumor Necrosis Factor-alpha/*antagonists & inhibitors | 81 | 81.0 |
Proto-Oncogene Proteins c-myc/*metabolism | 3 | 3.0 |
Tumor Markers, Biological/*metabolism | 4 | 0.0 |
Antigens, CD/analysis | 28 | 1.0 |
Antigens, Differentiation, Myelomonocytic/analysis | 7 | 1.0 |
Arthritis, Rheumatoid/*immunology | 8 | 3.0 |
Cytokines/*immunology | 21 | 23.0 |
Enzyme-Linked Immunosorbent Assay/methods | 13 | 4.0 |
Flow Cytometry | 236 | 3.0 |
Immunohistochemistry/methods | 12 | 1.0 |
Macrophages/enzymology/*immunology | 2 | 66.0 |
Synovial Membrane/*immunology | 2 | 5.0 |
Tumor Necrosis Factor-alpha/analysis/*metabolism | 11 | 91.0 |
China/epidemiology | 6 | 3.0 |
Chronic Disease | 89 | 5.0 |
Gene Frequency | 108 | 2.0 |
Genetic Predisposition to Disease | 60 | 2.0 |
*Helicobacter pylori | 6 | 5.0 |
Lymphotoxin/*genetics | 52 | 73.0 |
Polymorphism, Genetic | 85 | 1.0 |
Prevalence | 12 | 0.0 |
Tumor Necrosis Factor-alpha/*genetics | 255 | 73.0 |
Aged, 80 and over | 225 | 2.0 |
Aging/*immunology | 7 | 5.0 |
Cell Division/immunology | 9 | 3.0 |
In Vitro | 458 | 7.0 |
Interleukin-10/metabolism | 18 | 27.0 |
Interleukin-6/*metabolism | 22 | 21.0 |
Leukocytes, Mononuclear/drug effects/*metabolism | 13 | 38.0 |
Lipopolysaccharides/pharmacology | 345 | 34.0 |
Research Support, U.S. Gov't, P.H.S. | 1707 | 2.0 |
Tumor Necrosis Factor-alpha/metabolism | 362 | 48.0 |
Antibodies, Monoclonal/adverse effects/*therapeutic use | 9 | 23.0 |
Antirheumatic Agents/adverse effects/*therapeutic use | 5 | 45.0 |
Dose-Response Relationship, Drug | 468 | 7.0 |
Drug Resistance | 53 | 8.0 |
Infusions, Intravenous | 52 | 7.0 |
Joints/pathology | 5 | 21.0 |
Pain Measurement | 4 | 5.0 |
Recurrence | 36 | 2.0 |
Skin/pathology | 6 | 2.0 |
Antibodies, Monoclonal/pharmacology/*therapeutic use | 2 | 18.0 |
Apoptosis/*drug effects | 104 | 13.0 |
Blood Donors | 6 | 2.0 |
Drug Resistance/genetics | 5 | 3.0 |
Gene Expression Regulation/genetics | 5 | 2.0 |
Genotype | 147 | 1.0 |
Leukocytes, Mononuclear/*drug effects/metabolism | 16 | 53.0 |
*Polymorphism, Genetic | 124 | 2.0 |
Prognosis | 124 | 1.0 |
Tumor Necrosis Factor-alpha/biosynthesis/*genetics | 34 | 91.0 |
Genetic Heterogeneity | 2 | 0.0 |
Graft Rejection/*genetics | 4 | 36.0 |
*Kidney Transplantation | 15 | 3.0 |
Linear Models | 25 | 5.0 |
*Tissue Donors | 5 | 3.0 |
Transplantation, Homologous | 24 | 3.0 |
Antirheumatic Agents/therapeutic use | 7 | 21.0 |
DNA Damage | 15 | 1.0 |
Genes, MHC Class I | 5 | 4.0 |
Genes, MHC Class II | 6 | 2.0 |
Genes, Tumor Suppressor | 2 | 0.0 |
*Genetic Predisposition to Disease | 25 | 2.0 |
Interleukin-1/genetics | 25 | 36.0 |
Cytokines/*blood | 151 | 49.0 |
Follow-Up Studies | 53 | 1.0 |
Statistics | 13 | 2.0 |
Antigen Presentation | 8 | 2.0 |
Autoimmune Diseases/immunology/physiopathology | 2 | 50.0 |
Autoimmunity/*physiology | 2 | 15.0 |
Feedback | 12 | 6.0 |
Gene Expression Regulation/physiology | 11 | 3.0 |
Glucocorticoids/*physiology | 2 | 11.0 |
Inflammation Mediators/*physiology | 6 | 24.0 |
Macrophage Activation | 45 | 26.0 |
Models, Immunological | 14 | 6.0 |
Rats, Inbred Lew | 21 | 8.0 |
Stress/*physiopathology | 2 | 6.0 |
Th1 Cells/immunology | 19 | 11.0 |
Th2 Cells/immunology | 14 | 8.0 |
Cattle | 74 | 2.0 |
Cytokines/*pharmacology | 99 | 25.0 |
Enzyme Induction/*drug effects | 2 | 11.0 |
Growth Substances/*pharmacology | 22 | 6.0 |
Mice | 1217 | 3.0 |
Phosphoproteins/biosynthesis/genetics | 2 | 11.0 |
Steroids/*biosynthesis | 4 | 7.0 |
Adrenal Cortex Hormones/*pharmacology/therapeutic use | 2 | 100.0 |
Anti-Inflammatory Agents/*pharmacology/therapeutic use | 3 | 60.0 |
Arthritis, Rheumatoid/*drug therapy/metabolism | 3 | 42.0 |
Cytokines/metabolism | 61 | 14.0 |
Gene Expression Regulation/drug effects | 70 | 7.0 |
Immunosuppressive Agents/*pharmacology/therapeutic use | 2 | 22.0 |
Macromolecular Substances | 26 | 1.0 |
Neuroimmunomodulation | 2 | 10.0 |
Signal Transduction | 238 | 4.0 |
Steroids | 2 | 8.0 |
Transcription Factors/metabolism | 29 | 2.0 |
Transcription, Genetic/drug effects | 57 | 9.0 |
Cells, Cultured | 1267 | 7.0 |
Endothelium, Vascular/cytology/*metabolism | 15 | 8.0 |
Enzyme-Linked Immunosorbent Assay | 386 | 9.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/*metabolism | 6 | 40.0 |
Microcirculation | 11 | 4.0 |
Umbilical Veins/cytology | 34 | 11.0 |
Phosphorylation/drug effects | 32 | 3.0 |
Proto-Oncogene Proteins c-jun/metabolism | 3 | 2.0 |
Pulmonary Surfactant-Associated Protein A | 5 | 16.0 |
Pulmonary Surfactant-Associated Proteins | 5 | 13.0 |
Signal Transduction/physiology | 38 | 3.0 |
Tumor Necrosis Factor-alpha/antagonists & inhibitors/*pharmacology | 14 | 58.0 |
p38 Mitogen-Activated Protein Kinases | 72 | 11.0 |
Dendritic Cells/*immunology | 9 | 3.0 |
Epitopes | 6 | 0.0 |
K562 Cells | 5 | 1.0 |
Peptides/immunology | 2 | 1.0 |
T-Lymphocytes, Cytotoxic/*immunology | 7 | 1.0 |
Tumor Cells, Cultured | 668 | 3.0 |
Antineoplastic Agents/therapeutic use | 6 | 2.0 |
Immunosuppressive Agents/therapeutic use | 21 | 10.0 |
Myelodysplastic Syndromes/drug therapy/immunology | 2 | 100.0 |
Tumor Necrosis Factor-alpha/*antagonists & inhibitors/immunology | 13 | 68.0 |
Anti-Bacterial Agents/pharmacology | 5 | 4.0 |
Anti-Infective Agents/*pharmacology | 4 | 12.0 |
Endotoxins/*pharmacology | 45 | 55.0 |
Interleukin-6/*biosynthesis | 42 | 39.0 |
Tumor Necrosis Factor-alpha/*biosynthesis | 310 | 78.0 |
Antineoplastic Combined Chemotherapy Protocols/*pharmacology | 11 | 22.0 |
Blotting, Western | 134 | 2.0 |
Caspases/metabolism | 75 | 11.0 |
Cell Survival/drug effects | 166 | 15.0 |
Cisplatin/pharmacology | 6 | 3.0 |
Combined Modality Therapy | 70 | 6.0 |
Doxorubicin/pharmacology | 11 | 5.0 |
Drug Synergism | 260 | 19.0 |
Etoposide/pharmacology | 7 | 4.0 |
Membrane Glycoproteins/*pharmacology | 22 | 27.0 |
Prostatic Neoplasms/*drug therapy/metabolism | 3 | 25.0 |
Proto-Oncogene Proteins c-bcl-2/genetics/metabolism | 2 | 3.0 |
Recombinant Proteins/pharmacology | 381 | 20.0 |
Tumor Cells, Cultured/drug effects | 52 | 8.0 |
Tumor Necrosis Factor-alpha/*pharmacology | 771 | 71.0 |
Tumor Stem Cell Assay | 12 | 6.0 |
Apoptosis/*immunology | 15 | 8.0 |
Inflammation/*immunology | 16 | 28.0 |
Signal Transduction/*immunology | 12 | 3.0 |
Carrier Proteins/*metabolism | 23 | 2.0 |
Cell Differentiation/physiology | 15 | 3.0 |
Membrane Glycoproteins/*metabolism | 27 | 5.0 |
Signal Transduction/*physiology | 53 | 4.0 |
Autoimmunity/*immunology | 5 | 10.0 |
Diabetes Mellitus, Type 1/*immunology | 2 | 2.0 |
Lymphotoxin/*immunology | 5 | 83.0 |
Membrane Proteins/immunology | 4 | 7.0 |
Mice, Inbred NOD | 7 | 3.0 |
Tumor Necrosis Factor-alpha/*immunology | 80 | 67.0 |
Anti-Inflammatory Agents, Non-Steroidal/adverse effects/therapeutic use | 3 | 50.0 |
Antirheumatic Agents/*adverse effects/therapeutic use | 4 | 66.0 |
Hypertension/chemically induced | 2 | 16.0 |
Isoxazoles/adverse effects/therapeutic use | 2 | 100.0 |
Risk Assessment | 23 | 2.0 |
Tumor Necrosis Factor-alpha/antagonists & inhibitors | 39 | 60.0 |
Antibodies, Monoclonal/*adverse effects/therapeutic use | 5 | 62.0 |
CD8-Positive T-Lymphocytes/metabolism | 2 | 2.0 |
Cytokines/analysis/genetics | 3 | 75.0 |
Methylation | 5 | 0.0 |
Phenotype | 95 | 1.0 |
RNA/analysis | 11 | 4.0 |
*Adaptor Proteins, Signal Transducing | 51 | 3.0 |
Antigens, CD/physiology | 17 | 8.0 |
Carrier Proteins/*chemistry/metabolism | 2 | 5.0 |
Jurkat Cells | 68 | 5.0 |
Receptors, Tumor Necrosis Factor/physiology | 42 | 59.0 |
Receptors, Tumor Necrosis Factor, Type I | 223 | 69.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 325 | 3.0 |
Structure-Activity Relationship | 78 | 2.0 |
TNF Receptor-Associated Factor 1 | 61 | 39.0 |
Two-Hybrid System Techniques | 11 | 1.0 |
Antibodies/*pharmacology | 6 | 18.0 |
Cecum/metabolism | 2 | 50.0 |
Colitis, Ulcerative/blood | 3 | 37.0 |
Collagenases/antagonists & inhibitors | 3 | 60.0 |
Colon/metabolism | 2 | 1.0 |
Crohn Disease/blood | 3 | 42.0 |
Interferon Type II/metabolism | 30 | 13.0 |
Interleukin-4/metabolism | 10 | 10.0 |
Mice, Inbred BALB C | 189 | 6.0 |
Mice, Inbred C57BL | 164 | 4.0 |
RNA, Messenger/metabolism | 181 | 4.0 |
*Trinitrobenzenesulfonic Acid | 2 | 100.0 |
Tumor Necrosis Factor-alpha/analysis | 225 | 52.0 |
Caco-2 Cells | 9 | 2.0 |
Cell Membrane/metabolism | 59 | 3.0 |
Enzyme Inhibitors/pharmacokinetics/*pharmacology | 2 | 18.0 |
Interferon Type II/pharmacology | 131 | 22.0 |
Intracellular Membranes/metabolism | 4 | 2.0 |
Permeability | 14 | 8.0 |
Tumor Necrosis Factor-alpha/pharmacology | 474 | 41.0 |
Antibodies, Monoclonal/*therapeutic use | 49 | 15.0 |
Carrier Proteins/*genetics | 7 | 0.0 |
Cohort Studies | 50 | 1.0 |
Gastrointestinal Agents/*therapeutic use | 7 | 63.0 |
*Intracellular Signaling Peptides and Proteins | 25 | 3.0 |
Predictive Value of Tests | 52 | 2.0 |
Reference Values | 148 | 3.0 |
Tumor Necrosis Factor-alpha/biosynthesis | 230 | 45.0 |
Apoptosis/drug effects/*physiology | 38 | 18.0 |
Cell Line | 785 | 4.0 |
Membrane Glycoproteins/physiology | 13 | 8.0 |
Membrane Proteins/*physiology | 5 | 3.0 |
Quinones/pharmacology | 4 | 2.0 |
Receptors, Tumor Necrosis Factor/*physiology | 59 | 66.0 |
Tumor Necrosis Factor-alpha/*physiology | 191 | 69.0 |
Decidua/*metabolism | 2 | 5.0 |
Fetus/metabolism | 3 | 1.0 |
Placenta/metabolism | 7 | 3.0 |
Receptors, Tumor Necrosis Factor/*biosynthesis/genetics | 12 | 85.0 |
Sequence Homology, Amino Acid | 88 | 1.0 |
Tissue Distribution | 50 | 1.0 |
Transcription, Genetic | 133 | 2.0 |
Trophoblasts/*metabolism | 3 | 6.0 |
Antibodies, Monoclonal/therapeutic use | 43 | 21.0 |
Antigens, CD/immunology | 12 | 2.0 |
Cytokines/antagonists & inhibitors | 3 | 27.0 |
T-Lymphocytes/immunology | 53 | 3.0 |
Treatment Failure | 11 | 4.0 |
NF-kappa B/*metabolism | 143 | 24.0 |
Receptors, Tumor Necrosis Factor/metabolism | 106 | 55.0 |
Tumor Necrosis Factor-alpha/*metabolism | 401 | 72.0 |
Cycloheximide/pharmacology | 121 | 18.0 |
Interleukin-1/pharmacology | 206 | 32.0 |
Interleukin-6/*antagonists & inhibitors | 2 | 22.0 |
Kinetics | 421 | 5.0 |
*MAP Kinase Signaling System | 4 | 3.0 |
Mitogen-Activated Protein Kinases/*physiology | 8 | 11.0 |
Prostaglandins/physiology | 3 | 17.0 |
*Protein Biosynthesis | 12 | 2.0 |
Protein Synthesis Inhibitors/pharmacology | 32 | 8.0 |
Tumor Necrosis Factor-alpha/antagonists & inhibitors/biosynthesis | 7 | 31.0 |
Up-Regulation/drug effects | 24 | 6.0 |
Forecasting | 12 | 3.0 |
Single-Blind Method | 9 | 4.0 |
Disease Models, Animal | 103 | 4.0 |
Immunization, Passive | 8 | 9.0 |
Interleukin-1/*physiology | 45 | 49.0 |
Mice, Transgenic | 52 | 1.0 |
Receptors, Tumor Necrosis Factor, Type II | 164 | 74.0 |
Blotting, Northern | 163 | 3.0 |
Cell Death | 31 | 9.0 |
Cell Survival | 89 | 8.0 |
Culture Media/pharmacology | 7 | 7.0 |
Dactinomycin/pharmacology | 66 | 21.0 |
Enzyme Inhibitors/pharmacology | 125 | 4.0 |
Indoles/*pharmacology | 7 | 7.0 |
Ligands | 123 | 4.0 |
Membrane Glycoproteins/metabolism | 40 | 6.0 |
Microscopy, Fluorescence | 34 | 1.0 |
Mitochondria/metabolism | 16 | 6.0 |
Receptors, Tumor Necrosis Factor/*metabolism | 141 | 68.0 |
*Transcription, Genetic | 24 | 1.0 |
Bronchi/cytology | 8 | 28.0 |
Particle Size | 9 | 3.0 |
Rabbits | 118 | 3.0 |
Asthma/*genetics | 4 | 6.0 |
Child | 274 | 2.0 |
Chromosomes, Human, Pair 6 | 7 | 4.0 |
Haplotypes | 61 | 2.0 |
Japan | 20 | 1.0 |
Linkage Disequilibrium | 21 | 2.0 |
Lymphotoxin/genetics | 36 | 61.0 |
Tumor Necrosis Factor-alpha/*genetics/metabolism | 27 | 75.0 |
Biological Transport | 24 | 1.0 |
Case-Control Studies | 199 | 3.0 |
Heart Catheterization | 2 | 3.0 |
Heart Transplantation | 3 | 7.0 |
Myocardium/*enzymology | 5 | 6.0 |
Preoperative Care | 3 | 1.0 |
Probability | 27 | 4.0 |
Severity of Illness Index | 90 | 7.0 |
*Apoptosis | 149 | 9.0 |
Endothelium, Vascular/cytology/drug effects/*metabolism | 18 | 19.0 |
Hydrogen Peroxide/pharmacology | 14 | 6.0 |
MAP Kinase Kinase Kinase 5 | 9 | 39.0 |
MAP Kinase Kinase Kinases/*metabolism | 2 | 5.0 |
Mutation | 71 | 0.0 |
Oxidation-Reduction | 34 | 2.0 |
Proteins/physiology | 9 | 6.0 |
TNF Receptor-Associated Factor 2 | 75 | 36.0 |
Acetylcysteine/pharmacology | 16 | 23.0 |
Antioxidants/*pharmacology | 14 | 11.0 |
Mitogen-Activated Protein Kinases/metabolism | 49 | 4.0 |
Monocytes/drug effects/*physiology | 13 | 33.0 |
Oxidative Stress/*physiology | 3 | 3.0 |
Tetradecanoylphorbol Acetate/pharmacology | 175 | 10.0 |
Tumor Necrosis Factor-alpha/*secretion | 67 | 69.0 |
U937 Cells | 42 | 10.0 |
Blood Glucose/*metabolism | 4 | 1.0 |
Body Composition | 11 | 4.0 |
Gestational Age | 15 | 1.0 |
Glucose Clamp Technique | 6 | 5.0 |
Hydrocortisone/blood | 28 | 6.0 |
*Insulin Resistance | 23 | 11.0 |
Leptin/blood | 2 | 3.0 |
Placenta/physiology | 2 | 5.0 |
Prolactin/blood | 3 | 0.0 |
Regression Analysis | 47 | 3.0 |
Body Mass Index | 33 | 3.0 |
Cell Differentiation/drug effects | 54 | 5.0 |
Glycerol/metabolism | 2 | 5.0 |
Hypoglycemic Agents/pharmacology | 4 | 12.0 |
Norepinephrine/pharmacology | 3 | 3.0 |
RNA, Messenger/genetics | 136 | 5.0 |
Skin | 3 | 4.0 |
Thiazoles/*pharmacology | 8 | 13.0 |
*Thiazolidinediones | 8 | 8.0 |
Tumor Necrosis Factor-alpha/secretion | 42 | 38.0 |
3' Untranslated Regions | 3 | 2.0 |
Chromatography | 6 | 3.0 |
Chromatography, High Pressure Liquid | 27 | 1.0 |
Genes, Reporter | 49 | 2.0 |
Hela Cells | 156 | 2.0 |
Isoenzymes/metabolism | 11 | 2.0 |
Macrophages/metabolism | 40 | 13.0 |
Peptides/chemistry | 10 | 2.0 |
Plasmids/metabolism | 26 | 2.0 |
Precipitin Tests | 52 | 1.0 |
Prostaglandin-Endoperoxide Synthase/metabolism | 10 | 13.0 |
Protein Binding | 117 | 1.0 |
Protein Isoforms | 5 | 0.0 |
Recombinant Proteins/metabolism | 80 | 3.0 |
Ribonucleases/metabolism | 6 | 4.0 |
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 4 | 1.0 |
Spectrum Analysis, Mass | 7 | 1.0 |
Subcellular Fractions/metabolism | 6 | 1.0 |
Antigens, CD/metabolism | 49 | 5.0 |
Cytokines/*secretion | 27 | 45.0 |
Interleukin-1/metabolism | 85 | 39.0 |
Lipopolysaccharides/metabolism | 14 | 12.0 |
Macrophages, Peritoneal/*metabolism | 3 | 14.0 |
Cell Division | 94 | 2.0 |
Lymphocyte Activation | 144 | 4.0 |
Monocytes/*immunology | 64 | 15.0 |
Prospective Studies | 194 | 4.0 |
T-Lymphocytes/*immunology | 45 | 2.0 |
C-Reactive Protein/analysis | 52 | 10.0 |
Coronary Angiography | 4 | 1.0 |
Inflammation | 75 | 18.0 |
Interleukin-6/analysis | 25 | 32.0 |
Myocardium/*pathology | 2 | 5.0 |
Antirheumatic Agents/*therapeutic use | 30 | 52.0 |
Apoptosis/drug effects | 50 | 7.0 |
Interleukins/antagonists & inhibitors | 3 | 75.0 |
Tumor Necrosis Factor-alpha/*antagonists & | 13 | 92.0 |
Adenocarcinoma/pathology | 6 | 7.0 |
Antigen-Antibody Reactions | 7 | 2.0 |
Binding Sites | 97 | 1.0 |
Biotransformation | 3 | 0.0 |
CHO Cells | 30 | 1.0 |
Coculture Techniques | 47 | 6.0 |
Colonic Neoplasms/pathology | 2 | 3.0 |
Cricetulus | 6 | 1.0 |
Drug Design | 8 | 2.0 |
Hamsters | 58 | 1.0 |
Models, Molecular | 41 | 1.0 |
Protein Conformation | 36 | 1.0 |
Protein Structure, Tertiary | 58 | 1.0 |
Recombinant Fusion Proteins/genetics/metabolism/pharmacology | 3 | 18.0 |
Tumor Cells, Cultured/metabolism/pathology | 7 | 15.0 |
Antigens, CD/*metabolism | 49 | 8.0 |
Cartilage, Articular/*metabolism/pathology | 3 | 37.0 |
Chondrocytes/*metabolism | 2 | 6.0 |
Disease Susceptibility | 24 | 3.0 |
Osteoarthritis/*metabolism/pathology | 2 | 16.0 |
Pressure | 3 | 2.0 |
Interleukin-10/blood | 44 | 52.0 |
Interleukin-12/blood | 8 | 36.0 |
Nitric Oxide/*blood | 6 | 23.0 |
Antibody Specificity | 27 | 1.0 |
Antineoplastic Agents/pharmacology | 27 | 5.0 |
Antioxidants/*metabolism | 4 | 4.0 |
Immune Sera/immunology | 14 | 8.0 |
Oxidative Stress/drug effects | 5 | 10.0 |
Paclitaxel/pharmacology | 8 | 8.0 |
Base Sequence | 435 | 1.0 |
Cadmium/pharmacology | 2 | 8.0 |
Chromosomes, Human, Pair 17 | 4 | 1.0 |
Gene Expression Regulation, Neoplastic | 18 | 0.0 |
Leukemia, Promyelocytic, Acute | 10 | 17.0 |
NF-kappa B/metabolism | 184 | 23.0 |
Neoplasm Proteins/*genetics | 4 | 0.0 |
*Nuclear Proteins | 6 | 0.0 |
Promoter Regions (Genetics) | 90 | 2.0 |
Proteins/*genetics | 16 | 1.0 |
Trans-Activation (Genetics) | 30 | 1.0 |
Transcription Factors/*genetics | 8 | 0.0 |
Translocation, Genetic | 3 | 0.0 |
Tumor Necrosis Factor-alpha/physiology | 72 | 47.0 |
Zinc Fingers | 10 | 1.0 |
Antiretroviral Therapy, Highly Active | 3 | 0.0 |
Biological Response Modifiers/pharmacology | 3 | 33.0 |
C-Reactive Protein/metabolism | 33 | 11.0 |
Drug Interactions | 58 | 4.0 |
Immunoglobulin G/*pharmacology | 6 | 37.0 |
Interleukin-6/*blood | 78 | 28.0 |
Receptors, Tumor Necrosis Factor | 226 | 93.0 |
Blotting, Southern | 20 | 0.0 |
Granulocyte Colony-Stimulating Factor/biosynthesis | 2 | 18.0 |
In Situ Hybridization, Fluorescence | 5 | 0.0 |
Karyotyping | 11 | 0.0 |
Mice, Nude | 75 | 3.0 |
Neoplasm Transplantation | 71 | 6.0 |
*Tumor Cells, Cultured | 2 | 2.0 |
Epitopes/genetics | 5 | 5.0 |
HLA-DR Antigens/*genetics | 18 | 3.0 |
Cloning, Molecular | 125 | 1.0 |
Tumor Necrosis Factor-alpha/*biosynthesis/*genetics | 9 | 90.0 |
Child, Preschool | 190 | 2.0 |
Infant | 118 | 1.0 |
Interleukin-10/*blood | 14 | 43.0 |
Interleukin-6/blood | 180 | 38.0 |
Interleukins/*blood | 12 | 50.0 |
Receptors, Interleukin-2/*blood | 15 | 28.0 |
Regional Blood Flow | 4 | 3.0 |
Tumor Necrosis Factor-alpha/*analysis | 181 | 72.0 |
Administration, Oral | 17 | 1.0 |
Interleukins/blood | 15 | 37.0 |
Lymphocyte Activation/drug effects | 45 | 8.0 |
Receptors, Tumor Necrosis Factor/blood | 55 | 67.0 |
Tumor Necrosis Factor-alpha/analysis/*biosynthesis | 15 | 83.0 |
Lipopolysaccharides/metabolism/toxicity | 2 | 50.0 |
Macrophages/drug effects/immunology/metabolism | 2 | 18.0 |
Blood Sedimentation | 11 | 6.0 |
Bone Marrow/physiology | 2 | 6.0 |
Erythropoiesis/*physiology | 2 | 4.0 |
Erythropoietin/blood | 2 | 3.0 |
Solubility | 147 | 10.0 |
Anti-Inflammatory Agents, Non-Steroidal/pharmacology | 18 | 26.0 |
Chemokines, CC/*metabolism | 2 | 3.0 |
Cysteine Proteinase Inhibitors/pharmacology | 23 | 10.0 |
DNA-Binding Proteins/metabolism | 43 | 2.0 |
Enzyme Activation | 171 | 4.0 |
Gene Expression Profiling | 19 | 1.0 |
*I-kappa B | 53 | 30.0 |
Imidazoles/pharmacology | 22 | 9.0 |
Leupeptins/pharmacology | 11 | 8.0 |
Mitogen-Activated Protein Kinases/*metabolism | 33 | 6.0 |
Pyridines/pharmacology | 19 | 7.0 |
Sodium Salicylate/pharmacology | 2 | 14.0 |
Analysis of Variance | 83 | 4.0 |
Cytokines/antagonists & inhibitors/*blood | 4 | 100.0 |
Infant, Newborn | 93 | 2.0 |
Leukocytes/*immunology | 6 | 4.0 |
Placenta/*immunology | 3 | 14.0 |
Umbilical Arteries | 3 | 16.0 |
Cytokines/*biosynthesis/blood | 10 | 50.0 |
Interferon Type II/blood | 42 | 35.0 |
Interleukin-2/blood | 31 | 43.0 |
Interleukin-4/blood | 19 | 41.0 |
Anti-Inflammatory Agents/*pharmacology | 19 | 28.0 |
*Cardiopulmonary Bypass/adverse effects | 3 | 37.0 |
Cytokines/blood/*drug effects | 6 | 75.0 |
Dexamethasone/*pharmacology | 37 | 16.0 |
Inflammation/*prevention & control | 5 | 50.0 |
Interleukin-8/blood | 47 | 48.0 |
Antigens, CD95/genetics | 4 | 17.0 |
Bone Morphogenetic Proteins/genetics | 3 | 9.0 |
Collagen/genetics | 3 | 3.0 |
Fibronectins/genetics | 2 | 6.0 |
Gelatinase B/genetics | 2 | 13.0 |
*Gene Expression Profiling | 3 | 0.0 |
Models, Animal | 7 | 2.0 |
Proteoglycans/genetics | 2 | 8.0 |
RNA, Messenger/genetics/metabolism | 88 | 3.0 |
*Transforming Growth Factor beta | 4 | 2.0 |
Tumor Necrosis Factor-alpha/genetics | 81 | 39.0 |
Chloramphenicol O-Acetyltransferase/analysis | 3 | 30.0 |
Leukocytes, Mononuclear/*drug effects/immunology | 9 | 60.0 |
NF-kappa B/*antagonists & inhibitors | 15 | 34.0 |
Tumor Necrosis Factor-alpha/immunology/pharmacology | 7 | 43.0 |
Anti-Bacterial Agents/*therapeutic use | 3 | 6.0 |
Double-Blind Method | 58 | 3.0 |
Forced Expiratory Volume | 6 | 6.0 |
Interleukins/biosynthesis | 14 | 31.0 |
Polymerase Chain Reaction | 203 | 1.0 |
Cell Adhesion/drug effects | 72 | 16.0 |
Cell Adhesion Molecules/biosynthesis | 7 | 8.0 |
E-Selectin/biosynthesis | 6 | 33.0 |
Endothelium, Vascular/cytology/*drug effects/metabolism | 18 | 20.0 |
Insulin-Like Growth Factor I/*pharmacology | 5 | 3.0 |
Intercellular Adhesion Molecule-1/biosynthesis | 17 | 20.0 |
MAP Kinase Kinase Kinase 3 | 3 | 42.0 |
Monocytes/cytology/drug effects | 4 | 11.0 |
NF-kappa B/genetics/metabolism | 13 | 23.0 |
Plasmids/genetics | 6 | 1.0 |
Trans-Activation (Genetics)/drug effects | 17 | 7.0 |
Vascular Cell Adhesion Molecule-1/biosynthesis | 13 | 38.0 |
*Macrophage Activation | 17 | 30.0 |
Monocytes/*immunology/metabolism | 4 | 10.0 |
*Antigens, CD | 19 | 2.0 |
Gene Expression | 183 | 3.0 |
*Gene Expression Regulation | 52 | 2.0 |
Heart Failure, Congestive/*immunology | 2 | 66.0 |
Leukocytes, Mononuclear/*immunology | 30 | 17.0 |
Membrane Glycoproteins/genetics | 7 | 3.0 |
Membrane Proteins/genetics | 9 | 2.0 |
Nuclear Proteins/genetics | 5 | 1.0 |
Oligonucleotide Array Sequence Analysis | 16 | 1.0 |
Receptors, Tumor Necrosis Factor/*genetics | 33 | 55.0 |
Statistics, Nonparametric | 44 | 4.0 |
Chemokines, CC/*genetics | 3 | 10.0 |
Gene Expression Regulation/drug effects/*immunology | 5 | 17.0 |
Glucocorticoids/*pharmacology | 17 | 11.0 |
Interleukin-13/pharmacology | 4 | 10.0 |
Interleukin-4/pharmacology | 30 | 8.0 |
Lung/*physiology | 2 | 10.0 |
Interleukin-8/*blood | 16 | 41.0 |
*Lipid Peroxidation | 4 | 8.0 |
Malondialdehyde/blood | 7 | 10.0 |
Cytokines/physiology | 33 | 16.0 |
Fever/*physiopathology | 6 | 54.0 |
Inflammation Mediators/physiology | 5 | 18.0 |
Survival Rate | 49 | 2.0 |
Fibroblasts/drug effects/secretion | 4 | 66.0 |
Gene Expression Regulation | 95 | 2.0 |
Interleukin-6/genetics/*secretion | 2 | 66.0 |
Interleukin-8/secretion | 9 | 22.0 |
Somatostatin/*pharmacology | 2 | 4.0 |
Tumor Necrosis Factor-alpha/*antagonists & inhibitors/metabolism | 17 | 89.0 |
DNA-Binding Proteins/*metabolism | 28 | 1.0 |
Down-Regulation | 98 | 4.0 |
JNK Mitogen-Activated Protein Kinases | 81 | 14.0 |
Mitogen-Activated Protein Kinase 1/metabolism | 19 | 5.0 |
Mitogen-Activated Protein Kinase 3 | 26 | 4.0 |
Phosphorylation | 151 | 1.0 |
RNA, Messenger/analysis | 151 | 4.0 |
Receptors, Tumor Necrosis Factor/*analysis/genetics | 5 | 100.0 |
Antigens, CD/biosynthesis | 6 | 1.0 |
Fibroblasts/metabolism | 44 | 4.0 |
Heat | 28 | 5.0 |
Receptors, Tumor Necrosis Factor/*biosynthesis | 14 | 70.0 |
Up-Regulation | 119 | 5.0 |
1-Phosphatidylinositol 3-Kinase/metabolism | 10 | 1.0 |
Cell Adhesion Molecules/metabolism | 21 | 8.0 |
Cell Communication | 17 | 5.0 |
Extracellular Matrix/metabolism | 5 | 2.0 |
HT29 Cells | 11 | 5.0 |
Insulin/pharmacology | 8 | 2.0 |
Insulin-Like Growth Factor I/*metabolism/pharmacology | 2 | 20.0 |
Interleukin-8/biosynthesis | 31 | 30.0 |
Phosphoproteins/metabolism | 9 | 1.0 |
*Protein-Serine-Threonine Kinases | 15 | 1.0 |
Protein-Tyrosine Kinase/metabolism | 10 | 1.0 |
Proto-Oncogene Proteins/metabolism | 12 | 1.0 |
*Signal Transduction | 96 | 4.0 |
*Stents | 2 | 3.0 |
Adenoviridae | 3 | 3.0 |
Biological Transport, Active | 3 | 1.0 |
*Disease Models, Animal | 7 | 2.0 |
Genetic Vectors | 41 | 2.0 |
Interleukin-1/*biosynthesis/genetics | 13 | 52.0 |
Tissue Inhibitor of Metalloproteinase-1/biosynthesis | 3 | 20.0 |
Tumor Necrosis Factor-alpha/*biosynthesis/genetics | 57 | 71.0 |
Ultrafiltration | 3 | 5.0 |
Cytokines/biosynthesis | 52 | 9.0 |
Immunity/drug effects | 5 | 38.0 |
Lipopolysaccharides | 69 | 57.0 |
Tumor Necrosis Factor-alpha/*antagonists & inhibitors/biosynthesis | 11 | 100.0 |
1-Phosphatidylinositol 3-Kinase/antagonists & inhibitors/*physiology | 3 | 10.0 |
Apoptosis/*physiology | 76 | 11.0 |
Caspases/antagonists & inhibitors/metabolism | 11 | 13.0 |
NF-kappa B/physiology | 17 | 17.0 |
Neutrophils/*physiology | 44 | 30.0 |
Protein Kinase C/antagonists & inhibitors/*physiology | 4 | 14.0 |
Tumor Necrosis Factor-alpha/pharmacology/*physiology | 28 | 75.0 |
Remission Induction | 19 | 3.0 |
T-Lymphocytes, Cytotoxic/immunology | 11 | 2.0 |
Transplantation, Autologous | 11 | 2.0 |
Vincristine/administration & dosage | 5 | 3.0 |
DNA Primers | 74 | 1.0 |
NF-kappa B/*physiology | 25 | 25.0 |
Anti-Bacterial Agents/therapeutic use | 13 | 12.0 |
Interleukin-1/blood | 95 | 58.0 |
Cytokines/*genetics | 38 | 28.0 |
Gene Frequency/genetics | 13 | 2.0 |
Genetic Screening | 7 | 0.0 |
Polymorphism, Genetic/*genetics | 37 | 3.0 |
Syndrome | 24 | 1.0 |
Dinoprostone/blood | 3 | 42.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology | 43 | 10.0 |
Interstitial Collagenase/*blood | 3 | 75.0 |
Lipoproteins, HDL/*pharmacology | 3 | 21.0 |
Lipoproteins, LDL/*pharmacology | 3 | 5.0 |
Tissue Inhibitor of Metalloproteinase-1/blood | 3 | 100.0 |
Biological Markers/analysis | 26 | 2.0 |
Sampling Studies | 6 | 3.0 |
Sensitivity and Specificity | 90 | 2.0 |
Synovial Fluid/*metabolism | 3 | 12.0 |
HLA Antigens/genetics | 13 | 4.0 |
Random Allocation | 13 | 2.0 |
Risk Factors | 77 | 1.0 |
Antibodies, Monoclonal/*administration & dosage | 5 | 16.0 |
Antirheumatic Agents/*administration & dosage | 3 | 50.0 |
Drug Administration Schedule | 38 | 4.0 |
Drug Therapy, Combination | 59 | 4.0 |
Methotrexate/*administration & dosage | 2 | 18.0 |
Anthropometry | 5 | 2.0 |
*Breast Feeding | 2 | 3.0 |
I-kappa B/metabolism | 22 | 27.0 |
MAP Kinase Signaling System | 11 | 4.0 |
Protein-Serine-Threonine Kinases/metabolism | 30 | 3.0 |
Tumor Necrosis Factor-alpha/chemistry/*metabolism | 2 | 100.0 |
Genetic Complementation Test | 3 | 0.0 |
Membrane Glycoproteins/*chemistry/genetics/*metabolism | 2 | 20.0 |
Mutagenesis, Site-Directed | 38 | 1.0 |
Recombinant Proteins/chemistry/genetics/metabolism | 8 | 2.0 |
Tumor Necrosis Factor-alpha/*chemistry/genetics/*metabolism | 3 | 100.0 |
Annexin A5/pharmacology | 4 | 10.0 |
Antineoplastic Agents, Phytogenic/*pharmacology | 6 | 3.0 |
Carrier Proteins/metabolism | 33 | 4.0 |
Cell Culture Techniques | 22 | 4.0 |
Cell Line, Tumor | 36 | 1.0 |
Cytochromes c/metabolism | 6 | 9.0 |
Cytosol/metabolism | 18 | 3.0 |
Dyes/pharmacology | 6 | 7.0 |
Genes, Dominant | 10 | 0.0 |
Membrane Potentials | 4 | 1.0 |
Mitochondrial Proteins/metabolism | 2 | 10.0 |
Paclitaxel/*pharmacology | 5 | 7.0 |
Poly(ADP-ribose) Polymerases/metabolism | 15 | 11.0 |
Proto-Oncogene Proteins c-bcl-2/metabolism | 13 | 2.0 |
Reactive Oxygen Species | 13 | 11.0 |
Receptors, Tumor Necrosis Factor, Type I/metabolism | 2 | 66.0 |
Tetrazolium Salts/pharmacology | 5 | 9.0 |
Thiazoles/pharmacology | 10 | 9.0 |
Transfection | 283 | 2.0 |
Antigens, CD95/biosynthesis | 2 | 6.0 |
Cathepsin B/metabolism | 2 | 18.0 |
Cathepsins/metabolism | 2 | 10.0 |
Cell Line, Transformed | 55 | 3.0 |
Endopeptidases/metabolism | 5 | 3.0 |
Fibroblasts/*metabolism | 22 | 13.0 |
Golgi Apparatus/metabolism | 4 | 2.0 |
Lymphocytes/metabolism | 10 | 4.0 |
Lysosomes/metabolism/ultrastructure | 2 | 33.0 |
Recombinant Proteins/chemistry | 4 | 1.0 |
Skin/cytology | 11 | 6.0 |
Crohn Disease/*drug therapy | 6 | 54.0 |
Drug Tolerance | 17 | 14.0 |
Pilot Projects | 37 | 6.0 |
*Tumor Necrosis Factor-alpha | 15 | 88.0 |
Bone Marrow Transplantation/*adverse effects | 7 | 14.0 |
Lung/pathology | 10 | 10.0 |
Mice, Inbred CBA | 30 | 9.0 |
Pneumonia/*etiology | 2 | 28.0 |
Tumor Necrosis Factor-alpha/analysis/*physiology | 13 | 81.0 |
Antineoplastic Agents/*pharmacology | 51 | 5.0 |
Bladder Neoplasms | 3 | 15.0 |
Mitochondria/drug effects/physiology | 4 | 14.0 |
Administration, Topical | 5 | 4.0 |
Androstadienes/*pharmacology | 4 | 19.0 |
Cell Division/drug effects | 203 | 5.0 |
Down-Regulation/drug effects | 17 | 6.0 |
Intercellular Adhesion Molecule-1/analysis/biosynthesis | 2 | 28.0 |
Interleukin-4/immunology/pharmacology | 2 | 25.0 |
Vascular Cell Adhesion Molecule-1/analysis/biosynthesis | 3 | 60.0 |
Bronchi/cytology/drug effects/*metabolism | 3 | 42.0 |
Dexamethasone/pharmacology | 68 | 14.0 |
Epithelial Cells/drug effects/metabolism | 13 | 15.0 |
Gene Expression Regulation/*physiology | 10 | 3.0 |
Interleukin-17/*physiology | 3 | 100.0 |
Interleukin-8/*genetics | 9 | 33.0 |
*Oncogenes | 2 | 0.0 |
*Apoptosis/drug effects | 16 | 13.0 |
Protein-Serine-Threonine Kinases/genetics/*metabolism | 6 | 2.0 |
Proto-Oncogene Proteins/genetics/*metabolism | 7 | 1.0 |
Endothelium, Vascular/*metabolism | 36 | 13.0 |
Fatty Acids/metabolism | 5 | 4.0 |
Fatty Acids, Essential/*metabolism | 2 | 100.0 |
Phosphatidylcholines/metabolism | 2 | 2.0 |
Phosphatidylethanolamines/metabolism | 2 | 10.0 |
Phosphatidylserines/metabolism | 5 | 9.0 |
Phospholipids/metabolism | 7 | 3.0 |
Sphingomyelins/metabolism | 6 | 20.0 |
*Drosophila Proteins | 15 | 1.0 |
Endotoxins/*toxicity | 13 | 61.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/*pharmacology | 18 | 11.0 |
Interferon Type II/*pharmacology | 79 | 18.0 |
Lipopolysaccharides/*toxicity | 22 | 38.0 |
Carrier Proteins/genetics/*physiology | 2 | 2.0 |
Caspases/*metabolism | 21 | 9.0 |
Enzyme Activation/drug effects | 62 | 6.0 |
Glucose/pharmacology | 2 | 1.0 |
Nitric Oxide/metabolism | 22 | 13.0 |
Nitric-Oxide Synthase/genetics | 3 | 8.0 |
Recombinant Proteins | 114 | 14.0 |
Cytokines/drug effects/secretion | 2 | 33.0 |
Fluorescent Antibody Technique, Indirect | 18 | 2.0 |
Membrane Proteins/metabolism | 14 | 2.0 |
Myocardium/metabolism/pathology | 5 | 17.0 |
T-Lymphocytes/metabolism/pathology | 3 | 15.0 |
Anti-Bacterial Agents/*pharmacology | 15 | 11.0 |
Cell Movement/*drug effects | 5 | 5.0 |
Interleukin-8/metabolism | 28 | 23.0 |
Macrolides | 3 | 12.0 |
Monocyte Chemoattractant Protein-1/metabolism | 7 | 11.0 |
Monocytes/*physiology | 27 | 17.0 |
Receptors, Tumor Necrosis Factor/chemistry/genetics/physiology | 2 | 100.0 |
Gliotoxin/pharmacology | 2 | 50.0 |
Electrophoretic Mobility Shift Assay | 14 | 3.0 |
Hydrogen Peroxide/*pharmacology | 5 | 8.0 |
Oxidation-Reduction/drug effects | 5 | 6.0 |
Oxidative Stress/drug effects/physiology | 3 | 21.0 |
Serine/*metabolism | 4 | 4.0 |
Signal Transduction/drug effects/physiology | 22 | 9.0 |
Gene Library | 15 | 1.0 |
Leukemia/metabolism | 2 | 8.0 |
Models, Genetic | 12 | 0.0 |
COS Cells | 28 | 1.0 |
Cercopithecus aethiops | 12 | 1.0 |
Homozygote | 18 | 0.0 |
Inflammatory Bowel Diseases/*genetics | 3 | 12.0 |
Hemodynamic Processes/*physiology | 4 | 12.0 |
Hemofiltration/*methods | 6 | 60.0 |
Interleukin-1/*blood | 31 | 55.0 |
Colon/*cytology | 2 | 16.0 |
Gene Expression/drug effects/immunology | 7 | 20.0 |
Interleukin-6/genetics/secretion | 2 | 40.0 |
Interleukin-8/genetics/secretion | 2 | 100.0 |
Mitogen-Activated Protein Kinases/antagonists & inhibitors/*metabolism | 9 | 11.0 |
NF-kappa B/antagonists & inhibitors/*metabolism | 18 | 34.0 |
Proline/*analogs & derivatives/pharmacology | 4 | 23.0 |
RNA, Messenger/analysis/metabolism | 6 | 4.0 |
Thiocarbamates/pharmacology | 17 | 32.0 |
Tosylphenylalanyl Chloromethyl Ketone/pharmacology | 4 | 30.0 |
Sialoglycoproteins/*genetics | 3 | 4.0 |
Tandem Repeat Sequences | 4 | 2.0 |
*Alleles | 23 | 1.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 17 | 3.0 |
Drug Resistance, Neoplasm | 19 | 3.0 |
HLA-DR Antigens/genetics | 29 | 7.0 |
Animals, Genetically Modified | 4 | 1.0 |
Interleukins/immunology | 6 | 35.0 |
Mice, Knockout | 58 | 2.0 |
Antirheumatic Agents/administration & dosage/*therapeutic use | 2 | 40.0 |
Image Processing, Computer-Assisted | 6 | 1.0 |
Immunoglobulin G/administration & dosage/*therapeutic use | 3 | 60.0 |
Injections, Subcutaneous | 12 | 3.0 |
Receptors, Tumor Necrosis Factor/administration & dosage/*therapeutic use | 5 | 83.0 |
Synovial Membrane/drug effects/metabolism/pathology | 3 | 75.0 |
Cytokines/*physiology | 63 | 33.0 |
Carrier Proteins/pharmacology | 8 | 12.0 |
DNA-Binding Proteins/genetics/metabolism | 2 | 0.0 |
Gene Expression/drug effects | 70 | 9.0 |
Membrane Glycoproteins/pharmacology | 9 | 16.0 |
Monocytes/cytology/drug effects/metabolism | 3 | 11.0 |
Proteins/genetics/metabolism | 3 | 1.0 |
Proto-Oncogene Proteins c-myc/metabolism | 2 | 2.0 |
*Repressor Proteins | 7 | 0.0 |
TNF Receptor-Associated Factor 6 | 27 | 21.0 |
*Transcription Factors | 9 | 0.0 |
Retrospective Studies | 42 | 1.0 |
Tumor Necrosis Factor-alpha/analysis/physiology | 4 | 80.0 |
Antigens, CD/blood | 30 | 12.0 |
Body Temperature | 13 | 13.0 |
Cholesterol/*blood | 4 | 1.0 |
Cytokines/blood | 56 | 27.0 |
Fever/*blood | 2 | 50.0 |
Lymphoma/blood | 3 | 33.0 |
Electrophoresis, Polyacrylamide Gel | 64 | 1.0 |
Gelatinase B/*metabolism | 4 | 12.0 |
Keratinocytes/metabolism | 5 | 4.0 |
Skin/metabolism | 9 | 4.0 |
Tissue Inhibitor of Metalloproteinase-1/*metabolism | 2 | 40.0 |
Tumor Necrosis Factor-alpha/metabolism/*pharmacology | 39 | 73.0 |
Cytoplasm/metabolism | 16 | 1.0 |
HL-60 Cells | 19 | 3.0 |
Hodgkin Disease/metabolism/*pathology | 3 | 100.0 |
Microscopy, Confocal | 19 | 1.0 |
Proteins/*metabolism | 39 | 4.0 |
Subcellular Fractions/chemistry | 2 | 3.0 |
TNF Receptor-Associated Factor 5 | 16 | 48.0 |
Alzheimer Disease/metabolism/*pathology | 2 | 6.0 |
Endothelium, Vascular/drug effects/metabolism | 8 | 14.0 |
Circadian Rhythm | 2 | 0.0 |
Growth Substances/physiology | 5 | 4.0 |
Models, Neurological | 2 | 1.0 |
Nerve Growth Factors/physiology | 2 | 10.0 |
Nitric Oxide/physiology | 7 | 15.0 |
Receptors, Tumor Necrosis Factor/drug effects/physiology | 4 | 66.0 |
Tumor Necrosis Factor-alpha/antagonists & | 26 | 74.0 |
Bronchial Provocation Tests | 6 | 8.0 |
Methacholine Chloride/diagnostic use | 2 | 11.0 |
Receptors, Tumor Necrosis Factor/analysis/*physiology | 2 | 100.0 |
Bronchoalveolar Lavage Fluid/cytology | 24 | 21.0 |
Epithelial Cells/metabolism | 18 | 5.0 |
In Situ Hybridization | 39 | 1.0 |
Macrophages, Alveolar/*metabolism | 12 | 40.0 |
Nitric-Oxide Synthase/*biosynthesis | 4 | 14.0 |
Pulmonary Alveoli/*metabolism | 3 | 21.0 |
Cytokines/*cerebrospinal fluid | 8 | 88.0 |
Magnetic Resonance Imaging | 9 | 0.0 |
Receptors, Tumor Necrosis Factor/*analysis | 30 | 90.0 |
Mitochondria/drug effects/metabolism | 4 | 12.0 |
Monocytes/cytology/drug effects/*metabolism | 3 | 33.0 |
Tumor Necrosis Factor-alpha/*biosynthesis/drug effects | 9 | 90.0 |
Age Factors | 19 | 0.0 |
Interleukin-1/*metabolism | 33 | 42.0 |
Otitis Media with Effusion/*metabolism | 2 | 50.0 |
Cell Death/physiology | 10 | 13.0 |
Receptors, Tumor Necrosis Factor/genetics/*physiology | 13 | 72.0 |
Signal Transduction/genetics/*physiology | 2 | 5.0 |
Receptors, Interleukin-2/blood | 14 | 19.0 |
Anisomycin/pharmacology | 2 | 6.0 |
Cell Separation | 47 | 4.0 |
Phospholipases A/metabolism | 12 | 20.0 |
Bone Density | 2 | 1.0 |
Antigens, CD95/immunology | 7 | 13.0 |
Chloroquine/*pharmacology | 3 | 27.0 |
Enzyme Inhibitors/*pharmacology | 18 | 2.0 |
Flavonoids/pharmacology | 20 | 6.0 |
Gene Expression Regulation/drug effects/immunology | 4 | 11.0 |
Immune Sera/pharmacology | 8 | 8.0 |
Immunity, Natural/immunology | 2 | 8.0 |
Immunosuppressive Agents/pharmacology | 10 | 6.0 |
Lipopolysaccharides/antagonists & inhibitors/pharmacology | 9 | 42.0 |
*MAP Kinase Kinase Kinase 1 | 11 | 7.0 |
Mitogen-Activated Protein Kinases/antagonists & inhibitors/metabolism | 4 | 4.0 |
Protein-Serine-Threonine Kinases/antagonists & inhibitors/metabolism | 5 | 5.0 |
Tumor Cells, Cultured/drug effects/immunology | 3 | 27.0 |
Adrenal Cortex Hormones/*therapeutic use | 3 | 13.0 |
Immunoglobulins, Intravenous/*therapeutic use | 4 | 13.0 |
Immunosuppressive Agents/*therapeutic use | 11 | 9.0 |
Plasmapheresis | 3 | 8.0 |
Cell Count | 47 | 4.0 |
Chemokines/biosynthesis | 3 | 7.0 |
Interleukin-1/analysis | 38 | 44.0 |
Membrane Glycoproteins/deficiency/genetics/*physiology | 2 | 13.0 |
Mice, Inbred C3H | 87 | 13.0 |
Neutrophils/immunology | 16 | 9.0 |
Phagocytosis | 33 | 8.0 |
Point Mutation | 11 | 0.0 |
Receptors, Cell Surface/deficiency/genetics/*physiology | 2 | 13.0 |
Cytokines/*metabolism | 83 | 31.0 |
Receptors, Interferon/genetics/physiology | 2 | 100.0 |
Th1 Cells/*metabolism | 4 | 14.0 |
Endothelial Growth Factors/metabolism | 3 | 1.0 |
Endothelium, Vascular/metabolism | 15 | 6.0 |
*Gene Therapy | 14 | 3.0 |
Gene Transfer Techniques | 14 | 2.0 |
Immunoenzyme Techniques | 57 | 1.0 |
*JNK Mitogen-Activated Protein Kinases | 9 | 9.0 |
Lymphokines/metabolism | 3 | 1.0 |
Matrix Metalloproteinases/metabolism | 2 | 4.0 |
Neovascularization, Pathologic/*prevention & control | 3 | 5.0 |
Peptide Fragments/*genetics | 2 | 4.0 |
RNA/metabolism | 17 | 3.0 |
Tumor Necrosis Factor-alpha/genetics/metabolism | 18 | 35.0 |
Vascular Endothelial Growth Factor A | 23 | 0.0 |
Vascular Endothelial Growth Factors | 23 | 0.0 |
Interleukin-10/*genetics/metabolism | 2 | 33.0 |
Lymphotoxin/*genetics/metabolism | 3 | 100.0 |
Phylogeny | 7 | 0.0 |
Anti-Inflammatory Agents/therapeutic use | 8 | 9.0 |
Disease Progression | 57 | 2.0 |
Health Status | 2 | 2.0 |
Quality of Life | 10 | 6.0 |
Diagnosis, Differential | 27 | 1.0 |
Adjuvants, Immunologic/*therapeutic use | 14 | 17.0 |
Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use | 13 | 35.0 |
Drug Evaluation | 29 | 11.0 |
Exudates and Transudates/chemistry | 2 | 22.0 |
Interleukins/analysis | 10 | 32.0 |
Nuclear Magnetic Resonance, Biomolecular | 6 | 3.0 |
*Phytotherapy | 10 | 10.0 |
Arthritis, Rheumatoid/*drug therapy/immunology | 6 | 30.0 |
Immunoglobulin G/*therapeutic use | 26 | 70.0 |
Immunoglobulins/blood | 5 | 5.0 |
Immunophenotyping | 58 | 1.0 |
Neutrophils/physiology | 23 | 22.0 |
Receptors, Tumor Necrosis Factor/*therapeutic use | 35 | 89.0 |
Immunosuppression/methods | 5 | 15.0 |
Immunosuppressive Agents/*adverse effects | 4 | 10.0 |
Interferon Type II/*genetics | 7 | 13.0 |
Interleukin-10/*genetics | 16 | 35.0 |
Interleukin-6/*genetics | 10 | 14.0 |
Liver Transplantation/*immunology | 4 | 12.0 |
Autoimmune Diseases/*metabolism/pathology | 2 | 50.0 |
Interleukin-1/pharmacology/*physiology | 3 | 37.0 |
Mice, Inbred MRL lpr | 2 | 7.0 |
Peroxidase/secretion | 3 | 75.0 |
Potassium Chloride/pharmacology | 3 | 5.0 |
Spectrometry, Fluorescence | 10 | 2.0 |
Chemokines/genetics/*metabolism | 3 | 23.0 |
Cytokines/genetics/*metabolism | 14 | 38.0 |
Interleukin-1/genetics/metabolism | 7 | 41.0 |
Interleukin-10/genetics/metabolism | 4 | 44.0 |
Interleukin-8/genetics/metabolism | 5 | 23.0 |
Lumbosacral Region | 2 | 6.0 |
RNA, Messenger/*biosynthesis | 16 | 6.0 |
Transforming Growth Factor beta/genetics/metabolism | 4 | 11.0 |
Acetylcysteine/*therapeutic use | 3 | 42.0 |
Antimalarials/*therapeutic use | 3 | 10.0 |
Lactic Acid/blood | 3 | 6.0 |
Quinine/*therapeutic use | 2 | 66.0 |
Adipose Tissue/drug effects/*metabolism | 4 | 25.0 |
Hypoglycemic Agents/*pharmacology | 3 | 6.0 |
Insulin/*pharmacology | 8 | 3.0 |
Lipolysis/*drug effects | 3 | 10.0 |
Sympathomimetics/pharmacology | 3 | 21.0 |
Postmenopause | 3 | 1.0 |
Biological Markers/blood | 79 | 5.0 |
Tumor Necrosis Factor-alpha/*physiology/therapeutic use | 5 | 100.0 |
Apoptosis/*drug effects/physiology | 12 | 10.0 |
Cytochrome c Group/metabolism | 16 | 11.0 |
Fibroblasts/cytology/drug effects/physiology | 2 | 18.0 |
Heat-Shock Proteins/genetics/*metabolism | 2 | 7.0 |
*MAP Kinase Kinase 4 | 4 | 7.0 |
Mitogen-Activated Protein Kinase Kinases/metabolism | 19 | 11.0 |
1-Phosphatidylinositol 3-Kinase/physiology | 2 | 1.0 |
Cell Movement | 30 | 3.0 |
Coronary Artery Bypass | 3 | 5.0 |
Endothelium, Vascular | 2 | 4.0 |
*Extracorporeal Circulation | 2 | 8.0 |
Mitogen-Activated Protein Kinase Kinases/physiology | 2 | 8.0 |
Dietary Fats/pharmacology | 2 | 5.0 |
Ethanol/pharmacology | 2 | 3.0 |
Interleukin-6/*pharmacology | 24 | 11.0 |
Mice, Obese | 3 | 6.0 |
Obesity/complications | 2 | 4.0 |
Trans-Activators/metabolism | 8 | 0.0 |
Transcription Factors/genetics/metabolism | 2 | 0.0 |
Triglycerides/metabolism | 3 | 1.0 |
Antigen-Antibody Complex/analysis | 3 | 2.0 |
Immunoassay/*methods | 4 | 5.0 |
Inflammation Mediators/analysis | 5 | 20.0 |
Interleukin-1/immunology | 18 | 40.0 |
Tumor Necrosis Factor-alpha/immunology | 45 | 42.0 |
DNA Mutational Analysis | 15 | 0.0 |
Evolution, Molecular | 3 | 0.0 |
*Mutation | 10 | 0.0 |
Sequence Homology, Nucleic Acid | 32 | 1.0 |
Antigens, CD/*genetics | 19 | 7.0 |
Exons | 12 | 0.0 |
Polymorphism, Restriction Fragment Length | 39 | 1.0 |
*Polymorphism, Single Nucleotide | 21 | 4.0 |
Sialoglycoproteins/blood | 18 | 62.0 |
Vascular Cell Adhesion Molecule-1/blood | 6 | 10.0 |
Antibodies, Monoclonal/*pharmacology | 15 | 7.0 |
Antirheumatic Agents/*pharmacology | 4 | 28.0 |
Recombinant Proteins/antagonists & inhibitors/metabolism | 2 | 4.0 |
Gene Products, nef/*physiology | 2 | 7.0 |
HIV-1/*physiology | 15 | 3.0 |
*Virus Activation | 6 | 19.0 |
*Virus Latency | 5 | 10.0 |
Antigens, CD95/metabolism | 23 | 15.0 |
Cell Death/drug effects | 21 | 13.0 |
Leukocytes, Mononuclear/cytology/drug effects/metabolism | 2 | 28.0 |
*Gene Frequency | 4 | 0.0 |
Great Britain | 6 | 2.0 |
Netherlands | 5 | 3.0 |
Promoter Regions (Genetics)/genetics | 34 | 3.0 |
*DNA-Binding Proteins | 13 | 0.0 |
Lipopolysaccharides/*pharmacology | 122 | 28.0 |
Lymphoma/metabolism | 2 | 9.0 |
RNA, Messenger/drug effects/metabolism | 13 | 9.0 |
Tumor Necrosis Factor-alpha/genetics/*metabolism | 40 | 76.0 |
Glucocorticoids/therapeutic use | 8 | 11.0 |
Receptors, Interleukin-6/*blood | 3 | 23.0 |
Blood Preservation | 3 | 4.0 |
Erythrocyte Transfusion/*adverse effects | 2 | 28.0 |
Fever | 6 | 35.0 |
Interleukin-6/blood/secretion | 2 | 100.0 |
Interleukin-8/blood/secretion | 2 | 100.0 |
Specimen Handling | 3 | 3.0 |
Antibodies, Monoclonal/pharmacology | 60 | 8.0 |
Antigens, CD40/*metabolism | 9 | 18.0 |
Interleukin-8/analysis | 11 | 26.0 |
NF-kappa B/immunology | 2 | 11.0 |
Cytokines/*biosynthesis | 136 | 34.0 |
Substrate Specificity | 31 | 1.0 |
Tetrazoles/*pharmacology | 3 | 15.0 |
Ubiquitin/*metabolism | 2 | 1.0 |
DNA/*metabolism | 5 | 1.0 |
Drug Combinations | 26 | 4.0 |
Fibroblasts/drug effects/metabolism/pathology | 3 | 27.0 |
Synovial Membrane/*drug effects/metabolism/pathology | 2 | 50.0 |
Transcription Factor AP-1/metabolism | 13 | 4.0 |
Immunity, Natural/*immunology | 3 | 15.0 |
Membrane Glycoproteins/*physiology | 23 | 8.0 |
Receptors, Cell Surface/*physiology | 14 | 6.0 |
Sepsis Syndrome/*immunology | 3 | 60.0 |
Up-Regulation/physiology | 7 | 6.0 |
Microsatellite Repeats | 24 | 2.0 |
Taiwan | 3 | 1.0 |
Autoantibodies/blood | 5 | 2.0 |
Interferon-alpha/administration & dosage | 2 | 18.0 |
Lipopolysaccharides/blood | 7 | 33.0 |
Gene Expression/physiology | 4 | 1.0 |
MAP Kinase Signaling System/*physiology | 5 | 5.0 |
Osmotic Pressure | 2 | 3.0 |
Adenocarcinoma/immunology | 3 | 6.0 |
Cytotoxicity, Immunologic | 86 | 9.0 |
Lung Neoplasms/*immunology | 6 | 12.0 |
Lymphocytes, Tumor-Infiltrating/*immunology | 7 | 10.0 |
Cell Differentiation | 62 | 1.0 |
Culture Media, Serum-Free/pharmacology | 2 | 1.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/metabolism | 11 | 18.0 |
Monocytes/metabolism | 65 | 20.0 |
Proto-Oncogene Proteins c-bcl-2/biosynthesis/*metabolism | 2 | 40.0 |
*Up-Regulation | 15 | 6.0 |
Cell Nucleus/metabolism | 55 | 2.0 |
Immunoblotting | 51 | 2.0 |
Oligonucleotides, Antisense/pharmacology | 13 | 4.0 |
Receptors, Cytoplasmic and Nuclear/metabolism | 6 | 4.0 |
Antigens, CD95/*physiology | 19 | 23.0 |
*Immune Tolerance | 12 | 7.0 |
Adipose Tissue/*metabolism | 9 | 8.0 |
*HIV-1 | 17 | 1.0 |
Interleukin-8/*secretion | 12 | 50.0 |
3T3 Cells | 47 | 2.0 |
Antigens, CD/*chemistry | 2 | 7.0 |
Ceramides/pharmacology | 12 | 40.0 |
Genes, p53 | 2 | 0.0 |
Protein p53/metabolism | 6 | 0.0 |
Proteins/metabolism | 51 | 5.0 |
Receptors, Tumor Necrosis Factor/*chemistry | 7 | 87.0 |
Interleukin-1/secretion | 19 | 45.0 |
Interleukin-6/secretion | 15 | 25.0 |
Macrophages, Alveolar/drug effects/*metabolism | 5 | 50.0 |
Transcription Factors/*metabolism | 17 | 1.0 |
Histocompatibility Antigens Class II/genetics | 5 | 4.0 |
Histocompatibility Testing | 22 | 2.0 |
Receptors, Cell Surface/genetics | 3 | 2.0 |
Ultraviolet Rays | 12 | 1.0 |
Cyclosporine/therapeutic use | 3 | 4.0 |
Immunoglobulin G/therapeutic use | 22 | 57.0 |
Interleukin-11/therapeutic use | 3 | 75.0 |
T-Lymphocytes/drug effects/immunology | 5 | 5.0 |
Antioxidants/pharmacology | 19 | 10.0 |
Cysteine Endopeptidases/*metabolism | 11 | 5.0 |
Glycoproteins/pharmacology | 5 | 13.0 |
NF-kappa B/antagonists & inhibitors | 10 | 27.0 |
Oligopeptides/pharmacology | 14 | 7.0 |
Proteasome Endopeptidase Complex | 18 | 3.0 |
Swine | 37 | 2.0 |
Radiotherapy, Adjuvant | 2 | 2.0 |
Interleukin-1/*antagonists & inhibitors | 9 | 56.0 |
China | 3 | 0.0 |
Ethnic Groups/*genetics | 3 | 1.0 |
Multigene Family | 12 | 1.0 |
Cytokines/blood/*secretion | 4 | 80.0 |
Immunoglobulin G/blood | 10 | 3.0 |
Leukocytes, Mononuclear/*secretion | 7 | 58.0 |
Interferon Type II/immunology | 13 | 14.0 |
Signal Transduction/immunology | 9 | 2.0 |
Virus Diseases/immunology | 2 | 10.0 |
*Alternative Splicing | 5 | 0.0 |
Antineoplastic Agents/*metabolism | 2 | 7.0 |
Cytokines/pharmacology | 48 | 12.0 |
Endothelium, Vascular/cytology/drug effects | 6 | 9.0 |
Neovascularization, Pathologic | 8 | 2.0 |
Tumor Necrosis Factor-alpha/*genetics/metabolism/secretion | 2 | 100.0 |
Xenograft Model Antitumor Assays | 4 | 1.0 |
Adrenal Cortex Hormones/blood | 3 | 27.0 |
Hormones/*blood | 3 | 2.0 |
Blood Cells/immunology | 3 | 9.0 |
Immunity | 6 | 9.0 |
Leukocytes, Mononuclear/immunology | 32 | 11.0 |
Malaria, Falciparum/*immunology/parasitology | 3 | 75.0 |
Parasitemia/immunology/parasitology | 2 | 66.0 |
Plasmodium falciparum/*immunology | 9 | 21.0 |
Candida albicans/*immunology | 6 | 30.0 |
Cytokines/blood/*immunology | 4 | 66.0 |
Interferon Type II/*biosynthesis | 21 | 13.0 |
Interleukin-12/immunology | 3 | 13.0 |
Macrophage Activation/*drug effects | 11 | 32.0 |
Macrophages/immunology | 24 | 8.0 |
Mitogen-Activated Protein Kinases/*antagonists & inhibitors | 4 | 22.0 |
Nitric Oxide/biosynthesis | 14 | 18.0 |
Nitric-Oxide Synthase/biosynthesis | 4 | 21.0 |
Streptococcus pneumoniae/*immunology | 6 | 18.0 |
NF-kappa B/drug effects/*metabolism | 4 | 57.0 |
Tumor Necrosis Factor-alpha/metabolism/pharmacology | 18 | 51.0 |
Culture Media, Conditioned/pharmacology | 7 | 3.0 |
Cytokines/metabolism/pharmacology | 3 | 16.0 |
Eosinophils/*metabolism | 5 | 15.0 |
RANTES/metabolism | 2 | 3.0 |
RNA Stability | 8 | 13.0 |
RNA, Messenger | 16 | 3.0 |
Carrier Proteins/*analysis | 3 | 3.0 |
Glycoproteins/*analysis | 3 | 4.0 |
Membrane Glycoproteins/*analysis | 5 | 3.0 |
Multiple Myeloma/*metabolism | 2 | 7.0 |
Stromal Cells/chemistry | 2 | 8.0 |
Bone and Bones/*metabolism | 7 | 10.0 |
Receptors, Interleukin-6/blood | 6 | 33.0 |
Cell Division/physiology | 23 | 2.0 |
Fibroblasts/*drug effects | 6 | 31.0 |
*Gene Expression | 28 | 2.0 |
Interleukin-1/*pharmacology | 152 | 37.0 |
Apoptosis/*radiation effects | 3 | 7.0 |
Receptors, Tumor Necrosis Factor/*genetics/*metabolism | 2 | 50.0 |
*Ultraviolet Rays | 9 | 4.0 |
Antigens, CD/genetics | 13 | 9.0 |
Colitis, Ulcerative/*genetics/*immunology | 2 | 66.0 |
Acute-Phase Proteins/analysis | 8 | 21.0 |
Corticotropin/blood | 10 | 6.0 |
Leukocyte Count | 73 | 4.0 |
Triglycerides/blood | 19 | 1.0 |
Inflammation Mediators/blood | 13 | 28.0 |
Lymphotoxin/*blood | 6 | 100.0 |
Receptors, Tumor Necrosis Factor/*blood | 38 | 80.0 |
Antibodies | 22 | 5.0 |
Immunoassay | 11 | 4.0 |
Tumor Necrosis Factor-alpha/*genetics/physiology | 3 | 75.0 |
Lung/physiopathology | 2 | 7.0 |
Escherichia coli | 51 | 10.0 |
HLA-DR Antigens/biosynthesis | 4 | 4.0 |
Interleukin-1/biosynthesis/blood | 7 | 70.0 |
Interleukin-6/biosynthesis/blood | 8 | 50.0 |
Phagocytosis/*physiology | 5 | 10.0 |
Antilipemic Agents/*therapeutic use | 2 | 2.0 |
Blood Glucose/analysis | 13 | 2.0 |
Cross-Over Studies | 18 | 2.0 |
Fibrinogen/analysis | 9 | 5.0 |
Inflammation Mediators/*metabolism | 16 | 27.0 |
Insulin/blood | 21 | 3.0 |
Interleukin-6/biosynthesis | 84 | 37.0 |
Lipids/blood | 8 | 1.0 |
Antigens, CD95/*metabolism | 19 | 16.0 |
Cell Death/*physiology | 3 | 7.0 |
Clinical Trials, Phase I | 5 | 8.0 |
Clinical Trials, Phase II | 5 | 9.0 |
Blood Glucose/metabolism | 17 | 2.0 |
C-Peptide/blood | 3 | 1.0 |
Psoriasis/drug therapy | 2 | 16.0 |
Myocardium/*immunology | 4 | 23.0 |
Anti-Infective Agents/therapeutic use | 4 | 10.0 |
Bronchoalveolar Lavage Fluid/chemistry | 10 | 15.0 |
Cytokines/analysis | 13 | 18.0 |
Graft Rejection/epidemiology | 3 | 13.0 |
Sialoglycoproteins/*analysis | 2 | 11.0 |
Adrenal Cortex Hormones/*blood | 2 | 11.0 |
Androstenedione/blood | 2 | 1.0 |
Dehydroepiandrosterone/*blood | 3 | 16.0 |
Dehydroepiandrosterone Sulfate/blood | 3 | 3.0 |
Inflammation/*blood | 5 | 11.0 |
DNA-Binding Proteins/drug effects/*metabolism | 2 | 11.0 |
Lipoproteins, LDL/pharmacology | 5 | 12.0 |
Lysophosphatidylcholines/pharmacology | 2 | 11.0 |
Immunosuppressive Agents/*pharmacology | 21 | 10.0 |
Keratinocytes/*drug effects/metabolism | 4 | 19.0 |
Reverse Transcriptase Polymerase Chain Reaction/methods | 7 | 2.0 |
Tacrolimus/*pharmacology | 2 | 5.0 |
Transforming Growth Factor beta/genetics/*metabolism | 2 | 5.0 |
Aging/metabolism | 8 | 5.0 |
Body Composition/physiology | 3 | 5.0 |
Obesity/*blood | 2 | 2.0 |
Cost-Benefit Analysis/economics/*methods | 2 | 22.0 |
Dermatology/*economics | 2 | 22.0 |
Diagnosis-Related Groups/*economics | 2 | 22.0 |
Germany | 6 | 1.0 |
Physician's Practice Patterns/*economics | 2 | 20.0 |
Quality Assurance, Health Care/*methods | 2 | 18.0 |
Skin Diseases/*classification/diagnosis/*economics/therapy | 2 | 22.0 |
Bacterial Infections/*physiopathology | 4 | 57.0 |
Cytokines/biosynthesis/pharmacology | 2 | 33.0 |
Dinoprostone/pharmacology | 16 | 19.0 |
Isoenzymes/pharmacology | 2 | 40.0 |
Lipopolysaccharides/toxicity | 39 | 52.0 |
Pyrogens/*pharmacology | 2 | 66.0 |
Age of Onset | 14 | 1.0 |
*Biological Markers | 2 | 1.0 |
Neutrophils/*metabolism | 24 | 12.0 |
Antibodies, Monoclonal/*adverse effects/*therapeutic use | 2 | 100.0 |
Arthritis, Rheumatoid/drug therapy | 6 | 54.0 |
Skin Diseases/drug therapy | 2 | 66.0 |
Czech Republic | 3 | 6.0 |
Antibodies/*immunology | 5 | 3.0 |
Antigens, CD95/*immunology | 5 | 13.0 |
Liver/cytology/pathology | 2 | 28.0 |
*Tumor Necrosis Factor Receptor-Associated Peptides and Proteins | 11 | 44.0 |
Adenine | 4 | 6.0 |
DNA, Complementary | 14 | 0.0 |
Membrane Proteins/*genetics | 4 | 0.0 |
Phytohemagglutinins/pharmacology | 51 | 9.0 |
Protein Sorting Signals | 3 | 4.0 |
Carcinogens | 3 | 3.0 |
Chromatin/metabolism | 5 | 1.0 |
Leukemia/*pathology | 4 | 9.0 |
Nitric Oxide/antagonists & inhibitors | 2 | 50.0 |
Protein Transport | 10 | 1.0 |
Tetradecanoylphorbol Acetate | 3 | 4.0 |
Animals, Newborn | 11 | 1.0 |
Organ Culture Techniques | 25 | 6.0 |
Interleukin-6/physiology | 17 | 27.0 |
Arthritis, Rheumatoid/metabolism/pathology | 3 | 17.0 |
Chemokines/*metabolism | 3 | 5.0 |
Dinoprostone/metabolism | 19 | 24.0 |
Fibroblasts/*drug effects/metabolism | 13 | 28.0 |
Interstitial Collagenase/metabolism | 3 | 12.0 |
Arthritis, Rheumatoid/*metabolism/pathology | 5 | 13.0 |
Cytokines/*genetics/metabolism | 8 | 50.0 |
RNA, Messenger/*metabolism | 27 | 4.0 |
1-Phosphatidylinositol 3-Kinase/antagonists & inhibitors/*metabolism | 3 | 4.0 |
Androstadienes/pharmacology | 12 | 4.0 |
Chromones/pharmacology | 10 | 4.0 |
Interleukin-10/*biosynthesis | 11 | 18.0 |
Macrophages/drug effects/*enzymology | 3 | 30.0 |
Morpholines/pharmacology | 11 | 4.0 |
Immunoglobulin G/*administration & dosage | 3 | 50.0 |
Platelet Count | 7 | 1.0 |
Receptors, Tumor Necrosis Factor/*administration & dosage/therapeutic use | 2 | 100.0 |
Histocompatibility Antigens Class II/biosynthesis | 3 | 6.0 |
Interferon Type II/physiology | 23 | 27.0 |
Interleukin-1/physiology | 37 | 41.0 |
Methotrexate/therapeutic use | 7 | 11.0 |
Receptors, Tumor Necrosis Factor/therapeutic use | 25 | 83.0 |
African Continental Ancestry Group/*genetics | 2 | 0.0 |
Genetic Predisposition to Disease/genetics | 9 | 2.0 |
Genetics, Population | 4 | 1.0 |
Oligonucleotide Probes | 14 | 2.0 |
Promoter Regions (Genetics)/*genetics | 22 | 2.0 |
Antibodies, Helminth/*blood | 2 | 5.0 |
Epitopes/immunology | 7 | 1.0 |
Immunity, Cellular | 43 | 6.0 |
Trichuris/*immunology | 2 | 100.0 |
Proto-Oncogene Proteins c-bcl-2/analysis | 2 | 1.0 |
Adenoviridae/genetics | 19 | 3.0 |
Cytoprotection | 2 | 9.0 |
Galactosamine/toxicity | 3 | 100.0 |
Hepatocytes/metabolism | 3 | 3.0 |
Inflammation/prevention & control | 6 | 85.0 |
Proteins/genetics/*physiology | 6 | 4.0 |
Receptors, Tumor Necrosis Factor/genetics | 24 | 55.0 |
In Situ Nick-End Labeling | 19 | 3.0 |
Membrane Glycoproteins/genetics/*physiology | 6 | 8.0 |
Antibiotics, Antineoplastic/*pharmacology | 5 | 4.0 |
Apoptosis/*genetics | 12 | 4.0 |
Fibroblasts/cytology/*drug effects/metabolism | 2 | 14.0 |
L-Lactate Dehydrogenase/metabolism | 15 | 10.0 |
Bronchi/cytology/*metabolism | 4 | 28.0 |
Cadherins/*biosynthesis | 3 | 9.0 |
Cytoskeletal Proteins/*biosynthesis | 2 | 11.0 |
Epithelial Cells/*metabolism | 2 | 1.0 |
Fluorescent Antibody Technique | 47 | 1.0 |
*Trans-Activators | 8 | 1.0 |
Antirheumatic Agents/*adverse effects | 6 | 54.0 |
Immunoglobulin G/*adverse effects | 3 | 100.0 |
Lupus Erythematosus, Systemic/*chemically induced | 2 | 66.0 |
Immunoglobulin E/*blood | 7 | 13.0 |
Parasite Egg Count | 6 | 16.0 |
Antibodies, Monoclonal/immunology | 72 | 4.0 |
*Bacterial Toxins | 13 | 9.0 |
Enterotoxins/*pharmacology | 11 | 20.0 |
HLA-DR Antigens/analysis | 18 | 2.0 |
*Superantigens | 8 | 17.0 |
Proteins/chemistry/genetics/*metabolism | 6 | 7.0 |
TNF Receptor-Associated Factor 3 | 15 | 22.0 |
Amino Acid Chloromethyl Ketones/pharmacology | 18 | 16.0 |
Cell Cycle | 15 | 1.0 |
G1 Phase | 5 | 1.0 |
Multienzyme Complexes/*metabolism | 5 | 3.0 |
Peptide Hydrolases/metabolism | 6 | 4.0 |
Protein Biosynthesis | 46 | 3.0 |
Bacterial Toxins/pharmacology | 4 | 9.0 |
Crystallography, X-Ray | 12 | 1.0 |
Peptide Fragments/chemistry/metabolism | 2 | 1.0 |
Protein Structure, Quaternary | 6 | 3.0 |
Protein Structure, Secondary | 15 | 1.0 |
Tumor Necrosis Factor-alpha/*chemistry/*metabolism | 3 | 100.0 |
Air Pollutants, Environmental/*toxicity | 3 | 25.0 |
Cell Cycle/drug effects | 18 | 3.0 |
Neoplasms/*drug therapy | 12 | 10.0 |
Recombinant Proteins/*metabolism | 3 | 9.0 |
Heterozygote | 14 | 0.0 |
Polymorphism, Single Nucleotide | 8 | 1.0 |
Vincristine/pharmacology | 5 | 8.0 |
Carrier Proteins/chemistry/genetics/*metabolism | 4 | 3.0 |
Interleukin-1/antagonists & inhibitors/*pharmacology | 6 | 46.0 |
Protein-Serine-Threonine Kinases/*metabolism | 24 | 3.0 |
*Zinc Fingers | 7 | 3.0 |
Cross-Sectional Studies | 23 | 1.0 |
Endothelial Growth Factors/blood | 2 | 3.0 |
Lymphokines/blood | 2 | 3.0 |
Transforming Growth Factor beta/blood | 4 | 15.0 |
von Willebrand Factor/metabolism | 5 | 1.0 |
RNA, Messenger/*analysis | 11 | 2.0 |
Biological Markers | 49 | 2.0 |
*Body Composition | 4 | 3.0 |
Bone and Bones/metabolism | 2 | 3.0 |
Connective Tissue/metabolism | 2 | 12.0 |
Cystic Fibrosis/*physiopathology | 2 | 15.0 |
Energy Intake | 6 | 3.0 |
Antibodies, Antineutrophil Cytoplasmic/*pharmacology | 3 | 60.0 |
Caspases/antagonists & inhibitors/*metabolism | 4 | 7.0 |
Hydroxamic Acids/pharmacology | 6 | 3.0 |
Leukocytes, Mononuclear/drug effects | 8 | 21.0 |
Protease Inhibitors/pharmacology | 17 | 7.0 |
Receptors, Cell Surface/*metabolism | 30 | 5.0 |
Apoptosis/drug effects/physiology | 9 | 9.0 |
Cells, Cultured/drug effects | 13 | 13.0 |
Inflammation/metabolism | 8 | 10.0 |
Nerve Growth Factors/pharmacology | 2 | 2.0 |
Oxidative Stress | 14 | 4.0 |
Tumor Necrosis | 2 | 100.0 |
Tumor Necrosis Factor-alpha/*antagonists & inhibitors/pharmacology | 22 | 81.0 |
Brain/*metabolism/pathology | 3 | 3.0 |
Brain Chemistry | 2 | 0.0 |
England | 3 | 2.0 |
HLA-B Antigens/*genetics | 5 | 1.0 |
HLA-DQ Antigens/*genetics | 3 | 0.0 |
*Introns | 2 | 0.0 |
DNA, Neoplasm | 3 | 2.0 |
HLA-DQ Antigens/genetics | 9 | 3.0 |
Melanoma/*genetics | 2 | 1.0 |
Psoriasis/*drug therapy | 4 | 26.0 |
Aging/*physiology | 2 | 0.0 |
Cell Movement/*physiology | 5 | 2.0 |
Epidermis/cytology | 2 | 5.0 |
Blood Cell Count | 20 | 8.0 |
Blood Transfusion | 4 | 2.0 |
Bone Marrow/pathology | 15 | 3.0 |
Tumor Necrosis Factor-alpha/*metabolism/pharmacology | 34 | 69.0 |
Cell Division/drug effects/physiology | 10 | 3.0 |
Interferon-alpha/pharmacology | 9 | 9.0 |
Tumor Necrosis Factor-alpha/*pharmacology/toxicity | 5 | 100.0 |
Incidence | 16 | 1.0 |
Logistic Models | 23 | 3.0 |
Multivariate Analysis | 30 | 2.0 |
*Drug Resistance, Neoplasm | 6 | 3.0 |
Neoplasms/*drug therapy/metabolism | 5 | 20.0 |
Antigens, CD40/*biosynthesis/metabolism | 2 | 66.0 |
Interferon Type II/*metabolism | 8 | 12.0 |
Macrophages/*metabolism | 26 | 10.0 |
Microglia/*metabolism | 3 | 16.0 |
Receptors, Nerve Growth Factor/*physiology | 5 | 35.0 |
Crystallization | 5 | 2.0 |
Electrostatics | 5 | 3.0 |
Neuropeptides/chemistry/metabolism | 2 | 33.0 |
Nuclear Proteins/chemistry/metabolism | 2 | 7.0 |
Receptors, Tumor Necrosis Factor/chemistry/metabolism | 2 | 50.0 |
Kidney Transplantation/*immunology | 8 | 3.0 |
Antigens, CD14/*blood | 4 | 12.0 |
Burns/*blood/complications | 3 | 60.0 |
Endotoxins/blood | 13 | 50.0 |
Amnion/drug effects/*metabolism | 2 | 28.0 |
Dinoprostone/biosynthesis | 13 | 22.0 |
Lipopolysaccharides/*antagonists & inhibitors | 6 | 50.0 |
Plant Extracts/pharmacology | 3 | 7.0 |
Plants, Medicinal/*chemistry | 4 | 23.0 |
Antineoplastic Agents/*administration & dosage/adverse effects | 2 | 12.0 |
*Extremities | 10 | 62.0 |
*Hyperthermia, Induced | 15 | 31.0 |
Lymphatic Metastasis | 5 | 0.0 |
Melanoma/*drug therapy/pathology | 2 | 66.0 |
Melphalan/administration & dosage | 10 | 20.0 |
Neoplasm Staging | 28 | 1.0 |
*Perfusion, Regional | 9 | 75.0 |
Skin Neoplasms/*drug therapy/pathology | 2 | 33.0 |
Tumor Necrosis Factor-alpha/administration & dosage | 16 | 72.0 |
Arthritis, Rheumatoid/*pathology | 2 | 10.0 |
Cell Division/genetics | 4 | 1.0 |
Fibroblasts/drug effects/metabolism | 20 | 13.0 |
Stimulation, Chemical | 51 | 10.0 |
Proteins/antagonists & inhibitors | 2 | 33.0 |
Amino Acid Substitution/genetics | 4 | 1.0 |
Deoxyribonucleases, Type II Site-Specific | 7 | 2.0 |
Graves' Disease/*genetics | 4 | 10.0 |
*Polymorphism, Restriction Fragment Length | 12 | 1.0 |
Antibodies, Monoclonal | 85 | 3.0 |
Antigens, CD40/*biosynthesis | 4 | 30.0 |
Autoimmune Diseases/genetics/immunology | 3 | 17.0 |
*Sex Characteristics | 5 | 3.0 |
Tumor Necrosis Factor-alpha/analysis/genetics | 7 | 58.0 |
Interleukin-10/*metabolism/pharmacology | 2 | 50.0 |
Neutrophils/drug effects/*metabolism | 12 | 19.0 |
Intestinal Mucosa/*metabolism | 3 | 3.0 |
Models, Chemical | 5 | 1.0 |
Software | 5 | 1.0 |
Ethanol/*administration & dosage | 2 | 11.0 |
Monocytes/*drug effects/metabolism | 31 | 31.0 |
T-Lymphocytes/*drug effects/metabolism | 3 | 8.0 |
CD4-Positive T-Lymphocytes | 4 | 1.0 |
Colitis/*immunology | 2 | 66.0 |
DNA-Binding Proteins/genetics | 7 | 0.0 |
Intestinal Mucosa/*immunology | 3 | 3.0 |
Tumor Necrosis Factor-alpha/genetics/*immunology | 7 | 58.0 |
Interleukin-6/genetics/metabolism | 11 | 45.0 |
Tumor Necrosis Factors/*genetics/metabolism | 2 | 100.0 |
Cytokines/*genetics/physiology | 2 | 50.0 |
T-Lymphocytes, Helper-Inducer/*physiology | 2 | 11.0 |
Th1 Cells/*physiology | 2 | 11.0 |
Th2 Cells/*physiology | 2 | 16.0 |
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use | 10 | 20.0 |
Controlled Clinical Trials | 2 | 8.0 |
Cyclooxygenase Inhibitors/therapeutic use | 2 | 18.0 |
Patient Education | 2 | 3.0 |
Thalidomide/therapeutic use | 4 | 28.0 |
Actins/genetics | 4 | 3.0 |
*Genes | 5 | 2.0 |
Interferons/genetics | 3 | 23.0 |
*Regulatory Sequences, Nucleic Acid | 2 | 0.0 |
*Software | 2 | 3.0 |
1-Phosphatidylinositol 3-Kinase/antagonists & inhibitors | 2 | 2.0 |
Cell Fusion | 2 | 0.0 |
Cysteine Endopeptidases | 2 | 4.0 |
Macrophage Colony-Stimulating Factor/pharmacology | 10 | 14.0 |
Membrane Glycoproteins/*metabolism/pharmacology | 3 | 42.0 |
Multienzyme Complexes/antagonists & inhibitors | 2 | 7.0 |
Osteoclasts/cytology/*drug effects | 3 | 60.0 |
*ABO Blood-Group System | 2 | 5.0 |
Bacterial Adhesion | 3 | 4.0 |
E-Selectin/blood | 6 | 10.0 |
Lymphocytes/drug effects/immunology | 7 | 21.0 |
Neutrophils/drug effects/immunology | 3 | 18.0 |
Spleen/cytology/drug effects/metabolism | 2 | 40.0 |
Blood Flow Velocity | 3 | 3.0 |
Endothelium, Vascular/*physiology | 14 | 10.0 |
*Bacterial Proteins | 5 | 2.0 |
DNA, Complementary/metabolism | 13 | 0.0 |
Glutathione Transferase/metabolism | 7 | 0.0 |
Recombinant Fusion Proteins/metabolism | 21 | 1.0 |
Species Specificity | 52 | 1.0 |
Labor, Obstetric/*physiology | 3 | 20.0 |
Leukocytes/metabolism | 13 | 9.0 |
Trophoblasts/metabolism | 2 | 5.0 |
DNA Fragmentation | 27 | 8.0 |
Interleukin-18/pharmacology | 3 | 42.0 |
Macrophage Colony-Stimulating Factor/*pharmacology | 5 | 12.0 |
Monocytes/drug effects/enzymology/*physiology | 2 | 28.0 |
Proto-Oncogene Proteins/*metabolism | 17 | 1.0 |
Culture Techniques | 24 | 5.0 |
Inflammation/immunology | 14 | 12.0 |
Receptors, Interleukin/blood | 3 | 37.0 |
Antigens, CD18/blood | 2 | 25.0 |
Intercellular Adhesion Molecule-1/*blood | 8 | 13.0 |
Macrophage-1 Antigen/*blood | 2 | 28.0 |
Tuberculosis, Pleural/blood/diagnosis | 2 | 100.0 |
Burkitt Lymphoma/pathology | 2 | 6.0 |
Caspases/antagonists & inhibitors/*physiology | 2 | 25.0 |
Complement Activation | 9 | 3.0 |
Gene Expression Regulation, Leukemic/drug effects | 2 | 8.0 |
Gene Expression Regulation, Neoplastic/drug effects | 14 | 3.0 |
Interleukins/pharmacology | 10 | 14.0 |
Mitoxantrone/pharmacology | 3 | 16.0 |
Neoplasm Proteins/antagonists & inhibitors/*physiology | 2 | 18.0 |
Arachidonic Acid/*metabolism | 3 | 8.0 |
Calcium/*physiology | 3 | 2.0 |
*Membrane Proteins | 24 | 2.0 |
Phosphoric Monoester Hydrolases/*physiology | 2 | 6.0 |
Transcription, Genetic/*physiology | 3 | 1.0 |
Tumor Suppressor Proteins/*physiology | 3 | 9.0 |
*Microsatellite Repeats | 7 | 3.0 |
Transcription Factor AP-1/*metabolism | 14 | 8.0 |
E-Selectin/genetics | 5 | 38.0 |
Transforming Growth Factor beta/genetics | 11 | 11.0 |
Chemotactic Factors/pharmacology | 6 | 18.0 |
Monocytes/drug effects/physiology | 7 | 38.0 |
Neutrophils/drug effects/physiology | 9 | 42.0 |
Respiratory Burst/*drug effects | 12 | 42.0 |
Superoxides/metabolism | 54 | 20.0 |
Pain | 2 | 6.0 |
Chimera | 3 | 1.0 |
Tumor Necrosis Factor-alpha/*administration & | 4 | 100.0 |
Amino Acids/blood | 3 | 6.0 |
Eukaryotic Initiation Factor-4E | 2 | 1.0 |
Hemodynamic Processes/drug effects | 12 | 7.0 |
Hormones/blood | 5 | 4.0 |
Muscle, Skeletal/*metabolism | 3 | 1.0 |
Myocardium/*metabolism | 8 | 3.0 |
Polyribosomes/metabolism | 3 | 10.0 |
Rats, Sprague-Dawley | 82 | 3.0 |
Conserved Sequence | 13 | 0.0 |
Protein-Tyrosine-Phosphatase/*metabolism | 4 | 3.0 |
Receptor, Nerve Growth Factor/*metabolism | 2 | 50.0 |
src-Family Kinases/metabolism | 3 | 1.0 |
MAP Kinase Kinase Kinases/metabolism | 6 | 19.0 |
*Saccharomyces cerevisiae Proteins | 7 | 0.0 |
Lymphocyte Activation/physiology | 5 | 7.0 |
Multiple Sclerosis/blood/*cerebrospinal fluid | 2 | 100.0 |
Receptors, Tumor Necrosis Factor/biosynthesis/blood/*metabolism | 2 | 100.0 |
Spinal Cord/*metabolism | 2 | 6.0 |
Tumor Necrosis Factor-alpha/cerebrospinal fluid | 8 | 66.0 |
Drugs, Chinese Herbal/*therapeutic use | 7 | 8.0 |
Endothelium, Vascular/*pathology | 3 | 4.0 |
Interleukin-6/metabolism | 60 | 27.0 |
Interleukin-8/*metabolism | 13 | 23.0 |
Malondialdehyde/metabolism | 4 | 14.0 |
*Medicine, Chinese Traditional | 2 | 8.0 |
Nitric Oxide/blood | 5 | 23.0 |
Stroke Volume/physiology | 4 | 16.0 |
Survival Analysis | 51 | 2.0 |
Demography | 3 | 2.0 |
Helicobacter pylori | 3 | 7.0 |
Basement Membrane/immunology | 2 | 3.0 |
Bronchoalveolar Lavage Fluid/immunology | 5 | 14.0 |
Cell Movement/*immunology | 3 | 4.0 |
Gelatinase A/metabolism | 5 | 8.0 |
Peroxidase/metabolism | 13 | 10.0 |
Phenylalanine/*analogs & derivatives/pharmacology | 2 | 11.0 |
Thiophenes/pharmacology | 2 | 5.0 |
Trypsin/pharmacology | 3 | 2.0 |
Hyperplasia | 7 | 1.0 |
Indicators and Reagents | 13 | 4.0 |
Interleukin-6/genetics/pharmacology | 2 | 66.0 |
Intestinal Mucosa/immunology/pathology | 5 | 26.0 |
Interleukin-8/*biosynthesis | 21 | 33.0 |
Macrophages | 6 | 7.0 |
Ozone/*adverse effects | 3 | 33.0 |
Proteolipids/*pharmacology | 2 | 25.0 |
Pulmonary Surfactants/*pharmacology | 5 | 35.0 |
*Genes, erbB-2 | 4 | 4.0 |
Insulin Resistance | 9 | 5.0 |
Phosphoproteins/*metabolism | 15 | 3.0 |
*Trans-Activation (Genetics) | 12 | 1.0 |
Tyrosine/metabolism | 16 | 1.0 |
Interleukin-6/*analysis | 11 | 29.0 |
Interleukin-8/*analysis | 3 | 21.0 |
Sputum/*chemistry | 3 | 25.0 |
Endothelium, Vascular/cytology | 13 | 5.0 |
Proteins/chemistry/*metabolism | 3 | 3.0 |
Liver/immunology | 3 | 6.0 |
Lymph Nodes/immunology | 2 | 2.0 |
Spleen/immunology | 8 | 4.0 |
Thymus Gland/immunology | 3 | 4.0 |
Endothelins/blood | 4 | 28.0 |
Antigens, CD/chemistry/*metabolism | 3 | 7.0 |
Bilirubin/blood | 5 | 5.0 |
Glutathione/blood | 4 | 9.0 |
Hepatitis, Alcoholic/*metabolism | 2 | 100.0 |
Receptors, Tumor Necrosis Factor/chemistry/*metabolism | 15 | 83.0 |
Thiobarbituric Acid Reactive Substances/metabolism | 3 | 7.0 |
Body Weight | 17 | 2.0 |
Doxorubicin/administration & dosage | 11 | 6.0 |
Drug Carriers | 18 | 14.0 |
Drug Screening Assays, Antitumor | 34 | 9.0 |
Liposomes | 19 | 7.0 |
Tumor Cells, Cultured/metabolism | 5 | 2.0 |
Chemotaxis, Leukocyte/*physiology | 3 | 9.0 |
Eosinophils/*physiology | 4 | 9.0 |
Fibroblasts/drug effects/physiology | 2 | 10.0 |
RANTES/pharmacology | 2 | 3.0 |
Cardiac Surgical Procedures/*adverse effects | 3 | 23.0 |
Cardiopulmonary Bypass/adverse effects | 2 | 25.0 |
Cytokines/immunology | 19 | 13.0 |
*Immunity, Cellular | 4 | 3.0 |
Tumor Necrosis Factor-alpha/antagonists & inhibitors/*physiology | 14 | 82.0 |
Cell Differentiation/*drug effects | 9 | 5.0 |
Microscopy, Electron | 41 | 1.0 |
Stem Cell Factor/*pharmacology | 3 | 5.0 |
Sarcoma/*blood/pathology | 2 | 100.0 |
Tumor Markers, Biological/*analysis | 5 | 0.0 |
Arthritis, Rheumatoid/immunology | 5 | 5.0 |
Cytokines/*analysis | 23 | 27.0 |
Lymphotoxin/analysis | 9 | 75.0 |
Osteoarthritis/immunology | 3 | 15.0 |
Receptors, Interleukin-1/analysis | 2 | 66.0 |
Receptors, Interleukin-2/analysis | 21 | 8.0 |
Synovial Fluid/*immunology | 4 | 7.0 |
Capillary Permeability/drug effects | 6 | 13.0 |
Endothelium, Vascular/drug effects/pathology | 2 | 18.0 |
Interferon-alpha/metabolism | 3 | 13.0 |
Necrosis | 30 | 8.0 |
*Xanthones | 4 | 28.0 |
I-kappa B/*metabolism | 4 | 28.0 |
Respiratory System/cytology/*metabolism | 2 | 25.0 |
Cytokines/secretion | 10 | 13.0 |
Immunoglobulin E/blood | 3 | 2.0 |
Growth Inhibitors/*analysis | 2 | 15.0 |
*Interleukin-6 | 11 | 3.0 |
Ovulation Induction | 4 | 10.0 |
Uterus/*metabolism | 2 | 4.0 |
Ascitic Fluid/*chemistry | 3 | 20.0 |
Interleukin-1/*analysis | 19 | 57.0 |
Laparoscopy | 2 | 5.0 |
Brain/cytology | 5 | 19.0 |
Microglia/*physiology | 3 | 20.0 |
Nerve Tissue Proteins/metabolism | 3 | 1.0 |
Receptors, Tumor Necrosis Factor/biosynthesis/*metabolism | 2 | 100.0 |
*Antigen Presentation | 2 | 1.0 |
Cytomegalovirus/*physiology | 4 | 14.0 |
Cytomegalovirus Infections/*immunology | 2 | 9.0 |
Gene Expression Regulation, Viral | 7 | 2.0 |
Interleukin-10/pharmacology | 10 | 14.0 |
Membrane Glycoproteins/biosynthesis/genetics | 4 | 8.0 |
Receptors, Tumor Necrosis Factor/genetics/physiology | 7 | 87.0 |
Recombinant Fusion Proteins/immunology | 4 | 3.0 |
T-Lymphocyte Subsets/immunology | 13 | 3.0 |
Tumor Necrosis Factor-alpha/biosynthesis/genetics | 23 | 38.0 |
1-Phosphatidylinositol 3-Kinase/antagonists & inhibitors/metabolism | 3 | 3.0 |
B-Lymphocytes/cytology/*metabolism | 2 | 8.0 |
Immunoglobulin M/immunology | 5 | 3.0 |
Receptor, trkA | 2 | 3.0 |
Chromosome Mapping | 44 | 0.0 |
Chromosomes, Human, Pair 6/genetics | 4 | 3.0 |
Ibuprofen/pharmacology | 7 | 50.0 |
Indomethacin/pharmacology | 51 | 24.0 |
Signal Transduction/drug effects | 44 | 6.0 |
Curcumin/*pharmacology | 4 | 16.0 |
*Down-Regulation | 13 | 4.0 |
Enzyme Precursors/metabolism | 7 | 5.0 |
Prostatic Neoplasms | 5 | 8.0 |
Chorionic Gonadotropin/pharmacology | 4 | 3.0 |
Leptin/pharmacology | 2 | 50.0 |
Interleukin-18/blood | 2 | 28.0 |
Amino Acid Motifs | 8 | 0.0 |
Mutation/genetics | 6 | 0.0 |
6-Ketoprostaglandin F1 alpha/biosynthesis | 6 | 33.0 |
Anti-Inflammatory Agents, Non-Steroidal/*pharmacology | 23 | 18.0 |
Cyclooxygenase Inhibitors/pharmacology | 6 | 8.0 |
Furans/pharmacology | 2 | 22.0 |
Prostaglandins/*biosynthesis | 4 | 8.0 |
Sulfonamides/pharmacology | 7 | 6.0 |
Calcium/*metabolism | 6 | 0.0 |
Electrophysiology | 3 | 0.0 |
Enzyme Activation/physiology | 9 | 5.0 |
Mutation/physiology | 5 | 4.0 |
Protein Kinases/*metabolism | 20 | 5.0 |
Receptors, Tumor Necrosis Factor/genetics/*metabolism | 24 | 68.0 |
Stress/*enzymology | 2 | 28.0 |
Tumor Necrosis Factor-alpha/genetics/metabolism/*physiology | 3 | 100.0 |
Neoplasm Proteins/*metabolism | 8 | 1.0 |
Neuroblastoma/*metabolism | 2 | 3.0 |
RNA, Neoplasm/metabolism | 2 | 2.0 |
RNA, Neoplasm | 2 | 15.0 |
Macrophage Activation/immunology | 4 | 10.0 |
Macrophages, Peritoneal/*immunology/metabolism | 3 | 50.0 |
Receptors, Interferon/metabolism | 2 | 5.0 |
Bone Resorption | 8 | 22.0 |
Interleukin-1/*biosynthesis | 64 | 52.0 |
Leukocytes, Mononuclear/cytology | 2 | 4.0 |
Bone Remodeling | 3 | 15.0 |
Glycoproteins/metabolism | 7 | 4.0 |
Angiotensin II/*physiology | 2 | 5.0 |
Sialoglycoproteins/physiology | 4 | 40.0 |
Transforming Growth Factor beta/physiology | 2 | 2.0 |
Acetylcholine/pharmacology | 5 | 7.0 |
Forearm/blood supply | 3 | 6.0 |
Immunoglobulin G/*pharmacology/therapeutic use | 2 | 100.0 |
Nitroprusside/pharmacology | 6 | 8.0 |
Regional Blood Flow/drug effects | 3 | 2.0 |
Vasodilator Agents/pharmacology | 4 | 6.0 |
T-Lymphocytes/drug effects/*immunology | 7 | 4.0 |
Tetradecanoylphorbol Acetate/*pharmacology | 22 | 7.0 |
*ADP Ribose Transferases | 3 | 3.0 |
*Membrane Transport Proteins | 3 | 0.0 |
Pseudomonas aeruginosa/*pathogenicity | 3 | 30.0 |
*Virulence Factors | 3 | 3.0 |
Cell Adhesion/*physiology | 7 | 5.0 |
E-Selectin/metabolism | 7 | 15.0 |
Neutrophils/*drug effects/metabolism/physiology | 3 | 42.0 |
P-Selectin/metabolism | 4 | 8.0 |
Pentoxifylline/*pharmacology | 22 | 59.0 |
Phosphodiesterase Inhibitors/pharmacology | 10 | 9.0 |
Glycolysis | 2 | 3.0 |
Blood Pressure/physiology | 6 | 3.0 |
*Cardiopulmonary Bypass | 14 | 15.0 |
Endothelium, Vascular/*physiopathology | 6 | 6.0 |
Metabolic Clearance Rate/physiology | 2 | 15.0 |
Peptide Fragments/blood | 4 | 3.0 |
Vascular Resistance/physiology | 2 | 9.0 |
Extracellular Matrix/*enzymology | 2 | 15.0 |
Matrix Metalloproteinases/*metabolism | 2 | 5.0 |
Receptors, Virus/*metabolism | 4 | 4.0 |
*Arthroplasty, Replacement, Hip | 3 | 15.0 |
Macrophages/*drug effects/metabolism | 8 | 23.0 |
Prosthesis Failure | 3 | 5.0 |
Calcium/metabolism | 30 | 1.0 |
DNA/biosynthesis | 19 | 3.0 |
Endothelium, Vascular/*cytology | 18 | 11.0 |
*Neovascularization, Pathologic | 3 | 0.0 |
Phospholipase C/*metabolism | 2 | 1.0 |
Pyrrolidinones/pharmacology | 6 | 11.0 |
Endothelium, Vascular/drug effects/*metabolism | 21 | 27.0 |
Nuclear Proteins/metabolism | 12 | 1.0 |
Protein Isoforms/metabolism | 6 | 3.0 |
Tosyllysine Chloromethyl Ketone/pharmacology | 4 | 26.0 |
Tyrphostins/pharmacology | 2 | 1.0 |
Genes, bcl-2 | 5 | 4.0 |
Tumor Necrosis Factor-alpha/administration & dosage/*pharmacology | 32 | 84.0 |
Blood Cells/metabolism | 2 | 6.0 |
Lung/metabolism | 6 | 3.0 |
Monocytes/*metabolism | 76 | 21.0 |
Neutrophils/pathology | 8 | 13.0 |
Pulmonary Fibrosis/*metabolism | 2 | 28.0 |
Chemokines, CC/*biosynthesis/genetics | 2 | 22.0 |
Cyclic AMP/physiology | 7 | 6.0 |
Cyclic GMP/physiology | 2 | 13.0 |
Dibutyryl Cyclic GMP/pharmacology | 3 | 30.0 |
Antibodies, Monoclonal/*administration & dosage/adverse effects | 4 | 33.0 |
Gene Expression/immunology | 8 | 9.0 |
Immunotherapy | 34 | 10.0 |
Interferon-beta/*genetics | 2 | 20.0 |
Gene Therapy | 9 | 2.0 |
Neoplasms/therapy | 8 | 16.0 |
Protein Sorting Signals/genetics | 3 | 4.0 |
NIH 3T3 Cells | 4 | 1.0 |
DNA Primers/chemistry | 22 | 1.0 |
Densitometry, X-Ray | 5 | 3.0 |
Japan/epidemiology | 5 | 1.0 |
Serine Endopeptidases/metabolism | 6 | 5.0 |
Fasting | 10 | 3.0 |
Glucose Tolerance Test | 7 | 1.0 |
Hypertension/*genetics | 3 | 2.0 |
Insulin Resistance/*genetics | 2 | 2.0 |
Lipoproteins/blood | 4 | 1.0 |
Proteins/*chemistry/metabolism | 2 | 6.0 |
Cell Adhesion Molecules/*biosynthesis | 17 | 19.0 |
Cell Membrane Permeability/drug effects | 5 | 9.0 |
Cell Movement/drug effects | 19 | 5.0 |
Leukocytes/cytology/*drug effects | 2 | 50.0 |
Pulsatile Flow | 2 | 4.0 |
Antigens, CD18/analysis | 2 | 9.0 |
Antigens, Differentiation, T-Lymphocyte/analysis | 10 | 2.0 |
Endothelium, Vascular/*immunology | 13 | 15.0 |
Intercellular Adhesion Molecule-1/blood | 12 | 14.0 |
Lymphocytes/*immunology | 17 | 4.0 |
Sialoglycoproteins/analysis | 3 | 8.0 |
Acquired Immunodeficiency Syndrome/*blood | 4 | 9.0 |
Leukocytes, Mononuclear/*metabolism | 46 | 33.0 |
Anti-Inflammatory Agents/pharmacology/therapeutic use | 3 | 33.0 |
Granulocytes/*drug effects/metabolism | 2 | 66.0 |
Body Weight/drug effects | 9 | 4.0 |
Glycoproteins/*therapeutic use | 5 | 71.0 |
Recombinant Proteins/therapeutic use | 53 | 15.0 |
Cytokines/*antagonists & inhibitors/*physiology | 3 | 100.0 |
Gene Therapy/methods | 5 | 5.0 |
Actins/biosynthesis/genetics | 4 | 26.0 |
Lymphotoxin/pharmacology | 16 | 72.0 |
Membrane Proteins/*pharmacology | 3 | 6.0 |
RANTES/biosynthesis | 3 | 17.0 |
RNA, Neoplasm/biosynthesis | 5 | 3.0 |
Remission Induction/methods | 2 | 8.0 |
Antibodies/pharmacology | 27 | 7.0 |
Goats | 4 | 4.0 |
Interferon Type II/*immunology | 7 | 17.0 |
DNA/drug effects/metabolism | 2 | 4.0 |
Promoter Regions (Genetics)/drug effects/genetics | 2 | 6.0 |
Pyridines/*pharmacology | 10 | 15.0 |
Tumor Necrosis Factor-alpha/drug effects/*physiology | 3 | 100.0 |
Homocysteine/blood | 3 | 2.0 |
Chi-Square Distribution | 19 | 2.0 |
HLA-DR Antigens | 3 | 0.0 |
Pedigree | 10 | 0.0 |
*Promoter Regions (Genetics) | 44 | 1.0 |
*Hematopoiesis | 6 | 3.0 |
Body Constitution | 5 | 3.0 |
Electric Impedance | 4 | 7.0 |
*Homeostasis | 5 | 8.0 |
Insulin-Like Growth Factor I/analysis | 2 | 1.0 |
Osteocalcin/blood | 3 | 4.0 |
Osteoclasts/physiology | 4 | 30.0 |
Procollagen/blood | 3 | 10.0 |
Cytokines/metabolism/*physiology | 4 | 44.0 |
HMGB1 Protein/metabolism/*physiology | 2 | 100.0 |
Adjuvants, Immunologic/*pharmacology | 35 | 21.0 |
Amino Acid Chloromethyl Ketones/*pharmacology | 2 | 25.0 |
Caspases/*antagonists & inhibitors | 2 | 18.0 |
Cysteine Proteinase Inhibitors/*pharmacology | 5 | 16.0 |
Genetic Markers | 19 | 0.0 |
Major Histocompatibility Complex/*genetics | 14 | 8.0 |
Interferon Type II/*blood | 11 | 35.0 |
Rheumatoid Factor/blood | 4 | 10.0 |
Confidence Intervals | 9 | 2.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/analysis | 7 | 29.0 |
Hematopoietic Stem Cell Transplantation/*adverse effects | 4 | 10.0 |
Macrophages, Alveolar/*physiology | 5 | 33.0 |
Calcimycin/pharmacology | 23 | 9.0 |
*Cell Death | 7 | 16.0 |
Endocytosis | 11 | 2.0 |
Exocytosis | 3 | 4.0 |
Hydrogen-Ion Concentration | 32 | 2.0 |
Lithium Chloride/pharmacology | 2 | 13.0 |
Lysosomes/metabolism | 3 | 2.0 |
Mutagenesis | 13 | 1.0 |
Retroviridae/genetics | 7 | 1.0 |
Drugs, Chinese Herbal/*pharmacology | 7 | 15.0 |
Interferon Type II/biosynthesis | 49 | 10.0 |
Interleukin-4/biosynthesis | 10 | 6.0 |
Tumor Cells, Cultured/drug effects/radiation effects | 2 | 11.0 |
Biopsy | 23 | 1.0 |
Dendritic Cells/immunology | 5 | 3.0 |
Lymphocytes/immunology | 16 | 4.0 |
Intercellular Adhesion Molecule-1/metabolism | 21 | 11.0 |
Interleukin-6/analysis/genetics | 3 | 50.0 |
Up-Regulation/immunology | 5 | 3.0 |
Vascular Cell Adhesion Molecule-1/metabolism | 11 | 13.0 |
Adenocarcinoma | 8 | 6.0 |
Dogs | 22 | 1.0 |
Protein Kinase C/*metabolism | 11 | 3.0 |
Chromosomes, Human, Pair 6/*genetics | 2 | 1.0 |
European Continental Ancestry Group/genetics | 13 | 1.0 |
HLA-DR3 Antigen/*genetics | 6 | 20.0 |
Lupus Erythematosus, Systemic/*genetics | 4 | 6.0 |
Microsatellite Repeats/*genetics | 10 | 3.0 |
Odds Ratio | 17 | 1.0 |
Polymorphism, Genetic/genetics | 11 | 1.0 |
Free Radical Scavengers/pharmacology | 10 | 16.0 |
Pyrrolidines/pharmacology | 14 | 32.0 |
Tissue Inhibitor of Metalloproteinase-1/metabolism | 6 | 21.0 |
Interleukin-10/*analysis | 2 | 33.0 |
*Lung Transplantation | 2 | 7.0 |
Postoperative Complications | 4 | 2.0 |
Antigens, CD40/metabolism | 5 | 7.0 |
Antigens, Neoplasm/*metabolism | 4 | 4.0 |
Cell Adhesion Molecules/*metabolism | 19 | 6.0 |
Leukemia, Myeloid/*metabolism | 2 | 6.0 |
Lymphocyte Function-Associated Antigen-1/metabolism | 2 | 4.0 |
Interferon-alpha/blood | 4 | 40.0 |
Neuroimmunomodulation/physiology | 4 | 25.0 |
Biotinylation | 3 | 2.0 |
Fibroblasts/physiology | 7 | 5.0 |
Antigens, CD95/physiology | 17 | 23.0 |
*Milk Proteins | 4 | 0.0 |
Sequence Deletion | 27 | 1.0 |
Tumor Necrosis Factor-alpha/toxicity | 8 | 66.0 |
Kidney | 9 | 2.0 |
Phosphoprotein Phosphatase/*metabolism | 2 | 2.0 |
Cells, Cultured/metabolism | 3 | 8.0 |
Chromosome Aberrations | 3 | 0.0 |
Colony-Forming Units Assay | 25 | 4.0 |
Hematopoietic Cell Growth Factors/pharmacology | 4 | 5.0 |
Leucine Zippers | 4 | 2.0 |
Membrane Glycoproteins/*biosynthesis/genetics/pharmacology | 2 | 100.0 |
Neoplasm Proteins/biosynthesis/genetics | 4 | 3.0 |
Recombinant Fusion Proteins/pharmacology | 8 | 8.0 |
Tumor Necrosis Factor-alpha/*biosynthesis/genetics/pharmacology | 6 | 85.0 |
Cytokines/genetics | 20 | 18.0 |
Macrophage-1 Antigen/metabolism | 8 | 11.0 |
Receptors, IgG/metabolism | 3 | 4.0 |
Virus Replication | 16 | 1.0 |
Interleukin-10/genetics | 14 | 32.0 |
Stem Cell Factor/genetics | 2 | 22.0 |
Vimentin/analysis | 2 | 0.0 |
Neoplasms/drug therapy | 10 | 18.0 |
Endotoxins/*adverse effects | 2 | 66.0 |
Macrophages, Alveolar/immunology | 5 | 31.0 |
Antigens, CD/biosynthesis/genetics | 4 | 11.0 |
Cell Adhesion Molecules/*biosynthesis/genetics | 5 | 31.0 |
Cell Separation/methods | 7 | 4.0 |
E-Selectin/biosynthesis/genetics | 2 | 33.0 |
Endotoxins/pharmacology | 30 | 44.0 |
Intercellular Adhesion Molecule-1/biosynthesis/genetics | 9 | 45.0 |
Vascular Cell Adhesion Molecule-1/biosynthesis/genetics | 4 | 57.0 |
Chemokines/*biosynthesis/genetics | 3 | 21.0 |
Granulocyte Colony-Stimulating Factor/pharmacology | 11 | 6.0 |
Macrophages/*physiology | 20 | 20.0 |
Arthritis, Rheumatoid/*metabolism | 9 | 15.0 |
Culture Media, Conditioned | 27 | 7.0 |
Fibroblast Growth Factor 2/pharmacology | 7 | 3.0 |
Glycoproteins/genetics/*metabolism | 3 | 7.0 |
Nitrobenzenes/pharmacology | 2 | 8.0 |
Receptors, Cytoplasmic and Nuclear/genetics/*metabolism | 2 | 4.0 |
Synovial Membrane/drug effects/*metabolism/pathology | 2 | 33.0 |
Tumor Cells, Cultured/drug effects/physiology | 2 | 25.0 |
Proteins/genetics/*metabolism | 24 | 5.0 |
Recombinant Fusion Proteins/genetics/metabolism | 12 | 1.0 |
Graft Rejection | 6 | 4.0 |
Interleukins/genetics/metabolism | 3 | 50.0 |
Cytochrome c Group/*metabolism | 3 | 9.0 |
Green Fluorescent Proteins | 8 | 0.0 |
Indicators and Reagents/metabolism | 2 | 5.0 |
Luminescent Proteins/genetics | 4 | 2.0 |
Uncoupling Agents/pharmacology | 3 | 37.0 |
Genes, Bacterial | 2 | 1.0 |
Molecular Structure | 21 | 2.0 |
Neutrophils/metabolism | 16 | 11.0 |
*Genes, MHC Class I | 5 | 1.0 |
*Genes, MHC Class II | 7 | 2.0 |
Heat-Shock Proteins 70/genetics | 5 | 13.0 |
Polymerase Chain Reaction/methods | 23 | 1.0 |
Thyroiditis, Autoimmune/*genetics | 2 | 18.0 |
Antibodies, Monoclonal/*pharmacology/therapeutic use | 3 | 16.0 |
Antigens, CD14/physiology | 5 | 13.0 |
Caspases/*physiology | 7 | 31.0 |
Monocytes/*drug effects/physiology | 3 | 14.0 |
Proto-Oncogene Proteins/genetics | 5 | 0.0 |
*Proto-Oncogene Proteins c-bcl-2 | 7 | 1.0 |
Leptin/*blood | 10 | 12.0 |
Autocrine Communication | 6 | 8.0 |
Carrier Proteins/metabolism/pharmacology | 2 | 18.0 |
Intracellular Membranes/*metabolism | 2 | 3.0 |
Carrier Proteins/physiology | 9 | 7.0 |
Virus Replication/drug effects | 17 | 7.0 |
Antigens, CD/genetics/*metabolism | 9 | 9.0 |
Apoptosis/physiology | 23 | 6.0 |
Acquired Immunodeficiency Syndrome/*complications | 3 | 1.0 |
HIV Infections/*complications | 5 | 1.0 |
Neoplasms/etiology | 3 | 7.0 |
Asthma/*physiopathology | 2 | 7.0 |
Protein Isoforms/physiology | 4 | 10.0 |
Interferons/*biosynthesis | 4 | 33.0 |
*Cell Cycle Proteins | 3 | 0.0 |
Hematopoietic Stem Cells/*drug effects/pathology | 2 | 33.0 |
Antigens, CD95/analysis | 3 | 9.0 |
Antigens, Surface/analysis | 13 | 3.0 |
Apoptosis/immunology | 10 | 10.0 |
Interferon Type II/analysis | 20 | 22.0 |
Membrane Glycoproteins/analysis | 10 | 3.0 |
Transforming Growth Factor beta/*pharmacology | 10 | 2.0 |
Enhancer Elements (Genetics) | 10 | 2.0 |
*Gene Expression Regulation/drug effects | 14 | 7.0 |
Insulin/metabolism | 7 | 5.0 |
Macrophages/cytology/drug effects/metabolism | 3 | 17.0 |
Thiazolidinediones/pharmacology | 2 | 12.0 |
Inflammation/*physiopathology | 9 | 15.0 |
Escherichia coli/genetics | 15 | 2.0 |
Half-Life | 9 | 1.0 |
Hemodynamic Processes/physiology | 2 | 3.0 |
Polyethylene Glycols | 3 | 3.0 |
Receptors, Tumor Necrosis Factor/immunology/*metabolism | 5 | 83.0 |
Dinucleotide Repeats | 2 | 2.0 |
Haplotypes/genetics | 13 | 2.0 |
Nuclear Family | 5 | 2.0 |
Caspase 1/metabolism | 4 | 20.0 |
Culture Media | 43 | 6.0 |
Lipopolysaccharides/*metabolism | 9 | 7.0 |
Microscopy, Immunoelectron | 8 | 1.0 |
Penicillins/*pharmacology | 2 | 13.0 |
Picibanil/*pharmacology | 7 | 41.0 |
RNA, Messenger/biosynthesis/isolation & purification | 2 | 9.0 |
Th1 Cells/drug effects/metabolism | 3 | 50.0 |
Antibodies, Monoclonal/immunology/*therapeutic use | 2 | 6.0 |
Antirheumatic Agents/immunology/*therapeutic use | 4 | 80.0 |
Immunoglobulin G/immunology/*therapeutic use | 3 | 100.0 |
Multicenter Studies | 2 | 1.0 |
Receptors, Tumor Necrosis Factor/immunology/*therapeutic use | 3 | 100.0 |
Tumor Necrosis Factor-alpha/*drug effects/immunology | 2 | 100.0 |
Alcohol Drinking/adverse effects | 2 | 4.0 |
Carcinoma, Squamous Cell/*genetics | 3 | 1.0 |
Head and Neck Neoplasms/*genetics | 2 | 2.0 |
Laryngeal Neoplasms/genetics | 2 | 15.0 |
Pharyngeal Neoplasms/genetics | 2 | 28.0 |
Smoking/adverse effects | 7 | 2.0 |
Hemoglobins/metabolism | 3 | 1.0 |
Inflammation/blood/*drug therapy/pathology | 2 | 100.0 |
Peptidoglycan/pharmacology | 2 | 12.0 |
Polysaccharides/pharmacology | 2 | 13.0 |
DNA Fragmentation/drug effects | 9 | 9.0 |
Free Radical Scavengers/*pharmacology | 3 | 18.0 |
Tumor Necrosis Factor-alpha/*toxicity | 32 | 78.0 |
Lymphotoxin/*metabolism | 7 | 87.0 |
Limulus Test | 9 | 39.0 |
Macrophages, Peritoneal/drug effects/metabolism | 6 | 46.0 |
Polymyxin B/pharmacology | 20 | 37.0 |
Tumor Necrosis Factor-alpha/analysis/biosynthesis | 10 | 50.0 |
Cephalosporins/*pharmacology | 2 | 50.0 |
Monocytes/*drug effects | 12 | 22.0 |
Antigens, Helminth/immunology | 3 | 9.0 |
Bladder/ultrasonography | 2 | 66.0 |
CD4-Positive T-Lymphocytes/immunology | 19 | 2.0 |
Interleukin-10/*metabolism | 5 | 17.0 |
Carrier Proteins/genetics | 7 | 1.0 |
*Ligands | 3 | 12.0 |
Placenta/*chemistry | 2 | 5.0 |
Central Nervous System/*immunology | 3 | 23.0 |
Encephalitis/*immunology | 2 | 40.0 |
Neuroglia/*immunology | 3 | 23.0 |
Tumor Necrosis Factor-alpha/*immunology/physiology | 2 | 100.0 |
Cell Communication/*immunology | 6 | 14.0 |
T-Lymphocytes/*immunology/metabolism | 3 | 1.0 |
Fatty Acids, Nonesterified/blood | 6 | 3.0 |
Monosaccharide Transport Proteins/metabolism | 2 | 5.0 |
*Muscle Proteins | 4 | 1.0 |
Muscle, Skeletal/metabolism | 6 | 3.0 |
*Skin Transplantation | 2 | 10.0 |
Adrenal Glands/*metabolism | 2 | 11.0 |
Cholangiopancreatography, Endoscopic Retrograde | 2 | 13.0 |
Cholestasis/*metabolism | 2 | 66.0 |
Hydrocortisone/biosynthesis/blood | 2 | 66.0 |
Endothelium, Vascular/*drug effects/*metabolism | 2 | 14.0 |
Phagocytes/drug effects/physiology | 2 | 100.0 |
Respiratory Burst/drug effects | 15 | 51.0 |
Brain/metabolism/pathology | 3 | 2.0 |
Tumor Necrosis Factor-alpha/immunology/metabolism | 6 | 30.0 |
Linkage Disequilibrium/genetics | 4 | 2.0 |
Antigens, CD | 9 | 6.0 |
Receptors, Tumor Necrosis Factor/antagonists & inhibitors | 2 | 66.0 |
Tumor Necrosis Factor-alpha/genetics/*physiology | 19 | 82.0 |
Brefeldin A/pharmacology | 4 | 5.0 |
Cysteine Endopeptidases/physiology | 2 | 8.0 |
*Viral Proteins | 13 | 7.0 |
Lymphocyte Culture Test, Mixed | 21 | 3.0 |
Follistatin | 2 | 13.0 |
Placenta/cytology | 2 | 11.0 |
Transforming Growth Factor beta/pharmacology | 27 | 8.0 |
Chemokines/metabolism | 9 | 12.0 |
*Chemokines, CXC | 7 | 10.0 |
Epinephrine/metabolism | 2 | 13.0 |
Exercise/*physiology | 15 | 3.0 |
Stress, Mechanical | 9 | 3.0 |
Inflammation Mediators/*analysis | 3 | 11.0 |
Macrophages, Alveolar/metabolism | 11 | 39.0 |
Sputum/cytology/*metabolism | 2 | 50.0 |
HIV-1/genetics/*physiology | 2 | 1.0 |
RNA, Messenger/biosynthesis/genetics | 15 | 2.0 |
Viral Load | 16 | 1.0 |
*Virus Replication | 8 | 2.0 |
CD4-Positive T-Lymphocytes/*physiology | 3 | 3.0 |
CD8-Positive T-Lymphocytes/*physiology | 2 | 11.0 |
HIV Infections/*drug therapy/immunology | 2 | 1.0 |
HIV-1/physiology | 2 | 2.0 |
Interleukin-2/*administration & dosage | 4 | 15.0 |
*Lymphocyte Activation | 26 | 1.0 |
Receptors, Interleukin-2/metabolism | 10 | 5.0 |
Antigens, CD14/immunology | 4 | 7.0 |
Okadaic Acid/pharmacology | 11 | 13.0 |
Xanthenes/*pharmacology | 3 | 42.0 |
Lod Score | 3 | 0.0 |
Nitrates/blood | 6 | 23.0 |
Nitric Oxide/*biosynthesis | 14 | 30.0 |
Antigens, CD4/*analysis | 2 | 1.0 |
Naphthyridines/pharmacology | 2 | 100.0 |
Genistein/pharmacology | 8 | 7.0 |
Liver/*drug effects | 4 | 26.0 |
Monocyte Chemoattractant Protein-1/*secretion | 2 | 100.0 |
DNA, Neoplasm/metabolism | 4 | 2.0 |
Gene Expression Regulation, Enzymologic | 9 | 1.0 |
Isoenzymes/genetics | 3 | 0.0 |
Luciferases/genetics | 9 | 2.0 |
NF-kappa B/*antagonists & inhibitors/metabolism | 9 | 39.0 |
Prostaglandin-Endoperoxide Synthase/genetics | 2 | 8.0 |
Doxorubicin/*pharmacology | 8 | 11.0 |
Reactive Oxygen Species/metabolism | 34 | 10.0 |
Superoxide Dismutase/metabolism | 13 | 15.0 |
Chromatography, Gel | 28 | 3.0 |
Cross-Linking Reagents/pharmacology | 3 | 2.0 |
Membrane Proteins/*metabolism | 10 | 2.0 |
Molecular Weight | 133 | 4.0 |
Platelet Membrane Glycoproteins/*physiology | 2 | 6.0 |
*Receptors, Cell Surface | 4 | 1.0 |
*Receptors, G-Protein-Coupled | 4 | 1.0 |
Antibodies, Monoclonal/metabolism | 6 | 1.0 |
Furin | 3 | 6.0 |
Crosses, Genetic | 7 | 1.0 |
Genes, Recessive | 2 | 0.0 |
Endothelium, Vascular/immunology | 8 | 19.0 |
Immune Tolerance | 11 | 3.0 |
Immunity, Mucosal | 4 | 5.0 |
Inflammatory Bowel Diseases/*immunology | 2 | 8.0 |
Crohn Disease/*drug therapy/pathology | 2 | 100.0 |
Cardiac Surgical Procedures | 2 | 10.0 |
Cytokines/*biosynthesis/blood/genetics | 2 | 50.0 |
Heart Failure, Congestive/*physiopathology | 3 | 15.0 |
Heart-Assist Devices | 2 | 40.0 |
Interleukin-1/biosynthesis/genetics | 16 | 59.0 |
Myocardium/chemistry/*metabolism | 2 | 22.0 |
Nitric-Oxide Synthase/biosynthesis/genetics | 3 | 50.0 |
RNA, Messenger/analysis/biosynthesis | 11 | 4.0 |
Membrane Glycoproteins/antagonists & inhibitors/*pharmacology | 2 | 66.0 |
Antigens, CD3/analysis | 4 | 1.0 |
Antigens, CD4/analysis | 8 | 1.0 |
Antigens, CD8/analysis | 6 | 2.0 |
HIV Infections/*pathology | 2 | 7.0 |
Lymphocyte Subsets | 7 | 3.0 |
Proto-Oncogene Proteins c-bcl-2/genetics/*metabolism | 2 | 3.0 |
Acetylation | 3 | 0.0 |
*Gene Expression Regulation, Enzymologic | 6 | 1.0 |
Luciferases/metabolism | 20 | 3.0 |
Lipopolysaccharides/immunology/pharmacology | 4 | 19.0 |
Membrane Glycoproteins/*genetics | 12 | 2.0 |
Receptors, Cell Surface/*genetics | 12 | 4.0 |
Staphylococcus aureus/immunology | 10 | 9.0 |
Antigens, CD95/pharmacology | 2 | 50.0 |
Caspases/antagonists & inhibitors | 7 | 14.0 |
DNA/analysis | 2 | 0.0 |
Galactosamine/pharmacology | 7 | 50.0 |
Oligopeptides/*pharmacology | 2 | 2.0 |
Membrane Glycoproteins/*biosynthesis | 3 | 3.0 |
Tumor Necrosis Factor-alpha/*biosynthesis/*pharmacology | 2 | 100.0 |
Cell Membrane Permeability/drug effects/physiology | 2 | 25.0 |
Hemostatics/*pharmacology | 2 | 15.0 |
Thrombin/*pharmacology | 3 | 2.0 |
MAP Kinase Kinase 1 | 7 | 4.0 |
MAP Kinase Kinase 2 | 3 | 6.0 |
Mitogen-Activated Protein Kinase 1/*metabolism | 3 | 2.0 |
NF-kappa B/antagonists & inhibitors/metabolism | 6 | 19.0 |
Antigens, CD/genetics/metabolism | 5 | 9.0 |
Cell Death/drug effects/physiology | 6 | 14.0 |
Receptors, Tumor Necrosis Factor/genetics/metabolism | 7 | 53.0 |
Sex Distribution | 4 | 1.0 |
Cytokines/*biosynthesis/*genetics | 5 | 71.0 |
Interleukin-10/biosynthesis/genetics | 4 | 26.0 |
Interleukin-6/biosynthesis/genetics | 18 | 47.0 |
Leukocytes, Mononuclear/*drug effects/*immunology | 3 | 75.0 |
Polysaccharides, Bacterial/pharmacology | 2 | 20.0 |
Interleukin-6/*secretion | 17 | 45.0 |
Lymphocyte Activation/immunology | 18 | 3.0 |
Cell Communication/physiology | 9 | 9.0 |
Monocytes/cytology/immunology/*metabolism | 2 | 22.0 |
Reactive Oxygen Species/*metabolism | 19 | 12.0 |
B-Lymphocytes/*metabolism | 10 | 5.0 |
HIV-1/*pathogenicity | 4 | 4.0 |
Human T-lymphotropic virus 1/*metabolism | 2 | 10.0 |
*Membrane Glycoproteins | 15 | 1.0 |
T-Lymphocytes/*metabolism | 13 | 3.0 |
Viral Envelope Proteins/metabolism | 2 | 3.0 |
Infection/*immunology | 4 | 19.0 |
Cytokines/drug effects/*metabolism | 5 | 62.0 |
Antigens, CD95/*pharmacology | 5 | 35.0 |
Membrane Proteins/genetics/*physiology | 3 | 5.0 |
*Proteins | 10 | 2.0 |
*Gene Expression Regulation, Viral | 5 | 1.0 |
HIV Long Terminal Repeat/*genetics | 2 | 2.0 |
Interleukin-1/biosynthesis | 94 | 49.0 |
Tumor Necrosis Factor-alpha/biosynthesis/*physiology | 11 | 100.0 |
Enterotoxins/*toxicity | 5 | 41.0 |
Ketamine/*pharmacology | 2 | 40.0 |
Stereoisomerism | 7 | 1.0 |
Alternative Splicing | 5 | 0.0 |
Nerve Growth Factors/*metabolism | 2 | 2.0 |
Receptors, Nerve Growth Factor/genetics/*metabolism | 2 | 12.0 |
*Coronary Artery Bypass | 7 | 9.0 |
Osteosarcoma | 5 | 5.0 |
Cytotoxicity, Immunologic/physiology | 2 | 40.0 |
Interleukin-2/*biosynthesis/immunology | 2 | 28.0 |
Lymphocytes/immunology/metabolism | 3 | 9.0 |
Phorbol Esters/pharmacology | 10 | 8.0 |
*Space Flight | 2 | 6.0 |
Tumor Necrosis Factor-alpha/*biosynthesis/immunology | 11 | 84.0 |
Weight Loss | 12 | 8.0 |
ADP-ribosyl Cyclase | 2 | 0.0 |
Antigens, CD34/analysis | 2 | 0.0 |
Antigens, Differentiation/analysis | 10 | 3.0 |
Fetal Blood/cytology | 5 | 2.0 |
Hematopoietic Stem Cell Transplantation | 2 | 1.0 |
Mice, SCID | 22 | 2.0 |
Receptors, Tumor Necrosis Factor/*metabolism/*physiology | 2 | 100.0 |
Adenoviridae/*physiology | 2 | 10.0 |
Adenovirus E3 Proteins/*physiology | 3 | 75.0 |
Estradiol/blood | 5 | 0.0 |
Monocytes/drug effects/*immunology | 17 | 24.0 |
Progesterone/blood | 2 | 0.0 |
Cytokines/*blood/metabolism | 3 | 50.0 |
Immunity, Natural | 12 | 5.0 |
Mycobacterium tuberculosis/*immunology | 8 | 12.0 |
Tuberculosis/*immunology | 6 | 20.0 |
*Cytokines | 6 | 15.0 |
Tumor Necrosis Factor-alpha/*pharmacology/therapeutic use | 11 | 100.0 |
Mitochondria/drug effects/*metabolism | 2 | 12.0 |
*Necrosis | 5 | 33.0 |
Receptors, Tumor Necrosis Factor/drug effects/*metabolism | 4 | 80.0 |
Serine Proteinase Inhibitors/pharmacology | 5 | 10.0 |
Tumor Cells, Cultured/cytology/drug effects/metabolism | 3 | 11.0 |
Receptors, Interleukin-6/*metabolism | 3 | 20.0 |
Antibody Affinity | 5 | 2.0 |
Binding Sites, Antibody | 5 | 1.0 |
Neutralization Tests | 39 | 8.0 |
Parathyroid Hormone-Related Protein | 9 | 10.0 |
Tumor Markers, Biological/*blood | 7 | 1.0 |
Interleukin-2/genetics | 7 | 8.0 |
Metalloendopeptidases/genetics | 2 | 7.0 |
Receptors, Interleukin-2/genetics | 2 | 5.0 |
Blood/*metabolism | 2 | 11.0 |
Vitreoretinopathy, Proliferative/*metabolism | 2 | 40.0 |
Vitreous Body/*metabolism | 2 | 6.0 |
Glycoproteins/*metabolism | 10 | 5.0 |
Macrophage Colony-Stimulating Factor/metabolism | 2 | 20.0 |
Osteoclasts/*metabolism | 2 | 15.0 |
Osteolysis/*metabolism | 2 | 66.0 |
Receptors, Cytoplasmic and Nuclear/*metabolism | 4 | 2.0 |
Chromatography, Thin Layer | 2 | 1.0 |
Dose-Response Relationship, Immunologic | 38 | 7.0 |
Endotoxins/*antagonists & inhibitors | 7 | 58.0 |
Macrophages/drug effects/immunology | 7 | 43.0 |
Magnetic Resonance Spectroscopy | 5 | 0.0 |
Monocytes/*drug effects/immunology | 14 | 35.0 |
Antibodies, Antineutrophil Cytoplasmic/*immunology | 3 | 10.0 |
Autoantigens/immunology | 4 | 2.0 |
Autoimmune Diseases/*immunology | 7 | 4.0 |
Immunoglobulin G/immunology | 12 | 3.0 |
N-Formylmethionine Leucyl-Phenylalanine/pharmacology | 47 | 18.0 |
Neutrophils/drug effects/*immunology | 6 | 20.0 |
Peroxidase/immunology | 3 | 8.0 |
Pertussis Toxin | 10 | 6.0 |
Receptors, IgG/*immunology | 3 | 9.0 |
Serine Endopeptidases/immunology | 2 | 9.0 |
*Signal Transduction/drug effects | 12 | 12.0 |
Virulence Factors, Bordetella/pharmacology | 11 | 5.0 |
Infant, Low Birth Weight | 2 | 7.0 |
Cytokines/genetics/metabolism | 9 | 29.0 |
Data Collection | 2 | 2.0 |
Epidemiology, Molecular | 3 | 3.0 |
Hypothalamo-Hypophyseal System/physiology | 2 | 6.0 |
Pituitary-Adrenal System/physiology | 2 | 11.0 |
*Extracellular Matrix Proteins | 2 | 1.0 |
Metalloendopeptidases/*physiology | 3 | 33.0 |
Proteoglycans/metabolism | 3 | 3.0 |
Antibodies, Monoclonal/*immunology | 15 | 2.0 |
Binding, Competitive | 44 | 2.0 |
Epitopes/analysis | 2 | 0.0 |
Tumor Necrosis Factor-alpha/*immunology/metabolism | 15 | 78.0 |
Aminosalicylic Acids/pharmacology | 2 | 40.0 |
Antigens, CD95/genetics/metabolism | 2 | 28.0 |
Caspases/antagonists & inhibitors/biosynthesis/genetics | 2 | 66.0 |
Endothelium, Vascular/*drug effects/metabolism | 14 | 24.0 |
Interferon Type II | 6 | 33.0 |
Carrier Proteins/*biosynthesis/*genetics | 3 | 12.0 |
DNA Primers/genetics | 25 | 1.0 |
RNA, Neoplasm/genetics/metabolism | 2 | 1.0 |
Interleukin-15/*blood | 2 | 40.0 |
Lupus Erythematosus, Systemic/*immunology | 3 | 2.0 |
Homeostasis | 15 | 3.0 |
Lymphoid Tissue/metabolism | 3 | 11.0 |
Mice, Inbred A | 2 | 3.0 |
RNA, Messenger/chemistry/genetics/metabolism | 2 | 25.0 |
Receptors, Tumor Necrosis Factor/chemistry/genetics/*metabolism | 5 | 55.0 |
Collagen/metabolism | 9 | 3.0 |
Cyclic AMP/metabolism | 21 | 3.0 |
Cyclic AMP-Dependent Protein Kinases/antagonists & inhibitors/metabolism | 3 | 12.0 |
Cyclic GMP/metabolism | 4 | 4.0 |
Dinoprostone/*metabolism | 12 | 31.0 |
Fibroblasts/*drug effects/*metabolism | 2 | 33.0 |
Gels | 2 | 2.0 |
Interferon-gamma, Recombinant/pharmacology | 37 | 24.0 |
Lung/cytology/drug effects/metabolism | 2 | 25.0 |
Nitric Oxide/*metabolism | 14 | 11.0 |
Nitric Oxide Donors/pharmacology | 5 | 9.0 |
omega-N-Methylarginine/pharmacology | 5 | 11.0 |
*Chemokines, CC | 6 | 8.0 |
RANTES/secretion | 2 | 25.0 |
Acetylcysteine/*pharmacology | 4 | 18.0 |
Cell Nucleus/drug effects/metabolism | 6 | 11.0 |
DNA/genetics/metabolism | 9 | 2.0 |
Glutathione/*pharmacology | 3 | 27.0 |
Interleukin-8/genetics | 10 | 19.0 |
Active Transport, Cell Nucleus | 11 | 4.0 |
Interleukin-5/metabolism | 2 | 11.0 |
Mast Cells/metabolism | 2 | 7.0 |
Trypan Blue/pharmacology | 2 | 12.0 |
Amino Acids/chemistry | 2 | 1.0 |
Eosinophils/metabolism | 2 | 7.0 |
Granulocytes/metabolism | 5 | 13.0 |
Inhibitory Concentration 50 | 3 | 1.0 |
Interleukin-3/pharmacology | 14 | 5.0 |
Polyethylene Glycols/pharmacology | 3 | 6.0 |
Receptors, Interleukin/metabolism | 5 | 8.0 |
Scattering, Radiation | 2 | 1.0 |
Protein Synthesis Inhibitors/*pharmacology | 3 | 9.0 |
*Ribonucleases | 7 | 3.0 |
Down-Regulation/*drug effects | 4 | 7.0 |
Growth Inhibitors/*pharmacology | 9 | 4.0 |
Interferon-alpha/*pharmacology | 11 | 8.0 |
Interleukin-10/*pharmacology | 21 | 22.0 |
Interleukin-4/*pharmacology | 31 | 13.0 |
Leukocytes, Mononuclear/cytology/drug effects/*metabolism | 2 | 66.0 |
Acute-Phase Reaction | 3 | 6.0 |
Immunosuppressive Agents/adverse effects/*therapeutic use | 6 | 33.0 |
Thalidomide/adverse effects/*therapeutic use | 3 | 50.0 |
*Plant Preparations | 3 | 37.0 |
*Plant Proteins | 4 | 6.0 |
Recombinant Proteins/chemistry/pharmacology | 2 | 8.0 |
Cardiotonic Agents/*pharmacology | 2 | 12.0 |
Heart Failure, Congestive/*blood/drug therapy | 4 | 50.0 |
Quinolines/*pharmacology | 2 | 6.0 |
Receptors, Cytokine/*blood | 5 | 35.0 |
Complement 2/genetics | 2 | 4.0 |
Complement 4/genetics | 2 | 3.0 |
*Major Histocompatibility Complex | 13 | 4.0 |
Inflammation/etiology/immunology | 3 | 100.0 |
Osteoblasts/metabolism | 2 | 3.0 |
Trans-Activators/*metabolism | 5 | 0.0 |
Phosphodiesterase Inhibitors/*pharmacology | 15 | 30.0 |
Transcription, Genetic/*drug effects | 30 | 9.0 |
Intestinal Mucosa/metabolism | 5 | 4.0 |
Epinephrine/*metabolism | 2 | 22.0 |
Antilymphocyte Serum/*therapeutic use | 2 | 6.0 |
Calcitonin/*blood | 3 | 4.0 |
Protein Precursors/*blood | 3 | 4.0 |
Enzyme Induction | 28 | 4.0 |
Immunity/*physiology | 2 | 9.0 |
Cytokines/immunology/*physiology | 2 | 33.0 |
Immune System/*physiology | 5 | 7.0 |
Immunosuppression | 6 | 3.0 |
Stress, Psychological/immunology | 2 | 50.0 |
Antigens, Surface/*immunology | 7 | 4.0 |
Hela Cells/drug effects | 6 | 21.0 |
Immunoglobulins, Fab | 2 | 3.0 |
Signal Transduction/*drug effects/physiology | 3 | 5.0 |
Tumor Necrosis Factor-alpha/chemistry/*pharmacology | 2 | 100.0 |
Bacterial Outer Membrane Proteins/pharmacology | 2 | 50.0 |
Inflammation Mediators/metabolism | 18 | 24.0 |
Macrophages, Peritoneal/drug effects | 3 | 100.0 |
Cell Adhesion | 91 | 6.0 |
Cell Communication/drug effects | 7 | 18.0 |
Chemotaxis, Leukocyte | 21 | 11.0 |
Endothelial Growth Factors/pharmacology | 2 | 1.0 |
Endothelium, Vascular/*cytology/drug effects | 7 | 16.0 |
Lymphokines/pharmacology | 5 | 2.0 |
Umbilical Veins | 59 | 13.0 |
Adrenal Cortex Hormones/therapeutic use | 4 | 5.0 |
Biological Markers/analysis/blood | 6 | 19.0 |
Intercellular Adhesion Molecule-1/*analysis | 3 | 15.0 |
Antigens, CD95/*analysis | 3 | 14.0 |
Convalescence | 5 | 15.0 |
Immune Sera/*pharmacology | 2 | 16.0 |
Mucocutaneous Lymph Node Syndrome/*immunology | 4 | 33.0 |
Umbilical Veins/immunology | 2 | 33.0 |
Calorimetry | 2 | 3.0 |
Escherichia coli/metabolism | 6 | 2.0 |
Leukocytes, Mononuclear/metabolism | 34 | 16.0 |
Lipopolysaccharides/*chemistry | 2 | 18.0 |
Spectroscopy, Fourier Transform Infrared | 2 | 4.0 |
Temperature | 22 | 2.0 |
Tumor Necrosis Factor-alpha/chemistry | 3 | 60.0 |
X-Ray Diffraction | 3 | 3.0 |
Collagenases/analysis | 2 | 22.0 |
Dyes/diagnostic use | 3 | 3.0 |
Epithelial Cells/pathology | 2 | 2.0 |
*Inflammation | 6 | 17.0 |
Drug Delivery Systems/*methods | 2 | 5.0 |
Electroporation | 3 | 5.0 |
Osteoarthritis/*metabolism | 4 | 20.0 |
Synovial Fluid/*chemistry | 5 | 21.0 |
Trans-Activators/physiology | 2 | 1.0 |
Epidermal Growth Factor/*metabolism/pharmacology | 2 | 3.0 |
Interferon Type II/metabolism/pharmacology | 5 | 35.0 |
Interleukin-1/metabolism/pharmacology | 7 | 50.0 |
Proteins/*physiology | 12 | 6.0 |
Carrier Proteins/*genetics/metabolism | 4 | 1.0 |
DNA Repair | 2 | 0.0 |
Databases, Factual | 3 | 1.0 |
Multigene Family/*genetics | 4 | 2.0 |
Area Under Curve | 4 | 0.0 |
*Body Weight | 2 | 3.0 |
Breath Tests | 2 | 2.0 |
Glucose/*metabolism | 11 | 7.0 |
Leptin | 8 | 7.0 |
Obesity/*metabolism | 5 | 6.0 |
Tumor Necrosis Factor-alpha | 174 | 87.0 |
Lipoproteins/*blood | 5 | 0.0 |
Lipoproteins, LDL Cholesterol/*blood | 2 | 2.0 |
Triglycerides/*blood | 2 | 0.0 |
Glial Fibrillary Acidic Protein/metabolism | 3 | 1.0 |
Interleukin-1/*metabolism/pharmacology | 10 | 55.0 |
Interleukin-6/*metabolism/pharmacology | 6 | 33.0 |
Membrane Glycoproteins/*antagonists & inhibitors/physiology | 2 | 66.0 |
Receptors, Tumor Necrosis Factor/metabolism/*physiology | 6 | 75.0 |
Tretinoin/pharmacology | 13 | 4.0 |
Tumor Necrosis Factor-alpha/*antagonists & inhibitors/physiology | 14 | 77.0 |
Gene Expression/*drug effects | 18 | 8.0 |
Oligonucleotides, Antisense/*pharmacology | 4 | 4.0 |
Neoplasm Metastasis | 15 | 1.0 |
B-Lymphocytes/immunology | 18 | 2.0 |
Lung/immunology | 4 | 12.0 |
Lymphocyte Count | 12 | 1.0 |
Anti-HIV Agents/*therapeutic use | 7 | 1.0 |
CD8-Positive T-Lymphocytes/immunology | 11 | 2.0 |
Immune System/*drug effects | 2 | 8.0 |
Immunocompromised Host | 5 | 6.0 |
Immunologic Memory | 2 | 0.0 |
Mitogens/pharmacology | 15 | 5.0 |
Analgesics, Non-Narcotic/*pharmacology | 2 | 28.0 |
DNA Probes | 16 | 1.0 |
Gene Expression Regulation/*drug effects | 66 | 10.0 |
Hydrolysis | 14 | 1.0 |
Lung/cytology/*drug effects/metabolism | 3 | 42.0 |
Protein-Tyrosine Kinase/antagonists & inhibitors | 7 | 3.0 |
Quinones/*pharmacology | 2 | 6.0 |
Tumor Necrosis Factor-alpha/antagonists & inhibitors/pharmacology | 9 | 52.0 |
Antigens, CD27/immunology | 2 | 22.0 |
B-Lymphocytes/*immunology | 15 | 1.0 |
Cell Membrane/immunology | 11 | 4.0 |
Immunoglobulin G/biosynthesis | 6 | 3.0 |
Immunoglobulins/*biosynthesis | 2 | 4.0 |
Arthritis, Rheumatoid/*drug therapy/pathology | 2 | 33.0 |
Biological Products/*therapeutic use | 7 | 46.0 |
B-Lymphocytes/drug effects | 2 | 11.0 |
Dexamethasone/pharmacology/therapeutic use | 2 | 100.0 |
Drug Evaluation, Preclinical | 10 | 5.0 |
Interleukin-6/pharmacology | 32 | 11.0 |
Membrane Glycoproteins/administration & dosage/*pharmacology | 2 | 50.0 |
Multiple Myeloma/*drug therapy | 2 | 12.0 |
Transplantation, Heterologous | 22 | 2.0 |
Interleukin-2/metabolism | 13 | 8.0 |
Gastrointestinal Agents/therapeutic use | 3 | 33.0 |
Pentoxifylline/therapeutic use | 3 | 50.0 |
Binding Sites/genetics/immunology | 2 | 4.0 |
HIV Infections/*immunology/metabolism | 3 | 25.0 |
HIV-1/*immunology | 9 | 1.0 |
Prostaglandins/*metabolism | 2 | 15.0 |
Carrier Proteins/*physiology | 6 | 2.0 |
Mitochondria/physiology | 6 | 10.0 |
Antineoplastic Agents/*pharmacology/therapeutic use | 3 | 3.0 |
Ceramides/physiology | 3 | 42.0 |
MAP Kinase Signaling System/drug effects | 3 | 3.0 |
Mitochondria/drug effects | 2 | 12.0 |
Receptors, Tumor Necrosis Factor/drug effects/*physiology | 3 | 100.0 |
Bone Remodeling/*physiology | 2 | 8.0 |
Osteoblasts/physiology | 2 | 15.0 |
Cytoskeletal Proteins/*metabolism | 2 | 1.0 |
Extracellular Matrix Proteins/*metabolism | 3 | 4.0 |
Growth Substances/*metabolism | 4 | 2.0 |
Caspases/physiology | 7 | 12.0 |
Neoplasms/*therapy | 20 | 19.0 |
Antirheumatic Agents/adverse effects/therapeutic use | 3 | 60.0 |
Antigens, CD/genetics/*physiology | 2 | 5.0 |
Arthritis, Rheumatoid/*genetics | 8 | 10.0 |
Peru | 3 | 6.0 |
Cell Adhesion Molecules/physiology | 7 | 7.0 |
Cytotoxicity, Immunologic/*physiology | 5 | 35.0 |
Killer Cells, Natural/*immunology | 15 | 3.0 |
Lectins | 3 | 3.0 |
Lymphoma, Non-Hodgkin/pathology | 2 | 14.0 |
Receptors, Immunologic/physiology | 8 | 7.0 |
Dose-Response Relationship, Radiation | 8 | 2.0 |
Skin/immunology/*radiation effects | 2 | 28.0 |
Up-Regulation/radiation effects | 2 | 15.0 |
*Membranes, Artificial | 10 | 11.0 |
Renal Dialysis/*adverse effects | 8 | 5.0 |
DNA/genetics | 25 | 1.0 |
Guanine | 3 | 3.0 |
Inflammation/*metabolism | 15 | 26.0 |
Cisplatin/*pharmacology | 6 | 4.0 |
Glycoproteins/*pharmacology | 46 | 46.0 |
Plants/chemistry | 2 | 33.0 |
Chimeric Proteins/metabolism | 4 | 2.0 |
Anti-Ulcer Agents/*pharmacology | 2 | 9.0 |
Antigens, Bacterial/immunology | 10 | 9.0 |
Cell Wall/immunology | 4 | 21.0 |
Interleukin-18/*immunology | 2 | 40.0 |
Lipopolysaccharides/immunology | 33 | 27.0 |
Staphylococcus aureus/*immunology | 7 | 7.0 |
Staphylococcus epidermidis/*immunology | 2 | 66.0 |
Superantigens/immunology | 2 | 4.0 |
Antibodies, Monoclonal/administration & dosage/*therapeutic use | 2 | 14.0 |
Melanoma/*immunology | 5 | 5.0 |
Spleen/cytology | 6 | 3.0 |
Tumor Necrosis Factor-alpha/*immunology/pharmacology | 2 | 40.0 |
Antibodies, Monoclonal/immunology/therapeutic use | 4 | 20.0 |
Receptors, Tumor Necrosis Factor/immunology/therapeutic use | 2 | 50.0 |
Research Design | 4 | 4.0 |
Arachidonic Acid/metabolism | 17 | 17.0 |
Isoenzymes/*metabolism | 5 | 1.0 |
Leukotriene B4/*metabolism | 3 | 37.0 |
Phospholipases A/*metabolism | 10 | 22.0 |
Receptor Cross-Talk | 2 | 5.0 |
Interferon-beta/*pharmacology | 16 | 27.0 |
Leukocytes, Mononuclear/drug effects/*immunology | 16 | 50.0 |
Interleukin-10/biosynthesis | 18 | 15.0 |
Erythrocytes/immunology | 5 | 2.0 |
Hemolysis/*immunology | 2 | 15.0 |
Immunoglobulin M/blood | 4 | 3.0 |
L-Lactate Dehydrogenase/blood | 4 | 3.0 |
CD8-Positive T-Lymphocytes/cytology/immunology | 2 | 7.0 |
HIV Infections/*immunology/pathology | 2 | 6.0 |
Killer Cells, Natural/cytology/immunology | 2 | 11.0 |
Clinical Trials/methods | 2 | 28.0 |
Anti-Infective Agents/pharmacology | 2 | 11.0 |
Biocompatible Materials | 7 | 11.0 |
Blood Proteins/pharmacology | 2 | 4.0 |
Fibrosarcoma | 16 | 32.0 |
Fibrosis | 3 | 2.0 |
Glucuronic Acid | 4 | 21.0 |
Hexuronic Acids | 2 | 20.0 |
Lipid A/*analogs & derivatives/pharmacology | 7 | 36.0 |
Tumor Necrosis Factor-alpha/biosynthesis/*immunology | 4 | 57.0 |
Clone Cells | 20 | 1.0 |
Endotoxins/*metabolism | 7 | 31.0 |
Membrane Glycoproteins/genetics/*metabolism | 8 | 4.0 |
Receptors, Cell Surface/genetics/*metabolism | 3 | 2.0 |
Antigens, CD95/blood | 4 | 33.0 |
Linkage (Genetics) | 16 | 0.0 |
*Liver Transplantation | 9 | 6.0 |
Apoptosis/drug effects/*immunology | 2 | 5.0 |
Antigens, CD/*blood | 23 | 13.0 |
Calibration | 3 | 2.0 |
Continental Population Groups | 2 | 1.0 |
Flow Cytometry/methods | 5 | 1.0 |
Kidney Failure, Chronic/blood/*immunology/therapy | 2 | 50.0 |
*Peritoneal Dialysis, Continuous Ambulatory | 5 | 4.0 |
*Renal Dialysis | 14 | 3.0 |
Polymorphism, Single Nucleotide/*genetics | 7 | 2.0 |
Synovial Membrane/immunology | 5 | 16.0 |
Tumor Virus Infections/*complications | 2 | 7.0 |
Autoimmune Diseases/*genetics/immunology | 2 | 11.0 |
HLA-B8 Antigen/*genetics | 3 | 25.0 |
Interleukin-10/biosynthesis/blood | 3 | 37.0 |
Arthritis, Rheumatoid/therapy | 2 | 33.0 |
Immunoglobulins, Fc/genetics | 2 | 12.0 |
Plasmids | 34 | 2.0 |
Receptors, Tumor Necrosis Factor/*genetics/metabolism | 8 | 61.0 |
Serum Amyloid A Protein/*genetics | 2 | 5.0 |
Antigens, Differentiation, Myelomonocytic/*metabolism | 2 | 3.0 |
CD40 Ligand/*pharmacology | 2 | 28.0 |
Monocytes/drug effects/immunology | 4 | 10.0 |
Tuberculin/immunology | 8 | 14.0 |
Neutrophils/drug effects/*physiology | 24 | 36.0 |
Transcription, Genetic/physiology | 3 | 1.0 |
Signal Transduction/*drug effects | 18 | 4.0 |
Endothelium, Vascular/cytology/*physiology | 6 | 9.0 |
Sphingomyelin Phosphodiesterase/metabolism | 16 | 55.0 |
Forced Expiratory Volume/drug effects | 2 | 9.0 |
Inflammation/drug therapy | 4 | 28.0 |
Leukocyte Elastase/analysis | 4 | 22.0 |
Neutrophils/cytology | 5 | 11.0 |
Reproducibility of Results | 15 | 1.0 |
Respiratory Function Tests | 9 | 5.0 |
Amino Acid Substitution | 7 | 0.0 |
Consensus Sequence | 9 | 1.0 |
Ectodermal Dysplasia/*genetics | 2 | 13.0 |
Recombinant Proteins/chemistry/metabolism | 9 | 1.0 |
Aging/physiology | 3 | 1.0 |
DNA/metabolism | 28 | 1.0 |
Growth Hormone/pharmacology | 2 | 5.0 |
Mice, Knockout/genetics | 2 | 5.0 |
NF-kappa B/*antagonists & inhibitors/genetics/metabolism | 2 | 33.0 |
Protein Processing, Post-Translational | 15 | 1.0 |
Ceramides/*metabolism | 7 | 29.0 |
Mitochondria/*metabolism | 2 | 1.0 |
Immunoglobulin G/metabolism | 7 | 3.0 |
Neutrophil Activation/*drug effects | 8 | 36.0 |
Proteins/pharmacology | 4 | 6.0 |
Serine Proteinase Inhibitors/*pharmacology | 3 | 7.0 |
Antirheumatic Agents/*pharmacology/therapeutic use | 2 | 40.0 |
Biological Products/*administration & dosage | 3 | 75.0 |
Receptors, Tumor Necrosis Factor/*administration & dosage | 3 | 100.0 |
Second Messenger Systems | 11 | 11.0 |
Adenocarcinoma/*pathology | 4 | 5.0 |
Breast Neoplasms/*pathology | 3 | 1.0 |
Gene Expression Regulation, Neoplastic/*drug effects | 8 | 3.0 |
Lymph Nodes/cytology/metabolism | 3 | 30.0 |
Rats, Inbred F344 | 20 | 5.0 |
Spleen/cytology/metabolism | 3 | 16.0 |
Cell Adhesion/drug effects/*physiology | 3 | 9.0 |
Cells, Cultured/drug effects/secretion | 2 | 33.0 |
Chemotaxis, Leukocyte/drug effects/*physiology | 2 | 10.0 |
Cytokines/pharmacology/*physiology | 9 | 39.0 |
Extracellular Matrix/*metabolism | 2 | 2.0 |
Fibronectins/metabolism | 7 | 3.0 |
Gelatinase B/secretion | 2 | 50.0 |
Laminin/metabolism | 5 | 4.0 |
Microscopy, Video | 2 | 2.0 |
Antigens, CD14/analysis | 6 | 5.0 |
Epinephrine/blood | 6 | 4.0 |
Monocytes/chemistry/immunology/*metabolism | 2 | 66.0 |
Norepinephrine/blood | 10 | 5.0 |
Epithelial Cells/cytology/metabolism | 3 | 5.0 |
Gelatin/metabolism | 2 | 14.0 |
Permeability/drug effects | 2 | 8.0 |
Pulmonary Alveoli/cytology/*metabolism | 2 | 33.0 |
Eicosanoids/physiology | 3 | 60.0 |
Mitogen-Activated Protein Kinases/metabolism/*physiology | 3 | 15.0 |
Phosphates/metabolism | 3 | 3.0 |
Phosphatidylcholines/biosynthesis | 2 | 40.0 |
Phospholipases A/*physiology | 2 | 28.0 |
Immunoglobulin G/pharmacology | 6 | 10.0 |
Peptides/pharmacology | 6 | 3.0 |
CD40 Ligand/*metabolism | 2 | 14.0 |
Dendritic Cells/metabolism | 4 | 9.0 |
Osteoclasts/metabolism | 2 | 9.0 |
Epithelial Cells/immunology | 2 | 5.0 |
Inflammation/etiology | 8 | 21.0 |
Cell Division/*physiology | 6 | 3.0 |
Hypothalamo-Hypophyseal System/*drug effects | 3 | 15.0 |
Pituitary-Adrenal System/*drug effects | 5 | 31.0 |
Sialoglycoproteins/*blood | 8 | 53.0 |
Steroids/therapeutic use | 3 | 8.0 |
Tablets | 3 | 8.0 |
Interleukin-10/genetics/*secretion | 2 | 66.0 |
Protein Engineering/methods | 2 | 12.0 |
Tumor Necrosis Factor-alpha/genetics/*secretion | 7 | 100.0 |
Cytoplasm/immunology | 3 | 3.0 |
Signal Transduction/genetics | 2 | 0.0 |
Cachexia/*blood | 3 | 100.0 |
Gastrointestinal Neoplasms/*blood | 3 | 50.0 |
Growth Substances/blood | 2 | 15.0 |
Drugs, Chinese Herbal/pharmacology | 2 | 18.0 |
Interleukin-8/biosynthesis/genetics | 7 | 29.0 |
Monocytes/immunology | 38 | 10.0 |
Endometriosis/*metabolism | 4 | 13.0 |
Endometrium/*metabolism | 2 | 2.0 |
Paracrine Communication | 2 | 5.0 |
Stromal Cells/drug effects/metabolism | 4 | 23.0 |
Extracellular Matrix/physiology | 5 | 5.0 |
Osteoblasts/metabolism/*pathology | 2 | 22.0 |
Arthritis, Rheumatoid/*genetics/immunology/physiopathology | 2 | 66.0 |
Microsatellite Repeats/genetics | 10 | 2.0 |
*Antigens, Surface | 3 | 4.0 |
Drug Interactions/physiology | 2 | 6.0 |
Fetus | 13 | 2.0 |
Neuroprotective Agents/*pharmacology | 2 | 2.0 |
Neurotoxins/*toxicity | 3 | 33.0 |
Phosphopyruvate Hydratase/metabolism | 2 | 3.0 |
Arachidonate 5-Lipoxygenase/antagonists & inhibitors | 2 | 28.0 |
Bacterial Proteins | 3 | 9.0 |
Leukotriene B4/metabolism | 4 | 23.0 |
NF-kappa B/chemistry/*metabolism | 3 | 25.0 |
Phosphates/pharmacology | 2 | 18.0 |
Histocompatibility Antigens Class I/*genetics | 3 | 0.0 |
Zinc Fingers/*physiology | 2 | 9.0 |
Perfusion, Regional/*methods | 9 | 81.0 |
Sarcoma/*drug therapy/pathology | 2 | 50.0 |
Soft Tissue Neoplasms/*drug therapy/pathology | 2 | 66.0 |
Tumor Necrosis Factor-alpha/*therapeutic use | 54 | 93.0 |
Antineoplastic Agents/*therapeutic use | 20 | 5.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 14 | 2.0 |
Membrane Glycoproteins/*therapeutic use | 4 | 66.0 |
*Arabidopsis Proteins | 4 | 4.0 |
Cell Membrane/*metabolism | 5 | 1.0 |
Fatty Acid Desaturases/metabolism | 3 | 8.0 |
Ionomycin/pharmacology | 7 | 3.0 |
Ionophores/pharmacology | 8 | 5.0 |
Antigens, CD34/*analysis | 4 | 1.0 |
Antigens, Viral/immunology | 2 | 1.0 |
Cell Culture Techniques/*methods | 2 | 2.0 |
Isoantigens/immunology | 2 | 2.0 |
Cell Size/drug effects | 4 | 4.0 |
Cytosol/drug effects/enzymology/metabolism | 2 | 40.0 |
Fibroblasts | 14 | 2.0 |
Genes, Dominant/genetics | 2 | 1.0 |
Endotoxins/administration & dosage/*pharmacology | 3 | 60.0 |
L-Selectin/metabolism | 3 | 9.0 |
Leukocytes/drug effects/metabolism | 8 | 57.0 |
Lipopolysaccharides/administration & dosage/*pharmacology | 3 | 27.0 |
Isoxazoles/therapeutic use | 4 | 66.0 |
Complement 3a/metabolism | 2 | 12.0 |
Complement 5a/metabolism | 2 | 14.0 |
*Complement Activation | 6 | 1.0 |
Leukocyte Elastase/metabolism | 4 | 18.0 |
Immunotherapy/*methods | 10 | 7.0 |
Interleukin-6/analysis/blood | 3 | 60.0 |
Ligation | 4 | 5.0 |
Plasma/chemistry | 2 | 6.0 |
Tumor Necrosis Factor-alpha/analysis/metabolism | 11 | 61.0 |
Biological Assay/*methods | 6 | 14.0 |
Immunoglobulin G | 4 | 3.0 |
Tumor Necrosis Factor-alpha/*analysis/toxicity | 2 | 100.0 |
CD4 Lymphocyte Count | 22 | 0.0 |
Radiography, Thoracic | 3 | 8.0 |
Biopolymers | 6 | 5.0 |
Postoperative Period | 17 | 5.0 |
Epoprostenol/*biosynthesis | 3 | 12.0 |
Receptors, Interleukin-1 | 9 | 50.0 |
Recombinant Proteins/blood/immunology | 2 | 100.0 |
Protein Subunits | 6 | 1.0 |
Arthritis, Rheumatoid/*etiology | 3 | 42.0 |
*Genes, Tumor Suppressor | 2 | 0.0 |
NF-kappa B/biosynthesis/*metabolism | 2 | 28.0 |
*Tumor Suppressor Proteins | 3 | 0.0 |
Estrogen Receptor alpha | 2 | 0.0 |
Glycoproteins/analysis/*genetics | 2 | 28.0 |
Stromal Cells/*metabolism | 3 | 8.0 |
Cell Line/drug effects | 5 | 10.0 |
Glycolipids/*pharmacology | 4 | 57.0 |
Leukocytes, Mononuclear/*drug effects | 4 | 22.0 |
Cytokines/*analysis/genetics/immunology | 2 | 100.0 |
DNA, Complementary/genetics | 20 | 1.0 |
Intercellular Adhesion Molecule-1/genetics | 7 | 24.0 |
Interferon Type II/genetics | 13 | 17.0 |
Interleukin-6/genetics | 20 | 29.0 |
Receptors, Interleukin-4/genetics | 3 | 27.0 |
Up-Regulation/*physiology | 5 | 11.0 |
Antibodies/therapeutic use | 5 | 29.0 |
Drug Administration Routes | 3 | 15.0 |
Lymphocyte Activation/drug effects/immunology | 4 | 6.0 |
Recombinant Fusion Proteins/therapeutic use | 10 | 41.0 |
Apoptosis/*genetics/*physiology | 2 | 22.0 |
Binding Sites/genetics | 12 | 1.0 |
Cell Cycle/physiology | 3 | 0.0 |
Fluorescein-5-isothiocyanate | 4 | 2.0 |
Fluorescent Dyes | 12 | 3.0 |
Antibodies, Blocking/pharmacology | 3 | 3.0 |
Instillation, Drug | 2 | 33.0 |
Membrane Potentials/drug effects | 8 | 6.0 |
Patch-Clamp Techniques | 2 | 0.0 |
Pulmonary Alveoli/*drug effects/metabolism | 3 | 60.0 |
3',5'-Cyclic-Nucleotide Phosphodiesterase/antagonists & inhibitors | 4 | 50.0 |
Chloroquine/pharmacology | 3 | 3.0 |
Macrophages/drug effects/metabolism | 15 | 35.0 |
Plants, Medicinal | 3 | 6.0 |
Stromal Cells/cytology/metabolism | 2 | 11.0 |
Heart/*drug effects | 3 | 7.0 |
Nitric-Oxide Synthase/metabolism | 7 | 5.0 |
CD40 Ligand/metabolism | 7 | 28.0 |
Chemokines, CX3C/*biosynthesis | 2 | 100.0 |
Dermatitis, Atopic/immunology | 2 | 15.0 |
Endothelium, Vascular/drug effects/*immunology | 5 | 38.0 |
Interleukin-13/metabolism | 3 | 18.0 |
Membrane Proteins/*biosynthesis | 5 | 8.0 |
Psoriasis/immunology | 2 | 13.0 |
Receptors, Cytokine/metabolism | 5 | 5.0 |
Th1 Cells/*immunology | 16 | 11.0 |
Adjuvants, Immunologic/*pharmacology/therapeutic use | 2 | 14.0 |
Interleukin-8/pharmacology | 10 | 20.0 |
Macrophages, Alveolar/*drug effects/metabolism | 6 | 66.0 |
Fibroblasts/*physiology | 9 | 15.0 |
Glutathione Transferase/genetics | 2 | 0.0 |
Carboxylic Acids/pharmacology | 3 | 50.0 |
Ceramides/metabolism | 10 | 29.0 |
Daunorubicin/*pharmacology | 2 | 25.0 |
*Fumonisins | 6 | 40.0 |
Plasminogen Activator Inhibitor 1/*biosynthesis/genetics | 2 | 25.0 |
Umbilical Veins/drug effects/metabolism | 3 | 75.0 |
Clinical Trials, Phase III | 2 | 4.0 |
Biopsy, Needle | 11 | 2.0 |
Electrophoresis | 7 | 2.0 |
NF-kappa B/drug effects/metabolism | 6 | 25.0 |
Antibodies, Monoclonal/pharmacology/therapeutic use | 3 | 18.0 |
Interleukin-1/*genetics | 9 | 11.0 |
RANTES/*biosynthesis | 3 | 25.0 |
Interleukin-6/biosynthesis/genetics/*secretion | 2 | 66.0 |
Lymphotoxin/biosynthesis/genetics | 3 | 75.0 |
Osteoblasts/*metabolism | 4 | 7.0 |
RNA, Messenger/genetics/*metabolism | 4 | 3.0 |
CD4-CD8 Ratio | 8 | 1.0 |
Cytotoxicity Tests, Immunologic | 32 | 7.0 |
Interferon-alpha/therapeutic use | 2 | 5.0 |
Interleukin-2/immunology | 4 | 3.0 |
Killer Cells, Natural/immunology | 20 | 4.0 |
Receptors, Interleukin-2 | 4 | 3.0 |
Nitric-Oxide Synthase/antagonists & inhibitors/metabolism | 2 | 18.0 |
Antigens, CD14/*analysis | 2 | 4.0 |
Gastrectomy | 2 | 3.0 |
HLA-DR Antigens/*analysis | 2 | 1.0 |
Lipopolysaccharides/*immunology/pharmacology | 4 | 25.0 |
Catalysis | 4 | 0.0 |
Bacterial Proteins/biosynthesis | 2 | 15.0 |
Helicobacter pylori/*pathogenicity | 3 | 16.0 |
Tumor Necrosis Factor-alpha/*biosynthesis/physiology | 6 | 100.0 |
Melanoma | 5 | 5.0 |
Radiation Dosage | 3 | 3.0 |
Monocyte Chemoattractant Protein-1/*genetics | 2 | 10.0 |
Interleukin-4/genetics | 6 | 15.0 |
Receptors, CCR5/genetics | 2 | 3.0 |
Receptors, Chemokine/genetics | 4 | 8.0 |
Receptors, Tumor Necrosis Factor/*blood/physiology | 3 | 100.0 |
Lipids/metabolism | 9 | 2.0 |
Influenza/*complications | 2 | 100.0 |
Dietary Fats/*administration & dosage | 2 | 2.0 |
Adjuvants, Immunologic/therapeutic use | 7 | 15.0 |
Azathioprine/therapeutic use | 5 | 12.0 |
Immunoglobulins/administration & dosage | 2 | 28.0 |
Immunosuppressive Agents/administration & dosage/therapeutic use | 3 | 37.0 |
Kidney Transplantation | 4 | 3.0 |
Trimethoprim-Sulfamethoxazole Combination/therapeutic use | 2 | 5.0 |
*DNA Damage | 3 | 0.0 |
DNA, Single-Stranded/*drug effects | 2 | 28.0 |
Dietary Supplements | 2 | 2.0 |
Killer Cells, Natural/metabolism | 5 | 9.0 |
Adverse Drug Reaction Reporting Systems | 2 | 18.0 |
Antibodies, Monoclonal/adverse effects | 2 | 100.0 |
Immunosuppressive Agents/*adverse effects/therapeutic use | 4 | 30.0 |
Tuberculin Test | 3 | 5.0 |
JNK Mitogen-Activated Protein Kinases/metabolism | 4 | 25.0 |
Asian Continental Ancestry Group/genetics | 10 | 2.0 |
Korea | 9 | 4.0 |
Polymorphism, Single-Stranded Conformational | 8 | 0.0 |
Sequence Analysis, DNA | 20 | 0.0 |
Interleukin-10/analysis/blood | 2 | 100.0 |
Radioimmunoassay | 53 | 2.0 |
Biological Assay | 45 | 17.0 |
Growth Substances/pharmacology | 14 | 7.0 |
Malaria, Falciparum/*immunology | 4 | 26.0 |
Th2 Cells/*immunology | 13 | 10.0 |
Age Distribution | 4 | 1.0 |
Sex Factors | 7 | 0.0 |
Europe | 3 | 1.0 |
Inflammatory Bowel Diseases/*drug therapy | 3 | 27.0 |
Histocompatibility | 2 | 1.0 |
Mutation, Missense | 2 | 0.0 |
Arthritis, Rheumatoid/immunology/physiopathology/*therapy | 2 | 50.0 |
Feasibility Studies | 7 | 3.0 |
*Hematopoietic Stem Cell Transplantation | 3 | 0.0 |
Questionnaires | 5 | 0.0 |
Safety | 3 | 2.0 |
Crohn Disease/*therapy | 4 | 80.0 |
Cell Death/*drug effects | 10 | 31.0 |
Genes, Viral | 8 | 3.0 |
Immediate-Early Proteins/*genetics | 3 | 4.0 |
*Models, Biological | 4 | 2.0 |
Chemokines/genetics/metabolism | 2 | 18.0 |
Membrane Glycoproteins/genetics/metabolism | 3 | 3.0 |
Bucladesine/pharmacology | 31 | 16.0 |
Enzyme Induction/drug effects | 23 | 6.0 |
Receptors, Tumor Necrosis Factor/analysis | 24 | 46.0 |
Second Messenger Systems/physiology | 4 | 10.0 |
Apoptosis/*drug effects/*physiology | 5 | 26.0 |
Colonic Neoplasms | 9 | 6.0 |
Liver Neoplasms/secondary | 2 | 3.0 |
RNA/analysis/genetics | 2 | 9.0 |
Cytokines/*therapeutic use | 5 | 27.0 |
Interleukin-2/therapeutic use | 8 | 20.0 |
Tumor Necrosis Factor-alpha/therapeutic use | 9 | 64.0 |
Antineoplastic Agents, Alkylating/therapeutic use | 2 | 8.0 |
Liver/*drug effects/metabolism | 3 | 6.0 |
Melphalan/therapeutic use | 2 | 11.0 |
Perfusion | 9 | 4.0 |
Cytokines/*administration & dosage | 4 | 80.0 |
Neck | 2 | 3.0 |
Receptors, Interleukin-1/antagonists & inhibitors | 25 | 49.0 |
Receptors, Tumor Necrosis Factor/administration & dosage | 5 | 71.0 |
Tumor Necrosis Factor-alpha/administration & dosage/antagonists & | 3 | 75.0 |
Antigens, CD40/genetics/*physiology | 5 | 50.0 |
Herpesvirus 4, Human/physiology | 2 | 6.0 |
Viral Matrix Proteins/*metabolism | 2 | 8.0 |
Cytokines/blood/physiology | 2 | 66.0 |
Interferon Type II/secretion | 9 | 8.0 |
Interleukin-10/secretion | 7 | 21.0 |
Interleukin-2/secretion | 5 | 6.0 |
Interleukin-4/secretion | 4 | 9.0 |
Psoriasis/*genetics | 5 | 8.0 |
Antigens, CD1/analysis | 2 | 2.0 |
Serum Albumin/pharmacology | 3 | 8.0 |
*CDC2-CDC28 Kinases | 3 | 0.0 |
Cyclin-Dependent Kinases/*antagonists & inhibitors | 2 | 1.0 |
Oxazoles/pharmacology | 3 | 7.0 |
Phosphoprotein Phosphatase/antagonists & inhibitors | 4 | 12.0 |
Protein-Serine-Threonine Kinases/*antagonists & inhibitors | 4 | 8.0 |
S Phase | 3 | 0.0 |
Echocardiography | 5 | 2.0 |
Heart/physiopathology | 3 | 8.0 |
Ethanol/*pharmacology | 5 | 4.0 |
Tumor Necrosis Factor-alpha/*drug effects/metabolism | 4 | 100.0 |
Cell Differentiation/immunology | 9 | 2.0 |
Cell Survival/drug effects/immunology | 2 | 11.0 |
Escherichia coli/immunology | 12 | 17.0 |
Interferon Type I/biosynthesis | 6 | 50.0 |
Monocytes/cytology/immunology | 2 | 5.0 |
Poly I-C/pharmacology | 6 | 25.0 |
1-Phosphatidylinositol 3-Kinase/*metabolism | 9 | 3.0 |
Insulin/*metabolism | 3 | 3.0 |
Phosphoric Monoester Hydrolases/*metabolism | 2 | 2.0 |
Phosphotransferases (Alcohol Group Acceptor)/*metabolism | 2 | 2.0 |
*Protein Kinases | 4 | 6.0 |
Serine/metabolism | 5 | 1.0 |
Growth Substances/metabolism | 8 | 6.0 |
Multiple Myeloma/*metabolism/pathology | 2 | 10.0 |
Tumor Necrosis Factor-alpha/*biosynthesis/metabolism | 5 | 62.0 |
Cytokines/blood/*physiology | 4 | 57.0 |
Acute-Phase Proteins/*analysis | 5 | 6.0 |
Ascorbic Acid/*pharmacology | 2 | 6.0 |
Hydrocortisone/*blood | 7 | 4.0 |
Placebos | 12 | 5.0 |
Running/*physiology | 4 | 10.0 |
Adenine Nucleotides/metabolism | 2 | 16.0 |
Cytokines/biosynthesis/*genetics | 5 | 29.0 |
Gene Expression Regulation, Neoplastic/physiology | 3 | 2.0 |
Dimerization | 14 | 0.0 |
Glycosylation | 13 | 1.0 |
Introns | 9 | 0.0 |
*Linkage (Genetics) | 8 | 0.0 |
Tumor Necrosis Factor-alpha/*chemistry | 5 | 100.0 |
Receptors, Tumor Necrosis Factor/chemistry/genetics/*physiology | 5 | 83.0 |
Serine | 2 | 2.0 |
Metalloendopeptidases/chemistry/*metabolism | 2 | 66.0 |
Carrier Proteins/genetics/physiology | 3 | 11.0 |
Macrophage Colony-Stimulating Factor/physiology | 2 | 25.0 |
Membrane Glycoproteins/genetics/physiology | 3 | 17.0 |
Osteoclasts/cytology/*physiology | 2 | 28.0 |
Biological Markers/*analysis | 4 | 3.0 |
Erythrocytes/pathology | 2 | 12.0 |
Infant, Premature | 5 | 4.0 |
Infection/*complications | 2 | 22.0 |
Active Transport, Cell Nucleus/drug effects | 2 | 5.0 |
Nitric-Oxide Synthase/*metabolism | 4 | 4.0 |
Protein Processing, Post-Translational/drug effects | 4 | 3.0 |
Nucleic Acid Synthesis Inhibitors/pharmacology | 6 | 5.0 |
RNA, Messenger/*blood | 2 | 5.0 |
Antigens, CD40/genetics/*metabolism | 2 | 40.0 |
Colonoscopy | 2 | 4.0 |
Interleukin-10/*physiology | 3 | 15.0 |
Interleukin-12/*physiology | 3 | 15.0 |
Receptor, IGF Type 1/*physiology | 3 | 25.0 |
Guinea Pigs | 28 | 3.0 |
Homeostasis/physiology | 3 | 5.0 |
Isoenzymes/*genetics | 2 | 0.0 |
Prostaglandin-Endoperoxide Synthase/*genetics | 2 | 7.0 |
Immunoglobulins/analysis | 5 | 2.0 |
Interleukin-10/analysis | 7 | 20.0 |
Lymphokines/analysis | 3 | 3.0 |
Transforming Growth Factor beta/analysis | 6 | 13.0 |
Leukocytes, Mononuclear/*physiology | 2 | 8.0 |
Antigens, CD/*biosynthesis/genetics | 4 | 6.0 |
Interleukin-1/*secretion | 23 | 69.0 |
Neoplasm Proteins/biosynthesis/genetics/*secretion | 2 | 100.0 |
Asthma/*metabolism | 3 | 13.0 |
Blood Proteins/*metabolism | 12 | 6.0 |
Eosinophil Granule Proteins | 6 | 2.0 |
Monocytes/*metabolism/physiology | 2 | 40.0 |
Antibody Formation/*immunology | 2 | 15.0 |
Membrane Proteins/*immunology | 4 | 6.0 |
Receptors, Tumor Necrosis Factor/genetics/*immunology | 4 | 57.0 |
Dermatologic Agents/*therapeutic use | 3 | 50.0 |
Apoptosis/drug effects/genetics | 2 | 5.0 |
Carboxylic Acids/*toxicity | 2 | 50.0 |
Mycotoxins/*toxicity | 2 | 25.0 |
Nerve Tissue Proteins/*metabolism | 2 | 0.0 |
Carcinogens/*pharmacology | 3 | 4.0 |
Interleukin-12/metabolism | 9 | 17.0 |
Cadaver | 3 | 1.0 |
Coronary Disease/diagnosis/*epidemiology/*genetics | 2 | 100.0 |
Coronary Vessels/pathology | 2 | 4.0 |
Drug Implants | 2 | 5.0 |
Granulocytes/cytology | 4 | 8.0 |
Lymphocyte Subsets/cytology | 2 | 11.0 |
Monocytes/cytology | 8 | 7.0 |
*Ovariectomy | 2 | 4.0 |
Bronchoalveolar Lavage Fluid/chemistry/cytology | 8 | 23.0 |
Forced Expiratory Volume/physiology | 4 | 10.0 |
Cerebrovascular Circulation/*physiology | 2 | 8.0 |
Adoptive Transfer | 3 | 3.0 |
Mice, Inbred AKR | 4 | 8.0 |
Mice, Inbred Strains | 34 | 3.0 |
Tumor Necrosis Factor-alpha/antagonists & inhibitors/immunology | 7 | 100.0 |
*Blood Bactericidal Activity | 3 | 6.0 |
Monocytes/*immunology/*microbiology | 4 | 80.0 |
Epithelial Cells/*drug effects | 2 | 15.0 |
Fluorescent Antibody Technique, Direct | 2 | 1.0 |
Intestines/*cytology | 2 | 12.0 |
Evaluation Studies | 13 | 1.0 |
Fibrinolysis/*drug effects | 4 | 6.0 |
Peritoneal Cavity/*cytology | 3 | 25.0 |
Plasminogen Activator Inhibitor 1/genetics | 2 | 6.0 |
Interleukin-15/metabolism | 2 | 50.0 |
Interleukins/metabolism | 10 | 31.0 |
Pregnancy Trimester, Second | 2 | 0.0 |
Transforming Growth Factor beta/metabolism | 7 | 3.0 |
Blood Coagulation | 6 | 3.0 |
Blood Coagulation Factors/physiology | 2 | 15.0 |
Phospholipids/blood | 2 | 1.0 |
Protein C/physiology | 3 | 11.0 |
Thromboplastin/physiology | 3 | 18.0 |
Biological Availability | 6 | 2.0 |
Drug Stability | 7 | 3.0 |
Monocytes/drug effects/metabolism | 21 | 24.0 |
Adrenergic beta-Antagonists/therapeutic use | 2 | 2.0 |
Angiotensin-Converting Enzyme Inhibitors/therapeutic use | 3 | 2.0 |
Creatine Kinase/blood | 3 | 2.0 |
Fetal Blood/metabolism | 3 | 4.0 |
Chemotaxis, Leukocyte/*drug effects | 8 | 12.0 |
Dendritic Cells/drug effects/immunology | 2 | 50.0 |
Fibronectins/*pharmacology | 2 | 11.0 |
HIV Infections/*immunology | 9 | 2.0 |
HLA-DR Antigens/immunology | 15 | 7.0 |
Tumor Necrosis Factor-alpha/biosynthesis/drug effects | 5 | 62.0 |
Monocytes/cytology/drug effects/*immunology | 2 | 12.0 |
Physical Endurance/*immunology | 2 | 50.0 |
Breast Neoplasms/*physiopathology | 2 | 9.0 |
Proto-Oncogene Proteins c-bcl-2/*biosynthesis | 2 | 1.0 |
Transforming Growth Factor beta/*metabolism | 2 | 0.0 |
Cholecalciferol/pharmacology | 4 | 12.0 |
Dendritic Cells/drug effects/*immunology/metabolism | 2 | 33.0 |
Leukocytes/immunology/metabolism | 2 | 18.0 |
Glucocorticoids/pharmacology | 13 | 10.0 |
Regulatory Sequences, Nucleic Acid/*genetics | 2 | 2.0 |
Prostatic Neoplasms/*drug therapy | 4 | 11.0 |
Lipid Peroxidation | 4 | 3.0 |
Lipoproteins, LDL/metabolism | 2 | 0.0 |
Oxidative Stress/*drug effects | 3 | 8.0 |
*Plants, Medicinal | 5 | 7.0 |
Cell Nucleus/chemistry | 2 | 1.0 |
Monocyte Chemoattractant Protein-1/blood | 5 | 38.0 |
Phosphoproteins/blood | 2 | 25.0 |
Plasminogen Activator Inhibitor 1/blood | 4 | 3.0 |
Endotoxemia/*immunology | 2 | 50.0 |
Endotoxins/administration & dosage | 5 | 100.0 |
Fever/chemically induced/*immunology | 2 | 100.0 |
Tumor Necrosis Factor-alpha/biosynthesis/pharmacology/*physiology | 2 | 66.0 |
Ammonium Chloride/pharmacology | 3 | 7.0 |
Cryptococcus neoformans/*immunology | 4 | 20.0 |
HIV Seropositivity/*immunology | 2 | 2.0 |
Hydrogen-Ion Concentration/drug effects | 2 | 28.0 |
*Macrolides | 2 | 5.0 |
Gene Therapy/*methods | 14 | 3.0 |
Carrier Proteins/chemistry | 2 | 5.0 |
Circular Dichroism | 7 | 1.0 |
Mutation/*genetics | 3 | 0.0 |
Exons/genetics | 4 | 0.0 |
Introns/genetics | 8 | 1.0 |
*Trans-Activation (Genetics)/drug effects | 3 | 7.0 |
Tumor Necrosis Factor-alpha/chemistry/*genetics | 4 | 100.0 |
Diabetes Mellitus, Type 1/genetics | 4 | 11.0 |
Receptors, Estrogen/genetics | 2 | 3.0 |
Receptors, Interferon/genetics | 2 | 12.0 |
Myocardial Infarction/*blood | 2 | 3.0 |
Cell Culture Techniques/methods | 5 | 2.0 |
Cytokines/biosynthesis/*immunology | 4 | 36.0 |
Membrane Glycoproteins/pharmacology/*physiology | 2 | 28.0 |
Signal Transduction/drug effects/*physiology | 8 | 3.0 |
Antigens, CD/biosynthesis/genetics/*physiology | 2 | 28.0 |
Cell Survival/physiology | 3 | 1.0 |
Receptors, Tumor Necrosis Factor/biosynthesis/genetics/*physiology | 2 | 33.0 |
Transduction, Genetic | 8 | 2.0 |
Tumor Necrosis Factor-alpha/deficiency/*physiology | 2 | 100.0 |
Fibroblasts/cytology | 9 | 4.0 |
Interferon Type II/biosynthesis/*immunology | 2 | 33.0 |
Interferon-alpha/biosynthesis | 2 | 8.0 |
Interleukin-2/biosynthesis | 32 | 7.0 |
Plaque Assay | 2 | 2.0 |
Prednisolone/therapeutic use | 4 | 4.0 |
Interferon Type II/*administration & dosage | 5 | 35.0 |
Monocytes/physiology | 13 | 11.0 |
B-Lymphocytes/metabolism | 4 | 2.0 |
Carrier Proteins/biosynthesis/*genetics | 2 | 4.0 |
Leukemia, Monocytic, Acute/pathology | 2 | 25.0 |
Mitogen-Activated Protein Kinase 8 | 4 | 5.0 |
Neoplasm Proteins/genetics/metabolism | 2 | 1.0 |
Protein-Serine-Threonine Kinases/antagonists & inhibitors | 3 | 3.0 |
Proteins/genetics | 9 | 1.0 |
RNA, Messenger/*biosynthesis/genetics | 3 | 5.0 |
Immunoglobulin G/adverse effects/*therapeutic use | 6 | 85.0 |
Tumor Necrosis Factor-alpha/antagonists & inhibitors/*metabolism | 13 | 92.0 |
Ventricular Function, Left/drug effects | 3 | 14.0 |
Arthritis, Rheumatoid/*immunology/metabolism | 3 | 33.0 |
Cartilage, Articular/cytology | 2 | 20.0 |
Chondrocytes/metabolism | 3 | 7.0 |
Synovial Membrane/cytology/metabolism | 3 | 33.0 |
Cyclosporine/pharmacology | 11 | 5.0 |
Pentoxifylline/pharmacology | 15 | 57.0 |
*Tobacco Smoke Pollution | 2 | 18.0 |
*Proto-Oncogene Proteins | 6 | 0.0 |
Antigens, CD95/immunology/*physiology | 3 | 25.0 |
DNA-Binding Proteins/drug effects/metabolism | 2 | 7.0 |
Adipose Tissue/metabolism | 6 | 4.0 |
Fibrinolysis/*physiology | 3 | 3.0 |
Obesity/*physiopathology | 3 | 5.0 |
Major Histocompatibility Complex/physiology | 2 | 12.0 |
Neurotoxins/pharmacology | 2 | 9.0 |
Neuropeptides/*pharmacology | 2 | 3.0 |
Substance P/pharmacology | 3 | 9.0 |
T-Lymphocytes, Helper-Inducer/*drug effects | 2 | 28.0 |
Cachexia/*physiopathology | 3 | 60.0 |
Leukocytes, Mononuclear/immunology/metabolism | 5 | 12.0 |
Matched-Pair Analysis | 4 | 4.0 |
Pulmonary Alveoli | 3 | 37.0 |
Antigens, CD/biosynthesis/*physiology | 7 | 24.0 |
Antigens, CD3/metabolism | 3 | 1.0 |
Carrier Proteins/biosynthesis | 2 | 3.0 |
Receptors, Tumor Necrosis Factor/biosynthesis/*physiology | 9 | 100.0 |
T-Lymphocytes/cytology/*drug effects | 4 | 26.0 |
Antigens, CD4/genetics | 2 | 3.0 |
Ethnic Groups/genetics | 2 | 1.0 |
Antigens, CD95/*blood | 4 | 23.0 |
Blood Gas Analysis | 2 | 5.0 |
Spirometry | 3 | 9.0 |
Tumor Necrosis Factor-alpha/*metabolism/physiology | 3 | 60.0 |
Cachexia/etiology | 5 | 55.0 |
Coronary Disease/complications | 2 | 14.0 |
Hypertension/complications | 2 | 3.0 |
*Chemotaxis, Leukocyte | 6 | 8.0 |
Cytokines/*analysis/genetics | 2 | 25.0 |
DNA, Complementary/analysis | 3 | 1.0 |
Neutrophils/*immunology | 19 | 10.0 |
Macrophages/*microbiology | 3 | 10.0 |
Receptors, Cell Surface/physiology | 16 | 13.0 |
Genetic Vectors/genetics | 5 | 2.0 |
Interleukin-1/analysis/biosynthesis | 4 | 100.0 |
Nitric Oxide/*physiology | 6 | 8.0 |
RNA Stability/drug effects | 2 | 14.0 |
Monocytes/*drug effects/immunology/metabolism | 3 | 30.0 |
Platelet Membrane Glycoproteins/metabolism | 3 | 3.0 |
DNA, Recombinant | 6 | 3.0 |
Protein Binding/drug effects | 12 | 3.0 |
Anti-Inflammatory Agents/pharmacology | 16 | 28.0 |
Calcitriol/pharmacology | 7 | 6.0 |
Calcium/blood | 7 | 3.0 |
Chickens | 7 | 0.0 |
Neoplasms/*pathology | 6 | 11.0 |
Tumor Cells, Cultured/drug effects/secretion | 3 | 25.0 |
Epithelium/drug effects/metabolism | 5 | 9.0 |
Isoenzymes/*biosynthesis | 3 | 4.0 |
Promoter Regions (Genetics)/physiology | 3 | 1.0 |
Prostaglandin-Endoperoxide Synthase/*biosynthesis | 4 | 9.0 |
Pulmonary Alveoli/cytology | 7 | 31.0 |
Sphingosine/*analogs & derivatives/pharmacology | 3 | 10.0 |
Cell Compartmentation | 4 | 1.0 |
Endothelium, Vascular/*drug effects | 10 | 18.0 |
Tumor Necrosis Factor-alpha/immunology/*pharmacology | 12 | 63.0 |
Dust/adverse effects | 3 | 37.0 |
Osteoarthritis/metabolism/pathology | 2 | 15.0 |
Altruism | 2 | 6.0 |
Tumor Necrosis Factor-alpha/antagonists & inhibitors/*immunology | 5 | 83.0 |
Glycoproteins/*physiology | 17 | 28.0 |
Receptors, Cytoplasmic and Nuclear/*physiology | 2 | 3.0 |
Down-Regulation/immunology | 4 | 4.0 |
Endotoxins/immunology | 3 | 37.0 |
Immune Tolerance/immunology | 4 | 8.0 |
Shock, Septic/*immunology | 4 | 28.0 |
Tumor Necrosis Factor-alpha/immunology/*metabolism | 12 | 80.0 |
Transcription, Genetic/genetics | 5 | 1.0 |
p38 Mitogen-Activated Protein Kinases/*metabolism | 2 | 10.0 |
Crohn Disease/*blood | 2 | 10.0 |
Heptanoic Acids/*pharmacology | 2 | 9.0 |
Hydroxymethylglutaryl-CoA Reductase Inhibitors/*pharmacology | 4 | 6.0 |
Pyrroles/*pharmacology | 2 | 4.0 |
Anesthetics, Inhalation/*pharmacology | 3 | 21.0 |
Isoflurane/*pharmacology | 2 | 33.0 |
MAP Kinase Kinase 3 | 2 | 10.0 |
Antigens, CD/*biosynthesis | 5 | 2.0 |
Antimetabolites, Antineoplastic/pharmacology | 2 | 2.0 |
CpG Islands | 2 | 0.0 |
Melanoma/drug therapy | 3 | 25.0 |
Mice, Inbred DBA | 21 | 6.0 |
Inflammation Mediators/analysis/metabolism | 2 | 100.0 |
Tumor Necrosis Factor-alpha/antagonists & inhibitors/metabolism | 6 | 60.0 |
Lymphocyte Function-Associated Antigen-1/physiology | 2 | 4.0 |
Mitochondria/pathology | 2 | 15.0 |
Tumor Necrosis Factor-alpha/*antagonists & inhibitors/*metabolism | 3 | 100.0 |
Keratinocytes/*metabolism | 6 | 6.0 |
Monocyte Chemoattractant Protein-1/biosynthesis | 3 | 12.0 |
*Infant, Premature | 3 | 5.0 |
Pregnancy Complications, Infectious/*diagnosis | 2 | 50.0 |
Drug Resistance/physiology | 3 | 12.0 |
Ribavirin/*pharmacology | 2 | 28.0 |
Autoantibodies/*biosynthesis | 2 | 3.0 |
Cisplatin/administration & dosage | 3 | 1.0 |
Cyclophosphamide/administration & dosage | 7 | 3.0 |
Fluorouracil/administration & dosage | 2 | 1.0 |
Interleukins/*immunology | 2 | 28.0 |
Killer Cells, Natural/*drug effects/immunology | 3 | 11.0 |
Macrophages/*drug effects/immunology | 3 | 33.0 |
Paclitaxel/administration & dosage | 2 | 7.0 |
Interferon-beta/pharmacology | 9 | 20.0 |
Lipoproteins, LDL/*metabolism | 4 | 2.0 |
Blood Proteins/metabolism | 5 | 2.0 |
Cachexia/etiology/*metabolism | 2 | 40.0 |
Muscle Proteins/*metabolism | 4 | 9.0 |
Neoplasms/complications/*metabolism | 2 | 50.0 |
Fibrin/*metabolism | 3 | 7.0 |
*Neovascularization, Physiologic | 2 | 1.0 |
Protein Kinases/metabolism | 25 | 5.0 |
Receptors, Cell Surface/biosynthesis | 3 | 8.0 |
Autoimmune Diseases/*genetics | 6 | 14.0 |
Lupus Erythematosus, Systemic/*genetics/immunology | 4 | 8.0 |
Polymorphism, Genetic/*immunology | 5 | 15.0 |
Organ Specificity/genetics/immunology | 2 | 5.0 |
Transcription, Genetic/*immunology | 3 | 9.0 |
Depression, Chemical | 21 | 10.0 |
Interleukin-10/*biosynthesis/genetics | 4 | 36.0 |
Lymphocytes/*drug effects/metabolism | 5 | 16.0 |
Sirolimus/*pharmacology | 2 | 6.0 |
Tacrolimus/pharmacology | 3 | 6.0 |
Teichoic Acids/pharmacology | 4 | 30.0 |
Carcinoma, Squamous Cell/*pathology | 3 | 3.0 |
Monocytes/cytology/drug effects/*secretion | 2 | 100.0 |
HIV Seronegativity | 3 | 2.0 |
Fetal Blood/*cytology | 6 | 3.0 |
Interferon Type II/biosynthesis/genetics | 2 | 5.0 |
Interleukin-2/biosynthesis/genetics | 2 | 5.0 |
Leukocytes/*metabolism | 12 | 12.0 |
Monocytes/secretion | 3 | 50.0 |
Receptors, Interleukin-2/biosynthesis/genetics | 2 | 20.0 |
*Antigens, Bacterial | 4 | 7.0 |
Colony Count, Microbial | 8 | 10.0 |
Monocytes/*microbiology | 3 | 11.0 |
Bronchi/cytology/metabolism | 2 | 13.0 |
Buthionine Sulfoximine/pharmacology | 4 | 11.0 |
RANTES/*metabolism | 3 | 21.0 |
Cytokines/*biosynthesis/genetics | 26 | 36.0 |
Interleukin-5/blood | 3 | 37.0 |
Pancreatic Neoplasms/*genetics/metabolism/pathology | 2 | 10.0 |
Tumor Necrosis Factor-alpha/*genetics/metabolism/pharmacology | 3 | 60.0 |
Family | 4 | 1.0 |
Genetic Markers/immunology | 2 | 10.0 |
Haplotypes/*immunology | 2 | 8.0 |
Histocompatibility Antigens Class I/genetics | 5 | 5.0 |
Linkage Disequilibrium/immunology | 2 | 33.0 |
Promoter Regions (Genetics)/immunology | 4 | 5.0 |
Histocompatibility Antigens Class I/genetics/*metabolism | 2 | 6.0 |
Maternal-Fetal Exchange/immunology | 3 | 18.0 |
Recombinant Proteins/genetics/metabolism | 5 | 0.0 |
Adjuvants, Immunologic/metabolism | 2 | 20.0 |
Electrophoresis, Agar Gel | 9 | 1.0 |
*Escherichia coli | 16 | 47.0 |
Superoxide Dismutase/*biosynthesis/genetics | 4 | 22.0 |
Blood Flow Velocity/physiology | 2 | 8.0 |
Inflammation Mediators/*blood | 10 | 21.0 |
Cyclosporine/*pharmacology | 6 | 5.0 |
E-Selectin/*metabolism | 3 | 25.0 |
Endothelium, Vascular/cytology/metabolism/*physiology | 2 | 33.0 |
*Postoperative Complications | 3 | 4.0 |
Tumor Necrosis Factor-alpha/analysis/*genetics | 11 | 78.0 |
Receptors, Vascular Endothelial Growth Factor | 2 | 0.0 |
*Mitogen-Activated Protein Kinases | 50 | 14.0 |
Sodium Salicylate/*pharmacology | 5 | 38.0 |
Immunoradiometric Assay | 6 | 5.0 |
Transplantation Immunology | 4 | 6.0 |
Liver/cytology/*metabolism | 2 | 2.0 |
Protein Biosynthesis/*drug effects | 4 | 12.0 |
Reverse Transcriptase Inhibitors/*therapeutic use | 2 | 1.0 |
Central Nervous System/immunology | 2 | 14.0 |
Injections, Intraventricular | 9 | 6.0 |
Sheep | 14 | 2.0 |
Breast/*metabolism | 2 | 3.0 |
Proteins/genetics/physiology | 2 | 3.0 |
Cesarean Section | 4 | 6.0 |
*Body Temperature | 2 | 7.0 |
Heat-Shock Proteins/metabolism | 6 | 10.0 |
Chemotaxis, Leukocyte/immunology | 3 | 5.0 |
Injections, Intradermal | 3 | 6.0 |
Interleukin-1/administration & dosage | 3 | 33.0 |
Receptors, Chemokine/metabolism | 2 | 1.0 |
Skin/immunology/metabolism | 2 | 18.0 |
Cytokines/genetics/immunology | 2 | 33.0 |
Gelatinase B/metabolism | 4 | 7.0 |
Metalloendopeptidases/metabolism | 6 | 9.0 |
Tumor Necrosis Factor-alpha/*genetics/immunology | 8 | 66.0 |
Aspirin/*pharmacology | 5 | 11.0 |
Cyclooxygenase Inhibitors/*pharmacology | 4 | 11.0 |
Prostaglandins/metabolism | 2 | 11.0 |
Antigens, CD14 | 22 | 7.0 |
Macrophages, Alveolar/immunology/metabolism | 2 | 50.0 |
Mycobacterium avium Complex/*immunology | 4 | 57.0 |
Mycobacterium avium-intracellulare Infection/*immunology | 3 | 33.0 |
Heart/drug effects | 4 | 8.0 |
Hypothalamo-Hypophyseal System/drug effects/physiopathology | 2 | 28.0 |
Myocardium/metabolism | 4 | 1.0 |
Sodium Channels/drug effects | 2 | 25.0 |
Fluorocarbons/*pharmacology | 4 | 80.0 |
Tumor Necrosis Factor-alpha/*metabolism/secretion | 5 | 100.0 |
Epidermal Growth Factor/pharmacology | 17 | 2.0 |
Giant Cells | 2 | 3.0 |
Lymphocyte Function-Associated Antigen-1/*metabolism | 2 | 7.0 |
T-Lymphocytes, Helper-Inducer/immunology | 7 | 3.0 |
Bone Resorption/metabolism | 2 | 16.0 |
*Terminology | 2 | 3.0 |
Inflammation Mediators/pharmacology | 4 | 17.0 |
Shock/*chemically induced | 2 | 100.0 |
Antigens, CD/*physiology | 13 | 4.0 |
Amino Acids/metabolism | 4 | 4.0 |
Glucose/metabolism | 7 | 2.0 |
Muscle, Skeletal/cytology/*metabolism | 2 | 9.0 |
Antirheumatic Agents/administration & dosage/therapeutic use | 2 | 100.0 |
Arthritis, Rheumatoid/drug therapy/immunology | 4 | 80.0 |
Immunoglobulin G/administration & dosage/therapeutic use | 2 | 66.0 |
Interferon Type II/therapeutic use | 3 | 27.0 |
Interleukin-1/therapeutic use | 2 | 66.0 |
Interleukin-10/therapeutic use | 3 | 75.0 |
Interleukin-4/therapeutic use | 3 | 42.0 |
Interleukin-6/therapeutic use | 2 | 50.0 |
Receptors, Tumor Necrosis Factor/administration & dosage/therapeutic use | 3 | 100.0 |
Cell Adhesion Molecules/drug effects/*physiology | 2 | 66.0 |
Antirheumatic Agents/administration & dosage | 2 | 40.0 |
Genetic Markers/genetics | 6 | 1.0 |
*Weight Loss | 4 | 8.0 |
Annexin A5/analysis | 2 | 9.0 |
Catalase/metabolism | 5 | 8.0 |
Cytosol/enzymology | 12 | 6.0 |
Enzyme Inhibitors/metabolism | 2 | 0.0 |
Leukemia/*metabolism | 3 | 6.0 |
Leukemia, Myeloid/metabolism | 2 | 16.0 |
Radiation Tolerance/genetics | 2 | 4.0 |
Superoxide Dismutase/*genetics/metabolism | 2 | 4.0 |
Transgenes | 4 | 1.0 |
Alzheimer Disease/*genetics | 2 | 0.0 |
Family Health | 2 | 0.0 |
*Haplotypes | 6 | 2.0 |
Spain | 7 | 2.0 |
*beta-Glucans | 3 | 25.0 |
Cyclic AMP/analysis | 2 | 8.0 |
Interleukin-8/*biosynthesis/genetics | 17 | 41.0 |
Intestinal Mucosa/*drug effects | 3 | 33.0 |
RNA, Neoplasm/analysis | 9 | 3.0 |
Haemophilus influenzae/isolation & purification | 2 | 25.0 |
Longitudinal Studies | 17 | 1.0 |
Antiviral Agents/*pharmacology | 8 | 5.0 |
Interferon Alfa-2b/*pharmacology | 4 | 18.0 |
Interferon Type I, Recombinant/*pharmacology | 9 | 18.0 |
Lymphocyte Activation/*drug effects | 12 | 3.0 |
*Bone Resorption | 4 | 21.0 |
*Carrier Proteins | 7 | 1.0 |
*Glycoproteins | 4 | 0.0 |
*Receptors, Cytoplasmic and Nuclear | 2 | 2.0 |
*Receptors, Tumor Necrosis Factor | 18 | 47.0 |
Pentoxifylline/*therapeutic use | 14 | 63.0 |
Phosphodiesterase Inhibitors/*therapeutic use | 5 | 41.0 |
Pyrogens/*metabolism | 2 | 100.0 |
Transforming Growth Factor beta/biosynthesis | 8 | 17.0 |
Endothelium, Vascular/cytology/metabolism | 9 | 7.0 |
Antigens, CD30/*physiology | 3 | 50.0 |
I-kappa B/genetics/physiology | 2 | 40.0 |
Recombinant Fusion Proteins/physiology | 6 | 2.0 |
Antifungal Agents/therapeutic use | 3 | 10.0 |
Cryptococcus neoformans/immunology/isolation & purification | 2 | 100.0 |
HIV Seronegativity/immunology | 4 | 7.0 |
ROC Curve | 8 | 4.0 |
Interleukin-6/analysis/*biosynthesis | 3 | 50.0 |
Placenta/*cytology | 2 | 11.0 |
Antibiotics, Antineoplastic/pharmacology | 4 | 4.0 |
Astrocytes/drug effects/*metabolism | 3 | 13.0 |
Daunorubicin/pharmacology | 3 | 12.0 |
PC12 Cells | 2 | 0.0 |
Plasminogen Activator Inhibitor 1/*metabolism | 3 | 13.0 |
Sphingosine/analogs & derivatives/pharmacology | 4 | 26.0 |
*Gene Expression Regulation, Neoplastic | 18 | 1.0 |
Sex Characteristics | 7 | 1.0 |
Adjuvants, Immunologic/administration & dosage | 3 | 17.0 |
Antineoplastic Agents/administration & dosage | 3 | 10.0 |
Mistletoe | 2 | 100.0 |
Plant Lectins | 2 | 4.0 |
Tumor Necrosis Factor-alpha/*administration & dosage | 22 | 84.0 |
B-Lymphocytes/*physiology | 6 | 4.0 |
*Cell Transformation, Neoplastic | 4 | 0.0 |
Membrane Proteins/genetics/*metabolism | 8 | 2.0 |
Forskolin/pharmacology | 17 | 4.0 |
Muscle, Smooth/cytology/*drug effects/metabolism | 2 | 66.0 |
RNA, Messenger/drug effects/genetics/metabolism | 4 | 4.0 |
Calcium Channel Blockers/*pharmacology | 2 | 5.0 |
Cell Migration Inhibition | 3 | 2.0 |
Epithelial Cells/*drug effects/metabolism | 5 | 27.0 |
Lung Neoplasms/*drug therapy/metabolism | 2 | 12.0 |
Nifedipine/*pharmacology | 2 | 15.0 |
Verapamil/pharmacology | 2 | 2.0 |
Deoxyglucose/pharmacology | 3 | 15.0 |
Oligomycins/pharmacology | 2 | 25.0 |
Down-Regulation/*physiology | 2 | 6.0 |
Enzyme Activators/pharmacology | 2 | 10.0 |
Hydrogen Peroxide/blood | 10 | 38.0 |
N-Formylmethionine Leucyl-Phenylalanine/metabolism | 3 | 17.0 |
Protein Kinase C/metabolism | 31 | 6.0 |
Receptors, Tumor Necrosis Factor/blood/*genetics | 3 | 37.0 |
Dendritic Cells/*physiology | 5 | 6.0 |
Interleukin-12/biosynthesis | 10 | 10.0 |
Monocytes/*cytology | 10 | 12.0 |
Exercise/physiology | 2 | 3.0 |
Immersion | 2 | 11.0 |
Malawi | 3 | 18.0 |
Culture Media, Serum-Free | 15 | 3.0 |
Granulosa Cells/*metabolism | 3 | 7.0 |
Macrophage Colony-Stimulating Factor/*secretion | 2 | 100.0 |
Fibronectins/*metabolism | 6 | 8.0 |
von Willebrand Factor/*metabolism | 2 | 0.0 |
Collagen/*metabolism | 4 | 2.0 |
Endothelium/metabolism | 3 | 5.0 |
Antigens, CD18/immunology | 3 | 16.0 |
Membrane Glycoproteins/immunology | 6 | 3.0 |
Neutrophil Activation/immunology | 3 | 20.0 |
Receptors, Cell Surface/immunology | 3 | 8.0 |
Cell Differentiation/*physiology | 3 | 1.0 |
Tumor Necrosis Factor-alpha/*genetics/*immunology | 3 | 75.0 |
Diphosphonates/therapeutic use | 2 | 33.0 |
*Hip Prosthesis | 3 | 9.0 |
*Prosthesis Failure | 4 | 19.0 |
Liver/metabolism/pathology | 4 | 8.0 |
Densitometry | 3 | 2.0 |
Lymphotoxin/*biosynthesis/genetics | 7 | 77.0 |
Sequence Analysis | 6 | 1.0 |
Spleen/cytology/drug effects | 3 | 23.0 |
Chemokines, CC/metabolism | 2 | 4.0 |
Chemotaxis, Leukocyte/drug effects | 11 | 13.0 |
Intensive Care Units | 12 | 20.0 |
Ascorbic Acid/pharmacology | 2 | 3.0 |
*Cell Differentiation/drug effects | 3 | 9.0 |
Osteoblasts/*cytology | 2 | 11.0 |
Lipopolysaccharides/*immunology | 18 | 24.0 |
Monocytes/*secretion | 14 | 73.0 |
Multiple Organ Failure/etiology | 4 | 44.0 |
Sepsis Syndrome/etiology | 2 | 50.0 |
Punctures | 3 | 33.0 |
Transgenes/immunology | 2 | 7.0 |
Apoptosis/genetics/*immunology | 2 | 11.0 |
Macrophages/*immunology | 34 | 13.0 |
Fetal Blood/*chemistry | 2 | 3.0 |
Heart/*physiopathology | 2 | 4.0 |
Interleukin-6/genetics/*metabolism | 4 | 22.0 |
Cardiopulmonary Bypass | 4 | 8.0 |
Intraoperative Period | 7 | 12.0 |
Obesity/*immunology | 2 | 50.0 |
Collagen/blood | 2 | 18.0 |
Hypercalcemia/*blood/*etiology | 2 | 100.0 |
Neoplasms/*complications | 4 | 11.0 |
Peptides/blood | 2 | 5.0 |
Proteins/analysis | 10 | 6.0 |
Synovial Membrane/pathology | 4 | 19.0 |
Granulocyte Colony-Stimulating Factor/blood | 4 | 40.0 |
*Leukocyte Count | 3 | 4.0 |
Proteoglycans/*metabolism | 2 | 3.0 |
Tumor Necrosis Factor-alpha/analysis/*pharmacology | 4 | 100.0 |
Interleukin-13/*metabolism | 2 | 16.0 |
Antigens, CD/*immunology | 9 | 1.0 |
Receptors, Tumor Necrosis Factor/*immunology | 14 | 70.0 |
Cytotoxicity, Immunologic/drug effects | 23 | 19.0 |
DNA-Binding Proteins/antagonists & inhibitors/metabolism | 2 | 9.0 |
Genes, Reporter/immunology | 2 | 16.0 |
Signal Transduction/drug effects/immunology | 2 | 4.0 |
Transcription Factor AP-1/*antagonists & inhibitors/metabolism | 2 | 33.0 |
Uridine/pharmacology | 2 | 40.0 |
Cell Differentiation/drug effects/immunology | 6 | 8.0 |
Imidazoles/*pharmacology | 11 | 14.0 |
Trans-Activation (Genetics)/drug effects/immunology | 2 | 33.0 |
Carcinoma, Squamous Cell/immunology | 2 | 7.0 |
Cytotoxicity, Immunologic/*drug effects | 21 | 28.0 |
Monocytes/*drug effects/*immunology/metabolism | 2 | 33.0 |
Recombinant Fusion Proteins | 4 | 1.0 |
Tumor Necrosis Factor-alpha/immunology/pharmacology/physiology | 2 | 100.0 |
Cytokines/biosynthesis/*blood | 4 | 44.0 |
Interleukin-8/biosynthesis/blood | 2 | 66.0 |
Virulence | 11 | 4.0 |
Docosahexaenoic Acids/blood | 2 | 22.0 |
Erythrocyte Membrane/*chemistry | 2 | 8.0 |
Fatty Acids, Omega-6 | 2 | 15.0 |
Linoleic Acid/blood | 2 | 50.0 |
alpha-Linolenic Acid/blood | 2 | 100.0 |
Blotting, Northern/methods | 2 | 3.0 |
RNA/isolation & purification | 3 | 4.0 |
RNA, Messenger/analysis/drug effects | 2 | 25.0 |
Roxithromycin/*pharmacology | 2 | 28.0 |
Tumor Necrosis Factor-alpha/analysis/*drug effects | 2 | 100.0 |
Melanoma, Experimental/drug therapy | 3 | 33.0 |
Neoplasms/drug therapy/*therapy | 3 | 60.0 |
Neoplasms, Experimental/drug therapy | 4 | 16.0 |
Phagocytosis/immunology | 5 | 7.0 |
Respiratory Syncytial Viruses/*immunology | 2 | 40.0 |
Genetic Vectors/administration & dosage | 2 | 6.0 |
Neovascularization, Physiologic | 2 | 1.0 |
RNA, Messenger/isolation & purification | 2 | 2.0 |
Tumor Necrosis Factor-alpha/drug effects | 4 | 66.0 |
Bone Resorption/physiopathology | 4 | 57.0 |
Interleukin-1/antagonists & inhibitors/*physiology | 4 | 100.0 |
Arthritis, Rheumatoid/*physiopathology | 2 | 15.0 |
*Transgenes | 3 | 6.0 |
Arthritis, Psoriatic/drug therapy | 4 | 100.0 |
Interleukin-12/pharmacology | 2 | 4.0 |
Leukocytes/*drug effects | 4 | 33.0 |
Corticotropin/*blood | 3 | 4.0 |
Tumor Necrosis Factor-alpha/*analysis/metabolism | 10 | 90.0 |
Erythrocytes/*parasitology | 3 | 10.0 |
Macrophage-1 Antigen/analysis | 2 | 4.0 |
Macrophages/drug effects/*physiology | 2 | 12.0 |
*Phagocytosis | 6 | 5.0 |
Plasmodium falciparum/*pathogenicity | 2 | 25.0 |
Cytotoxicity, Immunologic/immunology | 10 | 14.0 |
Enzyme Activation/immunology | 4 | 3.0 |
Gene Expression Regulation/immunology | 12 | 7.0 |
Interferon-alpha/*physiology | 2 | 15.0 |
Tumor Necrosis Factor-alpha/antagonists & inhibitors/genetics/*physiology | 4 | 80.0 |
Cell Transformation, Viral | 11 | 3.0 |
Cyclophosphamide/adverse effects/therapeutic use | 2 | 28.0 |
Fatal Outcome | 8 | 1.0 |
Prednisolone/adverse effects/therapeutic use | 2 | 100.0 |
Lipopolysaccharides/*antagonists & inhibitors/toxicity | 2 | 33.0 |
Liver Function Tests | 4 | 2.0 |
Transaminases/blood | 2 | 11.0 |
Aging/*metabolism | 5 | 2.0 |
Antigens, CD18/metabolism | 5 | 11.0 |
Cell Adhesion/physiology | 12 | 4.0 |
Respiratory Burst/*physiology | 4 | 40.0 |
Eosinophils/*drug effects | 4 | 36.0 |
Interleukin-5/pharmacology | 5 | 19.0 |
Mifepristone/pharmacology | 7 | 8.0 |
Melphalan/administration & dosage/*therapeutic use | 4 | 80.0 |
*Perfusion, Regional/methods | 2 | 100.0 |
Tumor Necrosis Factor-alpha/administration & dosage/*therapeutic use | 15 | 88.0 |
Interleukin-2/pharmacology | 42 | 7.0 |
Interleukin-7/pharmacology | 2 | 4.0 |
Cell Transplantation | 4 | 4.0 |
Synovial Membrane/cytology | 4 | 22.0 |
Bacterial Infections/*immunology | 7 | 21.0 |
Drainage | 3 | 15.0 |
Endotoxins/*blood | 18 | 51.0 |
Sepsis Syndrome/blood/*immunology | 3 | 100.0 |
NF-kappa B/*antagonists & inhibitors/*metabolism | 6 | 75.0 |
Brain/*drug effects/metabolism | 2 | 11.0 |
Chimeric Proteins/*therapeutic use | 2 | 25.0 |
Inflammatory Bowel Diseases/*drug therapy/immunology | 2 | 100.0 |
Monocytes/*drug effects/*metabolism | 7 | 50.0 |
Breast Neoplasms | 19 | 6.0 |
Cell Survival/*drug effects | 21 | 26.0 |
L Cells (Cell Line) | 38 | 16.0 |
Tumor Necrosis Factor-alpha/genetics/pharmacokinetics/*toxicity | 2 | 100.0 |
Interferon Type II/*physiology | 15 | 23.0 |
Chemokines/genetics | 2 | 11.0 |
RNA, Messenger/chemistry | 2 | 5.0 |
Interleukin-6/biosynthesis/*genetics | 6 | 42.0 |
Sialoglycoproteins/genetics | 5 | 16.0 |
Second Messenger Systems/*physiology | 2 | 7.0 |
Receptors, Tumor Necrosis Factor/*chemistry/*metabolism | 2 | 100.0 |
Serpins/metabolism | 3 | 18.0 |
Recombinant Proteins/metabolism/pharmacology | 20 | 19.0 |
Tumor Necrosis Factor-alpha/genetics/*metabolism/pharmacology | 6 | 85.0 |
Inflammation/immunology/metabolism/pathology | 2 | 25.0 |
Interleukin-12/*blood | 3 | 23.0 |
Biological Markers/*blood | 5 | 2.0 |
Enterotoxins/metabolism | 2 | 28.0 |
Lung/*immunology | 3 | 7.0 |
Macrophages, Alveolar/*immunology/metabolism | 3 | 50.0 |
Carrier Proteins/*metabolism/*pharmacology | 2 | 50.0 |
Intercellular Adhesion Molecule-1/drug effects/metabolism | 2 | 40.0 |
Interleukin-6/metabolism/secretion | 2 | 50.0 |
Amylases/blood | 2 | 9.0 |
Lipase/blood | 2 | 2.0 |
Lipopolysaccharides/administration & dosage | 16 | 61.0 |
AIDS-Related Opportunistic Infections/*immunology | 3 | 10.0 |
Antineoplastic Agents/pharmacology/*therapeutic use | 3 | 8.0 |
Lung Neoplasms/*drug therapy/pathology | 2 | 6.0 |
Recombinant Proteins/pharmacology/therapeutic use | 12 | 30.0 |
Respiratory Burst | 12 | 18.0 |
Protein Structure, Tertiary/genetics | 3 | 1.0 |
Cytokines/genetics/*secretion | 2 | 33.0 |
HLA Antigens/*genetics | 16 | 1.0 |
HLA-B8 Antigen/genetics | 3 | 16.0 |
HLA-DR3 Antigen/genetics | 6 | 24.0 |
Interleukin-2/biosynthesis/immunology | 2 | 22.0 |
Virus Activation | 3 | 5.0 |
*Cardiac Surgical Procedures | 2 | 4.0 |
Acute-Phase Reaction/metabolism | 2 | 25.0 |
Ligases/metabolism | 2 | 3.0 |
Mutagenesis/physiology | 3 | 4.0 |
NF-kappa B/immunology/*metabolism | 2 | 33.0 |
Administration, Inhalation | 4 | 2.0 |
Osmolar Concentration | 22 | 3.0 |
RNA/genetics | 3 | 2.0 |
Lymphotoxin/blood | 4 | 80.0 |
APACHE | 18 | 32.0 |
Tumor Necrosis Factor-alpha/*analysis/*genetics | 4 | 100.0 |
Biological Response Modifiers | 2 | 50.0 |
Immunosuppressive Agents/immunology/*therapeutic use | 2 | 100.0 |
Amino Acid Sequence/genetics | 2 | 0.0 |
Tumor Necrosis Factor-alpha/genetics/*pharmacology | 5 | 62.0 |
Neuropeptides/*physiology | 3 | 7.0 |
Cell Movement/physiology | 5 | 2.0 |
Lymphokines/biosynthesis | 3 | 2.0 |
Macrophages/*immunology/pathology | 2 | 20.0 |
Bronchoalveolar Lavage Fluid/*chemistry | 7 | 12.0 |
NF-kappa B/genetics/*metabolism | 10 | 13.0 |
Uterus/*cytology/*metabolism | 2 | 100.0 |
HMGB1 Protein | 2 | 28.0 |
Macrophage Inflammatory Protein-1/metabolism | 2 | 3.0 |
Monocytes/drug effects/*immunology/metabolism | 2 | 15.0 |
Prostatic Neoplasms/*pathology | 3 | 2.0 |
Testosterone/pharmacology | 3 | 5.0 |
Macrophages/physiology | 13 | 17.0 |
Titanium/*pharmacology | 2 | 66.0 |
Macrophages/*drug effects | 5 | 22.0 |
Interleukin-12/*biosynthesis | 7 | 20.0 |
Antibody Formation | 15 | 3.0 |
*Genes, Reporter | 2 | 4.0 |
Interferon Type II/biosynthesis/immunology | 4 | 25.0 |
Tumor Necrosis Factor-alpha/biosynthesis/immunology | 6 | 42.0 |
Bacterial Proteins/*physiology | 4 | 23.0 |
Blood Proteins/*pharmacology | 3 | 7.0 |
Adenosine/*analogs & derivatives/pharmacology | 2 | 18.0 |
Chemotactic Factors/metabolism | 2 | 13.0 |
*Intercellular Signaling Peptides and Proteins | 7 | 1.0 |
Phenethylamines/pharmacology | 2 | 14.0 |
Receptor, Adenosine A2A | 2 | 12.0 |
Receptors, Purinergic P1/*agonists/antagonists & inhibitors | 2 | 100.0 |
Triazoles/pharmacology | 3 | 10.0 |
Matrix Metalloproteinases/*antagonists & inhibitors | 3 | 37.0 |
Metalloendopeptidases/*antagonists & inhibitors | 3 | 11.0 |
Proportional Hazards Models | 4 | 0.0 |
Interleukin-1/*cerebrospinal fluid | 6 | 75.0 |
Tumor Necrosis Factor-alpha/*cerebrospinal fluid | 11 | 91.0 |
Cytokines/biosynthesis/immunology | 2 | 11.0 |
*Linkage Disequilibrium | 4 | 2.0 |
Genetic Engineering | 3 | 3.0 |
Mice, Inbred NZB | 2 | 6.0 |
Leukocytes, Mononuclear/drug effects/metabolism | 19 | 34.0 |
NF-kappa B/*drug effects/metabolism | 3 | 75.0 |
Pregnancy Trimester, First | 7 | 2.0 |
Trophoblasts/cytology/drug effects/*metabolism | 2 | 28.0 |
Simvastatin/*pharmacology | 2 | 16.0 |
Endothelin-1/*metabolism | 2 | 12.0 |
Sputum/chemistry/cytology/microbiology | 2 | 66.0 |
Interferon-beta/*therapeutic use | 4 | 17.0 |
Myelin Basic Proteins/immunology | 3 | 3.0 |
T-Lymphocytes/immunology/metabolism | 5 | 4.0 |
Brain/metabolism | 4 | 0.0 |
Glioma/*drug therapy/pathology | 2 | 40.0 |
Liver/chemistry/pathology | 2 | 12.0 |
Mitochondria/enzymology | 2 | 1.0 |
Specific Pathogen-Free Organisms | 6 | 7.0 |
Hepacivirus | 2 | 33.0 |
Arachidonic Acids/pharmacology | 2 | 6.0 |
Eicosanoids/*biosynthesis | 2 | 28.0 |
Spleen/immunology/virology | 2 | 100.0 |
Antibodies/immunology/pharmacology | 5 | 15.0 |
Antigens, CD28/immunology | 2 | 1.0 |
Antigens, CD3/immunology | 7 | 2.0 |
T-Lymphocytes/*drug effects/immunology | 5 | 5.0 |
Intercellular Adhesion Molecule-1/*biosynthesis/genetics | 6 | 30.0 |
Promoter Regions (Genetics)/drug effects | 3 | 2.0 |
Lipid Peroxidation/drug effects | 3 | 5.0 |
Interleukin-8/biosynthesis/*genetics | 3 | 50.0 |
Monocytes/immunology/metabolism | 11 | 22.0 |
*Body Mass Index | 3 | 3.0 |
Viscera | 2 | 6.0 |
Asthma/*genetics/immunology | 2 | 12.0 |
Tumor Necrosis Factor-alpha/classification/*genetics | 3 | 75.0 |
Respiration, Artificial | 7 | 13.0 |
MAP Kinase Signaling System/physiology | 4 | 5.0 |
NF-kappa B/metabolism/physiology | 3 | 37.0 |
Acquired Immunodeficiency Syndrome/etiology | 2 | 15.0 |
CD4-Positive T-Lymphocytes/*cytology | 2 | 4.0 |
Kenya | 3 | 6.0 |
Cloning, Molecular/methods | 5 | 3.0 |
Genetic Techniques | 2 | 2.0 |
Mammals | 5 | 1.0 |
Peptide Fragments/metabolism | 6 | 1.0 |
Solutions | 3 | 1.0 |
Surface Plasmon Resonance | 2 | 1.0 |
Receptors, Tumor Necrosis Factor/*metabolism/physiology | 2 | 66.0 |
Antigens, CD27/*metabolism | 4 | 28.0 |
Kidney Diseases/metabolism | 2 | 7.0 |
Kidney Glomerulus/*metabolism | 2 | 6.0 |
Biological Transport/drug effects | 13 | 5.0 |
Obesity/metabolism | 2 | 4.0 |
Plasminogen Activator Inhibitor 1/metabolism | 4 | 8.0 |
*Chromosome Mapping | 3 | 0.0 |
Cytochalasin B/pharmacology | 8 | 8.0 |
Cytoskeleton/metabolism | 4 | 1.0 |
Nocodazole/pharmacology | 3 | 2.0 |
Umbilical Veins/drug effects/*metabolism | 2 | 100.0 |
Adrenal Glands/metabolism | 2 | 4.0 |
Nuclease Protection Assays | 2 | 10.0 |
Spleen/metabolism | 10 | 7.0 |
Zinc/blood | 3 | 15.0 |
*CD4-CD8 Ratio | 2 | 3.0 |
Immunoglobulin M/metabolism | 3 | 3.0 |
*Heart Transplantation | 5 | 6.0 |
Anti-Bacterial Agents/pharmacology/therapeutic use | 2 | 28.0 |
Neutrophil Activation/drug effects | 6 | 33.0 |
T-Lymphocytes/metabolism | 16 | 5.0 |
Immune System | 2 | 16.0 |
Intracellular Fluid/chemistry | 2 | 13.0 |
Endotoxins/*immunology | 5 | 41.0 |
Granulocytes/immunology | 7 | 12.0 |
Interleukin-10/blood/*immunology | 2 | 100.0 |
T-Lymphocytes, Suppressor-Effector/immunology | 2 | 1.0 |
Tumor Necrosis Factor-alpha/administration & dosage/*metabolism | 3 | 100.0 |
Blood Platelets/metabolism | 2 | 1.0 |
Linkage (Genetics)/genetics | 2 | 0.0 |
RNA, Messenger/analysis/genetics | 11 | 2.0 |
Caspases/metabolism/*physiology | 2 | 28.0 |
Exercise | 2 | 1.0 |
Fasting/blood | 2 | 3.0 |
Insulin/blood/*physiology | 2 | 20.0 |
Muscle, Skeletal/drug effects/*metabolism | 2 | 10.0 |
Receptors, Cytokine/*metabolism | 6 | 7.0 |
Receptors, Interleukin-1/metabolism | 7 | 30.0 |
Receptors, Interleukin-6/metabolism | 3 | 11.0 |
Tumor Necrosis Factor-alpha/metabolism/physiology | 3 | 60.0 |
Infection/immunology | 4 | 13.0 |
Interferon Type II/*biosynthesis/blood | 6 | 54.0 |
Lymphocytes/drug effects/*immunology | 5 | 12.0 |
Phytohemagglutinins | 5 | 5.0 |
Organ Transplantation | 2 | 16.0 |
Immune System/physiology | 4 | 17.0 |
Leptin/*secretion | 2 | 50.0 |
Bacterial Proteins/metabolism | 4 | 6.0 |
*Cytotoxicity, Immunologic | 46 | 9.0 |
CD40 Ligand | 18 | 10.0 |
Carcinoma/*metabolism/pathology | 2 | 3.0 |
CD4-Positive T-Lymphocytes/*immunology | 9 | 1.0 |
Interleukin-4/*blood | 2 | 14.0 |
Multiple Trauma/*blood | 2 | 40.0 |
Transforming Growth Factor beta/*blood | 2 | 7.0 |
Wounds, Nonpenetrating/*blood | 2 | 100.0 |
Blood Cells/*metabolism | 2 | 15.0 |
Angiotensin II/pharmacology | 4 | 5.0 |
Corticotropin/pharmacology | 4 | 7.0 |
Phorbol 12,13-Dibutyrate/pharmacology | 5 | 8.0 |
Autoimmunity | 5 | 3.0 |
Fetus/*immunology | 2 | 4.0 |
Pregnancy/*immunology | 2 | 3.0 |
Trophoblasts/immunology | 3 | 9.0 |
Chemokines/*genetics/metabolism | 2 | 33.0 |
Transcription Factors/physiology | 4 | 1.0 |
Bacteria/immunology | 2 | 20.0 |
Lymphotoxin/*genetics/immunology | 2 | 66.0 |
Antigens, CD14/blood | 4 | 13.0 |
Calcitonin/blood | 2 | 6.0 |
Cardiac Surgical Procedures/adverse effects | 2 | 50.0 |
Critical Illness | 11 | 39.0 |
Endotoxemia/blood | 2 | 50.0 |
Glycoproteins/blood | 2 | 3.0 |
HLA-DR Antigens/blood | 3 | 5.0 |
Immunoglobulin M/*therapeutic use | 3 | 60.0 |
Multiple Organ Failure/immunology | 2 | 100.0 |
Protein Precursors/blood | 3 | 8.0 |
Sepsis Syndrome/immunology | 2 | 33.0 |
CD4-Positive T-Lymphocytes/drug effects/*metabolism | 2 | 20.0 |
Concanavalin A | 6 | 12.0 |
Tumor Necrosis Factor-alpha/drug effects/*metabolism | 5 | 83.0 |
Peptides/*immunology | 2 | 2.0 |
Ceramides/pharmacology/*physiology | 2 | 66.0 |
Endothelium, Vascular/cytology/*drug effects | 16 | 21.0 |
Protein p53/*metabolism | 2 | 0.0 |
Retinoblastoma Protein/*metabolism | 4 | 2.0 |
Umbilical Cord/cytology | 4 | 21.0 |
Burkitt Lymphoma | 4 | 4.0 |
Lymphoma, B-Cell | 3 | 8.0 |
Recombinant Proteins/immunology | 23 | 6.0 |
Tonsil/immunology | 2 | 3.0 |
Dendritic Cells/immunology/*metabolism | 2 | 11.0 |
Sialoglycoproteins/biosynthesis | 8 | 36.0 |
Neutrophils/cytology/*drug effects/metabolism | 3 | 37.0 |
Nucleosomes/drug effects/metabolism | 2 | 66.0 |
Phagocytosis/drug effects | 17 | 20.0 |
Multiple Sclerosis/*immunology | 3 | 2.0 |
Arachidonic Acid/blood | 3 | 42.0 |
Nitrites/blood | 6 | 24.0 |
*Oxidative Stress | 9 | 4.0 |
Respiratory Distress Syndrome, Adult/*blood | 2 | 100.0 |
Thiobarbituric Acid Reactive Substances/analysis | 3 | 14.0 |
Adipocytes/*cytology/*metabolism | 2 | 66.0 |
Monosaccharide Transport Proteins/genetics/metabolism | 2 | 18.0 |
Stromal Cells/cytology | 2 | 4.0 |
8-Bromo Cyclic Adenosine Monophosphate/pharmacology | 3 | 3.0 |
Adrenergic beta-Antagonists/pharmacology | 2 | 10.0 |
Bronchoalveolar Lavage Fluid/cytology/immunology | 7 | 18.0 |
Histocytochemistry | 6 | 0.0 |
Isoantigens/*immunology | 2 | 2.0 |
Cell Survival/drug effects/physiology | 5 | 6.0 |
Antigens, CD95/genetics/*metabolism | 2 | 10.0 |
Complement/immunology | 3 | 3.0 |
Endothelial Cells/cytology/*drug effects/metabolism | 2 | 66.0 |
Skin/immunology | 8 | 8.0 |
Vascular Cell Adhesion Molecule-1/*genetics | 3 | 33.0 |
Hospital Mortality | 5 | 16.0 |
Arthrography | 2 | 10.0 |
Bone Density/drug effects | 3 | 10.0 |
Calcitonin/pharmacology | 2 | 9.0 |
Diphosphonates/*pharmacology | 2 | 20.0 |
Glucocorticoids/administration & dosage | 2 | 25.0 |
Prednisone/administration & dosage | 6 | 7.0 |
Uric Acid/chemistry/*pharmacology | 2 | 100.0 |
Gastric Mucosa/*metabolism | 2 | 6.0 |
Helicobacter Infections/*metabolism | 2 | 16.0 |
Helicobacter pylori/*genetics | 2 | 33.0 |
Interleukin-1/analysis/genetics | 3 | 60.0 |
Intestines/pathology | 2 | 11.0 |
Bone Marrow Transplantation | 5 | 1.0 |
Injections, Intravenous | 48 | 7.0 |
Nausea/chemically induced | 3 | 10.0 |
Burns/*blood/*complications | 2 | 100.0 |
DNA-Binding Proteins/*physiology | 2 | 0.0 |
Receptors, Cytoplasmic and Nuclear/genetics | 2 | 5.0 |
Transcription Factors/genetics | 5 | 0.0 |
Cytotoxins/*pharmacology | 3 | 33.0 |
Lymphocytes/*drug effects/physiology | 2 | 28.0 |
Sesquiterpenes/*pharmacology | 2 | 5.0 |
Cerebrovascular Circulation/*drug effects | 3 | 18.0 |
Microcirculation/drug effects | 3 | 11.0 |
Hemodynamic Processes | 17 | 8.0 |
L-Selectin/blood | 2 | 22.0 |
Neutrophils/drug effects/metabolism | 7 | 23.0 |
Hybrid Cells | 6 | 0.0 |
Aging/*blood | 2 | 2.0 |
Macrophage Colony-Stimulating Factor/blood | 2 | 28.0 |
Chimeric Proteins/genetics/metabolism | 3 | 3.0 |
Deoxyribonuclease I/metabolism | 2 | 1.0 |
Receptors, Nerve Growth Factor/genetics/metabolism | 2 | 25.0 |
Subcellular Fractions/drug effects/metabolism | 2 | 28.0 |
Arthritis, Rheumatoid/*genetics/immunology | 5 | 10.0 |
Anticoagulants/blood | 2 | 11.0 |
Cytokines/*pharmacology/physiology | 3 | 50.0 |
Hematopoietic Stem Cells/physiology | 2 | 4.0 |
Radiation, Ionizing | 2 | 1.0 |
Tyrosine/*analogs & derivatives/metabolism | 4 | 7.0 |
Histamine Release/drug effects | 3 | 12.0 |
Skin/*drug effects/metabolism | 2 | 33.0 |
Substance P/*pharmacology | 4 | 12.0 |
Arthritis, Rheumatoid/*genetics/*immunology | 2 | 9.0 |
Flavonoids/*pharmacology | 3 | 3.0 |
Interferon Type I, Recombinant/pharmacology | 7 | 21.0 |
Recombinant Fusion Proteins/biosynthesis | 12 | 2.0 |
Calcitonin/*pharmacology | 2 | 11.0 |
Peptide Fragments/pharmacology | 13 | 5.0 |
Protein Precursors/*pharmacology | 2 | 10.0 |
Adjuvants, Immunologic/administration & dosage/therapeutic use | 2 | 100.0 |
Growth Substances/*physiology | 9 | 6.0 |
Electric Stimulation | 2 | 0.0 |
Colorimetry | 3 | 5.0 |
GTP-Binding Proteins/*metabolism | 3 | 0.0 |
Hela Cells/drug effects/metabolism | 5 | 26.0 |
Cytokines/*antagonists & inhibitors/immunology | 2 | 100.0 |
Interleukin-1/antagonists & inhibitors/immunology | 2 | 100.0 |
Endotoxemia/*blood | 3 | 30.0 |
Neutrophil Activation/*immunology | 2 | 13.0 |
Respiratory Burst/immunology | 2 | 20.0 |
Sphingosine/pharmacology | 4 | 22.0 |
Tetradecanoylphorbol Acetate/antagonists & inhibitors/pharmacology | 2 | 15.0 |
Bone Marrow Cells/*metabolism | 2 | 4.0 |
Osteoclasts/*cytology | 3 | 33.0 |
Sulfasalazine/pharmacology | 2 | 33.0 |
Transcription Factors/agonists/*metabolism | 2 | 25.0 |
Cisplatin/administration & dosage/*pharmacology | 2 | 50.0 |
Cytokines/*drug effects | 3 | 50.0 |
von Willebrand Factor/analysis | 8 | 2.0 |
Cytokines/biosynthesis/*physiology | 3 | 42.0 |
Oxygen/blood | 7 | 6.0 |
Partial Pressure | 2 | 4.0 |
Epithelial Cells/*drug effects/physiology | 2 | 40.0 |
Lung Neoplasms | 4 | 3.0 |
*Receptor Aggregation | 3 | 23.0 |
Multiple Organ Failure/blood/etiology | 5 | 62.0 |
Wounds and Injuries/*blood | 4 | 30.0 |
Adaptation, Physiological | 2 | 2.0 |
Alcoholism/complications | 3 | 14.0 |
Gene Expression Regulation/drug effects/*physiology | 3 | 3.0 |
Hepatectomy | 2 | 2.0 |
Liver Regeneration/*physiology | 4 | 16.0 |
Propionibacterium acnes/immunology | 4 | 50.0 |
Endothelins/*blood | 2 | 7.0 |
Lymphokines/secretion | 2 | 5.0 |
Melphalan/pharmacology | 4 | 25.0 |
Thromboplastin/*metabolism | 2 | 1.0 |
Hypothermia, Induced | 2 | 22.0 |
Tumor Necrosis Factor-alpha/metabolism/*physiology | 15 | 75.0 |
Docosahexaenoic Acids/*pharmacology | 2 | 16.0 |
U937 Cells/drug effects | 2 | 40.0 |
Mice, Mutant Strains | 14 | 1.0 |
Lupus Erythematosus, Systemic/immunology/*metabolism | 2 | 33.0 |
T-Lymphocytes | 10 | 4.0 |
Dendritic Cells/*cytology | 6 | 10.0 |
Integrins/biosynthesis | 2 | 8.0 |
Receptors, Tumor Necrosis Factor/chemistry/*physiology | 6 | 100.0 |
Caspases/*genetics | 2 | 9.0 |
*Gene Transfer Techniques | 9 | 2.0 |
Transforming Growth Factor beta/*genetics | 3 | 3.0 |
Fibroblasts/cytology/drug effects/metabolism | 3 | 5.0 |
Interleukin-13/*pharmacology | 7 | 15.0 |
Breast Neoplasms/*metabolism/pathology | 2 | 1.0 |
Cell Count/drug effects | 4 | 5.0 |
Cell Hypoxia | 5 | 3.0 |
Intercellular Adhesion Molecule-1/*metabolism | 7 | 12.0 |
Reperfusion Injury/*metabolism | 2 | 33.0 |
Ascitic Fluid/*metabolism | 7 | 29.0 |
Endometriosis/*metabolism/pathology | 2 | 12.0 |
Infertility, Female/metabolism | 2 | 28.0 |
Interferon Inducers/pharmacology | 6 | 30.0 |
Membrane Glycoproteins/*immunology | 5 | 2.0 |
Receptors, Cell Surface/*immunology | 7 | 8.0 |
Protein-Tyrosine Kinase/antagonists & inhibitors/*metabolism | 3 | 5.0 |
Stilbenes/pharmacology | 2 | 6.0 |
Rats, Inbred Strains | 53 | 6.0 |
Interferons/*immunology | 3 | 60.0 |
Leucine/*analogs & derivatives/pharmacology | 2 | 16.0 |
Monocytes/*immunology/microbiology | 5 | 38.0 |
Streptococcus agalactiae/*immunology | 5 | 45.0 |
Protein-Serine-Threonine Kinases/chemistry/*physiology | 2 | 22.0 |
Disease Susceptibility/immunology | 4 | 5.0 |
Hypersensitivity, Delayed/immunology | 2 | 3.0 |
Tritium | 5 | 2.0 |
Behcet Syndrome/*genetics | 2 | 8.0 |
Major Histocompatibility Complex/genetics | 4 | 7.0 |
Protein-Serine-Threonine Kinases/*antagonists & inhibitors/metabolism | 3 | 9.0 |
Chorionic Gonadotropin/*pharmacology | 4 | 7.0 |
Drug Antagonism | 3 | 6.0 |
Ceramides/*pharmacology | 5 | 25.0 |
Mitogen-Activated Protein Kinase Kinases/*metabolism | 2 | 3.0 |
Pituitary-Adrenal System/immunology | 2 | 66.0 |
Stress/*immunology | 2 | 33.0 |
Intensive Care | 2 | 11.0 |
HIV Infections/drug therapy | 2 | 4.0 |
Gene Dosage | 2 | 0.0 |
Gene Expression Regulation, Viral/immunology | 2 | 15.0 |
Lung/*cytology | 4 | 12.0 |
Spodoptera | 5 | 1.0 |
Bronchoalveolar Lavage Fluid/*cytology | 6 | 13.0 |
Bronchoscopy | 2 | 3.0 |
Monocytes/*drug effects/metabolism/secretion | 3 | 75.0 |
Peptide Fragments/chemistry/*pharmacology | 2 | 6.0 |
Thromboplastin/*biosynthesis | 6 | 8.0 |
Celiac Disease/*genetics | 2 | 7.0 |
Indoles/pharmacology | 9 | 4.0 |
Maleimides/pharmacology | 4 | 4.0 |
Indomethacin/*pharmacology | 7 | 17.0 |
Infant, Premature/*metabolism | 2 | 10.0 |
Inflammation/*etiology | 5 | 33.0 |
Calcium/pharmacology | 8 | 3.0 |
Phagocytes/metabolism | 2 | 33.0 |
Superoxide Dismutase/genetics/*metabolism | 4 | 8.0 |
Superoxides/*metabolism | 22 | 23.0 |
Concanavalin A/immunology | 4 | 22.0 |
Macrophage Migration-Inhibitory Factors/metabolism | 2 | 40.0 |
Th2 Cells/*metabolism | 2 | 8.0 |
Recombinant Proteins/administration & dosage/pharmacology | 11 | 18.0 |
Caenorhabditis elegans | 2 | 2.0 |
Bacterial Proteins/*metabolism | 3 | 6.0 |
Tetradecanoylphorbol Acetate/metabolism | 2 | 6.0 |
Xenopus | 4 | 0.0 |
Receptors, Granulocyte-Macrophage Colony-Stimulating Factor/metabolism | 6 | 42.0 |
Antitubercular Agents/therapeutic use | 2 | 6.0 |
RNA, Viral/analysis | 5 | 1.0 |
Complement 3/*biosynthesis/genetics | 2 | 11.0 |
Complement Factor B/*biosynthesis/genetics | 2 | 40.0 |
Gene Expression Regulation/*immunology | 2 | 1.0 |
Interleukin-4/physiology | 4 | 10.0 |
Skin/*immunology | 6 | 5.0 |
Angiogenesis Inhibitors/pharmacology | 2 | 5.0 |
Helicobacter Infections/*immunology | 2 | 14.0 |
Leukocytes/immunology | 11 | 8.0 |
Nucleic Acid Hybridization | 30 | 1.0 |
Peptidoglycan/*pharmacology | 2 | 33.0 |
*Staphylococcus aureus | 3 | 14.0 |
Electroencephalography | 4 | 1.0 |
Electromyography | 2 | 1.0 |
Heart Rate/drug effects | 6 | 2.0 |
Lipopolysaccharides/*administration & dosage | 4 | 40.0 |
Peptides/chemical synthesis/*pharmacology | 2 | 18.0 |
RNA Processing, Post-Transcriptional | 5 | 4.0 |
RNA, Messenger/*genetics | 5 | 1.0 |
Protein-Tyrosine Kinase/*metabolism | 13 | 1.0 |
Concanavalin A/toxicity | 2 | 66.0 |
Luciferases/analysis/genetics | 2 | 8.0 |
Transcription Factor AP-1/antagonists & inhibitors | 2 | 50.0 |
Adenoviridae/*genetics | 6 | 2.0 |
Ploidies | 3 | 1.0 |
*Transduction, Genetic | 3 | 4.0 |
Monocytes/cytology/drug effects/immunology | 2 | 20.0 |
BCG Vaccine/administration & dosage | 2 | 25.0 |
Leprosy, Tuberculoid/immunology | 2 | 100.0 |
Mycobacterium leprae/*immunology | 3 | 10.0 |
Skin Tests | 6 | 3.0 |
Vaccination | 5 | 3.0 |
Cell Membrane/immunology/metabolism | 3 | 2.0 |
Intracellular Fluid/immunology/metabolism | 2 | 6.0 |
Epidermal Growth Factor/biosynthesis | 2 | 16.0 |
Epithelium/physiology | 8 | 9.0 |
Peritoneum | 2 | 22.0 |
Tumor Markers, Biological/analysis | 4 | 0.0 |
Endothelium, Vascular/physiology | 5 | 7.0 |
Cell Membrane/enzymology | 3 | 1.0 |
Interleukin-1/administration & dosage/pharmacology | 5 | 83.0 |
RNA, Messenger/drug effects/genetics | 5 | 21.0 |
Regeneration | 4 | 6.0 |
Tumor Necrosis Factor-alpha/administration & dosage/pharmacology | 9 | 75.0 |
Antigens, Viral/analysis | 6 | 7.0 |
DNA Transposable Elements | 3 | 2.0 |
*Genome, Viral | 2 | 2.0 |
Receptors, Interleukin-1/genetics | 2 | 16.0 |
Viral Proteins/genetics | 2 | 3.0 |
Anticarcinogenic Agents/pharmacology | 2 | 7.0 |
Cell Transformation, Neoplastic | 4 | 0.0 |
Receptors, Interleukin/*metabolism | 3 | 9.0 |
T-Lymphocytes/drug effects/metabolism | 5 | 14.0 |
Radiation Tolerance | 3 | 3.0 |
Protein-Tyrosine-Phosphatase/antagonists & inhibitors | 2 | 5.0 |
Vanadates/*pharmacology | 2 | 8.0 |
Lipopolysaccharides/administration & dosage/pharmacology | 5 | 71.0 |
Monocytes/*enzymology | 2 | 7.0 |
Membrane Proteins/*genetics/metabolism | 3 | 1.0 |
Tumor Cells, Cultured/cytology/drug effects | 2 | 5.0 |
Neopterin/blood | 4 | 14.0 |
Receptors, Cytokine/blood | 2 | 40.0 |
Thalidomide/*pharmacology | 4 | 23.0 |
*Neoplasm Proteins | 7 | 0.0 |
Carrier Proteins/*pharmacology | 6 | 12.0 |
Leukocytes/physiology | 7 | 13.0 |
Hyperinsulinism/blood | 2 | 18.0 |
Insulin Resistance/*physiology | 3 | 4.0 |
Recombinant Proteins/*pharmacology | 22 | 25.0 |
Kidney Function Tests | 2 | 1.0 |
Retreatment | 2 | 11.0 |
Europe/ethnology | 2 | 2.0 |
Blood Coagulation/*physiology | 3 | 2.0 |
Fibrinogen/metabolism | 5 | 2.0 |
Lipoproteins, HDL Cholesterol/blood | 6 | 0.0 |
Cholesterol/blood | 8 | 0.0 |
Lipoproteins, LDL Cholesterol/blood | 5 | 0.0 |
Immediate-Early Proteins/genetics/metabolism | 2 | 11.0 |
Luciferases | 2 | 5.0 |
*Complement Pathway, Alternative | 2 | 1.0 |
Herpesvirus 4, Human | 2 | 1.0 |
Lymph Nodes/metabolism | 3 | 5.0 |
RNA, Viral/metabolism | 3 | 3.0 |
Myocardial Contraction | 3 | 6.0 |
Liver/*physiology | 2 | 4.0 |
Injections, Intramuscular | 6 | 3.0 |
Interleukin-6/*blood/immunology | 4 | 44.0 |
*Parenteral Nutrition, Total | 7 | 11.0 |
Interleukin-1/immunology/pharmacology | 4 | 44.0 |
Transforming Growth Factor beta/pharmacology/*physiology | 3 | 12.0 |
Adjuvants, Immunologic/*physiology | 3 | 9.0 |
Tumor Necrosis Factor-alpha/antagonists & inhibitors/secretion | 2 | 15.0 |
Interferons/blood | 5 | 55.0 |
Recombinant Proteins/administration & dosage | 17 | 19.0 |
Ghana | 2 | 10.0 |
Malaria, Falciparum/blood/*immunology/physiopathology | 2 | 100.0 |
Lymphocytes/*drug effects/immunology | 3 | 12.0 |
Roxithromycin/administration & dosage/*pharmacology | 2 | 100.0 |
Trachea | 6 | 23.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/biosynthesis | 9 | 22.0 |
Recombinant Proteins/chemistry/immunology | 2 | 7.0 |
*Artemisinins | 3 | 23.0 |
Cytokines/*antagonists & inhibitors | 5 | 33.0 |
Fibroblasts/cytology/drug effects | 6 | 15.0 |
Cytokines/metabolism/*pharmacology | 2 | 22.0 |
Endometrium/cytology/*metabolism | 2 | 6.0 |
Immunoglobulin G/*immunology | 7 | 7.0 |
Tuberculin/*immunology | 3 | 17.0 |
MAP Kinase Kinase Kinases/genetics/*metabolism | 3 | 33.0 |
Adjuvants, Immunologic/administration & dosage/*therapeutic use | 3 | 33.0 |
Monte Carlo Method | 3 | 4.0 |
Periodontitis/genetics/*immunology | 2 | 28.0 |
Colorimetry/methods | 2 | 22.0 |
Tetrazolium Salts | 4 | 7.0 |
Thiazoles | 4 | 7.0 |
Lung/microbiology | 2 | 11.0 |
Endothelium, Vascular/cytology/drug effects/metabolism | 3 | 7.0 |
Monocytes/cytology/drug effects/immunology/metabolism | 2 | 50.0 |
Nucleic Acid Hybridization/*methods | 2 | 4.0 |
Alanine Transaminase/blood | 7 | 3.0 |
Dactinomycin/administration & dosage | 3 | 15.0 |
Galactosamine/administration & dosage | 2 | 100.0 |
Liver/drug effects/pathology | 4 | 21.0 |
Tumor Necrosis Factor-alpha/administration & dosage/*toxicity | 5 | 100.0 |
Chlamydophila pneumoniae/*immunology | 2 | 11.0 |
Leukocytes, Mononuclear/*immunology/microbiology | 3 | 75.0 |
Dyes | 2 | 1.0 |
Fibrosarcoma/pathology | 5 | 27.0 |
Interferon Alfa-2b/pharmacology | 2 | 22.0 |
Selection (Genetics) | 3 | 2.0 |
Liver/microbiology | 3 | 30.0 |
Spleen/microbiology | 3 | 30.0 |
Ceftazidime/therapeutic use | 2 | 66.0 |
Cephalosporins/therapeutic use | 2 | 33.0 |
Lactates/blood | 9 | 12.0 |
Macrophage Inflammatory Protein-1/blood | 4 | 44.0 |
4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone/pharmacology | 3 | 42.0 |
Adenosine Deaminase/pharmacology | 2 | 50.0 |
Chemotactic Factors/*pharmacology | 4 | 11.0 |
Complement 5a/pharmacology | 6 | 25.0 |
Homeostasis/*physiology | 2 | 4.0 |
Neutrophils/*drug effects/metabolism/ultrastructure | 2 | 100.0 |
Pancreatic Elastase/*metabolism | 3 | 18.0 |
Weight Gain/*physiology | 2 | 33.0 |
Biological Markers/cerebrospinal fluid | 2 | 7.0 |
Interleukin-1/cerebrospinal fluid | 6 | 85.0 |
Interleukin-6/cerebrospinal fluid | 3 | 27.0 |
Interleukin-8/cerebrospinal fluid | 2 | 66.0 |
Protein Kinase C/*antagonists & inhibitors | 3 | 9.0 |
Autoantibodies/immunology | 3 | 2.0 |
Cell Adhesion Molecules/immunology | 3 | 4.0 |
Intestinal Mucosa/immunology | 2 | 3.0 |
Receptors, Cytokine/antagonists & inhibitors | 2 | 100.0 |
Antigens, CD/genetics/immunology/*physiology | 2 | 25.0 |
DNA-Binding Proteins/physiology | 3 | 1.0 |
Interleukin-8/*genetics/metabolism | 3 | 33.0 |
Luciferases/genetics/metabolism | 2 | 0.0 |
Bacterial Infections/*blood | 3 | 25.0 |
Fetal Blood/*metabolism | 3 | 6.0 |
RNA, Messenger/blood | 5 | 9.0 |
Listeria monocytogenes/*immunology | 2 | 40.0 |
Receptors, Cell Surface/immunology/*physiology | 3 | 20.0 |
Fibroblasts/drug effects | 14 | 15.0 |
Arthritis, Rheumatoid/*therapy | 2 | 11.0 |
Blood Pressure | 12 | 1.0 |
Iodine Radioisotopes/diagnostic use | 9 | 2.0 |
Peptides/*blood | 3 | 4.0 |
NF-kappa B/antagonists & inhibitors/*physiology | 2 | 11.0 |
Cystic Fibrosis/*metabolism | 3 | 6.0 |
Norepinephrine/metabolism | 2 | 4.0 |
Receptors, Fc/metabolism | 6 | 12.0 |
Receptors, Interleukin-8A | 3 | 9.0 |
Tumor Necrosis Factor-alpha/analysis/pharmacology/*physiology | 2 | 50.0 |
Fibroblasts/cytology/physiology | 5 | 6.0 |
Gene Targeting | 5 | 1.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/genetics/metabolism | 2 | 50.0 |
Cross-Linking Reagents | 19 | 5.0 |
Cytokines/biosynthesis/drug effects | 5 | 38.0 |
Lymphocyte Activation/*immunology | 9 | 2.0 |
Mitogen-Activated Protein Kinases/drug effects/metabolism | 2 | 4.0 |
NF-kappa B/metabolism/*physiology | 2 | 13.0 |
RNA Interference | 3 | 1.0 |
Ubiquitin/metabolism | 3 | 1.0 |
Chemotherapy, Adjuvant | 3 | 1.0 |
Cytokines/*analysis/metabolism | 2 | 66.0 |
*Exercise | 3 | 2.0 |
Cytokines/genetics/*physiology | 2 | 28.0 |
Inflammation/pathology | 4 | 7.0 |
Thromboxane B2/biosynthesis | 3 | 13.0 |
Blood Platelets/*chemistry | 2 | 5.0 |
CCAAT-Enhancer-Binding Proteins/metabolism | 2 | 4.0 |
Epithelium, Corneal/*drug effects/metabolism | 2 | 66.0 |
Inflammation/genetics/immunology | 2 | 25.0 |
Free Radical Scavengers/metabolism | 2 | 14.0 |
Glutathione Peroxidase/blood | 3 | 8.0 |
Superoxide Dismutase/blood | 2 | 4.0 |
Factor V/genetics | 2 | 2.0 |
Peptidyl-Dipeptidase A/genetics | 2 | 2.0 |
Premature Birth/epidemiology/*genetics | 2 | 100.0 |
Joint Prosthesis/*adverse effects | 3 | 42.0 |
Membrane Glycoproteins/*genetics/*metabolism | 3 | 12.0 |
DNA, Complementary/biosynthesis/genetics | 2 | 4.0 |
Ovulation/*physiology | 2 | 10.0 |
Anemia, Sickle Cell/*blood | 2 | 6.0 |
Adjuvants, Immunologic/pharmacology/*therapeutic use | 2 | 33.0 |
Interferon Type II/drug effects/*metabolism | 2 | 100.0 |
Multiple Sclerosis/*drug therapy/immunology | 2 | 14.0 |
Antineoplastic Agents/*adverse effects/therapeutic use | 2 | 25.0 |
Lymphoma/*drug therapy | 3 | 27.0 |
Antigens, Differentiation, T-Lymphocyte/*metabolism | 2 | 1.0 |
Conjunctivitis/*metabolism/pathology | 2 | 66.0 |
HLA-DR Antigens/metabolism | 7 | 4.0 |
Pentoxifylline/administration & dosage | 2 | 66.0 |
B-Lymphocytes/drug effects/*metabolism | 2 | 9.0 |
Furans/*pharmacology | 2 | 16.0 |
T-Lymphocytes/drug effects/*metabolism | 3 | 6.0 |
Cell Movement/drug effects/physiology | 2 | 3.0 |
Neutrophils/*cytology | 2 | 10.0 |
Photomicrography | 2 | 14.0 |
Liver/pathology | 9 | 4.0 |
Monocytes | 14 | 15.0 |
Trypsin | 3 | 1.0 |
Interleukin-8/*pharmacology | 6 | 35.0 |
Multiple Myeloma/metabolism/*pathology | 2 | 10.0 |
Cell Movement/immunology | 6 | 6.0 |
Macrophages/immunology/*metabolism | 6 | 20.0 |
Socioeconomic Factors | 2 | 1.0 |
Immunoglobulin E/*biosynthesis | 3 | 6.0 |
Lymphotoxin/*physiology | 6 | 100.0 |
Microfilament Proteins/*metabolism | 2 | 3.0 |
Receptors, Immunologic/metabolism | 4 | 2.0 |
Cadherins/*metabolism | 3 | 4.0 |
Cytokines/biosynthesis/*metabolism | 2 | 33.0 |
HLA-DR Antigens/*immunology | 3 | 2.0 |
Glutathione/metabolism | 11 | 5.0 |
Tumor Necrosis Factor-alpha/*immunology/*metabolism | 3 | 100.0 |
Reactive Oxygen Species/physiology | 2 | 25.0 |
*Enhancer Elements (Genetics) | 4 | 1.0 |
Antigens, Differentiation, T-Lymphocyte | 2 | 0.0 |
CD8-Positive T-Lymphocytes | 2 | 2.0 |
Cytomegalovirus Infections/etiology/*immunology | 2 | 50.0 |
Kidney Transplantation/*adverse effects | 3 | 5.0 |
Respiratory Distress Syndrome, Adult/*metabolism | 2 | 22.0 |
Monocytes/cytology/*immunology | 4 | 11.0 |
Receptors, Nerve Growth Factor/*metabolism | 2 | 4.0 |
Leukocyte Count/drug effects | 24 | 20.0 |
Receptors, Tumor Necrosis Factor/*blood/immunology | 2 | 100.0 |
Antioxidants/metabolism | 4 | 4.0 |
Hydrogen Peroxide/metabolism | 11 | 8.0 |
Sulfhydryl Compounds/metabolism | 2 | 5.0 |
Pulmonary Artery/*metabolism | 2 | 40.0 |
Blood Transfusion/*adverse effects | 4 | 6.0 |
Chemokines/blood | 2 | 20.0 |
Fever/*etiology | 5 | 50.0 |
Leukapheresis | 2 | 1.0 |
Platelet Transfusion/*adverse effects | 2 | 25.0 |
Arthritis, Rheumatoid/metabolism | 8 | 25.0 |
Calcium-Binding Proteins/metabolism | 2 | 2.0 |
Gene Expression Regulation, Enzymologic/drug effects | 4 | 2.0 |
Osteoarthritis/metabolism | 5 | 14.0 |
Transforming Growth Factors/pharmacology | 3 | 16.0 |
Caspases/*antagonists & inhibitors/*metabolism | 3 | 75.0 |
Fatty Acid Desaturases/*metabolism | 2 | 22.0 |
Arthritis, Rheumatoid/*drug therapy/physiopathology | 3 | 75.0 |
Methotrexate/*therapeutic use | 2 | 8.0 |
Metoprolol/pharmacology | 3 | 60.0 |
Receptors, Adrenergic, beta-1/antagonists & inhibitors | 2 | 100.0 |
T-Lymphocytes/drug effects | 9 | 15.0 |
Tetanus Toxoid/pharmacology | 3 | 12.0 |
Antibodies, Antinuclear/blood | 2 | 4.0 |
Autoantibodies/*blood | 2 | 0.0 |
Immunoglobulin A/blood | 4 | 3.0 |
Immunoglobulins/metabolism | 3 | 2.0 |
Membrane Proteins/*genetics/*immunology | 2 | 50.0 |
Autoantibodies/analysis | 5 | 2.0 |
Skin Diseases, Vesiculobullous/*immunology | 2 | 9.0 |
Immunoglobulin E/*immunology | 2 | 8.0 |
Mast Cells/*immunology | 2 | 7.0 |
Biological Response Modifiers/*therapeutic use | 8 | 34.0 |
Leukocytes, Mononuclear/immunology/*metabolism | 8 | 53.0 |
*Evolution | 2 | 1.0 |
Likelihood Functions | 3 | 1.0 |
Heterozygote Detection | 3 | 0.0 |
Interleukin-6/*blood/*genetics | 2 | 66.0 |
Outcome Assessment (Health Care) | 2 | 4.0 |
Finland | 3 | 1.0 |
Electrophoresis, Gel, Two-Dimensional | 8 | 2.0 |
*Genetic Techniques | 2 | 3.0 |
Genome | 4 | 1.0 |
Arthritis, Rheumatoid/*drug therapy/pathology/physiopathology | 2 | 66.0 |
Lymphocytes/drug effects | 4 | 5.0 |
Synovial Membrane/pathology/physiopathology | 2 | 50.0 |
Sialoglycoproteins/*therapeutic use | 2 | 100.0 |
Weight Loss/*physiology | 5 | 15.0 |
Monensin/pharmacology | 6 | 11.0 |
Monocytes/immunology/*metabolism | 8 | 16.0 |
European Continental Ancestry Group | 7 | 1.0 |
Poland | 2 | 1.0 |
African Americans | 3 | 2.0 |
Antioxidants/therapeutic use | 2 | 14.0 |
Neutrophils/metabolism/*physiology | 3 | 17.0 |
Receptor, Epidermal Growth Factor/physiology | 2 | 2.0 |
Breast Neoplasms/*genetics/*pathology | 2 | 3.0 |
Genetic Predisposition to Disease/*genetics | 7 | 1.0 |
Gene Expression Regulation, Bacterial | 2 | 3.0 |
Granulocyte-Macrophage Colony-Stimulating Factor | 32 | 40.0 |
Interleukin-1 | 3 | 25.0 |
Interleukin-6 | 15 | 33.0 |
Inflammation Mediators/immunology/*metabolism | 2 | 66.0 |
Th1 Cells/immunology/metabolism | 4 | 10.0 |
Th2 Cells/immunology/metabolism | 3 | 7.0 |
Antigens, CD14/genetics/*metabolism | 2 | 11.0 |
Dendritic Cells/cytology/*immunology | 2 | 3.0 |
*Genetic Vectors | 6 | 1.0 |
Lentivirus/*genetics | 2 | 5.0 |
Neoplasm Proteins/metabolism | 4 | 1.0 |
DNA/genetics/isolation & purification | 6 | 2.0 |
Data Interpretation, Statistical | 5 | 2.0 |
HLA-B Antigens/genetics | 8 | 3.0 |
Cell Adhesion Molecules/*genetics | 9 | 9.0 |
DNA | 13 | 1.0 |
Down-Regulation/genetics | 2 | 3.0 |
*Response Elements | 2 | 3.0 |
Poisoning/metabolism/pathology | 2 | 100.0 |
Toxins/*toxicity | 2 | 100.0 |
Xenobiotics/*toxicity | 2 | 20.0 |
Creatinine/metabolism | 2 | 2.0 |
Kidney Failure, Chronic/*blood/therapy | 4 | 7.0 |
Membrane Glycoproteins/*blood | 3 | 5.0 |
Cell Wall/*chemistry/*immunology | 2 | 100.0 |
Membrane Glycoproteins/immunology/metabolism | 3 | 10.0 |
Bone Marrow/*metabolism/pathology | 3 | 16.0 |
HIV Infections/*metabolism/pathology | 2 | 33.0 |
Intercellular Adhesion Molecule-1/*biosynthesis | 11 | 25.0 |
Th2 Cells/drug effects/metabolism | 2 | 33.0 |
Vascular Cell Adhesion Molecule-1/*biosynthesis | 7 | 43.0 |
Asthma/immunology | 2 | 5.0 |
Bronchi | 2 | 16.0 |
Bronchiectasis/immunology | 2 | 100.0 |
Bronchiolitis/immunology | 2 | 100.0 |
Histamine/pharmacology | 2 | 3.0 |
Interleukin-16/genetics/*metabolism | 2 | 100.0 |
Sputum/immunology | 3 | 60.0 |
HIV-1/genetics/isolation & purification | 2 | 10.0 |
Antigens, CD30/*analysis | 2 | 10.0 |
Hodgkin Disease/*immunology | 3 | 11.0 |
Sphingosine/analogs & derivatives/metabolism/pharmacology | 2 | 40.0 |
Protein Engineering | 5 | 5.0 |
HIV-1/*genetics | 5 | 1.0 |
Leukemia | 5 | 7.0 |
HLA-DQ Antigens/blood/genetics | 2 | 66.0 |
HLA-DR Antigens/blood/genetics | 2 | 28.0 |
Catalase/pharmacology | 7 | 17.0 |
Fibrinolysis | 8 | 5.0 |
Free Radicals/metabolism | 6 | 11.0 |
Killer Cells, Natural/*immunology/metabolism | 2 | 5.0 |
Tumor Cells, Cultured/immunology/metabolism | 3 | 18.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/genetics | 7 | 25.0 |
Leukocytes, Mononuclear/cytology/drug effects/immunology | 2 | 12.0 |
Annexin A5/metabolism | 6 | 7.0 |
HIV Protease Inhibitors/*pharmacology | 2 | 7.0 |
Arteriosclerosis/metabolism | 2 | 3.0 |
Endothelium, Vascular/drug effects | 7 | 11.0 |
*Lysophospholipids | 2 | 5.0 |
Phosphotransferases (Alcohol Group Acceptor)/metabolism | 2 | 2.0 |
Breast Neoplasms/metabolism/*pathology | 3 | 3.0 |
Nuclear Proteins/*metabolism | 9 | 1.0 |
Staurosporine/pharmacology | 10 | 5.0 |
Pulmonary Alveoli/metabolism | 2 | 20.0 |
Receptors, Interleukin-1/*antagonists & inhibitors | 21 | 61.0 |
Sialoglycoproteins/*metabolism | 2 | 7.0 |
Cytokines/*metabolism/pharmacology | 2 | 15.0 |
Granulocyte Colony-Stimulating Factor/metabolism/pharmacology | 2 | 100.0 |
Interleukin-8/metabolism/pharmacology | 2 | 50.0 |
Neutrophil Activation | 11 | 22.0 |
Collagenases/metabolism | 4 | 11.0 |
Interleukin-12/*pharmacology | 3 | 6.0 |
Colitis, Ulcerative/genetics | 4 | 23.0 |
*Gene Expression Regulation, Developmental | 3 | 0.0 |
Membrane Proteins/*genetics/*metabolism | 2 | 4.0 |
Morphogenesis | 2 | 0.0 |
Protein Isoforms/genetics/metabolism | 2 | 1.0 |
Receptor, Epidermal Growth Factor/metabolism | 4 | 0.0 |
Endothelin-1/*blood | 2 | 9.0 |
Pulmonary Circulation/*physiology | 5 | 38.0 |
Multiple Sclerosis/*metabolism | 2 | 10.0 |
Protein Kinase C/antagonists & inhibitors | 9 | 7.0 |
Bacterial Infections/*immunology/physiopathology | 2 | 100.0 |
Inflammation/*immunology/physiopathology | 2 | 66.0 |
Lung Compliance | 2 | 22.0 |
Islets of Langerhans/pathology | 2 | 28.0 |
Antibodies, Viral/immunology | 5 | 6.0 |
Peptides/*pharmacology | 4 | 1.0 |
Vesicular stomatitis-Indiana virus/immunology/physiology | 2 | 66.0 |
Interleukin-6/blood/physiology | 2 | 50.0 |
Jejunum/metabolism | 2 | 14.0 |
Adjuvants, Immunologic/pharmacology | 12 | 13.0 |
Neoplasms/immunology | 7 | 12.0 |
Receptors, Interleukin/physiology | 2 | 13.0 |
Interleukin-6/*urine | 2 | 66.0 |
Tumor Necrosis Factor-alpha/*urine | 5 | 100.0 |
Down-Regulation/*immunology | 3 | 5.0 |
Immunoglobulins, Fab/immunology | 5 | 4.0 |
Protein Binding/immunology | 2 | 1.0 |
Carrier Proteins/genetics/metabolism | 3 | 1.0 |
DNA-Binding Protein, Cyclic AMP-Responsive/*metabolism | 3 | 4.0 |
Kidney Diseases/chemically induced/metabolism | 2 | 66.0 |
Chromium Radioisotopes/metabolism | 2 | 18.0 |
Fluorescent Dyes/metabolism | 3 | 4.0 |
Asthma/*immunology | 4 | 4.0 |
Cytokines/*drug effects/metabolism | 2 | 40.0 |
Sputum/*cytology | 2 | 18.0 |
Tumor Necrosis Factor-alpha/drug effects/metabolism | 4 | 44.0 |
Liver/*immunology | 3 | 7.0 |
Bronchi/metabolism | 2 | 8.0 |
*Occupational Exposure | 3 | 2.0 |
Respiratory Mucosa/metabolism | 3 | 20.0 |
Cytokines/analysis/*metabolism | 6 | 85.0 |
Interleukin-6/analysis/metabolism | 2 | 66.0 |
Interleukin-6/*analysis/blood | 3 | 30.0 |
Plasminogen Activator Inhibitor 1/analysis | 3 | 9.0 |
alpha 1-Antitrypsin/analysis | 4 | 4.0 |
Cell Cycle Proteins/metabolism | 3 | 0.0 |
Sarcoma/*drug therapy | 2 | 22.0 |
Histamine/*pharmacology | 2 | 5.0 |
Monocytes/drug effects/immunology/*metabolism | 3 | 23.0 |
Receptors, Tumor Necrosis Factor, Type I/blood | 3 | 100.0 |
Drug Delivery Systems | 5 | 5.0 |
Microspheres | 5 | 2.0 |
Neoplasms/*metabolism | 3 | 3.0 |
Anti-Infective Agents, Local/pharmacology | 2 | 66.0 |
Formaldehyde/pharmacology | 2 | 7.0 |
Gamma Rays | 8 | 3.0 |
Polymers/pharmacology | 2 | 9.0 |
Sodium Dodecyl Sulfate/pharmacology | 2 | 8.0 |
Breast Neoplasms/*immunology/pathology | 2 | 8.0 |
Lung/drug effects/pathology | 2 | 50.0 |
Inflammation/physiopathology | 14 | 24.0 |
Apoptosis/*drug effects/genetics | 2 | 6.0 |
Lung/drug effects/*metabolism | 2 | 20.0 |
Anti-Inflammatory Agents, Non-Steroidal/pharmacology/*therapeutic use | 3 | 50.0 |
Macaca fascicularis | 8 | 2.0 |
Mice, Inbred ICR | 14 | 6.0 |
Monocytes/drug effects/immunology/metabolism | 4 | 21.0 |
Phagocytosis/drug effects/immunology | 2 | 22.0 |
Prednisolone/pharmacology/therapeutic use | 2 | 66.0 |
T-Lymphocytes/drug effects/immunology/metabolism | 2 | 11.0 |
Superoxide Dismutase/*genetics | 6 | 3.0 |
Cell Aggregation/drug effects | 6 | 13.0 |
Cytokines/*biosynthesis/secretion | 2 | 40.0 |
Germinal Center/cytology | 2 | 25.0 |
Lymphocytes/*metabolism | 4 | 2.0 |
Tonsil/cytology | 4 | 4.0 |
Macrophages/drug effects | 11 | 36.0 |
T-Lymphocytes/*drug effects | 3 | 4.0 |
Tumor Necrosis Factor-alpha/antagonists & inhibitors/*biosynthesis | 9 | 100.0 |
*Immune Tolerance/drug effects | 2 | 40.0 |
Interleukin-6/*biosynthesis/genetics | 14 | 37.0 |
Intracellular Fluid/metabolism | 4 | 3.0 |
Microscopy, Electron, Scanning | 9 | 3.0 |
NG-Nitroarginine Methyl Ester/pharmacology | 7 | 14.0 |
Threonine/metabolism | 3 | 3.0 |
Liver/metabolism | 15 | 1.0 |
Receptors, Tumor Necrosis Factor/blood/genetics/*metabolism | 2 | 100.0 |
Tumor Cells, Cultured/drug effects/metabolism | 10 | 5.0 |
*Enteral Nutrition | 3 | 12.0 |
Glutamine/administration & dosage/*therapeutic use | 2 | 100.0 |
Injury Severity Score | 8 | 23.0 |
Sepsis/*prevention & control | 2 | 100.0 |
Aminoquinolines/*therapeutic use | 2 | 16.0 |
Cytokines/biosynthesis/genetics | 8 | 13.0 |
Hypothermia/chemically induced | 2 | 100.0 |
Organ Size/drug effects | 5 | 5.0 |
Glasgow Coma Scale | 2 | 7.0 |
Bacterial Toxins/*toxicity | 7 | 33.0 |
Cytotoxins/*toxicity | 5 | 45.0 |
Endothelium, Vascular/drug effects/*pathology | 2 | 66.0 |
Recombinant Proteins/toxicity | 12 | 57.0 |
Shiga Toxins | 6 | 40.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/*metabolism | 25 | 8.0 |
Protein-Serine-Threonine Kinases/biosynthesis/chemistry/*metabolism | 3 | 100.0 |
Proteins/genetics/metabolism/*physiology | 2 | 5.0 |
Signal Transduction/genetics/*immunology | 3 | 3.0 |
Administration, Intravesical | 6 | 23.0 |
BCG Vaccine/*therapeutic use | 2 | 11.0 |
Bronchoalveolar Lavage Fluid/*chemistry/cytology | 5 | 38.0 |
Ferritin/*metabolism | 2 | 7.0 |
Iron/*metabolism | 4 | 3.0 |
Antiviral Agents/*therapeutic use | 7 | 5.0 |
Interferon Alfa-2b/*therapeutic use | 4 | 10.0 |
Survivors | 3 | 3.0 |
Bronchoalveolar Lavage Fluid/cytology/*immunology | 2 | 18.0 |
Receptors, Tumor Necrosis Factor/blood/*metabolism | 2 | 100.0 |
Dexamethasone/*therapeutic use | 3 | 16.0 |
Alzheimer Disease/*blood | 5 | 35.0 |
Brain/*blood supply | 4 | 12.0 |
Gelatinase B | 5 | 6.0 |
Integrin alpha4beta1 | 5 | 5.0 |
Integrins/physiology | 3 | 4.0 |
Intercellular Adhesion Molecule-1/physiology | 2 | 8.0 |
Leukocytes/*drug effects/physiology | 2 | 66.0 |
Microcirculation/cytology | 3 | 15.0 |
Receptors, Lymphocyte Homing/physiology | 2 | 9.0 |
Vascular Cell Adhesion Molecule-1/physiology | 2 | 16.0 |
Epithelial Cells/drug effects | 2 | 6.0 |
Interleukin-1/pharmacology/physiology | 3 | 60.0 |
Recombination, Genetic | 6 | 0.0 |
Sialoglycoproteins/*pharmacology | 5 | 35.0 |
Apoptosis/drug effects/genetics/*physiology | 3 | 15.0 |
DNA Probes/genetics | 3 | 2.0 |
Heart Transplantation/*immunology | 6 | 9.0 |
Tumor Necrosis Factor-alpha/*genetics/*metabolism | 4 | 80.0 |
*Obesity | 3 | 5.0 |
Omentum | 2 | 12.0 |
Asthma/epidemiology/*genetics | 2 | 28.0 |
Australia/epidemiology | 2 | 3.0 |
Haplotypes/*genetics | 5 | 2.0 |
Eicosanoids/*metabolism | 2 | 25.0 |
*Hemodynamic Processes | 3 | 6.0 |
Genes | 2 | 0.0 |
Mucocutaneous Lymph Node Syndrome/*genetics | 2 | 50.0 |
Protein Kinase C/*physiology | 9 | 10.0 |
Trauma Severity Indices | 4 | 23.0 |
Estradiol/*pharmacology | 10 | 4.0 |
Tumor Necrosis Factor-alpha/biosynthesis/*genetics/pharmacology | 2 | 100.0 |
Brain/pathology | 2 | 0.0 |
*Immunoglobulins, Heavy-Chain | 2 | 33.0 |
Multiple Sclerosis/*drug therapy/physiopathology | 3 | 60.0 |
Protein-Tyrosine-Phosphatase/*antagonists & inhibitors | 5 | 25.0 |
*Acute-Phase Proteins | 6 | 3.0 |
Immunity, Cellular/*immunology | 2 | 7.0 |
Immunoglobulin E/analysis | 3 | 5.0 |
Sepsis/*genetics/mortality | 2 | 100.0 |
Nitric-Oxide Synthase/antagonists & inhibitors | 7 | 14.0 |
Sepsis/*physiopathology | 4 | 36.0 |
Cytokines | 60 | 56.0 |
Pulmonary Alveoli/cytology/drug effects/*metabolism | 2 | 66.0 |
Interleukin-5/genetics | 2 | 15.0 |
Receptors, Interleukin/genetics | 3 | 10.0 |
Fetal Blood | 4 | 2.0 |
Th1 Cells/immunology/*metabolism | 2 | 25.0 |
Moscow/epidemiology | 2 | 25.0 |
Lymphocytes, Tumor-Infiltrating/drug effects/*immunology | 3 | 100.0 |
Neoplasm Proteins/*biosynthesis | 5 | 5.0 |
Endothelial Growth Factors/*metabolism | 2 | 0.0 |
Lymphokines/*metabolism | 2 | 0.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/metabolism | 15 | 4.0 |
Epithelial Cells | 21 | 4.0 |
Thymus Gland/cytology | 6 | 6.0 |
Discriminant Analysis | 2 | 2.0 |
Leukocytes, Mononuclear/drug effects/immunology/metabolism | 2 | 14.0 |
Adipocytes/drug effects/*metabolism | 2 | 15.0 |
Epidermal Growth Factor/metabolism | 3 | 0.0 |
Extracellular Space/metabolism | 2 | 3.0 |
DNA, Satellite/genetics | 2 | 1.0 |
Genes, Structural | 11 | 1.0 |
*Protein Processing, Post-Translational | 7 | 2.0 |
Saccharomyces cerevisiae/genetics | 5 | 1.0 |
Antigens, CD/*analysis | 14 | 1.0 |
Fibrin Fibrinogen Degradation Products/metabolism | 3 | 3.0 |
Adsorption | 5 | 3.0 |
Convection | 2 | 66.0 |
Diffusion | 4 | 4.0 |
Renal Replacement Therapy/*methods | 2 | 100.0 |
Bone Resorption/immunology | 2 | 66.0 |
Quality of Health Care | 2 | 18.0 |
Antibodies, Monoclonal/adverse effects/therapeutic use | 6 | 66.0 |
Neutrophils/*cytology/metabolism | 3 | 42.0 |
Polysaccharides/*pharmacology | 4 | 17.0 |
Wound Healing/drug effects | 3 | 9.0 |
Antigens, CD40/*physiology | 6 | 16.0 |
Buffers | 3 | 2.0 |
Hepatocytes/*metabolism | 2 | 4.0 |
Receptor, Epidermal Growth Factor/*metabolism | 5 | 0.0 |
Thymidine/metabolism | 18 | 5.0 |
Antithrombin III/analysis | 2 | 1.0 |
Carrier Proteins/blood | 4 | 3.0 |
Fibrin Fibrinogen Degradation Products/analysis | 2 | 1.0 |
Thrombomodulin/analysis | 3 | 10.0 |
Tissue Plasminogen Activator/analysis | 4 | 10.0 |
Recombinant Fusion Proteins/adverse effects/*therapeutic use | 3 | 75.0 |
Bone Morphogenetic Proteins/analysis | 2 | 33.0 |
DNA, Complementary/isolation & purification | 2 | 1.0 |
Myocardium/*metabolism/pathology | 3 | 11.0 |
MAP Kinase Kinase 6 | 3 | 10.0 |
Stress/*metabolism | 2 | 11.0 |
*Caenorhabditis elegans Proteins | 2 | 1.0 |
GTP-Binding Proteins/metabolism | 5 | 1.0 |
Interleukin-6/*blood/secretion | 3 | 100.0 |
Macrophages/drug effects/secretion | 2 | 100.0 |
Tumor Necrosis Factor-alpha/*analysis/secretion | 3 | 100.0 |
Membrane Proteins/*chemistry/genetics | 2 | 15.0 |
Pancreas/enzymology | 2 | 5.0 |
Tumor Necrosis Factor-alpha/*chemistry/genetics/pharmacology | 2 | 100.0 |
Culture Media, Conditioned/metabolism | 3 | 10.0 |
Sialoglycoproteins/metabolism | 3 | 6.0 |
Ischemic Preconditioning, Myocardial | 2 | 50.0 |
Kidney/metabolism/pathology | 2 | 6.0 |
Tumor Necrosis Factor-alpha/*adverse effects/antagonists & | 2 | 100.0 |
Antigens, Viral/*blood | 2 | 15.0 |
DNA, Viral/analysis | 6 | 1.0 |
Leukocytes, Mononuclear/virology | 3 | 2.0 |
Virus Latency | 4 | 6.0 |
Ovarian Neoplasms | 3 | 8.0 |
Sepsis/genetics | 2 | 100.0 |
Antigens, CD14/immunology/*physiology | 2 | 22.0 |
*Gene Expression Regulation, Neoplastic/drug effects | 2 | 3.0 |
Neoplasm Proteins/*biosynthesis/genetics | 2 | 1.0 |
Antigens, CD/genetics/metabolism/*physiology | 2 | 50.0 |
Lymphotoxin/genetics/*physiology | 3 | 100.0 |
Receptors, Tumor Necrosis Factor/genetics/metabolism/*physiology | 3 | 100.0 |
Tumor Necrosis Factor-alpha/deficiency/genetics/*physiology | 2 | 100.0 |
Granulocyte Colony-Stimulating Factor/*therapeutic use | 4 | 6.0 |
L-Selectin/biosynthesis | 2 | 10.0 |
Tretinoin/*therapeutic use | 2 | 9.0 |
Killer Cells, Natural/drug effects | 3 | 8.0 |
Rosette Formation | 4 | 1.0 |
BCG Vaccine/therapeutic use | 3 | 60.0 |
Immunotherapy, Adoptive | 5 | 7.0 |
Interferons/therapeutic use | 5 | 17.0 |
Lentinan/therapeutic use | 3 | 100.0 |
Picibanil/therapeutic use | 4 | 80.0 |
Proteoglycans/therapeutic use | 2 | 100.0 |
Receptor, Nerve Growth Factor | 2 | 6.0 |
DNA-Binding Proteins/genetics/*metabolism | 4 | 0.0 |
I-kappa B | 5 | 50.0 |
Lung Neoplasms/secondary | 4 | 4.0 |
1-Methyl-3-isobutylxanthine/pharmacology | 15 | 15.0 |
Adenylate Cyclase/metabolism | 5 | 3.0 |
Estradiol/*secretion | 3 | 37.0 |
Receptors, Antigen, T-Cell, gamma-delta/*immunology | 2 | 4.0 |
Proto-Oncogene Proteins c-bcl-2/genetics/physiology | 2 | 22.0 |
Serpins/genetics/physiology | 2 | 50.0 |
HLA Antigens/*immunology | 4 | 1.0 |
Histocompatibility Antigens Class I/*immunology | 3 | 2.0 |
Bacteremia/*blood | 2 | 50.0 |
Endotoxins/blood/*toxicity | 2 | 100.0 |
Lethal Dose 50 | 10 | 16.0 |
Concanavalin A/pharmacology | 19 | 9.0 |
Leukocytes, Mononuclear/drug effects/immunology | 5 | 10.0 |
Pyrazoles/pharmacology | 2 | 4.0 |
Pyrimidines/pharmacology | 3 | 2.0 |
Critical Care | 7 | 41.0 |
Erythroid Progenitor Cells/*drug effects | 2 | 15.0 |
Erythropoiesis/*drug effects | 6 | 12.0 |
Sphingomyelin Phosphodiesterase/pharmacology | 4 | 25.0 |
Carrier Proteins/genetics/*metabolism | 5 | 1.0 |
Gene Products, tax/genetics/metabolism | 2 | 66.0 |
Protein-Serine-Threonine Kinases/genetics/metabolism | 5 | 4.0 |
Yeasts/genetics | 2 | 2.0 |
Stroke Volume | 4 | 6.0 |
Carrier Proteins/genetics/pharmacology/*physiology | 2 | 50.0 |
Oligodeoxyribonucleotides/genetics/metabolism | 2 | 14.0 |
Recombinant Proteins/genetics/pharmacology | 2 | 6.0 |
Sarcoma, Experimental/*drug therapy | 2 | 100.0 |
Abdomen | 2 | 2.0 |
Adipocytes/metabolism | 3 | 7.0 |
Interferons/pharmacology | 12 | 17.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/physiology | 5 | 17.0 |
Interleukin-3/physiology | 2 | 6.0 |
Osteoclasts/*physiology | 4 | 20.0 |
Interferon Type II/*biosynthesis/immunology | 2 | 15.0 |
Glyceraldehyde-3-Phosphate Dehydrogenases/genetics | 4 | 10.0 |
Interleukin-1/genetics/pharmacology | 3 | 75.0 |
Thiophenes/*pharmacology | 2 | 12.0 |
Binding, Competitive/immunology | 5 | 5.0 |
Interleukin-1/antagonists & inhibitors | 5 | 41.0 |
Phosphotyrosine/metabolism | 5 | 1.0 |
Acquired Immunodeficiency Syndrome/immunology | 4 | 4.0 |
Hydroxyeicosatetraenoic Acids/*pharmacology | 2 | 20.0 |
Monokines/metabolism | 3 | 42.0 |
Neutrophils/*drug effects | 5 | 13.0 |
DNA, Recombinant/metabolism | 2 | 10.0 |
Regulatory Sequences, Nucleic Acid | 3 | 0.0 |
*Dust | 3 | 21.0 |
Interleukin-2/*pharmacology | 24 | 9.0 |
Somatostatin/*metabolism | 3 | 13.0 |
Ovary/*metabolism | 2 | 3.0 |
Energy Metabolism | 6 | 3.0 |
Growth Substances/*genetics | 2 | 1.0 |
Lymphokines/genetics | 3 | 3.0 |
Platelet-Derived Growth Factor/genetics | 2 | 6.0 |
Tumor Necrosis Factor-alpha/metabolism/pharmacology/*physiology | 2 | 100.0 |
Neopterin/*blood | 3 | 37.0 |
Calcitriol/*analogs & derivatives/pharmacology | 2 | 10.0 |
Cyclins/genetics | 2 | 1.0 |
Genes, myc | 6 | 2.0 |
Leukemia, Myelocytic, Acute/*pathology | 7 | 17.0 |
Tumor Necrosis Factor-alpha/*genetics/pharmacology | 5 | 83.0 |
Dimethyl Sulfoxide/pharmacology | 5 | 5.0 |
Interleukin-6/antagonists & inhibitors/*biosynthesis | 2 | 100.0 |
Acute-Phase Proteins/metabolism | 7 | 10.0 |
Hepatectomy/*adverse effects | 2 | 50.0 |
Leukocytes, Mononuclear/*chemistry | 3 | 18.0 |
Phenylpropionates/*pharmacology | 2 | 40.0 |
Brain Ischemia/*immunology | 2 | 100.0 |
Cell Adhesion Molecules/blood | 5 | 16.0 |
Complement | 2 | 4.0 |
Complement Activation/*immunology | 2 | 3.0 |
Simvastatin/*pharmacology/therapeutic use | 2 | 25.0 |
Lupus Erythematosus, Systemic/blood/*immunology | 3 | 7.0 |
Tumor Necrosis Factor-alpha/analysis/*immunology | 9 | 90.0 |
Antineoplastic Agents/pharmacology/therapeutic use | 2 | 6.0 |
Bone Marrow/drug effects/pathology | 3 | 33.0 |
Clone Cells/drug effects/pathology | 2 | 66.0 |
Methotrexate/administration & dosage | 2 | 2.0 |
Neovascularization, Physiologic/*drug effects | 3 | 3.0 |
Cytokines/*antagonists & inhibitors/*biosynthesis | 4 | 100.0 |
B-Lymphocytes/cytology/*immunology | 2 | 2.0 |
Proto-Oncogene Proteins c-bcl-2/physiology | 4 | 9.0 |
Lipids/immunology | 2 | 28.0 |
Phospholipases/metabolism | 4 | 22.0 |
Interphase | 3 | 1.0 |
Guanidines/pharmacology | 3 | 7.0 |
Receptor Aggregation | 2 | 2.0 |
Protein-Serine-Threonine Kinases | 2 | 10.0 |
Herpesvirus 4, Human/genetics/*metabolism | 2 | 25.0 |
Protein-Tyrosine Kinase/genetics/*metabolism | 2 | 1.0 |
Antigens, CD/chemistry/genetics/*physiology | 2 | 18.0 |
Interferon Type II/antagonists & inhibitors/pharmacology | 2 | 50.0 |
Tumor Necrosis Factor-alpha/*pharmacology/physiology | 10 | 76.0 |
Fibroblast Growth Factors/pharmacology | 3 | 4.0 |
Eosinophils/immunology | 2 | 3.0 |
Immunoglobulin A/*immunology | 2 | 7.0 |
Leukocytes/*physiology | 11 | 20.0 |
Gram-Negative Bacterial Infections/blood | 2 | 100.0 |
Shock, Septic/*microbiology | 2 | 66.0 |
HIV Infections/*blood | 5 | 10.0 |
Regeneration/physiology | 2 | 11.0 |
*Immunotherapy, Adoptive | 6 | 9.0 |
Neoplasms/immunology/*therapy | 7 | 13.0 |
Cell Division/*drug effects | 22 | 7.0 |
Cytokines/drug effects/metabolism | 2 | 33.0 |
Interleukins/*biosynthesis | 12 | 50.0 |
Complement 3/*biosynthesis | 3 | 6.0 |
Stomach Neoplasms/*immunology | 2 | 11.0 |
Islets of Langerhans/drug effects/*metabolism | 2 | 20.0 |
Tumor Necrosis Factor-alpha/pharmacology/physiology | 9 | 60.0 |
Antigens, CD27/*analysis | 2 | 20.0 |
Monocytes/*immunology/secretion | 2 | 40.0 |
Leukocytes, Mononuclear/cytology/metabolism | 2 | 12.0 |
Bronchoalveolar Lavage Fluid | 9 | 20.0 |
Sarcoidosis, Pulmonary/*metabolism | 2 | 66.0 |
Fetus/immunology | 2 | 5.0 |
Pre-Eclampsia/*genetics/immunology | 2 | 100.0 |
Antigens, CD95/metabolism/*physiology | 2 | 33.0 |
Cells, Cultured/drug effects/metabolism | 4 | 9.0 |
Extracellular Matrix/drug effects/metabolism | 2 | 11.0 |
Gelatinase A | 5 | 6.0 |
Spondylitis, Ankylosing/*genetics/immunology | 3 | 33.0 |
Rheumatoid Factor/analysis | 2 | 3.0 |
Recombinant Proteins/administration & dosage/pharmacokinetics | 3 | 30.0 |
Mitogens/*pharmacology | 5 | 4.0 |
Receptors, IgG/analysis | 2 | 3.0 |
Creatinine/blood | 5 | 1.0 |
Heart Failure, Congestive/*metabolism | 3 | 11.0 |
Pseudomonas aeruginosa/*isolation & purification | 2 | 100.0 |
Angiotensin II/*pharmacology | 3 | 2.0 |
Vasoconstrictor Agents/*pharmacology | 2 | 5.0 |
Interleukin-1/analysis/*biosynthesis | 2 | 33.0 |
Free Radical Scavengers/*therapeutic use | 2 | 28.0 |
Lymphocyte Subsets/*immunology | 4 | 3.0 |
Sepsis/*etiology | 2 | 100.0 |
Monocytes/drug effects/*metabolism | 40 | 32.0 |
Receptors, Immunologic/analysis | 4 | 4.0 |
T-Lymphocyte Subsets/*immunology | 7 | 1.0 |
Endotoxins | 9 | 40.0 |
Heart Rate/physiology | 2 | 2.0 |
Sepsis/physiopathology | 2 | 40.0 |
Superoxide Dismutase/genetics | 6 | 7.0 |
Fluorometry | 3 | 4.0 |
Hyaluronic Acid/*analysis | 2 | 10.0 |
Aortic Aneurysm, Abdominal/*blood/*surgery | 2 | 66.0 |
Italy | 8 | 1.0 |
Corticosterone/pharmacology | 2 | 18.0 |
Diffusion Chambers, Culture | 2 | 8.0 |
Extracellular Matrix/*physiology | 2 | 4.0 |
Membrane Proteins/biosynthesis | 2 | 3.0 |
Body Height | 4 | 2.0 |
Metalloendopeptidases/*metabolism | 7 | 7.0 |
Antineoplastic Agents, Alkylating/*pharmacology | 2 | 5.0 |
*Phenanthrenes | 2 | 33.0 |
Succinimides | 3 | 16.0 |
Lymphotoxin/metabolism | 8 | 80.0 |
*Molecular Chaperones | 4 | 2.0 |
Neoplasm Proteins/*physiology | 3 | 3.0 |
Pregnancy/*blood | 3 | 1.0 |
Hyaluronic Acid/metabolism | 2 | 2.0 |
Liver/*pathology | 4 | 7.0 |
Crohn Disease/blood/pathology/*therapy | 2 | 100.0 |
Interferon Type II/biosynthesis/blood | 4 | 23.0 |
Cytokines/*biosynthesis/blood/*immunology | 2 | 100.0 |
Leukocytes, Mononuclear/*immunology/metabolism | 3 | 23.0 |
Phagocytes/*immunology | 6 | 18.0 |
Serotyping | 6 | 2.0 |
Multiple Sclerosis/blood/cerebrospinal fluid/*metabolism | 3 | 60.0 |
Antineoplastic Agents/*administration & dosage | 10 | 17.0 |
DNA/biosynthesis/drug effects | 2 | 7.0 |
Interleukin-2/*biosynthesis/genetics | 2 | 11.0 |
Tumor Necrosis Factor-alpha/drug effects/genetics/metabolism | 2 | 100.0 |
Macrophages/*immunology/microbiology | 3 | 18.0 |
Mycobacterium avium/*immunology | 2 | 22.0 |
Apoptosis/genetics/*physiology | 2 | 5.0 |
DNA Fragmentation/physiology | 2 | 20.0 |
Minisatellite Repeats | 3 | 2.0 |
Research/trends | 2 | 20.0 |
Cysteine Endopeptidases/metabolism | 6 | 2.0 |
Multienzyme Complexes/metabolism | 3 | 1.0 |
Biological Therapy/*methods | 2 | 66.0 |
Endothelial Cells/*drug effects | 2 | 25.0 |
Umbilical Veins/drug effects | 2 | 66.0 |
Antigens, CD14/biosynthesis | 3 | 4.0 |
Endotoxins/metabolism | 6 | 42.0 |
Intercellular Adhesion Molecule-1/*physiology | 2 | 12.0 |
Protease Inhibitors/*pharmacology | 6 | 12.0 |
Tumor Necrosis Factor-alpha/analysis/immunology | 3 | 33.0 |
Casein Kinases | 4 | 8.0 |
Lipopolysaccharides/diagnostic use | 3 | 75.0 |
B-Lymphocytes/cytology/immunology | 2 | 6.0 |
Synovial Membrane/metabolism | 4 | 14.0 |
T-Lymphocytes/cytology/immunology | 4 | 5.0 |
*Genome, Human | 2 | 0.0 |
Multiple Sclerosis/*genetics | 4 | 4.0 |
Multiple Myeloma/immunology/*therapy | 2 | 18.0 |
*Genes, Immunoglobulin | 2 | 1.0 |
Ceramides/*physiology | 4 | 50.0 |
*Conserved Sequence | 2 | 1.0 |
Cell Adhesion/drug effects/physiology | 3 | 5.0 |
Endothelium, Vascular/drug effects/*physiology | 9 | 17.0 |
Vascular Cell Adhesion Molecule-1/genetics | 4 | 23.0 |
Serum Albumin/analysis | 10 | 5.0 |
Sleep/*drug effects | 2 | 22.0 |
Tumor Necrosis Factor-alpha/*analysis/*pharmacology | 2 | 100.0 |
Ceramides/biosynthesis | 2 | 18.0 |
Tumor Necrosis Factor-alpha/biosynthesis/*pharmacology | 9 | 100.0 |
Antigens, CD4/metabolism | 4 | 1.0 |
Macrophages/metabolism/*virology | 2 | 9.0 |
T-Lymphocytes/*cytology | 3 | 3.0 |
Immunization | 7 | 1.0 |
*Lipopolysaccharides | 10 | 31.0 |
Monocyte Chemoattractant Protein-1/*metabolism | 2 | 6.0 |
Leukemia, Myelocytic, Acute/immunology/*pathology | 2 | 15.0 |
Vitamin D/pharmacology | 2 | 16.0 |
Colitis, Ulcerative/*metabolism | 2 | 11.0 |
Crohn Disease/*metabolism | 2 | 13.0 |
Lymphotoxin/*secretion | 2 | 66.0 |
Shock, Septic/*drug therapy/prevention & control | 2 | 100.0 |
Antigens, CD95/immunology/metabolism | 2 | 15.0 |
Leukocyte Elastase/blood | 2 | 16.0 |
Thromboplastin/biosynthesis | 5 | 29.0 |
Antigens, Differentiation, T-Lymphocyte/metabolism | 3 | 2.0 |
Chemotaxis/drug effects/physiology | 2 | 9.0 |
Feces/*chemistry | 2 | 7.0 |
Thyrotropin/blood | 6 | 1.0 |
Anorexia/chemically induced | 2 | 28.0 |
Body Temperature/drug effects | 15 | 39.0 |
Eating/drug effects | 3 | 7.0 |
Energy Metabolism/physiology | 2 | 3.0 |
DNA Replication | 2 | 0.0 |
*Mitosis | 3 | 2.0 |
*Models, Immunological | 3 | 7.0 |
Vehicle Emissions/toxicity | 2 | 66.0 |
Transfection/genetics | 4 | 2.0 |
Blood Physiology | 4 | 5.0 |
Cytokines/*biosynthesis/*blood/immunology | 2 | 100.0 |
Acetophenones/pharmacology | 4 | 18.0 |
Lipoxygenase Inhibitors/pharmacology | 2 | 12.0 |
Nordihydroguaiaretic Acid/pharmacology | 5 | 22.0 |
DNA, Neoplasm/genetics | 3 | 0.0 |
Muscle, Smooth, Vascular/drug effects | 2 | 8.0 |
Hypertonic Solutions/pharmacology | 2 | 18.0 |
Proto-Oncogene Proteins c-jun/*metabolism | 4 | 5.0 |
Tumor Cells, Cultured/drug effects/enzymology | 2 | 6.0 |
Interferon Inducers/*pharmacology | 5 | 27.0 |
Cell Transformation, Neoplastic/*drug effects | 3 | 8.0 |
Protein-Tyrosine Kinase/antagonists & inhibitors/metabolism | 3 | 4.0 |
Vanadates/pharmacology | 8 | 5.0 |
Membranes, Artificial | 7 | 8.0 |
Crohn Disease/*genetics | 2 | 5.0 |
Antigens, Differentiation/metabolism | 5 | 4.0 |
*Receptors, Immunologic | 2 | 1.0 |
Skin/drug effects/*metabolism | 2 | 16.0 |
Antibodies/blood | 3 | 5.0 |
Sepsis Syndrome/*blood | 2 | 22.0 |
Recombinant Proteins/biosynthesis | 7 | 1.0 |
Glomerular Mesangium/cytology/*metabolism | 3 | 12.0 |
Tumor Necrosis Factor-alpha/*biosynthesis/genetics/physiology | 2 | 100.0 |
Animals, Newborn/*metabolism | 2 | 15.0 |
Cyclic AMP-Dependent Protein Kinases/metabolism | 6 | 3.0 |
Isoproterenol/pharmacology | 4 | 3.0 |
Heart Failure, Congestive/*blood/etiology/physiopathology | 2 | 100.0 |
Absorption | 4 | 3.0 |
Chemotaxis | 5 | 2.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/secretion | 5 | 31.0 |
Nitric Oxide/*pharmacology | 4 | 9.0 |
Nitric-Oxide Synthase/antagonists & inhibitors/*biosynthesis | 2 | 50.0 |
Cell Adhesion Molecules/genetics/metabolism | 2 | 4.0 |
Colon | 2 | 7.0 |
Anti-HIV Agents/*pharmacology | 3 | 2.0 |
HIV Long Terminal Repeat | 7 | 5.0 |
Virus Replication/*drug effects | 19 | 12.0 |
Ciliary Neurotrophic Factor | 5 | 4.0 |
Granulocyte Colony-Stimulating Factor/analysis | 2 | 28.0 |
Interleukin-6/genetics/*physiology | 2 | 33.0 |
*Multigene Family | 6 | 0.0 |
Nerve Tissue Proteins/analysis | 2 | 2.0 |
Peptides/analysis | 2 | 2.0 |
Antiviral Agents/therapeutic use | 3 | 2.0 |
Interferon Alfa-2b/therapeutic use | 3 | 21.0 |
Nitric Oxide/*metabolism/physiology | 2 | 50.0 |
Antibodies, Protozoan/blood | 2 | 10.0 |
Plasmodium falciparum/immunology | 3 | 14.0 |
Arteriosclerosis/etiology/metabolism | 2 | 33.0 |
Microscopy, Phase-Contrast | 5 | 5.0 |
Vitamin E/pharmacology | 2 | 6.0 |
Culture Media, Conditioned/metabolism/pharmacology | 2 | 22.0 |
Glioma/pathology | 2 | 10.0 |
Tumor Cells, Cultured/*drug effects/pathology | 3 | 18.0 |
Intercellular Adhesion Molecule-1/*genetics/metabolism | 2 | 33.0 |
Naphthalenes/pharmacology | 7 | 8.0 |
Menstrual Cycle/physiology | 3 | 7.0 |
Obesity/genetics | 2 | 3.0 |
Chemotactic Factors/*biosynthesis | 4 | 26.0 |
Growth Substances/*biosynthesis | 3 | 6.0 |
*Cholecystectomy | 2 | 20.0 |
Postoperative Complications/*immunology | 3 | 18.0 |
Immunoglobulin G/genetics | 3 | 7.0 |
Interleukin-4/biosynthesis/genetics | 2 | 11.0 |
Transplantation, Heterotopic | 2 | 12.0 |
Transplantation, Homologous/*immunology | 3 | 11.0 |
Hemoglobin A, Glycosylated/metabolism | 2 | 1.0 |
Crohn Disease/drug therapy | 2 | 66.0 |
Anti-Inflammatory Agents/*administration & dosage | 2 | 6.0 |
Cysteine/chemistry | 6 | 5.0 |
Bacteremia/blood | 2 | 50.0 |
Inflammation Mediators/*pharmacology | 6 | 37.0 |
Guanylate Cyclase/metabolism | 2 | 10.0 |
Phospholipase C/antagonists & inhibitors | 2 | 13.0 |
Platelet Activating Factor/pharmacology | 8 | 18.0 |
Postoperative Complications/blood | 3 | 17.0 |
*Bone Marrow Transplantation | 9 | 2.0 |
*Lymphocyte Transfusion | 3 | 11.0 |
Whole-Body Irradiation | 3 | 3.0 |
beta-Galactosidase/biosynthesis/genetics | 3 | 14.0 |
Anesthesia | 2 | 6.0 |
C-Reactive Protein/*metabolism | 7 | 2.0 |
*Escherichia coli Proteins | 3 | 1.0 |
Transcription Factor, Sp1/metabolism | 4 | 1.0 |
Cytokines/*blood/genetics | 5 | 62.0 |
Interferon Type II/blood/genetics | 3 | 75.0 |
RNA, Messenger/blood/genetics | 4 | 22.0 |
Fibronectins/physiology | 2 | 5.0 |
Protein Kinase Inhibitors | 11 | 8.0 |
DNA-Binding Proteins/*genetics | 5 | 0.0 |
*Homeodomain Proteins | 4 | 1.0 |
Monocytes/immunology/*physiology | 4 | 25.0 |
Appetite Stimulants/pharmacology/*therapeutic use | 2 | 100.0 |
Medroxyprogesterone 17-Acetate/pharmacology/*therapeutic use | 2 | 66.0 |
Megestrol Acetate/pharmacology/*therapeutic use | 2 | 100.0 |
Progesterone Congeners/pharmacology/*therapeutic use | 2 | 50.0 |
Ovarian Neoplasms/metabolism | 3 | 8.0 |
RNA, Messenger/biosynthesis/metabolism | 4 | 8.0 |
Blood Coagulation Factors/metabolism | 2 | 3.0 |
Pan troglodytes | 6 | 4.0 |
Tissue Plasminogen Activator/blood | 5 | 4.0 |
Blood Cell Count/drug effects | 3 | 14.0 |
Electroencephalography/drug effects | 2 | 8.0 |
Piperidines/*pharmacology | 4 | 7.0 |
Thyroxine/blood | 7 | 2.0 |
Triiodothyronine/blood | 4 | 1.0 |
Triiodothyronine, Reverse/blood | 2 | 7.0 |
Theophylline/pharmacology | 3 | 7.0 |
Chemokines/*biosynthesis | 2 | 6.0 |
Macrophage Activation/*physiology | 4 | 17.0 |
Macrophage Inflammatory Protein-1/biosynthesis | 4 | 20.0 |
Tumor Necrosis Factor-alpha/biosynthesis/secretion | 3 | 42.0 |
*Cell Communication | 4 | 4.0 |
T-Lymphocytes/*enzymology | 2 | 3.0 |
Arthritis/metabolism | 2 | 40.0 |
Leukocytes/*chemistry | 4 | 14.0 |
Immunoglobulin E/immunology | 2 | 3.0 |
Interleukin-8/physiology | 5 | 38.0 |
Neutrophils/drug effects/metabolism/*physiology | 2 | 33.0 |
Epithelium/pathology | 3 | 2.0 |
Osteoclasts/pathology | 2 | 22.0 |
Porphyromonas gingivalis/physiology | 2 | 66.0 |
Physical Endurance/physiology | 3 | 9.0 |
Running/physiology | 2 | 12.0 |
Lipopolysaccharides/*antagonists & inhibitors/metabolism/pharmacology | 2 | 66.0 |
Drug Resistance, Multiple/genetics | 2 | 4.0 |
*Genes, p53 | 3 | 0.0 |
Teniposide/pharmacology | 2 | 25.0 |
Vinblastine/pharmacology | 3 | 8.0 |
Interstitial Collagenase | 5 | 11.0 |
Apoptosis/drug effects/*physiology/radiation effects | 3 | 37.0 |
Acetylmuramyl-Alanyl-Isoglutamine/toxicity | 2 | 100.0 |
Gram-Negative Bacteria | 3 | 33.0 |
Aorta/cytology | 3 | 3.0 |
Cell Compartmentation/drug effects | 5 | 25.0 |
Proto-Oncogene Proteins c-rel | 3 | 5.0 |
Ribosomal Protein S6 Kinases/metabolism | 2 | 2.0 |
Endometrium/cytology/drug effects/*metabolism | 2 | 15.0 |
Protease Inhibitors/*metabolism | 2 | 11.0 |
Tissue Inhibitor of Metalloproteinase-2/metabolism | 2 | 9.0 |
Tumor Necrosis Factor-alpha/pharmacology/*therapeutic use | 3 | 100.0 |
Antigens, CD44/*metabolism | 2 | 1.0 |
Drug Resistance, Neoplasm/*genetics | 2 | 2.0 |
Retroviridae | 3 | 4.0 |
Disease-Free Survival | 7 | 0.0 |
*Point Mutation | 2 | 0.0 |
Monocytes/drug effects/metabolism/*physiology | 2 | 40.0 |
Burns/*blood/complications/mortality | 2 | 100.0 |
Iodine Radioisotopes | 15 | 4.0 |
Interferon-alpha/*therapeutic use | 9 | 14.0 |
Tumor Necrosis Factor-alpha/*pharmacology/*physiology | 2 | 100.0 |
*Autocrine Communication | 2 | 8.0 |
NF-kappa B/*genetics | 5 | 11.0 |
*Casein Kinases | 2 | 100.0 |
Receptors, Interleukin-1/*metabolism | 8 | 29.0 |
Pneumonia, Bacterial/blood | 2 | 66.0 |
Hypersensitivity/*immunology | 2 | 4.0 |
Hypersensitivity, Immediate/immunology | 2 | 9.0 |
Colonic Neoplasms/blood | 2 | 66.0 |
Antibodies/immunology | 21 | 6.0 |
Fluorouracil/*pharmacology | 3 | 7.0 |
Cytokines/biosynthesis/blood | 2 | 22.0 |
Macrophages/drug effects/*metabolism | 13 | 21.0 |
Medicine, Traditional | 2 | 50.0 |
Hemoglobins/*metabolism | 2 | 4.0 |
Leukocytes/pathology | 3 | 10.0 |
Free Radical Scavengers | 3 | 13.0 |
Hemostasis/physiology | 2 | 6.0 |
*Platelet Activation | 2 | 1.0 |
Crohn Disease/complications/*drug therapy | 2 | 66.0 |
Polyethylene Glycols/therapeutic use | 3 | 42.0 |
Endothelial Cells/*cytology | 3 | 18.0 |
Granulocyte Colony-Stimulating Factor/*physiology | 2 | 50.0 |
*Mitogen-Activated Protein Kinase Kinases | 4 | 4.0 |
Neutrophils/*enzymology | 4 | 3.0 |
Angiotensin II/metabolism | 3 | 7.0 |
Mesocricetus | 7 | 4.0 |
Chitosan | 2 | 40.0 |
Endothelium, Vascular/*cytology/*drug effects/metabolism | 2 | 66.0 |
Umbilical Veins/cytology/metabolism | 3 | 27.0 |
Pancreatitis/*blood | 2 | 11.0 |
Carcinoembryonic Antigen/blood | 2 | 3.0 |
Metallothionein/*genetics | 2 | 13.0 |
Cell Nucleus/*metabolism | 5 | 1.0 |
Tissue Distribution/drug effects | 2 | 25.0 |
Asialoglycoprotein Receptor | 3 | 12.0 |
HLA-B27 Antigen/genetics | 3 | 18.0 |
Tumor Necrosis Factor-alpha/*analysis/genetics | 2 | 100.0 |
Extracellular Matrix Proteins/metabolism | 2 | 2.0 |
Neoplasms/drug therapy/*metabolism | 2 | 11.0 |
*Evolution, Molecular | 3 | 0.0 |
Zinc Fingers/genetics | 2 | 1.0 |
Chick Embryo | 3 | 0.0 |
Haplorhini | 3 | 1.0 |
N-Formylmethionine Leucyl-Phenylalanine/*pharmacology | 14 | 31.0 |
Partial Thromboplastin Time | 2 | 1.0 |
Colchicine/*therapeutic use | 2 | 50.0 |
Antigen-Antibody Complex | 4 | 2.0 |
Gambia | 5 | 13.0 |
Fever/etiology | 8 | 34.0 |
RNA, Viral/blood | 2 | 0.0 |
Tumor Necrosis Factor-alpha/*analysis/metabolism/pharmacology | 2 | 100.0 |
Antigens, CD/*analysis/blood | 2 | 14.0 |
Receptors, Tumor Necrosis Factor/*analysis/blood | 2 | 66.0 |
Antigens, CD95/*genetics | 2 | 7.0 |
Cats | 8 | 2.0 |
Hormones/*metabolism | 2 | 8.0 |
Septicemia/*physiopathology | 3 | 100.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/*physiology | 3 | 12.0 |
Interleukin-4/*physiology | 4 | 8.0 |
Transcription Factors/*physiology | 3 | 0.0 |
Proto-Oncogene Proteins c-bcl-2/*metabolism | 3 | 1.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/*genetics | 3 | 16.0 |
Antineoplastic Agents, Alkylating/*administration & dosage | 3 | 27.0 |
Arm | 2 | 6.0 |
Leg | 3 | 7.0 |
Melphalan/*administration & dosage | 4 | 40.0 |
Palliative Care/*methods | 2 | 40.0 |
Antigens, CD95/genetics/immunology/*physiology | 2 | 66.0 |
Cycloheximide/*pharmacology | 4 | 19.0 |
Endothelium, Vascular/chemistry | 2 | 3.0 |
Interleukin-6/analysis/biosynthesis | 4 | 100.0 |
Phospholipase D/metabolism | 3 | 11.0 |
Phospholipases/*metabolism | 3 | 25.0 |
Lipopolysaccharides/antagonists & inhibitors/toxicity | 4 | 100.0 |
Lymphotoxin/toxicity | 2 | 100.0 |
Erythrocytes/physiology | 2 | 5.0 |
Monocytes/drug effects/immunology/*physiology | 2 | 40.0 |
Pigments/pharmacology | 2 | 66.0 |
Plasmodium falciparum | 4 | 11.0 |
Carcinoma | 2 | 5.0 |
T-Lymphocytes/cytology | 6 | 6.0 |
Tumor Necrosis Factor-alpha/metabolism/*toxicity | 3 | 100.0 |
Tumor Necrosis Factor-alpha/analysis/*secretion | 4 | 80.0 |
Lymphoma, Large-Cell/immunology | 2 | 40.0 |
Receptors, Tumor Necrosis Factor/immunology | 12 | 54.0 |
*Immunization, Passive | 4 | 7.0 |
Interferon-gamma, Recombinant/therapeutic use | 2 | 50.0 |
Oxygen Consumption | 9 | 3.0 |
Ceramides/*metabolism/pharmacology | 2 | 50.0 |
Endosomes/metabolism | 2 | 1.0 |
*Complement 3a/*analogs & derivatives | 2 | 10.0 |
Fatty Acids, Unsaturated/pharmacology | 2 | 3.0 |
Proto-Oncogene Proteins c-bcl-2/genetics | 2 | 1.0 |
*Proto-Oncogenes | 9 | 1.0 |
Melanoma/pathology/*therapy | 2 | 40.0 |
Recombinant Proteins/administration & dosage/adverse effects | 4 | 36.0 |
Mitogen-Activated Protein Kinase Kinases | 2 | 5.0 |
Estradiol/analysis | 3 | 15.0 |
Follicular Fluid/*chemistry | 2 | 8.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/*analysis | 2 | 40.0 |
Infertility, Female/*immunology | 2 | 25.0 |
Progesterone/analysis | 3 | 15.0 |
Testosterone/analysis | 2 | 18.0 |
Antigens, CD95 | 20 | 51.0 |
Membrane Proteins/analysis | 5 | 4.0 |
Receptors, Tumor Necrosis Factor/analysis/*metabolism | 3 | 100.0 |
Renal Dialysis | 10 | 3.0 |
Cause of Death | 4 | 2.0 |
Graft vs Host Disease/etiology/*genetics | 2 | 66.0 |
Myelodysplastic Syndromes/therapy | 2 | 11.0 |
Tissue Donors | 4 | 1.0 |
Transplantation, Homologous/*adverse effects | 2 | 33.0 |
Receptors, Tumor Necrosis Factor/*blood/*genetics | 2 | 100.0 |
Capillary Permeability/*drug effects | 4 | 16.0 |
Antimetabolites, Antineoplastic/*administration & dosage | 2 | 20.0 |
Interleukin-13/*blood | 2 | 66.0 |
Sepsis/*blood | 2 | 10.0 |
Shock, Septic/*blood | 7 | 35.0 |
Glutathione/analysis | 2 | 15.0 |
Lymphoma, Large-Cell | 9 | 34.0 |
Polysomnography | 2 | 4.0 |
Serum Amyloid A Protein/analysis | 4 | 10.0 |
Blood Glucose | 3 | 3.0 |
Premenopause | 2 | 2.0 |
Cell Adhesion Molecules/biosynthesis/*genetics | 2 | 18.0 |
Gene Products, tat/*pharmacology | 2 | 10.0 |
Chemotaxis, Leukocyte/physiology | 2 | 10.0 |
Equipment Design | 2 | 1.0 |
Hemoglobins/analysis | 4 | 1.0 |
Adenocarcinoma/enzymology/metabolism/*pathology | 2 | 100.0 |
*Circadian Rhythm | 2 | 0.0 |
Epithelial Cells/cytology | 2 | 2.0 |
Histocompatibility Antigens Class II/*immunology | 2 | 1.0 |
Dinoprost/*biosynthesis | 2 | 33.0 |
Dinoprostone/*biosynthesis | 13 | 30.0 |
Fatty Acids, Omega-3/*pharmacology | 2 | 18.0 |
Hypothalamus/*metabolism | 3 | 9.0 |
Glycoproteins/*biosynthesis | 10 | 20.0 |
Antineoplastic Agents/administration & dosage/*therapeutic use | 2 | 11.0 |
Administration, Cutaneous | 2 | 2.0 |
Interleukin-6/blood/metabolism | 2 | 15.0 |
Cell Adhesion Molecules/*physiology | 8 | 7.0 |
Lymphotoxin/physiology | 5 | 71.0 |
Neutrophils/*drug effects/*physiology | 2 | 66.0 |
*Salmonella | 3 | 75.0 |
*Staphylococcus | 2 | 50.0 |
Teichoic Acids/*pharmacology | 5 | 20.0 |
Body Composition/drug effects | 3 | 21.0 |
Energy Metabolism/drug effects | 2 | 9.0 |
Oligodeoxyribonucleotides/chemistry/metabolism | 2 | 6.0 |
Plant Roots | 2 | 25.0 |
Cell Size | 6 | 2.0 |
Platelet-Derived Growth Factor/pharmacology | 10 | 5.0 |
MAP Kinase Kinase Kinases | 2 | 20.0 |
Hepatitis, Toxic/etiology/*metabolism | 2 | 66.0 |
Macrophages, Peritoneal/metabolism | 4 | 17.0 |
Endotoxemia/etiology | 2 | 100.0 |
HIV-1/*drug effects/physiology | 2 | 2.0 |
Interleukin-18/*pharmacology | 2 | 16.0 |
Interleukin-6/*physiology | 11 | 13.0 |
Nervous System Diseases/*physiopathology | 3 | 37.0 |
Receptors, Cytokine/physiology | 3 | 11.0 |
Injections | 10 | 9.0 |
Cycloheximide/toxicity | 2 | 66.0 |
Angiotensin-Converting Enzyme Inhibitors/*pharmacology | 4 | 2.0 |
Captopril/*pharmacology | 2 | 5.0 |
Receptors, Angiotensin/*antagonists & inhibitors | 2 | 2.0 |
Acute-Phase Proteins/*metabolism | 2 | 3.0 |
Acute-Phase Reaction/*metabolism | 2 | 22.0 |
Transferrin/metabolism | 2 | 1.0 |
Allergens/immunology | 3 | 4.0 |
Bleomycin/*toxicity | 2 | 16.0 |
Lung/drug effects/pathology/*physiopathology | 2 | 100.0 |
Calcium/*blood | 5 | 5.0 |
Chemiluminescent Measurements | 12 | 7.0 |
Respiratory Burst/drug effects/*physiology | 2 | 66.0 |
Superoxides/blood | 7 | 23.0 |
Antineoplastic Agents/*metabolism/pharmacology | 2 | 20.0 |
Homosexuality, Male | 3 | 3.0 |
Antigens, CD30/metabolism | 3 | 15.0 |
HIV Seropositivity/blood/*immunology | 2 | 13.0 |
Arginine/*metabolism | 2 | 4.0 |
Macrophage Activation/drug effects/physiology | 2 | 66.0 |
Pancreatic Neoplasms/metabolism/*pathology | 3 | 10.0 |
Blood Circulation | 2 | 10.0 |
Interleukins/blood/immunology | 2 | 100.0 |
Lymphokines/*secretion | 2 | 4.0 |
Cell Extracts | 2 | 1.0 |
DNA-Binding Proteins/*biosynthesis/genetics | 2 | 2.0 |
RNA, Messenger/*biosynthesis/blood/cerebrospinal fluid | 2 | 100.0 |
Blood Coagulation Factors/biosynthesis | 6 | 60.0 |
Inflammation Mediators/*antagonists & inhibitors | 3 | 60.0 |
Macrophages, Alveolar/*drug effects/*metabolism | 2 | 100.0 |
Cryopreservation | 2 | 1.0 |
Amikacin/*pharmacology | 2 | 100.0 |
Tumor Necrosis Factor-alpha/biosynthesis/*secretion | 5 | 62.0 |
Protein Kinase C/physiology | 8 | 4.0 |
Tumor Necrosis Factor-alpha/*genetics/*pharmacology | 5 | 83.0 |
Alzheimer Disease/*metabolism/pathology | 3 | 3.0 |
Fibronectins/pharmacology | 2 | 4.0 |
Laminin/pharmacology | 2 | 4.0 |
Proteins/*analysis | 3 | 2.0 |
Monocytes/*immunology/pathology | 3 | 27.0 |
*Coal Mining | 4 | 44.0 |
Herpes Simplex/*immunology | 2 | 12.0 |
Blood/drug effects/*metabolism | 2 | 100.0 |
Zymosan/pharmacology | 14 | 15.0 |
Membrane Proteins/biosynthesis/genetics/*physiology | 2 | 15.0 |
Infusions, Parenteral | 2 | 1.0 |
Perfusion, Regional | 6 | 60.0 |
Tumor Necrosis Factor-alpha/*administration & dosage/adverse effects | 7 | 100.0 |
Lymphocytes, Tumor-Infiltrating | 3 | 18.0 |
Recombinant Fusion Proteins/biosynthesis/metabolism | 3 | 3.0 |
Pancreatic Elastase/pharmacology | 3 | 27.0 |
Multiple Organ Failure/mortality | 2 | 66.0 |
HIV Envelope Protein gp120/pharmacology | 2 | 9.0 |
Ion Channels/metabolism | 2 | 7.0 |
Lung Neoplasms/*metabolism | 2 | 2.0 |
Up-Regulation/drug effects/physiology | 7 | 14.0 |
Bacterial Toxins/*pharmacology | 4 | 12.0 |
Pyridinium Compounds/pharmacology | 2 | 25.0 |
Estrogens/physiology | 2 | 6.0 |
Lymphocytes/*physiology | 5 | 6.0 |
Thrombin/pharmacology | 7 | 3.0 |
Thromboplastin/*biosynthesis/drug effects | 2 | 33.0 |
Umbilical Veins/cytology/drug effects/*metabolism | 2 | 50.0 |
Xanthines/pharmacology | 4 | 25.0 |
Platelet-Derived Growth Factor/analysis | 2 | 8.0 |
Multiple Sclerosis/*blood | 2 | 18.0 |
Cervix Neoplasms/metabolism | 2 | 22.0 |
Granulocyte Colony-Stimulating Factor/metabolism | 2 | 13.0 |
Epinephrine/*pharmacology | 4 | 14.0 |
Thionucleotides/pharmacology | 2 | 3.0 |
Endothelium/*cytology | 2 | 9.0 |
Chemotaxis/*physiology | 2 | 5.0 |
Constriction | 2 | 9.0 |
Nitric Oxide/antagonists & inhibitors/*physiology | 3 | 37.0 |
Interleukins/*physiology | 3 | 10.0 |
HIV Infections/immunology | 3 | 3.0 |
Tuberculosis, Pulmonary/*immunology | 3 | 7.0 |
Staphylococcus aureus | 6 | 9.0 |
Acylation | 4 | 5.0 |
Escherichia coli/*pathogenicity | 3 | 17.0 |
Arthritis, Rheumatoid/immunology/pathology | 2 | 22.0 |
Osteoarthritis/immunology/pathology | 2 | 33.0 |
Antigens, CD/therapeutic use | 2 | 100.0 |
Antigens, CD/genetics/physiology | 2 | 12.0 |
T-Lymphocytes/*physiology | 15 | 5.0 |
Autoantibodies/administration & dosage | 2 | 100.0 |
Lectins/metabolism | 3 | 3.0 |
Acid Phosphatase/metabolism | 3 | 4.0 |
Cytoplasmic Granules/ultrastructure | 2 | 5.0 |
Macrophage Activation/*immunology | 4 | 13.0 |
Monocytes/*immunology/ultrastructure | 2 | 66.0 |
Carcinoma, Small Cell/*pathology | 2 | 15.0 |
*Cell Differentiation | 5 | 2.0 |
Lung Neoplasms/*pathology | 2 | 2.0 |
Glutathione/*metabolism | 4 | 6.0 |
Oxidative Stress/drug effects/*physiology | 2 | 9.0 |
Molecular Conformation | 2 | 0.0 |
Aprotinin/pharmacology | 2 | 9.0 |
Endothelium, Vascular/*cytology/drug effects/physiology | 2 | 28.0 |
Extracellular Matrix/drug effects/physiology | 2 | 33.0 |
Pulmonary Artery | 5 | 25.0 |
Insulin/secretion | 3 | 5.0 |
Protein Binding/genetics | 2 | 0.0 |
Caspase 1 | 10 | 25.0 |
*Caspases | 10 | 17.0 |
Cysteine Endopeptidases/*physiology | 5 | 15.0 |
Wounds and Injuries | 2 | 33.0 |
Endothelium, Vascular/cytology/drug effects/*physiology | 5 | 11.0 |
Interferon Type II/administration & dosage/*pharmacology | 2 | 40.0 |
Immunity, Cellular/immunology | 3 | 5.0 |
beta 2-Microglobulin/analysis | 6 | 4.0 |
Arthritis, Rheumatoid/*blood | 3 | 6.0 |
Antigen Presentation/drug effects | 2 | 6.0 |
Antigens, CD14/*physiology | 2 | 4.0 |
Hematopoiesis/*drug effects | 6 | 6.0 |
Hematopoietic Stem Cells/cytology/*drug effects | 2 | 3.0 |
Fibroblasts/pathology | 2 | 2.0 |
Tissue Inhibitor of Metalloproteinase-1/*biosynthesis | 2 | 40.0 |
Injections, Intraperitoneal | 11 | 7.0 |
Liver/*enzymology | 3 | 0.0 |
Blood | 7 | 3.0 |
Superoxides/*blood | 6 | 35.0 |
Bronchoalveolar Lavage Fluid/*immunology | 3 | 9.0 |
Zidovudine/therapeutic use | 3 | 1.0 |
Sweden | 2 | 0.0 |
Tumor Necrosis Factor-alpha/*analysis/biosynthesis | 8 | 80.0 |
Chromatography, Affinity | 16 | 2.0 |
Receptors, Tumor Necrosis Factor/isolation & purification/*metabolism | 2 | 100.0 |
Tumor Necrosis Factor-alpha/*metabolism/*pharmacology | 4 | 100.0 |
Cytokines/*analysis/blood | 3 | 30.0 |
Exudates and Transudates/immunology | 2 | 25.0 |
*Mycobacterium tuberculosis | 3 | 25.0 |
Antineoplastic Combined Chemotherapy Protocols/pharmacology | 2 | 11.0 |
Phenanthridines/pharmacology | 2 | 10.0 |
Protein Kinase C/antagonists & inhibitors/physiology | 4 | 18.0 |
Sphingosine/*analogs & derivatives/*pharmacology | 2 | 10.0 |
Genes, MHC Class II/*genetics | 2 | 2.0 |
Erythromycin/*pharmacology | 2 | 9.0 |
Interleukin-6/*biosynthesis/blood | 7 | 70.0 |
Ethanol/*toxicity | 3 | 9.0 |
NF-kappa B/genetics | 2 | 5.0 |
Transfection/*genetics | 2 | 18.0 |
Tumor Cells, Cultured/*drug effects | 8 | 18.0 |
Lipopolysaccharides/metabolism/pharmacology | 4 | 22.0 |
Seeds/chemistry | 2 | 18.0 |
Laparoscopy/*methods | 2 | 15.0 |
Video Recording | 2 | 7.0 |
Umbilical Veins/metabolism | 2 | 6.0 |
Fibroblasts/drug effects/enzymology | 3 | 14.0 |
Liver Neoplasms/*metabolism/pathology | 4 | 5.0 |
Lymphokines/genetics/*metabolism | 2 | 2.0 |
Adrenalectomy | 5 | 10.0 |
Metabolic Clearance Rate | 7 | 2.0 |
Shock, Septic/*prevention & control | 2 | 33.0 |
Activities of Daily Living | 2 | 5.0 |
Antirheumatic Agents/*administration & dosage/adverse effects | 3 | 60.0 |
Suramin/*pharmacology | 4 | 19.0 |
Adrenergic beta-Agonists/*pharmacology | 2 | 9.0 |
Antigens, CD40/biosynthesis | 2 | 7.0 |
CD40 Ligand/biosynthesis | 2 | 18.0 |
Fluorescent Dyes/chemistry | 2 | 8.0 |
Sickness Impact Profile | 2 | 25.0 |
Endopeptidases/*metabolism | 5 | 3.0 |
Immunoglobulin G/classification/*immunology | 2 | 25.0 |
Antibodies/immunology/*pharmacology | 2 | 28.0 |
Simian virus 40/physiology | 2 | 10.0 |
Interleukin-8/genetics/*metabolism | 4 | 19.0 |
RNA, Messenger/drug effects | 9 | 13.0 |
Bleomycin/administration & dosage | 2 | 2.0 |
Mechlorethamine/administration & dosage | 3 | 37.0 |
Procarbazine/administration & dosage | 2 | 14.0 |
Renal Dialysis/*instrumentation | 2 | 16.0 |
Serum Albumin | 2 | 6.0 |
Fatty Acids, Unsaturated/*administration & dosage | 2 | 25.0 |
Fish Oils/administration & dosage | 2 | 28.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/blood | 4 | 26.0 |
Nitrogen/metabolism | 3 | 12.0 |
Dinoprostone/*pharmacology | 9 | 17.0 |
Macrophages/cytology | 7 | 10.0 |
Australia | 2 | 1.0 |
Acetophenones/*pharmacology | 2 | 33.0 |
Electron Transport/drug effects | 4 | 44.0 |
Free Radicals | 20 | 13.0 |
Metyrapone/pharmacology | 2 | 15.0 |
Neutrophils/enzymology | 2 | 2.0 |
Vascular Cell Adhesion Molecule-1/*biosynthesis/genetics | 5 | 62.0 |
Interferons/immunology | 2 | 50.0 |
Carcinoma, Hepatocellular | 10 | 3.0 |
Liver Neoplasms | 9 | 3.0 |
Fibroblasts/metabolism/ultrastructure | 2 | 11.0 |
Antigens, CD11/immunology | 2 | 18.0 |
Dendritic Cells/*cytology/immunology | 3 | 6.0 |
Integrins/immunology | 2 | 9.0 |
Cytoplasm/physiology | 2 | 5.0 |
Interferons/*pharmacology | 14 | 18.0 |
Skin/blood supply | 5 | 8.0 |
Malaria, Cerebral/*blood/complications | 2 | 100.0 |
Malaria, Falciparum/*blood/complications | 2 | 66.0 |
Protein Precursors/*metabolism | 3 | 3.0 |
Growth Substances/*blood | 2 | 7.0 |
Tumor Necrosis Factor-alpha/analysis/biosynthesis/*genetics | 4 | 100.0 |
Recombinant Proteins/antagonists & inhibitors/biosynthesis/metabolism | 2 | 66.0 |
HIV-1/*drug effects/isolation & purification/physiology | 2 | 100.0 |
Breast Neoplasms/*metabolism | 2 | 0.0 |
Choline/metabolism | 2 | 5.0 |
Phospholipids/*metabolism | 2 | 1.0 |
Hematopoietic Stem Cells/*pathology | 2 | 2.0 |
Superoxide Dismutase/pharmacology | 8 | 20.0 |
Thiourea/analogs & derivatives/pharmacology | 2 | 28.0 |
Growth Substances/genetics | 3 | 4.0 |
Antigens, CD29/metabolism | 2 | 3.0 |
Hyperthermia, Induced | 8 | 38.0 |
Breast Neoplasms/metabolism | 2 | 1.0 |
Receptors, Nerve Growth Factor/metabolism | 2 | 5.0 |
Erythrocytes/metabolism | 3 | 1.0 |
Erythropoietin/physiology | 2 | 16.0 |
Fibrinolysis/physiology | 3 | 6.0 |
Bone Marrow Cells/*cytology | 2 | 4.0 |
Lymphocytes/cytology | 2 | 2.0 |
Macrophage Activation/drug effects | 21 | 40.0 |
Cachexia/etiology/immunology | 2 | 100.0 |
Neoplasms/drug therapy/*physiopathology | 2 | 100.0 |
*Adjuvants, Immunologic | 6 | 19.0 |
Exchange Transfusion, Whole Blood | 2 | 18.0 |
*Plasma Exchange | 3 | 13.0 |
Leprosy, Borderline/blood/drug therapy | 2 | 100.0 |
Leprosy, Tuberculoid/blood/drug therapy | 2 | 100.0 |
Mycobacterium leprae/immunology | 2 | 9.0 |
Thalidomide/administration & dosage/adverse effects/*therapeutic use | 2 | 50.0 |
Endotoxins/toxicity | 9 | 52.0 |
Horses | 6 | 4.0 |
Birth Weight | 3 | 1.0 |
Interleukin-10/cerebrospinal fluid | 3 | 50.0 |
GTP Phosphohydrolases/metabolism | 2 | 1.0 |
Receptors, Interleukin-1/physiology | 3 | 30.0 |
*Antibodies, Monoclonal | 3 | 1.0 |
B-Lymphocytes/immunology/metabolism | 2 | 3.0 |
Dactinomycin/*pharmacology | 5 | 35.0 |
Cell Adhesion/*drug effects | 8 | 14.0 |
Endothelium/cytology/drug effects | 2 | 18.0 |
Plant Extracts/*pharmacology | 4 | 5.0 |
Antigens, CD1/*analysis | 2 | 9.0 |
Hematopoiesis | 5 | 2.0 |
Stem Cell Factor/pharmacology | 4 | 2.0 |
Antigens, Differentiation/immunology | 2 | 1.0 |
Lymphokines/immunology | 2 | 10.0 |
Biological Response Modifiers/*pharmacology | 6 | 30.0 |
Neoplasms/*immunology | 5 | 4.0 |
Cell Adhesion Molecules/analysis | 5 | 3.0 |
Cattle/*genetics/*immunology | 2 | 50.0 |
DNA, Complementary/*genetics | 3 | 1.0 |
Receptors, Tumor Necrosis Factor/chemistry/*genetics | 3 | 50.0 |
Repetitive Sequences, Nucleic Acid | 10 | 1.0 |
Interferons/*biosynthesis/blood | 2 | 100.0 |
Pancreatic Elastase/blood | 3 | 12.0 |
Postoperative Care | 3 | 4.0 |
Respiratory Distress Syndrome, Adult/*etiology | 2 | 66.0 |
Blood Platelets/*physiology | 3 | 1.0 |
Granulocytes/*physiology | 2 | 11.0 |
Carbohydrate Sequence | 7 | 2.0 |
Polymers | 9 | 8.0 |
Polystyrenes | 2 | 8.0 |
*Anti-Inflammatory Agents, Non-Steroidal | 2 | 66.0 |
Zinc Oxide/*adverse effects | 2 | 100.0 |
Exercise Test | 3 | 1.0 |
Heart Failure, Congestive/blood/*physiopathology | 2 | 28.0 |
Aspirin/pharmacology | 4 | 6.0 |
Factor X/metabolism | 2 | 3.0 |
Cell Adhesion Molecules/*blood | 5 | 8.0 |
Genes, Immediate-Early | 2 | 3.0 |
Interleukin-10/immunology | 2 | 7.0 |
Interleukin-6/immunology | 6 | 21.0 |
Pseudomonas Infections/immunology | 2 | 40.0 |
Oligodeoxyribonucleotides | 27 | 3.0 |
Superoxide Dismutase/*metabolism | 3 | 7.0 |
Antiviral Agents/pharmacology | 6 | 9.0 |
Interferon Type II/*biosynthesis/genetics | 3 | 14.0 |
Virus Diseases/*immunology | 3 | 16.0 |
Recombinant Proteins/biosynthesis/pharmacology | 3 | 10.0 |
Neuroblastoma | 4 | 2.0 |
RNA Splicing | 2 | 0.0 |
Recombinant Proteins/biosynthesis/metabolism | 2 | 1.0 |
Multiple Organ Failure/blood | 3 | 100.0 |
Shock, Hemorrhagic/blood | 2 | 100.0 |
Lactic Acid/*pharmacology | 2 | 28.0 |
Dexamethasone/therapeutic use | 2 | 11.0 |
Interleukin-1/*biosynthesis/blood | 4 | 100.0 |
Shiga-Like Toxin I/metabolism/*toxicity | 2 | 100.0 |
Up-Regulation/*drug effects | 4 | 5.0 |
Radiotherapy Dosage | 2 | 1.0 |
*Tomography, X-Ray Computed | 3 | 3.0 |
Androgens/pharmacology | 2 | 4.0 |
Ovarian Neoplasms/*genetics | 2 | 0.0 |
Monocytes/drug effects | 10 | 19.0 |
Macrophages/*cytology | 5 | 15.0 |
Transcription Initiation Site | 2 | 1.0 |
Endothelial Cells/*drug effects/metabolism | 3 | 37.0 |
Leukemia, Erythroblastic, Acute/pathology | 3 | 9.0 |
Leukemia, Promyelocytic, Acute/pathology | 3 | 18.0 |
Plicamycin/*analogs & derivatives/*pharmacology | 2 | 50.0 |
Smoking/*immunology | 3 | 30.0 |
Diabetes Mellitus/metabolism | 3 | 8.0 |
Progesterone/*metabolism | 2 | 5.0 |
Gene Expression/genetics | 7 | 3.0 |
Intercellular Adhesion Molecule-1/drug effects/genetics | 2 | 66.0 |
Interleukin-10/*therapeutic use | 2 | 50.0 |
Diabetes Mellitus, Type 1/*genetics/immunology | 2 | 3.0 |
Crohn Disease/genetics | 2 | 13.0 |
Cell Adhesion Molecules/*analysis | 9 | 7.0 |
Cell Membrane/drug effects | 2 | 5.0 |
E-Selectin/immunology | 2 | 28.0 |
Intercellular Adhesion Molecule-1/immunology | 3 | 7.0 |
Monocytes/cytology/*drug effects | 4 | 30.0 |
Infection/*complications/metabolism | 2 | 100.0 |
Muscle Proteins/metabolism | 5 | 10.0 |
Wasting Syndrome/etiology | 2 | 100.0 |
Receptors, Antigen, T-Cell/*immunology | 2 | 1.0 |
Kidney/drug effects/pathology | 2 | 20.0 |
Liver Neoplasms, Experimental/pathology/*therapy | 2 | 100.0 |
Ascites/metabolism | 2 | 28.0 |
Peritonitis/*complications | 2 | 100.0 |
Acquired Immunodeficiency Syndrome/complications | 2 | 4.0 |
Herpesvirus 4, Human/genetics/*physiology | 3 | 20.0 |
Coronary Disease/*blood | 2 | 3.0 |
Macrophage-1 Antigen/*immunology | 2 | 18.0 |
Peptide Fragments/*pharmacology | 5 | 2.0 |
*Antimicrobial Cationic Peptides | 2 | 10.0 |
Carrier Proteins/*therapeutic use | 2 | 100.0 |
Intercellular Adhesion Molecule-1/analysis | 6 | 5.0 |
Receptors, Interferon/analysis | 2 | 66.0 |
Chloramphenicol O-Acetyltransferase/genetics | 7 | 2.0 |
Hydroquinones/pharmacology | 2 | 6.0 |
Protein-Tyrosine Kinase/*antagonists & inhibitors | 4 | 2.0 |
Interleukin-1/genetics/*metabolism | 4 | 40.0 |
Synovial Fluid/metabolism | 3 | 9.0 |
Synovial Membrane/cytology/*metabolism | 7 | 46.0 |
Apoptosis/*drug effects/radiation effects | 2 | 15.0 |
Protein p53/*physiology | 3 | 2.0 |
HIV Seropositivity | 2 | 1.0 |
Lung/metabolism/pathology | 4 | 18.0 |
Antigens, CD/*genetics/metabolism | 4 | 8.0 |
Tumor Necrosis Factor-alpha/chemistry/metabolism/*pharmacology | 2 | 100.0 |
Arthritis, Rheumatoid/*immunology/pathology | 2 | 6.0 |
Cytokines/antagonists & inhibitors/*immunology | 2 | 50.0 |
Interleukin-4/immunology | 3 | 5.0 |
Neoplasm Recurrence, Local | 3 | 0.0 |
Cell Degranulation | 3 | 7.0 |
Papio | 14 | 8.0 |
Shock, Septic/physiopathology/*therapy | 2 | 100.0 |
Thrombin/metabolism | 5 | 3.0 |
Acute-Phase Proteins/biosynthesis | 6 | 46.0 |
Cholesterol/metabolism | 3 | 1.0 |
Communicable Diseases/*physiopathology | 2 | 100.0 |
Lipoproteins/metabolism | 2 | 1.0 |
Cytoplasm | 3 | 4.0 |
Autoantibodies/*immunology | 3 | 1.0 |
HLA-DQ Antigens/genetics/immunology | 2 | 10.0 |
Endothelium, Vascular/cytology/*drug effects/physiology | 5 | 25.0 |
Antimalarials/therapeutic use | 3 | 18.0 |
Cytokines/*blood/drug effects | 2 | 66.0 |
Pentoxifylline/pharmacology/*therapeutic use | 3 | 60.0 |
Sesquiterpenes/therapeutic use | 2 | 100.0 |
Tumor Necrosis Factor-alpha/analysis/drug effects | 3 | 75.0 |
Host-Parasite Relations/immunology | 2 | 22.0 |
Antigen-Antibody Complex/immunology | 3 | 5.0 |
Cytokines/immunology/pharmacology | 2 | 28.0 |
L-Selectin/*immunology | 2 | 66.0 |
Receptors, Fc/*immunology | 3 | 9.0 |
Respiratory Burst/*immunology | 2 | 28.0 |
Phosphatidylinositol Diacylglycerol-Lyase | 2 | 2.0 |
Trans-Activation (Genetics)/drug effects/*physiology | 2 | 18.0 |
Lupus Erythematosus, Systemic/*genetics/*immunology | 2 | 13.0 |
Receptors, Tumor Necrosis Factor/*chemistry/genetics | 2 | 100.0 |
Glycosaminoglycans/metabolism | 3 | 6.0 |
Mesoderm/*cytology | 2 | 7.0 |
Carrier Proteins | 3 | 5.0 |
Sphingomyelin Phosphodiesterase/*metabolism | 9 | 50.0 |
Antigens, CD/chemistry | 2 | 13.0 |
Computer Simulation | 4 | 1.0 |
Adenosine/pharmacology | 3 | 12.0 |
Calcium/physiology | 11 | 5.0 |
Neutrophils/*drug effects/metabolism | 13 | 28.0 |
Macrophages, Alveolar/*immunology | 3 | 7.0 |
Phospholipase C/metabolism | 3 | 1.0 |
Respiratory Distress Syndrome, Adult/etiology | 3 | 37.0 |
*Oncogene Proteins | 2 | 3.0 |
Cyclins/metabolism | 3 | 0.0 |
Spectrophotometry | 2 | 1.0 |
Genetic Predisposition to Disease/epidemiology | 2 | 2.0 |
Interleukins/genetics | 4 | 25.0 |
Pokeweed Mitogens/pharmacology | 3 | 3.0 |
Bursa of Fabricius/immunology | 2 | 100.0 |
Membrane Glycoproteins/genetics/immunology/*metabolism | 4 | 28.0 |
*Mutagenesis, Site-Directed | 3 | 3.0 |
Receptors, Tumor Necrosis Factor/genetics/immunology/*metabolism | 2 | 66.0 |
Autoimmune Diseases/genetics/*immunology | 2 | 10.0 |
HLA-DR2 Antigen/*genetics | 2 | 10.0 |
Multiple Sclerosis/genetics/*immunology | 2 | 10.0 |
Cytokines/*biosynthesis/immunology | 3 | 23.0 |
Antigens, CD11/metabolism | 4 | 21.0 |
Receptors, Tumor Necrosis Factor/*antagonists & inhibitors | 4 | 80.0 |
Protein-Tyrosine Kinase/*physiology | 4 | 2.0 |
Transcortin/*analysis | 2 | 22.0 |
Alprostadil/*pharmacology | 2 | 18.0 |
Endothelium, Vascular/*drug effects/physiology | 2 | 11.0 |
Tumor Necrosis Factor-alpha/pharmacology/secretion | 3 | 50.0 |
Apoptosis/genetics | 3 | 1.0 |
Transcription Factors/*genetics/metabolism | 2 | 0.0 |
Cell Nucleus/physiology | 3 | 4.0 |
NF-kappa B/*biosynthesis | 4 | 28.0 |
Curcumin/pharmacology | 2 | 15.0 |
Shock, Septic/*physiopathology | 4 | 50.0 |
Tumor Necrosis Factor-alpha/administration & | 10 | 100.0 |
Proto-Oncogene Proteins c-jun/biosynthesis | 2 | 10.0 |
Leukemia, Monocytic, Acute/*metabolism/pathology | 2 | 100.0 |
Chelating Agents/pharmacology | 2 | 2.0 |
Superoxide Dismutase/*pharmacology | 2 | 25.0 |
Binding Sites/drug effects | 2 | 3.0 |
Carbon Radioisotopes/diagnostic use | 2 | 3.0 |
Guanosine Triphosphate/metabolism | 2 | 0.0 |
Protein-Serine-Threonine Kinases/drug effects/metabolism | 2 | 11.0 |
Protein-Tyrosine Kinase/drug effects/metabolism | 2 | 15.0 |
ras Proteins/metabolism | 2 | 1.0 |
Histocompatibility Antigens Class II/*metabolism | 3 | 5.0 |
Interleukin-2/*metabolism | 2 | 4.0 |
Heart Failure, Congestive/drug therapy/*metabolism | 2 | 50.0 |
Lupus Erythematosus, Systemic/*blood | 3 | 10.0 |
Trans-Activation (Genetics)/*drug effects | 3 | 3.0 |
Sarcoma/therapy | 2 | 100.0 |
Shock, Septic/blood | 4 | 57.0 |
Tumor Necrosis Factor-alpha/administration & dosage/adverse | 5 | 100.0 |
Tumor Necrosis Factor-alpha/immunology/metabolism/pharmacology | 3 | 75.0 |
Hepatitis C, Chronic/*blood/immunology | 2 | 100.0 |
Nitriles/pharmacology | 3 | 2.0 |
*Tyrphostins | 2 | 3.0 |
Antibody-Dependent Cell Cytotoxicity/*drug effects | 4 | 28.0 |
*Lectins, C-Type | 3 | 1.0 |
Melanoma/immunology | 2 | 5.0 |
Receptors, IgG/physiology | 2 | 5.0 |
Calcitriol/*pharmacology | 9 | 4.0 |
Cytoplasm/enzymology | 4 | 5.0 |
Phospholipases A/antagonists & inhibitors/*metabolism | 3 | 60.0 |
*Drug Design | 3 | 3.0 |
*Immunotherapy | 16 | 10.0 |
Protein Folding | 4 | 0.0 |
G2 Phase/drug effects | 2 | 4.0 |
Mitosis/drug effects | 5 | 4.0 |
Tumor Necrosis Factor-alpha/*biosynthesis/pharmacology | 11 | 73.0 |
*Virus Replication/drug effects | 3 | 21.0 |
Chromosomes, Human, Pair 8 | 2 | 1.0 |
Cyclic AMP-Dependent Protein Kinases/antagonists & inhibitors | 3 | 11.0 |
Epoprostenol/analogs & derivatives/pharmacology | 3 | 60.0 |
Rolipram | 11 | 42.0 |
Interleukin-5/*blood | 2 | 50.0 |
Electrophoresis, Polyacrylamide Gel/methods | 2 | 1.0 |
Prostaglandins/*pharmacology | 4 | 16.0 |
Extracellular Matrix/chemistry/metabolism | 2 | 18.0 |
Heparitin Sulfate/metabolism | 3 | 7.0 |
Receptors, Tumor Necrosis Factor/biosynthesis/*drug effects | 2 | 100.0 |
Acquired Immunodeficiency Syndrome/*immunology | 6 | 2.0 |
Candida albicans/immunology | 3 | 6.0 |
Anesthesia, General | 2 | 11.0 |
*Rhodobacter sphaeroides | 2 | 100.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/*biosynthesis | 7 | 46.0 |
Leukemia, Monocytic, Acute | 3 | 42.0 |
Lymphokines/*biosynthesis | 5 | 1.0 |
Isomerism | 3 | 1.0 |
Mitogen-Activated Protein Kinases/genetics/metabolism | 2 | 10.0 |
Transcription Factor AP-1/genetics | 3 | 10.0 |
Postmenopause/physiology | 2 | 14.0 |
Vasodilation | 2 | 5.0 |
Neurons/*drug effects | 3 | 7.0 |
Thyrotropin/pharmacology | 2 | 3.0 |
Myelodysplastic Syndromes/*metabolism | 2 | 100.0 |
*Growth Substances | 2 | 11.0 |
Carcinogens/pharmacology | 6 | 6.0 |
Lactones/pharmacology | 3 | 7.0 |
Hormones/physiology | 2 | 6.0 |
Adenocarcinoma/metabolism/*pathology | 2 | 3.0 |
Brain/physiology | 2 | 3.0 |
Cell Aggregation | 3 | 2.0 |
Microfilaments/metabolism | 2 | 5.0 |
Epinephrine/administration & dosage/*pharmacology | 2 | 100.0 |
Tumor Necrosis Factor-alpha/immunology/*physiology | 6 | 66.0 |
Adrenergic beta-Antagonists/*pharmacology | 2 | 11.0 |
1-(5-Isoquinolinesulfonyl)-2-methylpiperazine/pharmacology | 2 | 6.0 |
Tumor Necrosis Factor-alpha/antagonists & inhibitors/*toxicity | 4 | 100.0 |
Interleukin-1/administration & dosage/*pharmacology | 2 | 16.0 |
Cytokines/analysis/*physiology | 4 | 57.0 |
Hydrocortisone/*pharmacology | 3 | 7.0 |
Hematocrit | 9 | 2.0 |
Protein p53/biosynthesis | 2 | 1.0 |
Antigens, Surface/biosynthesis | 5 | 8.0 |
B-Lymphocytes/cytology | 2 | 2.0 |
Receptors, Tumor Necrosis Factor/metabolism/physiology | 2 | 66.0 |
B-Lymphocytes/physiology | 2 | 3.0 |
Tumor Necrosis Factor-alpha/genetics/physiology | 2 | 33.0 |
Disaccharides/*pharmacology | 2 | 33.0 |
Tumor Necrosis Factor-alpha/adverse effects/*physiology/therapeutic use | 2 | 100.0 |
Breast Neoplasms/therapy | 2 | 13.0 |
Graft vs Host Disease/diagnosis | 2 | 66.0 |
Leukemia/therapy | 3 | 8.0 |
Disease | 3 | 13.0 |
Receptors, Nerve Growth Factor/chemistry | 2 | 40.0 |
Lactates/metabolism | 2 | 10.0 |
Peptides/metabolism | 3 | 1.0 |
Phosphoserine/metabolism | 3 | 3.0 |
CCAAT-Enhancer-Binding Proteins | 9 | 5.0 |
Cell Death/immunology | 3 | 9.0 |
Hodgkin Disease/*immunology/pathology | 2 | 12.0 |
Endothelium/cytology/drug effects/metabolism | 2 | 66.0 |
Chemotaxis/*drug effects | 3 | 6.0 |
Cytokines/administration & dosage/*pharmacology | 4 | 80.0 |
Fibroblasts/*immunology | 3 | 16.0 |
Lung/drug effects/*pathology | 3 | 42.0 |
Blood Proteins/*biosynthesis | 2 | 15.0 |
Interferon Type II/cerebrospinal fluid | 3 | 60.0 |
Interleukin-8/*cerebrospinal fluid | 2 | 100.0 |
Leukocytosis | 2 | 25.0 |
Receptors, Tumor Necrosis Factor/*analysis/*genetics | 2 | 100.0 |
Up-Regulation/drug effects/immunology | 2 | 5.0 |
Interleukin-6/*cerebrospinal fluid | 4 | 100.0 |
Anthracenes/pharmacology | 2 | 10.0 |
Mitochondria/*enzymology | 3 | 2.0 |
Neutrophils/immunology/*metabolism | 2 | 10.0 |
Intestines/metabolism | 3 | 2.0 |
Oligonucleotides/chemistry | 4 | 3.0 |
C-Reactive Protein/biosynthesis/*genetics | 2 | 28.0 |
*Immunity, Natural | 6 | 10.0 |
Serum Amyloid P-Component/biosynthesis/*genetics | 2 | 66.0 |
Interleukins/physiology | 2 | 13.0 |
Antibodies, Monoclonal/diagnostic use | 19 | 2.0 |
*Arm | 2 | 40.0 |
*Leg | 2 | 20.0 |
Melanoma/*drug therapy | 9 | 47.0 |
Skin Neoplasms/*drug therapy | 3 | 15.0 |
*Graft Rejection | 5 | 5.0 |
Injections, Intra-Articular | 2 | 8.0 |
Irrigation | 3 | 5.0 |
False Positive Reactions | 4 | 1.0 |
Leishmania major/*immunology | 2 | 28.0 |
Tumor Necrosis Factor-alpha/*biosynthesis/genetics/secretion | 5 | 100.0 |
Shock, Septic/metabolism | 2 | 40.0 |
Antibodies/administration & dosage | 3 | 21.0 |
Escherichia coli/*physiology | 3 | 33.0 |
Peritoneal Dialysis | 2 | 5.0 |
Hydrazones/*pharmacology | 3 | 100.0 |
*Molecular Mimicry | 2 | 5.0 |
Bronchi/*metabolism | 2 | 6.0 |
Gelatinases/*biosynthesis | 2 | 33.0 |
Inhalation Exposure | 2 | 9.0 |
Lung/*drug effects/metabolism | 3 | 37.0 |
Occupational Diseases/*metabolism | 2 | 100.0 |
Kidney Failure, Chronic/metabolism/therapy | 2 | 15.0 |
Renal Dialysis/*methods | 4 | 13.0 |
Cyclic AMP/metabolism/physiology | 2 | 50.0 |
Fibroblasts/cytology/*drug effects | 2 | 16.0 |
Liver/*metabolism | 13 | 3.0 |
Leukocytes/drug effects/immunology | 2 | 25.0 |
Deferoxamine/pharmacology | 2 | 4.0 |
Complement 3/analysis | 3 | 0.0 |
Complement 3b/analysis | 3 | 14.0 |
Malaria, Falciparum/blood/*immunology | 2 | 50.0 |
Antibodies, Monoclonal/administration & dosage | 2 | 6.0 |
Cyclophosphamide/pharmacology | 5 | 12.0 |
Recombinant Proteins/adverse effects | 3 | 42.0 |
B-Lymphocytes/*drug effects/immunology | 2 | 6.0 |
Cell Fractionation | 4 | 1.0 |
*Lymphocyte Activation/drug effects | 2 | 1.0 |
Diabetes Mellitus, Type 1/*genetics/metabolism | 2 | 50.0 |
Lymphotoxin/*biosynthesis | 9 | 75.0 |
*Drugs, Chinese Herbal | 2 | 28.0 |
Polysaccharides/*chemistry/isolation & purification/pharmacology | 2 | 100.0 |
Arsenicals/pharmacology | 2 | 9.0 |
Diamide/pharmacology | 4 | 20.0 |
Vascular Cell Adhesion Molecule-1/*metabolism | 5 | 33.0 |
Edetic Acid/pharmacology | 6 | 3.0 |
False Negative Reactions | 2 | 1.0 |
Gram-Negative Bacteria/immunology | 3 | 23.0 |
Interleukin-4/*immunology | 2 | 11.0 |
Listeria/immunology | 2 | 100.0 |
B-Lymphocytes/cytology/metabolism | 3 | 17.0 |
Tumor Necrosis Factor-alpha/biosynthesis/pharmacology | 3 | 60.0 |
Biological Response Modifiers/immunology/*therapeutic use | 2 | 100.0 |
Killer Cells, Lymphokine-Activated/*drug effects/immunology | 2 | 33.0 |
Neoplasms/*drug therapy/immunology | 4 | 40.0 |
Bacteremia/*etiology/physiopathology/therapy | 2 | 100.0 |
Streptococcal Infections/*etiology/physiopathology/therapy | 2 | 100.0 |
Metalloendopeptidases/*biosynthesis/genetics | 2 | 12.0 |
Adjuvants, Immunologic | 2 | 3.0 |
Endothelium, Vascular/cytology/enzymology/*immunology | 2 | 100.0 |
GTP-Binding Proteins/*physiology | 2 | 1.0 |
Tumor Necrosis Factor Receptor-Associated Peptides and Proteins | 2 | 66.0 |
Fibronectins/*biosynthesis | 3 | 27.0 |
Anti-Arrhythmia Agents/*pharmacology | 2 | 10.0 |
Heart Failure, Congestive/drug therapy | 2 | 6.0 |
Interleukin-6/antagonists & inhibitors | 2 | 22.0 |
Lidocaine/pharmacology | 2 | 18.0 |
Membrane Proteins/*chemistry | 2 | 4.0 |
Protein Biosynthesis/drug effects | 6 | 9.0 |
Luciferases/biosynthesis | 2 | 2.0 |
Transfection/methods | 2 | 1.0 |
Fibronectins/analysis | 2 | 3.0 |
Austria/epidemiology | 2 | 14.0 |
*Severity of Illness Index | 3 | 5.0 |
Platelet Aggregation Inhibitors/*pharmacology | 2 | 3.0 |
Theophylline/analogs & derivatives/pharmacology | 2 | 9.0 |
Mucocutaneous Lymph Node Syndrome/*blood | 3 | 42.0 |
NF-kappa B | 6 | 40.0 |
Proto-Oncogene Proteins c-bcl-2 | 10 | 6.0 |
Neoplasms | 2 | 13.0 |
*Virus Diseases | 2 | 66.0 |
DNA/chemistry | 3 | 1.0 |
Zinc/metabolism | 2 | 2.0 |
Nuclear Proteins/*genetics | 3 | 0.0 |
Receptors, Immunologic/*genetics | 2 | 1.0 |
Antigens, CD14/metabolism | 2 | 1.0 |
Receptors, Cell Surface/metabolism | 41 | 10.0 |
Recombinant Proteins/genetics/isolation & purification/metabolism | 2 | 2.0 |
Middle Ear Ventilation | 2 | 50.0 |
Receptors, Cell Surface/*analysis/genetics | 3 | 21.0 |
Endothelium, Vascular/*cytology/metabolism | 5 | 9.0 |
Recombinant Proteins/antagonists & inhibitors/pharmacology | 4 | 30.0 |
Ascitic Fluid/chemistry | 2 | 9.0 |
Inflammation/blood | 5 | 9.0 |
Neoplasms/blood | 4 | 11.0 |
Biopterin/*analogs & derivatives/biosynthesis | 2 | 50.0 |
Immunoglobulin M/*blood | 2 | 5.0 |
Immunoglobulins/*blood | 3 | 9.0 |
Viral Proteins/genetics/*physiology | 3 | 25.0 |
Receptors, Interleukin-6 | 10 | 11.0 |
DNA Probes/chemistry | 3 | 8.0 |
Quercetin/*pharmacology | 2 | 8.0 |
Plasmodium falciparum/*drug effects | 2 | 33.0 |
HIV Core Protein p24/blood | 2 | 2.0 |
*Neutrophil Activation | 2 | 6.0 |
*Respiratory Burst | 5 | 25.0 |
Cytokines/genetics/metabolism/*physiology | 2 | 100.0 |
Gene Products, tat/genetics/*metabolism | 3 | 7.0 |
HIV-1/*metabolism | 3 | 1.0 |
Lymph Nodes/pathology | 5 | 1.0 |
Antineoplastic Agents/*toxicity | 2 | 3.0 |
Arachidonic Acid/pharmacology | 4 | 9.0 |
DNA, Neoplasm/drug effects | 3 | 9.0 |
E-Selectin/*biosynthesis | 5 | 50.0 |
Surface Properties | 3 | 1.0 |
Granulocytes/physiology | 5 | 26.0 |
Interferon Alfa-2a/*therapeutic use | 2 | 10.0 |
Azepines/pharmacology | 2 | 9.0 |
Platelet Activating Factor/*pharmacology | 3 | 13.0 |
Proteins/*pharmacology | 5 | 7.0 |
Tumor Necrosis Factor-alpha/analysis/genetics/*physiology | 2 | 100.0 |
Genes, MHC Class II/genetics | 3 | 10.0 |
Endothelium, Vascular/*drug effects/pathology | 2 | 25.0 |
Recombinant Fusion Proteins/*therapeutic use | 5 | 25.0 |
Heart Failure, Congestive/*metabolism/physiopathology | 2 | 28.0 |
Hydroxamic Acids/*pharmacology | 3 | 6.0 |
Cytoplasmic Granules/secretion | 2 | 15.0 |
Neutrophils/*drug effects/physiology | 4 | 25.0 |
Liver/drug effects/metabolism | 2 | 2.0 |
Adrenal Cortex Hormones/*pharmacology | 2 | 11.0 |
X-Rays | 2 | 1.0 |
*Polymerase Chain Reaction | 3 | 1.0 |
Terminology | 2 | 1.0 |
KB Cells | 4 | 4.0 |
Peptide Mapping | 6 | 1.0 |
Complement 3/metabolism | 3 | 1.0 |
Receptors, Complement/*metabolism | 2 | 1.0 |
Receptors, Fc/*metabolism | 2 | 5.0 |
Cell Aging | 3 | 3.0 |
Fever/*immunology | 5 | 83.0 |
Influenza A Virus, Human/*physiology | 2 | 28.0 |
Cysteine Endopeptidases/*genetics/metabolism | 2 | 66.0 |
Lymphocyte Subsets/immunology | 3 | 2.0 |
Receptors, Interleukin-2/*biosynthesis | 2 | 5.0 |
Tyrosine/*metabolism | 5 | 1.0 |
Cytomegalovirus/immunology | 3 | 4.0 |
Phosphoproteins/analysis | 2 | 5.0 |
Ceramides/biosynthesis/pharmacology/*physiology | 2 | 100.0 |
Cell Transformation, Viral/physiology | 3 | 50.0 |
Interleukin-6/*biosynthesis/secretion | 2 | 50.0 |
Proteins/metabolism/*physiology | 4 | 9.0 |
Viral Matrix Proteins/genetics/*physiology | 2 | 25.0 |
Mitogen-Activated Protein Kinase 1 | 3 | 2.0 |
Neutrophils/drug effects/*enzymology | 3 | 23.0 |
Protein Kinase C/antagonists & inhibitors/*metabolism | 12 | 13.0 |
Receptors, IgG/biosynthesis | 2 | 7.0 |
Receptors, Tumor Necrosis Factor/biosynthesis | 8 | 47.0 |
Ceftriaxone/pharmacology | 2 | 66.0 |
*Fluoroquinolones | 2 | 28.0 |
Intubation, Intratracheal | 2 | 10.0 |
Neutrophils/*pathology | 5 | 33.0 |
Nitroblue Tetrazolium/metabolism | 3 | 33.0 |
Arthritis, Rheumatoid/blood/*immunology | 4 | 15.0 |
Adenosine Triphosphate/physiology | 2 | 11.0 |
Membrane Glycoproteins/biosynthesis | 3 | 1.0 |
Tumor Necrosis Factor-alpha/immunology/physiology | 2 | 100.0 |
Carrier Proteins/metabolism/*pharmacology | 2 | 33.0 |
Lung Neoplasms/pathology | 3 | 5.0 |
Cytokines/antagonists & inhibitors/*biosynthesis | 3 | 50.0 |
Macrophages/drug effects/*immunology | 4 | 21.0 |
Blood Coagulation/drug effects | 5 | 4.0 |
Fibrinolysis/drug effects | 2 | 5.0 |
Inflammation/etiology/prevention & control | 2 | 50.0 |
Neutrophils | 2 | 2.0 |
Phospholipases A/blood | 2 | 15.0 |
Centrifugation, Density Gradient | 5 | 1.0 |
Dendritic Cells/drug effects/*immunology | 4 | 15.0 |
*Flow Cytometry | 2 | 1.0 |
*Blood Transfusion | 2 | 1.0 |
Erythropoiesis/drug effects | 2 | 4.0 |
Erythropoietin/*pharmacology | 2 | 1.0 |
Antigens, CD/biosynthesis/metabolism | 2 | 18.0 |
Metalloendopeptidases/antagonists & inhibitors/*metabolism | 4 | 23.0 |
Protein Precursors/metabolism | 5 | 4.0 |
Corticosterone/blood | 5 | 13.0 |
Adjuvants, Immunologic/*administration & dosage | 3 | 9.0 |
Picibanil/*administration & dosage | 5 | 35.0 |
Apoptosis/drug effects/immunology/*physiology | 2 | 40.0 |
CD4-Positive T-Lymphocytes/pathology | 2 | 2.0 |
*Hyperthermia, Induced/adverse effects | 3 | 75.0 |
Melphalan/adverse effects/*therapeutic use | 2 | 66.0 |
*Perfusion, Regional/adverse effects | 2 | 100.0 |
Endopeptidases/blood | 2 | 22.0 |
*Biological Products | 2 | 33.0 |
Interleukin-1/antagonists & inhibitors/physiology | 5 | 62.0 |
Pentoxifylline/administration & dosage/*therapeutic use | 2 | 50.0 |
Acrylic Resins | 2 | 8.0 |
Antigens, CD/analysis/blood | 2 | 66.0 |
*Hemofiltration/instrumentation | 2 | 100.0 |
Interleukin-1/analysis/blood | 3 | 60.0 |
Receptors, Tumor Necrosis Factor/analysis/blood | 2 | 100.0 |
Sialoglycoproteins/analysis/blood | 2 | 100.0 |
Pyrrolidinones/*pharmacology | 5 | 45.0 |
Tumor Necrosis Factor-alpha/*drug effects | 2 | 100.0 |
Antigens, CD40 | 6 | 10.0 |
Codon | 3 | 0.0 |
Membrane Glycoproteins/chemistry/*genetics | 2 | 5.0 |
*X Chromosome | 2 | 0.0 |
Glioma/*metabolism/pathology | 3 | 11.0 |
Integrins/metabolism | 4 | 2.0 |
*Diet | 2 | 0.0 |
Proteins/metabolism/physiology | 2 | 18.0 |
Aspartate Aminotransferases/blood | 2 | 1.0 |
Neutrophils/drug effects | 16 | 30.0 |
Nitrates/metabolism | 4 | 21.0 |
Nitrites/metabolism | 6 | 14.0 |
Nitrates/*blood | 2 | 28.0 |
Nitrites/*blood | 2 | 40.0 |
Adrenal Cortex Hormones/pharmacology | 3 | 27.0 |
Pneumonia, Pneumocystis/*immunology | 3 | 50.0 |
Surgical Procedures, Elective | 3 | 13.0 |
Mitochondria/*physiology | 3 | 5.0 |
Interleukins/*biosynthesis/genetics | 2 | 40.0 |
Antigens/immunology | 7 | 4.0 |
*Peptide Library | 3 | 5.0 |
Rhabdomyosarcoma/immunology | 2 | 100.0 |
Chromosomes, Human, Pair 1/genetics | 2 | 1.0 |
Okadaic Acid/metabolism | 2 | 100.0 |
Smoking | 4 | 1.0 |
Peptides/*pharmacology/therapeutic use | 2 | 50.0 |
Premenopause/*blood | 2 | 11.0 |
Acetamides/*pharmacology | 2 | 16.0 |
Bacterial Adhesion/drug effects | 2 | 33.0 |
Antibodies, Bacterial/*immunology | 2 | 8.0 |
Immunophenotyping/methods | 2 | 4.0 |
Cytokines/*antagonists & inhibitors/*immunology | 2 | 100.0 |
Immunoglobulin G/administration & dosage | 2 | 16.0 |
Acute-Phase Proteins/*biosynthesis | 2 | 9.0 |
Phospholipases A/*biosynthesis | 3 | 75.0 |
*Recombinant Proteins | 2 | 14.0 |
Gene Deletion | 12 | 0.0 |
Intestinal Mucosa/cytology | 3 | 23.0 |
Oligodeoxyribonucleotides/genetics | 2 | 2.0 |
Antigens, Differentiation, Myelomonocytic | 2 | 7.0 |
Basidiomycota/*chemistry | 2 | 50.0 |
Antisense Elements (Genetics) | 2 | 3.0 |
Antigens, Bacterial/*immunology | 7 | 6.0 |
Monocytes/*immunology/*metabolism | 3 | 20.0 |
Mycobacterium bovis/immunology | 10 | 41.0 |
Epithelium/immunology | 5 | 3.0 |
Cervix Neoplasms | 4 | 16.0 |
Chromium Radioisotopes | 3 | 25.0 |
Glycyrrhizic Acid | 3 | 50.0 |
Salmonella typhimurium | 3 | 33.0 |
Ofloxacin/therapeutic use | 2 | 50.0 |
Skin/*metabolism | 3 | 2.0 |
Monocyte Chemoattractant Protein-1/*blood | 3 | 21.0 |
Malaria, Falciparum/*blood | 2 | 15.0 |
Tumor Necrosis Factor-alpha/biosynthesis/genetics/*metabolism | 2 | 100.0 |
Antigens, Surface/blood | 2 | 9.0 |
Interleukin-10/*immunology | 2 | 10.0 |
Interleukin-15/pharmacology | 2 | 8.0 |
Antigens/*immunology | 2 | 2.0 |
Receptors, Fc/immunology | 4 | 8.0 |
*Hemostasis | 3 | 2.0 |
HLA Antigens/analysis | 3 | 1.0 |
Intercellular Adhesion Molecule-1/genetics/metabolism | 2 | 11.0 |
Interferon-gamma, Recombinant/*pharmacology | 28 | 21.0 |
Papillomavirus, Human/*genetics | 3 | 4.0 |
Binding Sites/immunology | 2 | 3.0 |
Superoxide Dismutase/biosynthesis | 2 | 40.0 |
Cyclic AMP/*metabolism | 7 | 3.0 |
S-Nitroso-N-Acetylpenicillamine | 3 | 25.0 |
Graft Rejection/prevention & control | 2 | 4.0 |
Muromonab-CD3/*adverse effects | 5 | 100.0 |
Tumor Necrosis Factor-alpha/analysis/antagonists & inhibitors | 2 | 50.0 |
Epoprostenol/*analogs & derivatives/pharmacology | 2 | 33.0 |
Staphylococcus epidermidis | 2 | 66.0 |
Aorta | 4 | 2.0 |
Cell Adhesion/immunology | 8 | 4.0 |
Cell Communication/immunology | 2 | 2.0 |
Cytokines/blood/drug effects | 2 | 28.0 |
Ceramides/*biosynthesis | 2 | 22.0 |
Proto-Oncogene Proteins c-bcl-2/*physiology | 2 | 8.0 |
Staurosporine/*pharmacology | 2 | 10.0 |
Allopurinol/pharmacology | 2 | 15.0 |
Antigens, Neoplasm/blood | 2 | 9.0 |
Neoplasm Proteins/*blood | 2 | 3.0 |
Cell Division/drug effects/immunology | 5 | 8.0 |
Tumor Necrosis Factor-alpha/drug effects/secretion | 3 | 60.0 |
Dipyridamole/pharmacology | 2 | 14.0 |
Leukocytes, Mononuclear/*immunology/*metabolism | 2 | 33.0 |
Tumor Necrosis Factor-alpha/*biosynthesis/*metabolism | 3 | 100.0 |
Acute-Phase Reaction/blood | 2 | 11.0 |
Inflammation/*chemically induced | 2 | 22.0 |
Materials Testing | 3 | 4.0 |
Dinoprostone/analysis | 3 | 21.0 |
Interleukin-1/biosynthesis/*pharmacology | 2 | 100.0 |
Sialoglycoproteins/pharmacology | 2 | 15.0 |
Body Temperature Regulation | 2 | 8.0 |
Granulocytes/*metabolism | 5 | 12.0 |
Serpins/*metabolism | 2 | 12.0 |
Viral Proteins/*metabolism | 2 | 3.0 |
Proto-Oncogene Proteins/*biosynthesis/drug effects | 2 | 100.0 |
DNA-Binding Protein, Cyclic AMP-Responsive/metabolism | 2 | 1.0 |
Growth Inhibitors/pharmacology | 4 | 2.0 |
*RNA Processing, Post-Transcriptional | 3 | 5.0 |
Saccharomyces cerevisiae/genetics/metabolism | 3 | 2.0 |
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage | 6 | 10.0 |
Fibroblasts/*drug effects/*physiology | 2 | 50.0 |
Osteoarthritis/pathology | 2 | 28.0 |
Polyamines/*metabolism | 3 | 11.0 |
Bone Marrow Transplantation/adverse effects | 2 | 13.0 |
Spironolactone/therapeutic use | 2 | 14.0 |
Vasodilator Agents/*therapeutic use | 3 | 10.0 |
Hodgkin Disease/*blood/pathology | 3 | 100.0 |
*Gamma Rays | 2 | 4.0 |
Interferon Type II/*therapeutic use | 6 | 40.0 |
Antigens, Neoplasm/biosynthesis | 2 | 12.0 |
Plant Extracts/isolation & purification/*pharmacology | 2 | 40.0 |
Antineoplastic Combined Chemotherapy Protocols/administration & dosage | 3 | 9.0 |
Kidney/metabolism | 6 | 1.0 |
Lymphocytes, Tumor-Infiltrating/immunology | 2 | 5.0 |
Lung Diseases/*metabolism | 3 | 23.0 |
Sarcoidosis/*metabolism | 3 | 42.0 |
HLA Antigens/metabolism | 2 | 6.0 |
Glomerulonephritis, IGA/*immunology | 2 | 11.0 |
Sepharose | 3 | 5.0 |
Rheumatic Diseases/*metabolism | 3 | 60.0 |
Chromosomes, Human, Pair 1 | 2 | 0.0 |
Cytoplasm/chemistry | 4 | 2.0 |
Melanoma/therapy | 3 | 37.0 |
Proteinuria/drug therapy | 2 | 15.0 |
Blood Coagulation/*drug effects | 5 | 4.0 |
Extremities | 6 | 23.0 |
Interferon Type II/administration & dosage | 9 | 64.0 |
Neoplasms/*physiopathology | 5 | 19.0 |
Nitric Oxide/analysis | 4 | 44.0 |
Gamma-Globulins/therapeutic use | 2 | 33.0 |
Tumor Necrosis Factor-alpha/administration & dosage/*adverse effects | 2 | 100.0 |
Epithelium/enzymology | 2 | 5.0 |
Interleukin-1/metabolism/*pharmacology | 3 | 33.0 |
Sialoglycoproteins/biosynthesis/*blood | 2 | 66.0 |
Blood Platelets/*metabolism | 2 | 0.0 |
Staphylococcus epidermidis/immunology | 4 | 57.0 |
Blood Bactericidal Activity | 7 | 7.0 |
Surgical Procedures, Operative/adverse effects | 2 | 66.0 |
Africa | 2 | 2.0 |
Antigens, CD14/*metabolism | 3 | 3.0 |
Thiocarbamates/*pharmacology | 3 | 23.0 |
Blood-Brain Barrier | 3 | 5.0 |
Corticosterone/*blood | 3 | 37.0 |
Interleukins/*metabolism | 2 | 15.0 |
Lectins/*pharmacology | 3 | 8.0 |
Iron/*blood | 2 | 5.0 |
Gelatinases/metabolism | 3 | 9.0 |
Synovial Membrane/*immunology/metabolism | 2 | 50.0 |
Estradiol/pharmacology | 4 | 1.0 |
Estrogen Antagonists/pharmacology | 2 | 2.0 |
Tamoxifen/pharmacology | 2 | 2.0 |
Oxidants/metabolism | 2 | 11.0 |
Rats, Inbred BN | 4 | 8.0 |
Tumor Necrosis Factor-alpha/*metabolism/toxicity | 5 | 100.0 |
Cross Reactions/immunology | 4 | 8.0 |
Serum Albumin, Bovine/pharmacology | 2 | 6.0 |
Blotting, Western/methods | 3 | 1.0 |
*Fluid Therapy | 2 | 16.0 |
Doxorubicin/*therapeutic use | 3 | 12.0 |
Hepatectomy/*methods | 2 | 16.0 |
Cyclic AMP/pharmacology | 2 | 1.0 |
Insulin-Like Growth Factor I/pharmacology | 3 | 1.0 |
Antibodies/immunology/therapeutic use | 2 | 100.0 |
Leukemia, Myelomonocytic, Acute | 2 | 50.0 |
HLA-B Antigens/analysis | 2 | 1.0 |
Receptors, Interleukin-2/biosynthesis | 6 | 5.0 |
Heart Failure, Congestive/*blood | 3 | 20.0 |
Interferon-alpha/physiology | 2 | 25.0 |
Interferon-beta/physiology | 2 | 66.0 |
Interleukin-10/physiology | 3 | 12.0 |
RNA-Directed DNA Polymerase | 5 | 4.0 |
Tumor Necrosis Factor-alpha/biosynthesis/immunology/physiology | 2 | 100.0 |
Erythrocytes/parasitology | 5 | 14.0 |
*Immunization | 2 | 4.0 |
Paracoccidioides/immunology | 2 | 66.0 |
Phytohemagglutinins/immunology | 4 | 8.0 |
Interferons/*physiology | 2 | 11.0 |
Endotoxins/administration & dosage/*toxicity | 2 | 66.0 |
*Immunity | 2 | 4.0 |
Weight Lifting/*physiology | 2 | 12.0 |
Interleukin-6/*immunology | 2 | 16.0 |
Leukocytes, Mononuclear/cytology/*immunology | 2 | 22.0 |
Cell Differentiation/drug effects/physiology | 4 | 4.0 |
Inflammation/*drug therapy | 3 | 30.0 |
Shivering | 2 | 33.0 |
Complement/analysis | 2 | 1.0 |
Autoimmune Diseases/physiopathology | 2 | 40.0 |
Endothelium/physiology | 3 | 20.0 |
Neoplasms/physiopathology | 2 | 12.0 |
Sepsis/etiology | 2 | 40.0 |
Pyrrolidines/*pharmacology | 3 | 14.0 |
*Apoptosis/drug effects/radiation effects | 2 | 18.0 |
Tretinoin/*pharmacology | 7 | 2.0 |
Enzyme Precursors/*metabolism | 2 | 1.0 |
Thrombin/*metabolism | 3 | 3.0 |
Antineoplastic Agents, Phytogenic/pharmacology | 4 | 4.0 |
Membrane Glycoproteins/chemistry/*physiology | 3 | 20.0 |
Danazol/*pharmacology | 2 | 28.0 |
Hormone Antagonists/pharmacology | 2 | 3.0 |
Progesterone/*pharmacology | 3 | 3.0 |
Perfusion, Regional/adverse effects/*methods | 2 | 100.0 |
Recombinant Proteins/administration & dosage/therapeutic use | 8 | 21.0 |
Monocytes/*drug effects/secretion | 6 | 75.0 |
Cytokines/genetics/*pharmacology | 2 | 50.0 |
Interleukin-6/analysis/*metabolism | 3 | 60.0 |
Neopterin | 21 | 21.0 |
*Cell Adhesion | 5 | 3.0 |
Neutrophils/drug effects/*physiology/ultrastructure | 2 | 50.0 |
Histocompatibility Antigens Class I/metabolism | 4 | 6.0 |
Killer Cells/*immunology | 2 | 5.0 |
Fibroblasts/cytology/metabolism | 2 | 1.0 |
Salvage Therapy | 2 | 2.0 |
Tumor Necrosis Factor-alpha/adverse effects/*therapeutic use | 7 | 77.0 |
Antigens, CD44/metabolism | 2 | 2.0 |
*Propionibacterium acnes | 2 | 40.0 |
*Nutritional Status | 3 | 3.0 |
Oxygen Consumption/drug effects | 4 | 10.0 |
Aprotinin/*therapeutic use | 2 | 20.0 |
Hemostatics/*therapeutic use | 3 | 23.0 |
Antigens, CD/immunology/*physiology | 2 | 6.0 |
Fibroblasts/enzymology | 2 | 1.0 |
Antigens, Neoplasm/genetics/immunology | 2 | 20.0 |
Enterotoxins/*immunology | 2 | 2.0 |
Membrane Glycoproteins/genetics/*immunology | 2 | 3.0 |
Neoplasm Proteins/genetics/*immunology | 2 | 14.0 |
Receptors, Antigen, T-Cell, alpha-beta/immunology | 3 | 4.0 |
Recombinant Fusion Proteins/*immunology | 2 | 9.0 |
Gene Expression Regulation/*radiation effects | 2 | 7.0 |
Thrombosis/etiology | 2 | 3.0 |
Epithelium/drug effects | 3 | 7.0 |
DNA, Satellite/*immunology | 2 | 66.0 |
Major Histocompatibility Complex/immunology | 2 | 4.0 |
Tumor Necrosis Factor-alpha/*genetics/*secretion | 2 | 100.0 |
Protein C/metabolism | 2 | 2.0 |
Thrombomodulin/*metabolism | 2 | 8.0 |
Transglutaminases/metabolism | 3 | 15.0 |
Immunoglobulin G/isolation & purification | 3 | 23.0 |
Culture Media, Conditioned/analysis | 2 | 25.0 |
*Surgical Procedures, Operative | 4 | 12.0 |
Tumor Necrosis Factor-alpha/*metabolism/*physiology | 2 | 66.0 |
Bronchiolitis/*genetics | 2 | 40.0 |
Collagen/*biosynthesis | 3 | 7.0 |
Prostaglandins/*physiology | 3 | 13.0 |
Oxidants/*pharmacology | 3 | 13.0 |
T-Lymphocytes/pathology | 3 | 2.0 |
Blood Circulation/*drug effects | 2 | 33.0 |
Prostaglandins E/*secretion | 2 | 50.0 |
Shock, Septic/immunology/mortality/*therapy | 2 | 100.0 |
Endothelium, Vascular/*enzymology | 5 | 10.0 |
Phagocytes/*metabolism | 2 | 11.0 |
Receptors, Immunologic/*metabolism | 6 | 3.0 |
Renal Dialysis/adverse effects | 3 | 10.0 |
Oligodeoxyribonucleotides/pharmacology | 2 | 8.0 |
Cerebrospinal Fluid/cytology | 2 | 8.0 |
DNA, Neoplasm/analysis | 4 | 0.0 |
Zinc/chemistry | 2 | 6.0 |
*Immunoconjugates | 3 | 0.0 |
Adipocytes/metabolism/pathology | 2 | 100.0 |
Growth Hormone/secretion | 2 | 2.0 |
2',5'-Oligoadenylate Synthetase/blood | 2 | 66.0 |
Biopterin/analogs & derivatives/analysis | 3 | 42.0 |
Fever/chemically induced | 5 | 35.0 |
Neoplasm Proteins/analysis | 2 | 0.0 |
Hepatitis, Chronic/*metabolism/pathology | 2 | 66.0 |
Liver/*metabolism/pathology | 3 | 10.0 |
Cold | 3 | 2.0 |
Cell Communication/*physiology | 3 | 4.0 |
Collagen/immunology | 2 | 7.0 |
Platelet Activating Factor/*physiology | 3 | 37.0 |
Virus Integration | 2 | 3.0 |
Microcirculation/physiology | 2 | 6.0 |
Ethers, Cyclic/pharmacology | 8 | 22.0 |
Okadaic Acid | 10 | 20.0 |
Terpenes/pharmacology | 2 | 7.0 |
Thalidomide/*analogs & derivatives/*pharmacology | 2 | 100.0 |
Thapsigargin | 2 | 7.0 |
DNA/chemistry/metabolism | 3 | 3.0 |
B-Lymphocytes | 4 | 2.0 |
Body Fluids/chemistry | 3 | 14.0 |
Hybridomas | 7 | 4.0 |
Isoelectric Focusing | 7 | 1.0 |
Albumins/analysis | 2 | 5.0 |
L-Lactate Dehydrogenase/analysis | 4 | 10.0 |
Hydrocortisone/pharmacology | 4 | 5.0 |
Neutrophils/drug effects/immunology/*metabolism | 2 | 40.0 |
Interleukin-10/antagonists & inhibitors/*pharmacology | 2 | 66.0 |
Lipopolysaccharides/antagonists & inhibitors | 2 | 40.0 |
*GTP-Binding Proteins | 2 | 3.0 |
Tumor Necrosis Factor-alpha/*adverse effects/therapeutic use | 3 | 100.0 |
France | 2 | 0.0 |
Methadone/therapeutic use | 2 | 20.0 |
Receptors, Cell Surface/*genetics/*metabolism | 2 | 14.0 |
Colitis, Ulcerative/*surgery | 2 | 100.0 |
Cell Membrane/chemistry | 3 | 2.0 |
HIV-1/*growth & development | 5 | 7.0 |
Virus Activation/*drug effects | 2 | 18.0 |
Heparin/*pharmacology | 2 | 1.0 |
Cytokines/drug effects/immunology | 2 | 40.0 |
Epithelium/chemistry | 2 | 1.0 |
Granulocytes/*cytology | 3 | 12.0 |
Hematopoiesis/*physiology | 4 | 4.0 |
Hematopoietic Stem Cells/*cytology | 4 | 1.0 |
Cyclic AMP/biosynthesis | 6 | 4.0 |
Interleukin-10/antagonists & inhibitors/*biosynthesis | 2 | 50.0 |
Infertility, Male/*metabolism | 2 | 9.0 |
Oligodeoxyribonucleotides/chemistry | 8 | 3.0 |
Shock, Septic/etiology | 6 | 42.0 |
*Cell Transformation, Viral | 4 | 2.0 |
DNA, Viral/genetics | 5 | 3.0 |
Gene Expression Regulation, Leukemic/*drug effects | 2 | 5.0 |
Photosensitizing Agents/*pharmacology | 2 | 13.0 |
Brain/*metabolism | 3 | 0.0 |
Arthritis, Rheumatoid/genetics/*immunology | 3 | 8.0 |
Glucagon/blood | 4 | 4.0 |
HIV-1/genetics | 4 | 6.0 |
Ethylmaleimide/pharmacology | 2 | 3.0 |
Radioligand Assay | 11 | 2.0 |
Oligonucleotide Probes/genetics | 3 | 2.0 |
*Plasmodium falciparum | 3 | 21.0 |
Peritoneal Cavity/cytology | 10 | 24.0 |
*Human T-lymphotropic virus 1 | 2 | 10.0 |
Carrier Proteins/*blood | 2 | 0.0 |
Transplantation, Isogeneic | 3 | 10.0 |
Delayed-Action Preparations | 3 | 2.0 |
Tumor Necrosis Factor-alpha/*adverse effects | 2 | 100.0 |
Superoxide Dismutase/*biosynthesis | 5 | 55.0 |
Acetylmuramyl-Alanyl-Isoglutamine/*pharmacology | 4 | 50.0 |
Cell Differentiation/genetics | 2 | 0.0 |
Monocytes/*drug effects/*immunology | 3 | 23.0 |
Macrophages, Alveolar/physiology | 3 | 42.0 |
Interleukin-1/*pharmacology/*physiology | 2 | 100.0 |
Ischemia | 3 | 17.0 |
Tumor Necrosis Factor-alpha/*therapeutic use/toxicity | 4 | 100.0 |
HIV Antigens/blood | 2 | 12.0 |
Nutritional Status | 4 | 2.0 |
Dust | 2 | 6.0 |
Hypersensitivity/immunology | 2 | 5.0 |
Mites/immunology | 3 | 7.0 |
Receptor, Insulin/metabolism | 2 | 2.0 |
Lung Neoplasms/drug therapy | 3 | 13.0 |
Neoplasms, Experimental/*drug therapy/pathology | 2 | 22.0 |
Sarcoma, Experimental/drug therapy | 2 | 40.0 |
Molecular Probes/genetics | 3 | 3.0 |
Cardiovascular System/physiopathology | 3 | 33.0 |
Tumor Necrosis Factor-alpha/biosynthesis/metabolism | 5 | 41.0 |
Adenosine Triphosphate/metabolism | 6 | 1.0 |
Cell Hypoxia/*physiology | 2 | 3.0 |
Endopeptidases | 3 | 8.0 |
Tumor Necrosis Factor-alpha/metabolism/*secretion | 2 | 100.0 |
Trans-Activation (Genetics)/drug effects/physiology | 2 | 10.0 |
Epithelium/metabolism | 9 | 2.0 |
*Tobacco | 2 | 8.0 |
Colonic Neoplasms/*pathology | 5 | 6.0 |
Vascular Cell Adhesion Molecule-1/biosynthesis/drug effects | 2 | 100.0 |
Bone Marrow/immunology | 3 | 2.0 |
Bone Marrow Cells | 18 | 4.0 |
src-Family Kinases/*physiology | 2 | 5.0 |
Gene Expression Regulation, Bacterial/*immunology | 2 | 100.0 |
Lymphotoxin/biosynthesis | 9 | 52.0 |
*Bone Marrow Cells | 6 | 2.0 |
Polysaccharides/isolation & purification/*pharmacology | 2 | 40.0 |
Interleukin-6/blood/immunology | 2 | 25.0 |
Complement/metabolism | 2 | 2.0 |
Filtration | 2 | 4.0 |
Plasma/immunology | 2 | 22.0 |
Cyclooxygenase Inhibitors/administration & dosage/*pharmacology | 2 | 100.0 |
Indomethacin/administration & dosage/*pharmacology | 2 | 66.0 |
Organ Size | 5 | 2.0 |
Endothelium, Vascular/*drug effects/ultrastructure | 3 | 100.0 |
Nitroglycerin/pharmacology | 2 | 11.0 |
Polyethylene Glycols/*pharmacology | 2 | 7.0 |
Fibroblast Growth Factors/*pharmacology | 3 | 6.0 |
Chloramphenicol O-Acetyltransferase/biosynthesis | 2 | 1.0 |
Cytomegalovirus/genetics | 2 | 2.0 |
Lymphotoxin/metabolism/*pharmacology | 2 | 100.0 |
Receptors, Tumor Necrosis Factor/biosynthesis/immunology/*physiology | 2 | 100.0 |
Graft Rejection/*prevention & control | 3 | 7.0 |
Graft Survival | 5 | 1.0 |
Oligopeptides/genetics | 2 | 22.0 |
HIV Core Protein p24/biosynthesis | 6 | 13.0 |
HIV-1/drug effects/*physiology | 6 | 15.0 |
Antigens, Neoplasm/analysis | 4 | 1.0 |
B-Lymphocytes/*pathology | 2 | 4.0 |
*Neoplasm Circulating Cells | 2 | 5.0 |
Ovarian Neoplasms/*drug therapy | 2 | 10.0 |
Lipid A/*pharmacology | 2 | 66.0 |
Blood Platelets/drug effects | 3 | 11.0 |
RNA, Neoplasm/genetics | 4 | 1.0 |
Complement 3a/analysis | 2 | 11.0 |
Blood Proteins/analysis | 3 | 1.0 |
*Cereals | 2 | 20.0 |
Endotoxins/adverse effects | 2 | 50.0 |
Bone Marrow/drug effects | 6 | 8.0 |
Vitamin E/*administration & dosage | 2 | 33.0 |
T-Lymphocyte Subsets | 6 | 4.0 |
*Chromosomes, Human, Pair 6 | 3 | 1.0 |
HLA-DR1 Antigen/genetics | 2 | 12.0 |
*Cell Cycle | 2 | 0.0 |
DNA Replication/drug effects | 10 | 5.0 |
G0 Phase | 3 | 4.0 |
Tumor Necrosis Factor-alpha/genetics/secretion | 4 | 50.0 |
Phosphoric Diester Hydrolases/metabolism | 2 | 7.0 |
*Transcription, Genetic/drug effects | 3 | 2.0 |
Epidermis/cytology/metabolism | 2 | 11.0 |
Tuberculosis, Pulmonary/*blood | 2 | 66.0 |
*Chromosomes, Human, Pair 19 | 2 | 0.0 |
Antigens, Differentiation, B-Lymphocyte/analysis | 3 | 1.0 |
Receptors, Transferrin/analysis | 2 | 5.0 |
Adenoviruses, Human/*genetics/immunology | 2 | 33.0 |
Antibodies, Monoclonal/administration & dosage/immunology | 2 | 50.0 |
Lymphocyte Depletion | 5 | 3.0 |
Muscle Fibers/pathology | 2 | 11.0 |
Cyclic AMP/*pharmacology | 2 | 3.0 |
Pancreatitis/*blood/complications | 2 | 50.0 |
Shock, Septic/*blood/immunology | 2 | 66.0 |
Macrophage Inflammatory Protein-1 | 4 | 21.0 |
Monokines/biosynthesis | 2 | 33.0 |
Mice/immunology | 3 | 13.0 |
Zidovudine/pharmacology | 2 | 3.0 |
*Genes, Structural | 10 | 1.0 |
Shock, Septic/*etiology/physiopathology/therapy | 2 | 100.0 |
Autoradiography | 8 | 1.0 |
Complement 3b/metabolism | 2 | 1.0 |
Receptors, Leukocyte-Adhesion/metabolism | 2 | 40.0 |
Antibodies, Antineutrophil Cytoplasmic | 3 | 7.0 |
Leukocytes, Mononuclear/*drug effects/*metabolism | 2 | 50.0 |
Isoquinolines/pharmacology | 14 | 11.0 |
Pigment Epithelium of Eye/cytology/drug effects/*metabolism | 2 | 18.0 |
Simian virus 40 | 3 | 6.0 |
Muscles/*metabolism | 2 | 2.0 |
*Liposomes | 5 | 13.0 |
Gene Expression Regulation, Neoplastic/*genetics | 2 | 1.0 |
Enterotoxins/pharmacology | 2 | 3.0 |
HLA-DR Antigens/*biosynthesis | 2 | 6.0 |
Xenon/*pharmacology | 2 | 100.0 |
Pemphigoid, Benign Mucous Membrane/*metabolism/pathology | 2 | 50.0 |
Natriuretic Peptide, Brain/metabolism | 2 | 66.0 |
Hydrophobicity | 3 | 4.0 |
*Protein Conformation | 3 | 1.0 |
Phospholipases A/*genetics | 2 | 9.0 |
Cadherins/physiology | 2 | 11.0 |
Blood Proteins/biosynthesis | 3 | 14.0 |
Bradykinin/*pharmacology | 2 | 5.0 |
Glioma | 3 | 4.0 |
Nerve Growth Factors/*pharmacology | 2 | 1.0 |
Neurons/cytology/*drug effects/pathology | 2 | 100.0 |
Escherichia coli/physiology | 3 | 23.0 |
Gram-Negative Bacteria/*physiology | 2 | 40.0 |
Neutrophils/cytology/*drug effects | 4 | 44.0 |
Melanoma/*therapy | 4 | 50.0 |
Soft Tissue Neoplasms/*therapy | 2 | 100.0 |
Autoimmune Diseases/immunology | 3 | 3.0 |
Antigens, CD4/immunology | 3 | 1.0 |
Methylprednisolone/therapeutic use | 3 | 6.0 |
Neural Conduction | 3 | 3.0 |
*Endotoxins | 3 | 60.0 |
Toxemia/*metabolism | 3 | 100.0 |
Macrophages/secretion | 3 | 33.0 |
Saphenous Vein | 4 | 25.0 |
Hemodynamic Processes/*drug effects | 3 | 2.0 |
Antigens, CD18/*physiology | 3 | 17.0 |
Cell-Free System | 13 | 4.0 |
Leukemia, Myeloid/*pathology | 2 | 3.0 |
Nerve Growth Factors/*biosynthesis | 2 | 14.0 |
Leukocytes, Mononuclear/drug effects/secretion | 2 | 50.0 |
Lymphoma, Large-Cell/pathology | 2 | 16.0 |
1-Phosphatidylinositol 3-Kinase | 2 | 1.0 |
Peritoneum/*immunology | 2 | 50.0 |
HLA-DR Antigens/*biosynthesis/genetics | 2 | 40.0 |
HLA-D Antigens/genetics | 2 | 5.0 |
Candida/*immunology | 3 | 37.0 |
RNA, Messenger/*drug effects | 2 | 22.0 |
Fibroblasts/drug effects/immunology | 5 | 45.0 |
Lymphokines/physiology | 3 | 3.0 |
Oxygen/*metabolism | 3 | 2.0 |
Membrane Proteins/physiology | 2 | 2.0 |
Molecular Biology | 3 | 1.0 |
Biological Factors/metabolism | 2 | 22.0 |
Muscles/*pathology | 2 | 8.0 |
Cytokines/therapeutic use | 4 | 28.0 |
Immunoglobulins | 2 | 8.0 |
Superoxides/analysis | 5 | 55.0 |
Lymphotoxin/*pharmacology | 31 | 86.0 |
Cachexia/*etiology | 2 | 50.0 |
Dinoprostone/physiology | 2 | 22.0 |
Lymphotoxin/*therapeutic use | 2 | 100.0 |
Neoplasms/pathology/*therapy | 3 | 21.0 |
Ion Channels/drug effects/physiology | 2 | 40.0 |
Membrane Proteins/drug effects/*physiology | 2 | 66.0 |
Carbohydrate Conformation | 4 | 3.0 |
*Lipopolysaccharides/chemistry/isolation & purification | 2 | 100.0 |
Carcinoma, Squamous Cell/*metabolism/pathology | 2 | 2.0 |
Granulocyte Colony-Stimulating Factor/*biosynthesis | 2 | 66.0 |
Lung Neoplasms/*metabolism/pathology | 2 | 2.0 |
Receptors, Granulocyte Colony-Stimulating Factor/metabolism | 3 | 25.0 |
Carcinoma, Renal Cell/*drug therapy | 2 | 28.0 |
Kidney Neoplasms/*drug therapy | 2 | 25.0 |
Cell Membrane | 3 | 4.0 |
Nephrosis, Lipoid/metabolism | 2 | 40.0 |
Plasminogen Activators/blood | 2 | 28.0 |
Major Histocompatibility Complex | 4 | 1.0 |
Alkaloids/pharmacology | 13 | 12.0 |
Staurosporine | 16 | 16.0 |
Hepatic Artery | 3 | 5.0 |
Liver Circulation/drug effects | 3 | 60.0 |
Diabetes Mellitus, Type 1/*etiology | 2 | 50.0 |
Lymphocytes/physiology | 5 | 5.0 |
Cell Degranulation/*drug effects | 5 | 27.0 |
Histocompatibility Antigens Class II/immunology | 4 | 2.0 |
Immunoglobulins/biosynthesis | 2 | 1.0 |
Growth Inhibitors | 2 | 25.0 |
Urinary Plasminogen Activator/metabolism | 2 | 4.0 |
Hemorrhagic Fever with Renal Syndrome/*blood | 2 | 50.0 |
Colonic Neoplasms/drug therapy | 2 | 14.0 |
Neoplasms/blood/*drug therapy | 3 | 23.0 |
Colonic Neoplasms/drug therapy/*therapy | 2 | 100.0 |
Disseminated Intravascular Coagulation/*blood | 2 | 9.0 |
Thrombosis/*blood/etiology | 2 | 22.0 |
Graft vs Host Disease/blood | 3 | 37.0 |
2-Amino-5-phosphonovalerate/pharmacology | 2 | 40.0 |
Dizocilpine Maleate/pharmacology | 2 | 11.0 |
Nitric Oxide/biosynthesis/*physiology | 2 | 25.0 |
Lymphotoxin/*analysis | 4 | 100.0 |
Rats, Inbred BB | 2 | 14.0 |
Spleen | 2 | 8.0 |
*Transfection | 5 | 2.0 |
Fentanyl/pharmacology | 2 | 33.0 |
Glucocorticoids/metabolism | 3 | 14.0 |
HIV Seropositivity/immunology | 2 | 2.0 |
Cell Membrane/physiology | 4 | 2.0 |
Escherichia coli Infections/*drug therapy | 2 | 50.0 |
Interferon-gamma, Recombinant/administration & dosage | 2 | 40.0 |
Immune Sera | 4 | 1.0 |
Bone Marrow Transplantation/*immunology | 4 | 3.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/therapeutic use | 2 | 7.0 |
Escherichia coli/pathogenicity | 3 | 33.0 |
Central Nervous System/drug effects | 2 | 25.0 |
Immunity, Cellular/drug effects | 4 | 6.0 |
*Cytotoxicity, Immunologic/drug effects | 4 | 15.0 |
Monocytes/*cytology/drug effects | 2 | 12.0 |
Tumor Necrosis Factor-alpha/*antagonists & inhibitors/*pharmacology | 3 | 100.0 |
Liver Neoplasms/secondary/*therapy | 2 | 40.0 |
Sarcoma/*therapy | 2 | 50.0 |
*Cell Cycle/drug effects | 2 | 16.0 |
DNA Topoisomerases, Type II/antagonists & inhibitors | 2 | 7.0 |
Dimethyl Sulfoxide/*pharmacology | 3 | 12.0 |
Tumor Cells, Cultured/drug effects/pathology | 5 | 12.0 |
Interleukin-2/*adverse effects | 4 | 40.0 |
Lymphotoxin/biosynthesis/*genetics | 2 | 66.0 |
Integrins/*metabolism | 2 | 1.0 |
NADH, NADPH Oxidoreductases/*metabolism | 3 | 9.0 |
NADPH Oxidase | 5 | 12.0 |
Antigens, CD4/*metabolism | 2 | 0.0 |
*Heat | 5 | 4.0 |
Shock/etiology | 2 | 50.0 |
Breast Neoplasms/*genetics/pathology | 2 | 0.0 |
Genomic Library | 2 | 0.0 |
Adenocarcinoma/metabolism | 2 | 2.0 |
Colonic Neoplasms/metabolism | 2 | 3.0 |
Salmonella | 3 | 12.0 |
Detergents/pharmacology | 3 | 2.0 |
Recombinant Proteins/analysis/immunology | 2 | 14.0 |
Insulin Resistance/physiology | 3 | 6.0 |
Exotoxins/*pharmacology | 2 | 8.0 |
HLA Antigens/immunology | 2 | 1.0 |
Streptococcus pyogenes/*immunology | 2 | 10.0 |
Superantigens/*pharmacology | 4 | 14.0 |
Methylmethacrylates | 4 | 36.0 |
Pulmonary Fibrosis/metabolism | 2 | 20.0 |
E-Selectin/*biosynthesis/genetics | 2 | 66.0 |
Alcoholism/*immunology | 2 | 25.0 |
Endothelium, Vascular/*cytology/physiology | 2 | 10.0 |
beta Carotene | 2 | 12.0 |
Genistein | 5 | 6.0 |
Isoflavones/pharmacology | 3 | 4.0 |
Antibodies, Anti-Idiotypic/pharmacology | 2 | 6.0 |
Immunoglobulin E/biosynthesis/genetics | 2 | 33.0 |
Serine Endopeptidases/*metabolism | 2 | 2.0 |
Chemotactic Factors/*biosynthesis/genetics | 2 | 33.0 |
Collagen/pharmacology | 2 | 1.0 |
Monocyte Chemoattractant Protein-1 | 10 | 62.0 |
Monocytes/*cytology/metabolism | 2 | 8.0 |
Vascular Cell Adhesion Molecule-1 | 26 | 31.0 |
Pulmonary Artery/cytology/*metabolism | 2 | 33.0 |
Embryo | 5 | 1.0 |
Granulocyte Colony-Stimulating Factor/*pharmacology | 8 | 6.0 |
Polymerase Chain Reaction/*methods | 2 | 0.0 |
Ascites/*therapy | 2 | 66.0 |
Follicle Stimulating Hormone/blood | 2 | 0.0 |
Luteinizing Hormone/blood | 2 | 0.0 |
*Proteasome Endopeptidase Complex | 2 | 3.0 |
Aminoquinolines/*pharmacology | 2 | 16.0 |
*Interferon Inducers | 2 | 33.0 |
Monitoring, Immunologic | 2 | 8.0 |
Cell Adhesion Molecules | 4 | 7.0 |
Hypersensitivity, Delayed/*immunology | 3 | 8.0 |
Escherichia coli/genetics/metabolism | 3 | 5.0 |
Spleen/physiology | 2 | 22.0 |
Chemokines, CC/immunology | 2 | 13.0 |
Interleukin-8/*immunology | 3 | 33.0 |
Receptors, Chemokine/immunology | 2 | 6.0 |
Macrophages/*immunology/metabolism | 6 | 26.0 |
Tumor Necrosis Factor-alpha/analysis/*metabolism/pharmacology | 2 | 100.0 |
Immunologic Techniques | 17 | 5.0 |
Membrane Proteins/chemistry/*physiology | 2 | 10.0 |
Phosphotyrosine | 5 | 1.0 |
E-Selectin | 30 | 37.0 |
Cell Physiology | 2 | 15.0 |
Genetics | 2 | 33.0 |
Interleukin-1/genetics/metabolism/*physiology | 2 | 100.0 |
1-(5-Isoquinolinesulfonyl)-2-methylpiperazine | 12 | 21.0 |
Piperazines/pharmacology | 13 | 12.0 |
Membrane Glycoproteins/chemistry/genetics | 2 | 22.0 |
Receptors, Tumor Necrosis Factor/*antagonists & inhibitors/metabolism | 2 | 100.0 |
Capillary Permeability | 3 | 3.0 |
*Antibody-Dependent Cell Cytotoxicity | 2 | 4.0 |
Antigens, Protozoan/immunology | 6 | 19.0 |
Plasmodium falciparum/growth & development/*immunology | 2 | 28.0 |
Immunoglobulin G/*metabolism | 2 | 3.0 |
Antigens, Differentiation, Myelomonocytic/*blood | 2 | 11.0 |
Receptors, Antigen, T-Cell, alpha-beta/genetics | 2 | 2.0 |
P-Selectin | 5 | 9.0 |
Plasminogen Activator Inhibitor 1/biosynthesis | 3 | 27.0 |
Bucladesine/*pharmacology | 3 | 18.0 |
Melanoma/*metabolism | 3 | 4.0 |
Umbilical Veins/cytology/drug effects/metabolism | 2 | 18.0 |
Endotoxins/*pharmacology/toxicity | 2 | 100.0 |
Lipopolysaccharides/*pharmacology/toxicity | 2 | 40.0 |
Bone Marrow/secretion | 2 | 66.0 |
Sialoglycoproteins/therapeutic use | 2 | 100.0 |
Adenocarcinoma/*immunology | 4 | 10.0 |
Fever/*chemically induced/*physiopathology | 2 | 100.0 |
Monocytes/*chemistry | 2 | 13.0 |
Fibroblasts/drug effects/*metabolism | 7 | 14.0 |
Lymphocyte Count/drug effects | 2 | 5.0 |
Receptors, Tumor Necrosis Factor/analysis/*biosynthesis | 2 | 66.0 |
Sepsis/*blood/immunology | 2 | 66.0 |
Lung/cytology/*immunology | 5 | 38.0 |
Macrophages, Alveolar/drug effects/*immunology | 3 | 60.0 |
Electron Spin Resonance Spectroscopy | 2 | 0.0 |
Membrane Fluidity/drug effects | 3 | 15.0 |
Lymphocytes/*secretion | 2 | 66.0 |
Colony-Stimulating Factors/pharmacology | 15 | 34.0 |
NF-kappa B/biosynthesis | 3 | 20.0 |
*Sulfonamides | 5 | 9.0 |
Tumor Necrosis Factor-alpha/*biosynthesis/secretion | 6 | 75.0 |
Interleukin-10/pharmacology/*physiology | 2 | 50.0 |
Multiple Organ Failure/etiology/prevention & control | 3 | 100.0 |
Amino Acid Oxidoreductases/*biosynthesis | 3 | 42.0 |
Nitric-Oxide Synthase | 6 | 17.0 |
Pancreatic Neoplasms | 2 | 5.0 |
omega-N-Methylarginine | 9 | 56.0 |
Chimeric Proteins/biosynthesis | 2 | 4.0 |
Ferritin/*biosynthesis | 2 | 66.0 |
Restriction Mapping | 15 | 0.0 |
Quinacrine/pharmacology | 5 | 33.0 |
Autoantibodies/biosynthesis | 2 | 5.0 |
Amyloid beta-Protein/metabolism | 2 | 3.0 |
Neurons/metabolism | 3 | 0.0 |
Neoplasm Proteins/chemistry | 2 | 18.0 |
Oligonucleotides | 3 | 4.0 |
Reverse Transcriptase Polymerase Chain Reaction/*methods | 2 | 3.0 |
Carbazoles/*pharmacology | 2 | 12.0 |
*Regeneration | 2 | 7.0 |
Receptors, Tumor Necrosis Factor/*chemistry/genetics/metabolism | 2 | 100.0 |
Leukemia, Hairy Cell/*physiopathology | 2 | 100.0 |
Transcription Factor AP-1/*physiology | 2 | 5.0 |
Tumor Necrosis Factor-alpha/analysis/*cerebrospinal fluid | 2 | 100.0 |
Interleukin-13/physiology | 2 | 33.0 |
Biopterin/analogs & derivatives/blood | 9 | 20.0 |
beta 2-Microglobulin/metabolism | 4 | 5.0 |
Interleukin-2/physiology | 7 | 8.0 |
Fluoresceins | 3 | 4.0 |
Hematopoietic Stem Cells/drug effects | 4 | 6.0 |
Leukemia/pathology | 2 | 6.0 |
Leukocytosis/chemically induced | 4 | 66.0 |
Interleukins/*pharmacology | 4 | 5.0 |
Fibrosarcoma/*pathology | 2 | 28.0 |
Recombinant Fusion Proteins/*biosynthesis | 3 | 12.0 |
Antibodies, Bacterial/blood | 3 | 4.0 |
Endotoxins/*blood/immunology | 2 | 66.0 |
Antigens, Differentiation, Myelomonocytic/metabolism | 5 | 3.0 |
Amino Acid Oxidoreductases/antagonists & inhibitors | 2 | 66.0 |
Arginine/*analogs & derivatives/pharmacology | 2 | 12.0 |
Epithelium/drug effects/physiology | 2 | 9.0 |
Interleukin-1/immunology/*pharmacology | 3 | 60.0 |
Recombinant Proteins/immunology/pharmacology | 3 | 12.0 |
HIV/*growth & development | 2 | 16.0 |
RNA-Directed DNA Polymerase/analysis | 2 | 7.0 |
Neoplasms, Experimental/*drug therapy | 5 | 26.0 |
Antigens, Surface/*physiology | 3 | 4.0 |
Transformation, Genetic | 3 | 1.0 |
*Blood-Brain Barrier | 2 | 8.0 |
Recombinant Proteins/pharmacokinetics | 2 | 11.0 |
src-Family Kinases/*metabolism | 3 | 1.0 |
Butyric Acid | 4 | 8.0 |
Hydrogen Peroxide/*metabolism | 2 | 5.0 |
Peroxidases/*pharmacology | 2 | 50.0 |
Lung/cytology/*metabolism | 6 | 18.0 |
Quinine/therapeutic use | 2 | 100.0 |
Interleukin-6/blood/*secretion | 2 | 66.0 |
Mycobacterium tuberculosis | 3 | 18.0 |
*Interleukin-1 | 2 | 100.0 |
Lipoprotein Lipase/*metabolism | 5 | 2.0 |
Skin/*cytology | 4 | 9.0 |
Ovarian Neoplasms/*metabolism | 2 | 3.0 |
Transforming Growth Factor beta/*physiology | 3 | 2.0 |
Leukocytes, Mononuclear/cytology/*metabolism | 2 | 50.0 |
Water | 2 | 3.0 |
Amniocentesis | 2 | 2.0 |
Escherichia coli/*metabolism | 2 | 7.0 |
Biological Response Modifiers/pharmacology/*therapeutic use | 2 | 28.0 |
Interleukin-2/*therapeutic use | 11 | 10.0 |
Neoplasm Recurrence, Local/*prevention & control | 2 | 14.0 |
Neoplasm Proteins/biosynthesis | 4 | 5.0 |
Receptors, Cell Surface/drug effects/immunology | 2 | 40.0 |
Diploidy | 3 | 2.0 |
Receptors, Cell Surface/immunology/*metabolism | 2 | 6.0 |
Cyclic AMP-Dependent Protein Kinases/physiology | 2 | 7.0 |
Leukocytes, Mononuclear/*drug effects/secretion | 3 | 100.0 |
Macrophages/*virology | 2 | 3.0 |
Arginine/pharmacology | 2 | 7.0 |
Malaria, Cerebral/*immunology | 2 | 66.0 |
Clone Cells/immunology | 4 | 2.0 |
Doxorubicin/administration & dosage/*pharmacology | 2 | 50.0 |
Host-Parasite Relations | 4 | 11.0 |
Melanoma/blood/therapy | 2 | 100.0 |
Carrier Proteins/chemistry/*physiology | 2 | 5.0 |
I-kappa B/physiology | 2 | 100.0 |
Antibodies, Monoclonal/*metabolism | 4 | 10.0 |
Blood/drug effects | 2 | 28.0 |
Dislocations/metabolism | 2 | 66.0 |
Temporomandibular Joint Disorders/*metabolism | 2 | 40.0 |
Chemotactic Factors/immunology | 2 | 66.0 |
Cytokines/*analysis/immunology | 3 | 42.0 |
Killer Cells, Lymphokine-Activated/immunology | 8 | 12.0 |
Cytoskeleton/drug effects | 2 | 9.0 |
Antibodies, Bacterial/immunology | 3 | 7.0 |
Silver Staining | 2 | 2.0 |
Eosinophils | 2 | 5.0 |
Phosphoprotein Phosphatase/pharmacology | 2 | 40.0 |
Antigens, CD3/*immunology | 3 | 2.0 |
Tumor Necrosis Factor-alpha/antagonists & inhibitors/physiology | 5 | 71.0 |
*Cell Division | 2 | 1.0 |
Tumor Necrosis Factor-alpha/*biosynthesis/immunology/pharmacology | 3 | 100.0 |
Proto-Oncogene Proteins/*physiology | 4 | 1.0 |
Mycobacterium bovis/*immunology | 6 | 30.0 |
Peptides/chemical synthesis/immunology | 2 | 4.0 |
Zinc/*pharmacology | 4 | 12.0 |
Fluorides/pharmacology | 2 | 7.0 |
Guanosine 5'-O-(3-Thiotriphosphate)/metabolism | 3 | 3.0 |
Receptors, Formyl Peptide | 8 | 11.0 |
Virulence Factors, Bordetella/metabolism | 2 | 50.0 |
Killer Cells, Lymphokine-Activated/*cytology | 2 | 33.0 |
Lactic Acid | 5 | 7.0 |
Dipeptides/*pharmacology | 2 | 11.0 |
Septicemia/*blood | 4 | 44.0 |
Chloroquine/therapeutic use | 3 | 20.0 |
Cytokines/*physiology/therapeutic use | 2 | 33.0 |
Growth Inhibitors/therapeutic use | 2 | 50.0 |
Immunoglobulin M/biosynthesis | 2 | 2.0 |
Genetic Vectors/*genetics | 2 | 2.0 |
*Immediate-Early Proteins | 3 | 1.0 |
Magnesium/pharmacology | 5 | 4.0 |
Neurons/*physiology | 2 | 1.0 |
Antibodies/analysis | 4 | 3.0 |
Actins/blood | 3 | 30.0 |
Lipopolysaccharides/*antagonists & inhibitors/pharmacology | 2 | 40.0 |
Antigens, CD/immunology/metabolism | 2 | 3.0 |
Escherichia coli/chemistry | 2 | 14.0 |
Nucleopolyhedrovirus/genetics | 2 | 9.0 |
HIV | 2 | 15.0 |
Interferon Type I/*biosynthesis | 2 | 18.0 |
Lymphocyte Function-Associated Antigen-1/biosynthesis | 2 | 9.0 |
Parainfluenza Virus 1, Human/*immunology | 2 | 40.0 |
Histamine Release/*drug effects | 2 | 6.0 |
Leukotrienes/secretion | 2 | 50.0 |
Lupus Erythematosus, Systemic/immunology | 3 | 2.0 |
Ascites | 3 | 27.0 |
Tumor Necrosis Factor-alpha/*administration & dosage/pharmacology | 3 | 100.0 |
Myocardium/cytology | 2 | 6.0 |
Antigens | 3 | 3.0 |
Interleukin-4/immunology/*pharmacology | 2 | 25.0 |
Staphylococcus aureus/physiology | 4 | 40.0 |
Interleukin-8/immunology | 4 | 40.0 |
Lipid A/immunology | 2 | 40.0 |
Phagocytosis/*immunology | 2 | 3.0 |
Antigen-Antibody Complex/*immunology | 4 | 4.0 |
C-Reactive Protein/*analysis | 3 | 0.0 |
Interferon Type II/administration & dosage/*therapeutic use | 3 | 60.0 |
Interleukin-1/biosynthesis/*blood | 2 | 66.0 |
Interleukin-2/*blood | 6 | 27.0 |
Receptors, Interleukin-2/*metabolism | 4 | 5.0 |
Antigens, Surface/metabolism | 5 | 4.0 |
Receptors, Tumor Necrosis Factor/classification/*metabolism | 2 | 100.0 |
Leukemia, Monocytic, Acute/*pathology | 2 | 15.0 |
Receptors, Interleukin-4 | 3 | 4.0 |
L-Selectin | 7 | 11.0 |
Biological Response Modifiers/*adverse effects | 2 | 100.0 |
Immunoglobulin G/adverse effects | 2 | 100.0 |
Interleukin-1/*immunology | 8 | 38.0 |
Macrophages, Alveolar/*drug effects/immunology | 4 | 80.0 |
Epithelial Cells/physiology | 2 | 2.0 |
Galactosamine/administration & dosage/*pharmacology | 2 | 100.0 |
Tumor Necrosis Factor-alpha/*analysis/physiology | 4 | 100.0 |
TATA Box | 2 | 0.0 |
Heat-Shock Proteins/*metabolism | 3 | 5.0 |
Hepatitis, Chronic/*blood | 3 | 25.0 |
Vesicular stomatitis-Indiana virus/drug effects | 2 | 15.0 |
Gene Expression Regulation, Developmental | 2 | 0.0 |
Sequence Homology | 3 | 0.0 |
Hypotension/chemically induced | 5 | 38.0 |
Cytokines/*biosynthesis/*physiology | 2 | 100.0 |
DNA, Recombinant/genetics | 2 | 3.0 |
Hela Cells/*metabolism | 2 | 28.0 |
Immunosorbent Techniques | 4 | 1.0 |
Endothelium, Vascular/metabolism/*physiology | 2 | 25.0 |
Sepsis/*therapy | 3 | 100.0 |
Immunoglobulin M/*pharmacology | 2 | 40.0 |
Killer Cells, Lymphokine-Activated | 2 | 25.0 |
Skin Neoplasms/*therapy | 2 | 33.0 |
Kidney Failure, Chronic/surgery | 2 | 25.0 |
Umbilical Veins/chemistry | 2 | 66.0 |
Disseminated Intravascular Coagulation/physiopathology | 2 | 66.0 |
Leukemia, Hairy Cell/*metabolism/pathology | 2 | 66.0 |
Kidney Glomerulus/*blood supply | 2 | 50.0 |
Lipoxygenase/*metabolism | 2 | 25.0 |
Colonic Neoplasms/*immunology | 2 | 8.0 |
Microcirculation/pathology | 2 | 2.0 |
Infusions, Intra-Arterial | 6 | 9.0 |
Arginine/analogs & derivatives/pharmacology | 5 | 16.0 |
Adenosine/*pharmacology | 2 | 20.0 |
Gene Expression/*immunology | 3 | 30.0 |
Lymphokines/*pharmacology | 7 | 2.0 |
Premedication | 2 | 10.0 |
Shock, Septic/physiopathology | 6 | 66.0 |
*Fertilization in Vitro | 4 | 3.0 |
Receptors, Interleukin-2/*analysis | 8 | 11.0 |
Veins | 2 | 3.0 |
Butyric Acids/pharmacology | 3 | 9.0 |
Genes, p53/*genetics | 2 | 0.0 |
Picibanil/administration & dosage | 2 | 66.0 |
Erythropoietin/*therapeutic use | 2 | 2.0 |
Sepsis/blood | 2 | 18.0 |
Intestinal Absorption | 2 | 1.0 |
Neoplasm Proteins/antagonists & inhibitors | 2 | 25.0 |
Recombinant Proteins/administration & dosage/pharmacology/therapeutic use | 2 | 33.0 |
Body Temperature Regulation/*drug effects | 2 | 14.0 |
Macrophages/metabolism/ultrastructure | 2 | 25.0 |
Encephalomyocarditis virus | 2 | 50.0 |
Hematopoiesis/drug effects | 5 | 6.0 |
Phytotherapy | 3 | 11.0 |
Arthritis, Rheumatoid/drug therapy/*immunology | 2 | 14.0 |
Autocrine Communication/*drug effects | 2 | 28.0 |
Mycobacterium tuberculosis/*immunology/pathogenicity | 2 | 40.0 |
Lymphocyte Subsets/physiology | 2 | 22.0 |
Cell Adhesion Molecules/biosynthesis/genetics | 2 | 12.0 |
*Thromboplastin | 2 | 66.0 |
Tumor Necrosis Factor-alpha/antagonists & inhibitors/*immunology/toxicity | 2 | 100.0 |
Lactoferrin/blood | 2 | 28.0 |
Macrophage-1 Antigen/blood | 2 | 16.0 |
Phagocytosis/physiology | 3 | 9.0 |
Phthalimides/chemistry/*pharmacology | 2 | 100.0 |
Sialoglycoproteins/*biosynthesis/genetics | 2 | 40.0 |
Gingiva/cytology/drug effects/enzymology | 2 | 100.0 |
Synovial Fluid/immunology | 2 | 5.0 |
Vital Capacity | 3 | 8.0 |
Blood Coagulation Factors/*metabolism | 2 | 2.0 |
Plasminogen Inactivators/blood | 3 | 11.0 |
Liposomes/immunology | 3 | 42.0 |
Phosphatidylinositols/*immunology | 3 | 75.0 |
Nucleic Acid Conformation | 2 | 0.0 |
*Protein Engineering | 2 | 9.0 |
Ascitic Fluid/*immunology | 3 | 27.0 |
Receptors, Estrogen/analysis | 2 | 0.0 |
Growth Inhibitors/*biosynthesis | 3 | 12.0 |
Acetyltransferases/metabolism | 2 | 2.0 |
Pancreatic Elastase/metabolism | 2 | 6.0 |
Platelet Activating Factor/*biosynthesis | 4 | 44.0 |
Bone Marrow/*drug effects | 2 | 7.0 |
Erythropoietin/*genetics | 2 | 5.0 |
Cytoskeleton/physiology | 2 | 2.0 |
Integrins/*physiology | 4 | 4.0 |
3T3 Cells/drug effects | 2 | 18.0 |
Protein Kinases/physiology | 5 | 10.0 |
Diglycerides/*biosynthesis | 2 | 66.0 |
Endothelium, Vascular/cytology/*immunology | 3 | 9.0 |
Mucocutaneous Lymph Node Syndrome/complications/*immunology | 2 | 50.0 |
Monocytes/pathology | 5 | 13.0 |
Adipose Tissue/physiopathology | 2 | 33.0 |
Diabetes Mellitus, Type 2/*physiopathology | 2 | 6.0 |
Leukocytes/*drug effects/metabolism | 3 | 30.0 |
Interleukin-6/pharmacology/physiology | 2 | 50.0 |
Receptors, Interleukin-1/*physiology | 2 | 14.0 |
Arteriosclerosis/*etiology | 2 | 5.0 |
Proteins/antagonists & inhibitors/*physiology | 2 | 50.0 |
Receptors, Tumor Necrosis Factor/biosynthesis/metabolism | 3 | 50.0 |
Tumor Cells, Cultured/cytology | 2 | 10.0 |
Keratinocytes/cytology/drug effects | 2 | 22.0 |
Liver/*injuries | 2 | 66.0 |
Aspirin/therapeutic use | 3 | 7.0 |
Fibroblasts/drug effects/*immunology | 2 | 66.0 |
Algorithms | 2 | 0.0 |
Amiloride/pharmacology | 2 | 5.0 |
Antibodies, Monoclonal/chemistry | 2 | 2.0 |
Cations | 2 | 2.0 |
Wound Healing | 2 | 1.0 |
Pancreatic Neoplasms/physiopathology | 2 | 28.0 |
Membranes/metabolism | 2 | 4.0 |
Spleen/cytology/immunology | 2 | 3.0 |
*Antineoplastic Agents | 6 | 27.0 |
Leukocyte Elastase | 4 | 9.0 |
Autoantibodies/*genetics | 2 | 13.0 |
HLA-D Antigens/*genetics | 5 | 3.0 |
Cosmids | 3 | 0.0 |
Malaria, Falciparum/immunology | 2 | 28.0 |
Sonication | 2 | 15.0 |
Tumor Necrosis Factor-alpha/*genetics/secretion | 2 | 50.0 |
Tumor Necrosis Factor-alpha/immunology/*isolation & purification | 4 | 100.0 |
Escherichia coli/*immunology | 3 | 8.0 |
Tumor Necrosis Factor-alpha/pharmacology/*secretion | 3 | 75.0 |
Antigens, Differentiation, Myelomonocytic/physiology | 3 | 14.0 |
Egtazic Acid/analogs & derivatives/pharmacology | 3 | 10.0 |
Stem Cell Factor | 2 | 2.0 |
Cell Adhesion Molecules/genetics/*metabolism | 6 | 14.0 |
Endothelium, Vascular/cytology/*drug effects/*metabolism | 3 | 23.0 |
Immunoglobulins/immunology | 2 | 4.0 |
Moloney murine leukemia virus/genetics | 2 | 6.0 |
Tumor Necrosis Factor-alpha/*genetics/pharmacology/physiology | 2 | 100.0 |
Liver/drug effects/*metabolism | 5 | 6.0 |
Progesterone/pharmacology | 4 | 3.0 |
*Blood Physiology | 3 | 10.0 |
Complement/physiology | 4 | 8.0 |
Immunoglobulin G/physiology | 2 | 10.0 |
Interleukin-4/analysis | 2 | 5.0 |
Biopterin/analogs & derivatives/urine | 2 | 50.0 |
GTP-Binding Proteins/physiology | 3 | 4.0 |
Amniotic Fluid/*chemistry | 2 | 4.0 |
Bone Marrow/*pathology | 3 | 2.0 |
Intercellular Adhesion Molecule-1 | 38 | 16.0 |
Antigens, CD58 | 3 | 2.0 |
Benzylidene Compounds/*pharmacology | 2 | 50.0 |
HIV Antigens/analysis | 2 | 5.0 |
Stromelysin 1 | 2 | 5.0 |
Cytoplasm/*metabolism | 2 | 1.0 |
Antibodies, Bacterial/biosynthesis | 2 | 13.0 |
Cysteine/metabolism | 3 | 3.0 |
Antigen-Presenting Cells/physiology | 2 | 3.0 |
Antibodies, Protozoan/*biosynthesis | 2 | 25.0 |
Liposomes/metabolism | 2 | 3.0 |
Malaria/*immunology | 6 | 30.0 |
Sphingomyelin Phosphodiesterase/*physiology | 2 | 100.0 |
Arthritis, Psoriatic/*drug therapy/physiopathology | 2 | 100.0 |
T-Lymphocytes/physiology | 3 | 2.0 |
Lipoproteins/*pharmacology | 2 | 4.0 |
Tetrazoles/pharmacology | 2 | 5.0 |
Gene Expression/*genetics | 3 | 2.0 |
Isoenzymes/biosynthesis/*metabolism | 2 | 22.0 |
Prostaglandin-Endoperoxide Synthase/biosynthesis/*metabolism | 2 | 50.0 |
Magnetic Resonance Imaging/*methods | 2 | 2.0 |
Amitrole/pharmacology | 2 | 20.0 |
Catalase/*metabolism | 2 | 20.0 |
Glutathione Peroxidase/*metabolism | 2 | 14.0 |
Monocytes/metabolism/physiology | 2 | 25.0 |
P-Glycoprotein | 2 | 4.0 |
RNA, Antisense/genetics | 2 | 8.0 |
Tumor Necrosis Factor-alpha/biosynthesis/genetics/*physiology | 2 | 40.0 |
Antigens, CD18 | 17 | 18.0 |
Interferons/physiology | 7 | 29.0 |
Interleukin-1/*administration & dosage | 3 | 42.0 |
Interleukin-6/*genetics/metabolism | 2 | 40.0 |
HIV/drug effects/genetics/*physiology | 2 | 28.0 |
Multiple Myeloma/*pathology | 2 | 3.0 |
Oligonucleotides/metabolism | 2 | 2.0 |
Alkaloids/*pharmacology | 4 | 7.0 |
Oligodeoxyribonucleotides/metabolism | 2 | 4.0 |
Tissue Inhibitor of Metalloproteinases | 3 | 4.0 |
Neoplasms/*blood/drug therapy | 2 | 66.0 |
Lipopolysaccharides/*blood | 5 | 50.0 |
Mucoproteins/analysis | 2 | 50.0 |
Tumor Cells, Cultured/pathology | 6 | 11.0 |
Interleukin-1/blood/metabolism | 2 | 33.0 |
Gangliosides/metabolism | 2 | 11.0 |
Antigens, CD11 | 10 | 12.0 |
Antigens, CD29 | 2 | 3.0 |
Epitopes/*immunology | 2 | 0.0 |
Antigens, Differentiation, B-Lymphocyte/physiology | 2 | 10.0 |
Schistosoma mansoni/immunology | 2 | 7.0 |
Platelet Count/drug effects | 3 | 8.0 |
Heparin/pharmacology | 5 | 2.0 |
Immune Sera/*immunology | 3 | 13.0 |
Lipolysis | 2 | 2.0 |
Cecum | 2 | 66.0 |
Peritoneal Cavity/pathology | 2 | 28.0 |
Diglycerides/pharmacology | 5 | 14.0 |
Vascular Resistance/drug effects | 7 | 10.0 |
Cytotoxicity Tests, Immunologic/methods | 6 | 23.0 |
Macrophage Colony-Stimulating Factor/biosynthesis | 3 | 42.0 |
Alcoholism/immunology | 2 | 40.0 |
Interleukins/*secretion | 2 | 40.0 |
Dinoprostone/secretion | 2 | 25.0 |
Monocytes/drug effects/secretion | 2 | 50.0 |
Antigens, CD27/physiology | 2 | 40.0 |
beta 2-Microglobulin/*analysis | 2 | 2.0 |
*Antigens, Differentiation | 2 | 2.0 |
Drug Resistance/*physiology | 2 | 16.0 |
Receptor, erbB-2 | 2 | 1.0 |
Interferon Type II/*secretion | 5 | 26.0 |
Secretory Rate/drug effects | 9 | 10.0 |
Protein Subunits/metabolism | 3 | 6.0 |
Acute-Phase Proteins/*biosynthesis/genetics | 2 | 22.0 |
Herpesvirus 4, Human/*metabolism | 2 | 4.0 |
Lung/cytology | 3 | 5.0 |
Phentolamine/pharmacology | 3 | 14.0 |
Sialoglycoproteins/*biosynthesis | 5 | 25.0 |
Tissue Plasminogen Activator/biosynthesis | 3 | 20.0 |
Meningitis, Bacterial/*cerebrospinal fluid | 2 | 50.0 |
Meningitis, Viral/*cerebrospinal fluid | 2 | 66.0 |
Diabetes Mellitus, Type 1/*genetics/*immunology | 2 | 9.0 |
Immune Tolerance/*drug effects | 3 | 16.0 |
Fever/*blood/etiology | 2 | 33.0 |
Leukocytes, Mononuclear/physiology | 6 | 20.0 |
Neoplasms/immunology/therapy | 2 | 11.0 |
Prostaglandins E/physiology | 2 | 50.0 |
Receptors, Antigen, B-Cell/physiology | 2 | 6.0 |
Interleukin-8/*blood/genetics | 2 | 100.0 |
Neutrophils/*drug effects/immunology/metabolism | 3 | 50.0 |
Leukemia, Promyelocytic, Acute/*microbiology | 2 | 100.0 |
Sphingomyelins/*physiology | 3 | 75.0 |
Actins/biosynthesis | 2 | 4.0 |
Platelet Aggregation/physiology | 2 | 5.0 |
Morphine/*pharmacology | 2 | 9.0 |
Esterases/metabolism | 4 | 20.0 |
Gene Expression Regulation, Viral/*drug effects | 2 | 7.0 |
HIV Envelope Protein gp120/*immunology | 2 | 1.0 |
Immunoglobulins, Fab/pharmacology | 2 | 9.0 |
Hela Cells/metabolism | 6 | 3.0 |
Leukemia, Promyelocytic, Acute/metabolism | 3 | 30.0 |
Naloxone/pharmacology | 4 | 8.0 |
Leukemia, Experimental | 3 | 20.0 |
Leukemia, Myeloid | 5 | 13.0 |
Antigens, Surface/immunology | 8 | 4.0 |
DNA, Neoplasm/biosynthesis | 2 | 1.0 |
*Autoimmunity | 2 | 3.0 |
Lymphokines/*immunology/therapeutic use | 2 | 100.0 |
Interleukin-1/antagonists & inhibitors/*blood | 2 | 100.0 |
Tumor Necrosis Factor-alpha/*analysis/antagonists & inhibitors | 2 | 100.0 |
Repetitive Sequences, Nucleic Acid/genetics | 2 | 2.0 |
Leukopenia/etiology | 2 | 25.0 |
Splanchnic Circulation | 3 | 30.0 |
Fibroblasts/immunology/*metabolism | 2 | 33.0 |
Lung/immunology/metabolism | 2 | 33.0 |
MAP Kinase Signaling System/drug effects/physiology | 2 | 6.0 |
Ribosomal Protein S6 Kinases, 90-kDa/*metabolism | 3 | 23.0 |
Tumor Cells, Cultured/immunology | 14 | 16.0 |
Oligopeptides/*therapeutic use | 2 | 11.0 |
Interleukin-2/administration & dosage | 2 | 10.0 |
Cellulose/analogs & derivatives | 3 | 10.0 |
Hemostasis/*drug effects | 3 | 4.0 |
Cytokines/*isolation & purification | 2 | 66.0 |
Interleukin-1/isolation & purification | 2 | 100.0 |
Interleukin-6/isolation & purification | 2 | 100.0 |
Tumor Necrosis Factor-alpha/isolation & purification | 2 | 50.0 |
Tumor Necrosis Factor-alpha/*analysis/immunology | 2 | 100.0 |
Monocytes, Activated Killer/*drug effects | 2 | 100.0 |
HLA Antigens/*analysis | 2 | 0.0 |
*Genes, MHC Class I/drug effects | 2 | 66.0 |
HLA-B7 Antigen/*biosynthesis/genetics | 2 | 100.0 |
Piroxicam/pharmacology | 2 | 28.0 |
Gram-Negative Bacterial Infections/metabolism | 2 | 66.0 |
Interleukin-2/*urine | 2 | 100.0 |
Phosphatidylethanolamines/administration & dosage/*pharmacology | 4 | 100.0 |
Monocytes/cytology/physiology | 3 | 23.0 |
Umbilical Veins/cytology/drug effects | 2 | 22.0 |
Gene Expression Regulation, Neoplastic/genetics | 2 | 1.0 |
Carcinoma, Hepatocellular/*metabolism/pathology | 3 | 4.0 |
Receptors, Cell Surface/*biosynthesis | 7 | 13.0 |
Leukocytes, Mononuclear/*microbiology | 2 | 15.0 |
Liver Cirrhosis/blood/complications | 2 | 20.0 |
Histocompatibility Antigens Class II/*physiology | 3 | 13.0 |
Isoflavones/*pharmacology | 2 | 8.0 |
Leukocytes/drug effects/*physiology | 3 | 25.0 |
Carcinoma, Hepatocellular/*metabolism | 3 | 2.0 |
Interferon Type I/*pharmacology | 8 | 16.0 |
Liver Neoplasms/*metabolism | 2 | 2.0 |
Acquired Immunodeficiency Syndrome/*blood/immunology | 4 | 20.0 |
Newcastle disease virus | 2 | 66.0 |
Tumor Necrosis Factor-alpha/biosynthesis/*metabolism | 7 | 77.0 |
Autopsy | 2 | 1.0 |
Glial Fibrillary Acidic Protein/analysis | 2 | 1.0 |
Rabbits/immunology | 2 | 2.0 |
Spinal Cord/*pathology | 2 | 10.0 |
Biological Response Modifiers/therapeutic use | 3 | 18.0 |
Interleukin-2/administration & dosage/*therapeutic use | 4 | 14.0 |
Platelet Activating Factor/antagonists & inhibitors/*pharmacology | 4 | 66.0 |
Bacterial Infections/complications/*immunology | 2 | 50.0 |
Infant, Premature, Diseases/*immunology | 2 | 50.0 |
Complement/*physiology | 2 | 2.0 |
Fibrin/metabolism | 4 | 6.0 |
Meningococcal Infections/*immunology | 2 | 25.0 |
Sialoglycoproteins/*biosynthesis/blood | 2 | 50.0 |
Antineoplastic Agents/administration & dosage/*pharmacology | 3 | 17.0 |
Picibanil/pharmacokinetics/*pharmacology | 2 | 100.0 |
Fever/blood | 3 | 37.0 |
Tumor Markers, Biological/blood | 3 | 1.0 |
Tumor Necrosis Factor-alpha/*isolation & purification/metabolism | 2 | 100.0 |
Tumor Necrosis Factor-alpha/*chemistry/genetics/metabolism | 2 | 100.0 |
Carcinoma, Renal Cell/*therapy | 5 | 50.0 |
Interferon Type I, Recombinant/*therapeutic use | 2 | 16.0 |
Kidney Neoplasms/*therapy | 6 | 42.0 |
Erythrocytes/*physiology | 2 | 4.0 |
Interferon Type II/administration & dosage/pharmacology | 3 | 75.0 |
Neoplasms, Experimental/therapy | 3 | 21.0 |
Malaria/drug therapy/*immunology | 2 | 100.0 |
Interleukins/*analysis | 3 | 37.0 |
Macrophages/pathology | 3 | 2.0 |
Kidney Failure, Chronic/blood/immunology/therapy | 2 | 50.0 |
*Lymphocytes, Tumor-Infiltrating | 2 | 12.0 |
Interleukin-8/*physiology | 3 | 33.0 |
Platelet-Derived Growth Factor/physiology | 2 | 5.0 |
Candida albicans/growth & development/*immunology | 2 | 100.0 |
Picibanil/*therapeutic use | 5 | 33.0 |
Arthritis, Reactive/immunology | 2 | 66.0 |
Interleukin-6/blood/*metabolism | 2 | 33.0 |
Peritoneal Dialysis, Continuous Ambulatory/adverse effects | 2 | 16.0 |
Uremia/immunology/therapy | 2 | 40.0 |
Central Nervous System/*virology | 2 | 66.0 |
Receptors, Interleukin-3/metabolism | 2 | 13.0 |
Adipose Tissue | 2 | 3.0 |
Heart Failure, Congestive/physiopathology | 2 | 18.0 |
Infection/physiopathology | 3 | 37.0 |
Tumor Necrosis Factor-alpha/*chemistry/pharmacology | 2 | 100.0 |
Keratinocytes/*drug effects | 2 | 11.0 |
Proto-Oncogene Proteins/*genetics | 6 | 0.0 |
Skin/drug effects | 2 | 9.0 |
Streptococcal Infections/immunology | 3 | 30.0 |
Fetal Blood/immunology | 4 | 5.0 |
Transforming Growth Factor alpha/pharmacology | 3 | 3.0 |
Toxins/*metabolism | 2 | 50.0 |
Shock, Septic/*therapy | 3 | 75.0 |
Antibodies/*physiology | 3 | 42.0 |
Vasodilation/*drug effects | 2 | 5.0 |
Hybridomas/immunology | 2 | 1.0 |
Antibodies/*blood | 2 | 4.0 |
Milk | 2 | 10.0 |
Leukemia, Hairy Cell/*metabolism | 2 | 40.0 |
Ethers, Cyclic/*pharmacology | 2 | 16.0 |
Genome, Human | 2 | 0.0 |
Inflammation/*etiology/immunology | 2 | 50.0 |
Shock, Septic/*etiology/immunology | 2 | 100.0 |
HIV-1 | 2 | 1.0 |
Hydrocortisone/*secretion | 2 | 8.0 |
Propranolol/pharmacology | 2 | 4.0 |
Prostaglandins/biosynthesis | 4 | 14.0 |
Septicemia/blood | 3 | 27.0 |
*Mannose-Binding Lectins | 2 | 4.0 |
Cell Division/drug effects/radiation effects | 2 | 8.0 |
Gene Expression/drug effects/radiation effects | 2 | 25.0 |
Recombinant Proteins/pharmacology/toxicity | 2 | 66.0 |
Renal Circulation | 2 | 5.0 |
Toxemia/*blood | 2 | 100.0 |
Macrophages/drug effects/*metabolism/pathology | 2 | 66.0 |
Clinical Protocols | 4 | 6.0 |
Placenta/*metabolism | 3 | 1.0 |
Endothelium, Vascular/*chemistry | 2 | 10.0 |
Carcinoma, Renal Cell/therapy | 2 | 66.0 |
RNA/genetics/isolation & purification | 12 | 9.0 |
Bacteria/isolation & purification | 3 | 18.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase | 2 | 5.0 |
Nitric-Oxide Synthase/analysis/biosynthesis | 2 | 100.0 |
Chromatography, Ion Exchange | 4 | 1.0 |
Cytosol/immunology | 2 | 28.0 |
Apoptosis/*immunology/physiology | 2 | 100.0 |
Neutrophils/drug effects/immunology/metabolism | 2 | 66.0 |
Azathioprine/administration & dosage | 2 | 22.0 |
Prednisolone/administration & dosage | 2 | 2.0 |
Receptors, Cell Surface/chemistry/*metabolism | 5 | 19.0 |
Receptors, Cell Surface/*analysis | 10 | 8.0 |
Labor, Obstetric/*metabolism | 2 | 15.0 |
Antigens, CD45/analysis | 2 | 0.0 |
Adenosine Diphosphate Ribose/metabolism | 4 | 7.0 |
Breast Neoplasms/pathology | 3 | 2.0 |
Injections, Intravenous/veterinary | 2 | 66.0 |
Phosphatidylserines/*pharmacology | 2 | 40.0 |
Epitopes/*analysis | 2 | 1.0 |
Gene Expression Regulation, Enzymologic/*drug effects | 3 | 2.0 |
Monocytes/drug effects/*secretion | 2 | 50.0 |
Receptors, Cell Surface/chemistry/genetics/*metabolism | 2 | 8.0 |
Vasculitis/immunology | 2 | 11.0 |
Lung | 3 | 3.0 |
Receptor, Epidermal Growth Factor/drug effects/*metabolism | 2 | 3.0 |
Leukemia, Myelocytic, Acute/metabolism/*pathology | 3 | 25.0 |
Chemotactic Factors/*physiology | 2 | 12.0 |
Monocytes/cytology/*drug effects/metabolism | 4 | 40.0 |
Interleukin-2/biosynthesis/blood | 2 | 28.0 |
Cell Transformation, Viral/immunology | 2 | 28.0 |
Herpesvirus 4, Human/*immunology | 2 | 2.0 |
Oligonucleotides, Antisense | 4 | 4.0 |
Antigens, Differentiation, Myelomonocytic/biosynthesis | 2 | 4.0 |
Peptide Fragments/physiology | 2 | 6.0 |
*Protozoan Proteins | 2 | 5.0 |
HIV-1/*drug effects/growth & development | 2 | 14.0 |
Antigens, CD30 | 2 | 7.0 |
Exotoxins/*immunology | 2 | 18.0 |
Interleukin-3/*pharmacology | 4 | 3.0 |
Recombinant Proteins/administration & dosage/toxicity | 3 | 50.0 |
Stem Cells/metabolism | 2 | 2.0 |
Neutrophils/cytology/drug effects/*physiology | 2 | 33.0 |
Bone Marrow Transplantation/immunology | 2 | 5.0 |
Leukocytes/drug effects | 3 | 14.0 |
Shock, Septic/immunology/*prevention & control | 2 | 100.0 |
Substance-Related Disorders/blood/immunology | 2 | 100.0 |
Tumor Necrosis Factor-alpha/*analysis/drug effects | 3 | 100.0 |
Killer Cells, Lymphokine-Activated/*physiology | 3 | 50.0 |
Killer Cells, Natural/*physiology | 2 | 4.0 |
Biopterin/*analogs & derivatives/blood | 4 | 18.0 |
Receptors, Interleukin-2/physiology | 4 | 8.0 |
Fibrosarcoma/drug therapy | 3 | 60.0 |
Pulmonary Circulation/drug effects | 3 | 27.0 |
Thromboxane B2/blood | 4 | 10.0 |
Leukocytes/*immunology/metabolism | 2 | 66.0 |
Chloramphenicol O-Acetyltransferase/genetics/metabolism | 3 | 1.0 |
DNA Restriction Enzymes | 3 | 0.0 |
C-Reactive Protein/*biosynthesis | 3 | 18.0 |
Endotoxins/*administration & dosage | 2 | 40.0 |
Killer Cells, Lymphokine-Activated/drug effects | 2 | 18.0 |
Histocompatibility Antigens Class I/analysis | 5 | 5.0 |
Histocompatibility Antigens Class II/analysis | 5 | 2.0 |
Receptors, Cell Surface/*drug effects/genetics/metabolism | 2 | 50.0 |
Cisplatin/*therapeutic use | 3 | 9.0 |
Calcium/metabolism/pharmacology | 2 | 6.0 |
Poly A/genetics/isolation & purification | 2 | 5.0 |
*Naphthalenes | 3 | 33.0 |
Polycyclic Compounds/pharmacology | 3 | 33.0 |
Immunity, Natural/*genetics | 2 | 12.0 |
Antigens, CD27 | 2 | 4.0 |
Immunoglobulins, Fc/metabolism | 2 | 14.0 |
Carcinoma, Squamous Cell/*metabolism | 2 | 1.0 |
Cervix Neoplasms/*metabolism | 2 | 6.0 |
HLA-D Antigens/analysis | 4 | 7.0 |
*Neoplasm Metastasis | 3 | 3.0 |
DNA/*genetics | 5 | 1.0 |
Neoplasms/metabolism/*therapy | 2 | 50.0 |
Fibroblasts/immunology | 6 | 8.0 |
Interferon-gamma, Recombinant/*antagonists & inhibitors/pharmacology | 2 | 100.0 |
RNA, Messenger/*analysis/genetics | 4 | 8.0 |
Apolipoprotein A-I/*pharmacology | 2 | 22.0 |
Leukopenia/prevention & control | 2 | 100.0 |
Shock, Septic/*drug therapy | 3 | 75.0 |
Carcinoma, Renal Cell/immunology/*therapy | 2 | 40.0 |
Kidney Neoplasms/immunology/*therapy | 3 | 42.0 |
Killer Cells, Lymphokine-Activated/*transplantation | 2 | 28.0 |
Brain/blood supply | 2 | 5.0 |
Histocompatibility Antigens Class I/*metabolism | 3 | 3.0 |
Cell Adhesion Molecules/*immunology | 2 | 3.0 |
Neutrophils/cytology/immunology/*metabolism | 2 | 100.0 |
Antigens, CD45 | 2 | 0.0 |
Integrins/immunology/*metabolism | 2 | 22.0 |
Skin/cytology/*metabolism | 3 | 8.0 |
Cross Reactions | 10 | 1.0 |
Plasmodium yoelii/immunology | 2 | 100.0 |
Kidney/cytology | 3 | 1.0 |
Tumor Virus Infections/*virology | 2 | 33.0 |
Antigens, CD40/physiology | 2 | 6.0 |
Plasmodium falciparum/*physiology | 2 | 6.0 |
Colchicine/therapeutic use | 2 | 18.0 |
S-Adenosylmethionine/therapeutic use | 2 | 100.0 |
Paracentesis | 2 | 25.0 |
Colony-Stimulating Factors/*pharmacology | 15 | 33.0 |
*Platelet Membrane Glycoproteins | 2 | 4.0 |
Receptors, Cell Surface/antagonists & inhibitors | 3 | 25.0 |
Ultracentrifugation | 2 | 1.0 |
Hyaluronic Acid/*metabolism | 5 | 4.0 |
Interleukin-1/*genetics/metabolism | 3 | 37.0 |
Receptors, Cell Surface/*drug effects/metabolism | 4 | 23.0 |
Injections, Intralesional | 3 | 6.0 |
Iodine Radioisotopes/*metabolism | 2 | 66.0 |
Zinc Fingers/*genetics | 2 | 1.0 |
Hypothalamo-Hypophyseal System/drug effects/*physiology | 2 | 20.0 |
Testosterone/blood | 2 | 0.0 |
Chemotaxis, Leukocyte/*immunology | 2 | 4.0 |
N-Formylmethionine Leucyl-Phenylalanine/immunology | 5 | 55.0 |
Dinoprostone/*analysis | 2 | 40.0 |
Lipids/*biosynthesis | 2 | 13.0 |
Receptors, Cell Surface/analysis/*physiology | 2 | 18.0 |
Corticotropin/blood/*secretion | 2 | 8.0 |
Receptors, Cell Surface/analysis/metabolism | 2 | 40.0 |
Tumor Cells, Cultured/*drug effects/metabolism | 3 | 11.0 |
Alprostadil/pharmacology | 3 | 11.0 |
Cholera Toxin/pharmacology | 7 | 9.0 |
Lymphocytosis/chemically induced | 2 | 100.0 |
Genes, fos | 4 | 3.0 |
Ornithine Decarboxylase/metabolism | 2 | 10.0 |
Receptor, Epidermal Growth Factor/*genetics | 2 | 0.0 |
Interferon-gamma, Recombinant/*immunology | 3 | 50.0 |
Cell Survival/drug effects/radiation effects | 4 | 9.0 |
Bacterial Infections/*blood/metabolism | 2 | 100.0 |
Arginase/pharmacology | 2 | 66.0 |
Estradiol/*biosynthesis | 2 | 20.0 |
Receptors, Cell Surface/analysis/*metabolism | 3 | 37.0 |
Carcinoma/*blood | 2 | 16.0 |
Membrane Glycoproteins/*biosynthesis/genetics | 3 | 5.0 |
Skin Window Technique | 2 | 50.0 |
Sodium Fluoride/pharmacology | 5 | 20.0 |
Peptide Fragments/metabolism/pharmacology | 3 | 10.0 |
Adenocarcinoma/*drug therapy/pathology | 2 | 28.0 |
Receptors, Cell Surface/drug effects/genetics/*metabolism | 3 | 37.0 |
Phenylisopropyladenosine/pharmacology | 2 | 50.0 |
Cytotoxicity, Immunologic/*immunology | 3 | 6.0 |
Interleukin-2/pharmacology/*therapeutic use | 2 | 28.0 |
beta 2-Microglobulin/drug effects | 2 | 66.0 |
Biological Assay/methods | 5 | 13.0 |
Interferon Type II/*analysis | 3 | 21.0 |
Immunity, Natural/drug effects | 2 | 15.0 |
Diglycerides/metabolism | 3 | 6.0 |
Tumor Necrosis Factor-alpha/*biosynthesis/isolation & | 3 | 100.0 |
Picibanil/pharmacology | 3 | 75.0 |
Recombinant Proteins/analysis | 5 | 10.0 |
Tumor Necrosis Factor-alpha/isolation & | 2 | 66.0 |
Thymus Extracts/*pharmacology | 2 | 50.0 |
Erythrocytes/*immunology | 2 | 1.0 |
*Intensive Care | 3 | 16.0 |
Imipenem/pharmacology | 2 | 33.0 |
Respiratory Syncytial Viruses/*physiology | 2 | 20.0 |
Lymphokines/isolation & purification/*pharmacology | 2 | 50.0 |
Macrophages/*drug effects/physiology | 2 | 22.0 |
Embryo/metabolism | 2 | 1.0 |
Prostaglandins E/*metabolism | 2 | 16.0 |
Cell Membrane Permeability | 4 | 2.0 |
Drug Industry | 2 | 11.0 |
Infection/etiology | 3 | 13.0 |
Prednisone/therapeutic use | 5 | 4.0 |
Biological Therapy | 2 | 100.0 |
Benzoates/pharmacology | 2 | 10.0 |
Lymphoma | 2 | 5.0 |
Narcotic Antagonists/pharmacology | 3 | 27.0 |
Tetrahydronaphthalenes/pharmacology | 2 | 16.0 |
Emulsions | 2 | 2.0 |
Interleukin-12 | 2 | 11.0 |
Killer Cells, Lymphokine-Activated/cytology/*drug effects | 2 | 100.0 |
Biological Factors/*pharmacology | 16 | 76.0 |
Leukocytes, Mononuclear/*cytology | 2 | 9.0 |
Lymphokines/*genetics | 4 | 1.0 |
Mitosis/*drug effects | 3 | 6.0 |
Phytohemagglutinins/*pharmacology | 2 | 5.0 |
Tuberculosis, Pulmonary/epidemiology/*immunology | 2 | 100.0 |
Amino Acids/*pharmacology | 2 | 8.0 |
Carbohydrates/*pharmacology | 2 | 50.0 |
Humic Substances/*pharmacology | 2 | 66.0 |
Soil/*analysis | 2 | 100.0 |
Uronic Acids/*pharmacology | 2 | 66.0 |
*Blood Coagulation | 3 | 1.0 |
*Fibrinolysis | 4 | 3.0 |
Receptors, Cell Surface/drug effects/*metabolism | 7 | 14.0 |
Lymphocytes | 3 | 1.0 |
Plasminogen Inactivators/*blood | 3 | 15.0 |
Eating | 4 | 2.0 |
Antimetabolites/pharmacology | 2 | 6.0 |
CD4-Positive T-Lymphocytes/drug effects/*immunology | 2 | 5.0 |
Killer Cells/drug effects/immunology | 2 | 66.0 |
Diabetes Mellitus, Type 1/*genetics | 2 | 0.0 |
Antigens, CD2 | 2 | 0.0 |
Receptors, Immunologic/*physiology | 2 | 1.0 |
Glomerular Mesangium/drug effects/*metabolism | 2 | 40.0 |
*Exchange Transfusion, Whole Blood | 2 | 33.0 |
Cell Adhesion Molecules/chemistry/immunology/*metabolism | 2 | 40.0 |
Magnetics | 3 | 3.0 |
Tumor Necrosis Factor-alpha/genetics/pharmacology/*physiology | 3 | 50.0 |
Antigens, CD19 | 3 | 1.0 |
Protein Denaturation | 2 | 0.0 |
Acetylmuramyl-Alanyl-Isoglutamine/pharmacology | 4 | 66.0 |
Phospholipases A/*blood | 3 | 16.0 |
Nervous System Diseases/blood/cerebrospinal fluid | 2 | 66.0 |
Tumor Necrosis Factor-alpha/*analysis/cerebrospinal fluid | 2 | 100.0 |
Nursing Evaluation Research | 2 | 28.0 |
Pennsylvania/epidemiology | 2 | 14.0 |
Leukemia, Myelocytic, Acute/*genetics/pathology | 2 | 6.0 |
Bone Marrow/metabolism | 4 | 3.0 |
Growth Inhibitors/metabolism | 2 | 6.0 |
Hematopoietic Stem Cells/cytology | 2 | 2.0 |
Leukemia, Myelocytic, Acute/*metabolism | 3 | 17.0 |
Prostaglandins E/metabolism | 3 | 25.0 |
Cytopathogenic Effect, Viral/drug effects | 2 | 8.0 |
Monocytes/microbiology | 2 | 12.0 |
Antigens, CD28 | 2 | 1.0 |
Microbial Collagenase/biosynthesis | 2 | 40.0 |
Hydroxyl Radical | 2 | 6.0 |
Lactoferrin/metabolism | 2 | 8.0 |
Arachidonic Acids/*metabolism | 5 | 15.0 |
Leukotriene Antagonists | 2 | 66.0 |
Receptors, Cell Surface/analysis | 15 | 18.0 |
Monocytes/cytology/*immunology/metabolism | 2 | 16.0 |
Growth Substances/therapeutic use | 2 | 40.0 |
Hepatocyte Growth Factor | 2 | 4.0 |
Cadmium/*pharmacology | 2 | 14.0 |
Chlorides/*pharmacology | 3 | 30.0 |
Bladder Neoplasms/*therapy | 2 | 22.0 |
*Glycosyltransferases | 2 | 5.0 |
*Transferases | 2 | 5.0 |
*Xenopus Proteins | 2 | 0.0 |
Immunotherapy/methods | 2 | 2.0 |
Neutral Red/pharmacokinetics | 2 | 100.0 |
Prostaglandins E/pharmacology | 2 | 7.0 |
DNA Replication/*drug effects | 4 | 7.0 |
Receptors, Cell Surface/biosynthesis/*metabolism | 2 | 15.0 |
Mycobacterium avium-intracellulare Infection/immunology | 2 | 50.0 |
Shock, Septic/*etiology | 4 | 57.0 |
Fibrinopeptide A/metabolism | 2 | 8.0 |
Phospholipids/*immunology | 2 | 20.0 |
Second Messenger Systems/drug effects | 2 | 10.0 |
Macrophages/*drug effects/secretion | 2 | 66.0 |
Recombinant Proteins/diagnostic use | 3 | 13.0 |
Tumor Cells, Cultured/*cytology | 2 | 13.0 |
Tumor Cells, Cultured/*immunology | 3 | 13.0 |
Carcinoma, Renal Cell/drug therapy | 2 | 66.0 |
Kidney Neoplasms/drug therapy | 2 | 33.0 |
Thyroid Function Tests | 2 | 2.0 |
Stroke Volume/drug effects | 3 | 10.0 |
Stem Cells/drug effects | 3 | 13.0 |
Antigens, CD5 | 2 | 0.0 |
Leukemia, B-Cell, Chronic/*pathology | 2 | 11.0 |
Carcinoma/*drug therapy | 2 | 15.0 |
Melanoma/*pathology | 2 | 3.0 |
Atrial Natriuretic Factor/blood | 3 | 3.0 |
Interleukin-2/analysis/metabolism | 2 | 66.0 |
Research | 2 | 3.0 |
Endothelium, Vascular/*metabolism/ultrastructure | 2 | 13.0 |
Chemotactic Factors/physiology | 2 | 20.0 |
Propionibacterium acnes | 2 | 50.0 |
Interleukin-1/*antagonists & inhibitors/metabolism | 2 | 66.0 |
Electrochemistry | 3 | 3.0 |
6-Ketoprostaglandin F1 alpha/blood | 3 | 16.0 |
Sulfones | 4 | 21.0 |
RNA/genetics/metabolism | 4 | 2.0 |
Siblings | 2 | 2.0 |
Antigen-Presenting Cells/immunology | 5 | 1.0 |
Macrophages/cytology/*metabolism | 2 | 10.0 |
Plastics | 3 | 9.0 |
Sister Chromatid Exchange/*drug effects | 2 | 6.0 |
Receptors, Cell Surface/drug effects/*physiology | 3 | 25.0 |
Antibodies/physiology | 2 | 20.0 |
Interleukin-2/*biosynthesis | 3 | 2.0 |
*Polymers | 2 | 12.0 |
Anemia/*blood/etiology | 3 | 21.0 |
Arthritis, Rheumatoid/*blood/complications | 3 | 27.0 |
Bone Marrow/drug effects/metabolism | 2 | 28.0 |
Iron/blood | 4 | 4.0 |
Blood Pressure/drug effects | 11 | 1.0 |
Vasodilation/drug effects | 2 | 3.0 |
Neoplasms/*blood | 7 | 16.0 |
Liver/drug effects/*enzymology | 2 | 5.0 |
Lung Diseases/*immunology | 2 | 16.0 |
Receptors, Cell Surface/*isolation & purification | 2 | 25.0 |
Blood Bactericidal Activity/drug effects | 3 | 30.0 |
Neutrophils/cytology/*physiology | 2 | 25.0 |
Methylamines/pharmacology | 2 | 9.0 |
Leukemia, Hairy Cell/*blood/therapy | 2 | 100.0 |
Factor Xa/*metabolism | 2 | 9.0 |
Listeria monocytogenes/immunology | 3 | 60.0 |
Cachexia/metabolism | 3 | 37.0 |
Antigens, CD20 | 2 | 2.0 |
Receptors, Very Late Antigen/*physiology | 2 | 16.0 |
Oxygen/metabolism | 5 | 2.0 |
Interferon-gamma, Recombinant/*therapeutic use | 7 | 58.0 |
Tumor Necrosis Factor-alpha/*physiology/toxicity | 2 | 100.0 |
Interleukin-1/*toxicity | 2 | 100.0 |
Pyruvates/metabolism | 2 | 11.0 |
Bone Marrow/*immunology | 2 | 3.0 |
Macrophages/*immunology/physiology | 3 | 33.0 |
Sternum | 2 | 50.0 |
Antigens, CD4/*analysis/genetics | 2 | 33.0 |
Cytotoxicity, Immunologic/drug effects/immunology | 2 | 20.0 |
Phospholipase C/immunology | 2 | 50.0 |
Protein Kinase C/*immunology | 2 | 40.0 |
Antibody Specificity/immunology | 3 | 4.0 |
Antigens, Protozoan/*immunology | 5 | 12.0 |
Immunoglobulin Isotypes/analysis | 2 | 13.0 |
Inositol Phosphates/*immunology | 2 | 100.0 |
Phospholipids/immunology | 2 | 33.0 |
Plasmodium yoelii/*immunology | 4 | 80.0 |
Killer Cells, Lymphokine-Activated/*immunology | 5 | 7.0 |
Transcobalamins/*analysis | 2 | 40.0 |
Lung/drug effects/*injuries/physiopathology | 2 | 100.0 |
*Oxygen | 2 | 33.0 |
Cytokines/analysis/*biosynthesis | 2 | 14.0 |
Ovary | 3 | 7.0 |
Photochemotherapy/*methods | 2 | 33.0 |
Thymidine Kinase/metabolism | 2 | 6.0 |
Clone Cells/drug effects | 2 | 8.0 |
Escherichia coli/*genetics | 5 | 6.0 |
*Genes, Synthetic | 2 | 9.0 |
Arrestin | 2 | 11.0 |
Peptides/chemical synthesis | 2 | 7.0 |
Interleukin-2/analysis | 2 | 4.0 |
Receptors, Immunologic/antagonists & inhibitors | 2 | 40.0 |
Receptors, Thrombin | 7 | 14.0 |
Acid-Base Equilibrium | 2 | 8.0 |
*Acrylic Resins | 2 | 22.0 |
Tumor Necrosis Factor-alpha/*isolation & purification | 2 | 100.0 |
*Sialoglycoproteins | 3 | 23.0 |
Interleukin-1/blood/physiology | 2 | 100.0 |
Neoplasm Proteins/*analysis | 2 | 0.0 |
Kidney Neoplasms/therapy | 2 | 22.0 |
Receptors, Leukocyte-Adhesion/analysis | 2 | 33.0 |
Gangliosides/*pharmacology | 2 | 15.0 |
Lipid Bilayers/chemistry | 2 | 15.0 |
Ovarian Follicle/*metabolism | 3 | 11.0 |
Interleukin-1/biosynthesis/*secretion | 2 | 100.0 |
*Critical Care | 2 | 25.0 |
Tumor Stem Cell Assay/methods | 2 | 100.0 |
Amino Acids/*metabolism | 2 | 5.0 |
Fever/*chemically induced | 2 | 40.0 |
Endothelium, Vascular/*cytology/*metabolism | 2 | 16.0 |
Granulocyte Colony-Stimulating Factor/*metabolism | 2 | 22.0 |
Antigens, Differentiation, B-Lymphocyte | 2 | 5.0 |
2-Chloroadenosine/pharmacology | 2 | 100.0 |
Exocytosis/drug effects | 3 | 13.0 |
Viral Core Proteins/metabolism | 2 | 33.0 |
Insulin/*blood | 2 | 1.0 |
Gene Expression Regulation/*genetics | 2 | 1.0 |
Herpesvirus 4, Human/*genetics | 3 | 4.0 |
Leukocyte Count/*drug effects | 2 | 22.0 |
Plasminogen Inactivators/metabolism | 3 | 18.0 |
Cachexia/physiopathology | 2 | 66.0 |
Interferons/biosynthesis | 3 | 20.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/*genetics/metabolism | 2 | 28.0 |
*Acute-Phase Reaction | 2 | 9.0 |
Serum Amyloid A Protein/*biosynthesis | 3 | 25.0 |
Receptors, Fc/analysis | 5 | 8.0 |
Receptors, IgG | 7 | 5.0 |
Graft Rejection/immunology | 3 | 4.0 |
Drug Contamination | 2 | 8.0 |
Neoplasms/*immunology/pathology | 3 | 23.0 |
Tumor Necrosis Factor-alpha/genetics/*immunology/therapeutic use | 2 | 100.0 |
Lipopolysaccharides/physiology | 3 | 100.0 |
Macrophage Activation/physiology | 3 | 30.0 |
Colony-Stimulating Factors/metabolism | 3 | 42.0 |
Colchicine/pharmacology | 2 | 3.0 |
Transferrin/analysis | 2 | 2.0 |
Growth Substances/immunology | 2 | 20.0 |
Macrophages/immunology/metabolism | 2 | 4.0 |
Malaria/immunology | 2 | 28.0 |
Central Nervous System/physiopathology | 2 | 33.0 |
Fibroblasts/microbiology | 3 | 30.0 |
Dinoprostone/biosynthesis/immunology | 2 | 66.0 |
Interleukin-1/biosynthesis/immunology | 3 | 42.0 |
Antibodies, Monoclonal/*adverse effects | 6 | 35.0 |
Praziquantel/therapeutic use | 2 | 15.0 |
DNA Topoisomerases, Type II/*metabolism | 2 | 10.0 |
Etoposide/*administration & dosage | 2 | 33.0 |
Autoimmune Diseases/etiology | 2 | 11.0 |
Neoplasms, Experimental/immunology/pathology/*therapy | 2 | 40.0 |
*Kidney, Artificial | 2 | 28.0 |
Superoxide Dismutase/biosynthesis/*metabolism | 2 | 100.0 |
Uremia/therapy | 2 | 25.0 |
Phospholipases A/physiology | 2 | 33.0 |
Protein S | 2 | 3.0 |
Tumor Necrosis Factor-alpha/metabolism/*physiology/therapeutic use | 2 | 100.0 |
Lung/embryology | 2 | 10.0 |
Monitoring, Physiologic | 3 | 3.0 |
Iodine Radioisotopes/metabolism | 3 | 8.0 |
Tritium/diagnostic use | 2 | 1.0 |
Carcinoma, Hepatocellular/*therapy | 3 | 12.0 |
Liver Neoplasms/*therapy | 3 | 13.0 |
Antigen-Presenting Cells/*immunology | 3 | 2.0 |
Lymphocyte Cooperation | 2 | 2.0 |
*Diterpenes | 2 | 16.0 |
Chromosome Deletion | 3 | 0.0 |
Carcinoma, Squamous Cell | 3 | 1.0 |
Phosphorus Radioisotopes | 2 | 3.0 |
Fatty Acids, Unsaturated/*metabolism | 2 | 9.0 |
Lymphocytes/drug effects/metabolism | 3 | 10.0 |
Blood Coagulation Tests | 3 | 1.0 |
Central Nervous System/pathology | 2 | 9.0 |
Mitomycin | 3 | 6.0 |
Interleukin-1/*genetics/pharmacology | 3 | 75.0 |
Recombinant Proteins/adverse effects/therapeutic use | 2 | 6.0 |
Neoplasms/*blood/pathology | 2 | 25.0 |
Ciprofloxacin/pharmacology | 2 | 16.0 |
Neoplasm Invasiveness | 4 | 0.0 |
Macrophages/*drug effects/immunology/metabolism | 3 | 50.0 |
Mycobacterium Infections/*immunology | 2 | 28.0 |
Wheat Germ Agglutinins/pharmacology | 2 | 40.0 |
Leukotrienes/blood | 2 | 50.0 |
Isoelectric Point | 4 | 3.0 |
Leukemia, Hairy Cell/metabolism/pathology/*physiopathology | 2 | 100.0 |
Enzyme-Linked Immunosorbent Assay/standards | 2 | 14.0 |
Knee Joint | 2 | 10.0 |
Septicemia/*metabolism | 2 | 100.0 |
Chemotactic Factors/*genetics | 4 | 28.0 |
Interleukin-1/*analysis/biosynthesis | 3 | 75.0 |
Endothelium, Vascular/*cytology/metabolism/ultrastructure | 2 | 50.0 |
Receptors, Vitronectin | 2 | 11.0 |
Antigens, CD3 | 5 | 1.0 |
Antigens, CD8 | 5 | 1.0 |
Plasmin/metabolism | 2 | 2.0 |
alpha-Macroglobulins/metabolism | 2 | 4.0 |
Cluster Analysis | 2 | 1.0 |
Pancreatitis/*genetics | 2 | 5.0 |
Ovarian Neoplasms/*pathology | 2 | 3.0 |
Angina Pectoris/blood/drug therapy | 2 | 100.0 |
Recombinant Proteins/physiology | 2 | 22.0 |
Emetine/pharmacology | 2 | 40.0 |
Shock, Septic/*metabolism | 2 | 50.0 |
Tumor Cells, Cultured/immunology/pathology | 2 | 11.0 |
Adenovirus Early Proteins | 3 | 4.0 |
HIV Core Protein p24 | 3 | 3.0 |
Macrophages/*metabolism/microbiology | 2 | 33.0 |
*Complement Inactivators | 2 | 2.0 |
Glycoproteins/therapeutic use | 2 | 66.0 |
Carcinoma, Renal Cell/*immunology/pathology | 2 | 20.0 |
Histocompatibility Antigens Class II/*analysis | 2 | 1.0 |
Kidney Neoplasms/*immunology/pathology | 2 | 16.0 |
Arachidonic Acid | 10 | 15.0 |
Arachidonic Acids/metabolism | 9 | 23.0 |
Interferon Type I/pharmacology | 17 | 36.0 |
Lactoferrin/*blood | 2 | 28.0 |
Streptococcus agalactiae/*physiology | 2 | 50.0 |
alpha 1-Antitrypsin/pharmacology | 2 | 15.0 |
Interferon-gamma, Recombinant/*metabolism | 2 | 50.0 |
*Drug Contamination | 2 | 28.0 |
*Cloning, Molecular | 5 | 1.0 |
Neuraminidase/pharmacology | 3 | 4.0 |
Platelet-Derived Growth Factor/*genetics | 2 | 6.0 |
Chemical Fractionation | 2 | 2.0 |
Gelatinase A/*metabolism | 2 | 6.0 |
Asian Continental Ancestry Group/*genetics | 2 | 0.0 |
L Cells (Cell Line)/cytology/drug effects | 6 | 100.0 |
Buthionine Sulfoximine | 2 | 20.0 |
Methionine Sulfoximine/analogs & derivatives/pharmacology | 2 | 22.0 |
Recombinant Proteins/isolation & purification/metabolism | 2 | 1.0 |
DNA-Binding Protein, Cyclic AMP-Responsive | 2 | 8.0 |
Proto-Oncogene Proteins c-jun | 4 | 8.0 |
Lipoprotein Lipase/*antagonists & inhibitors/genetics | 2 | 66.0 |
Rats, Inbred BUF | 2 | 9.0 |
Fibrosarcoma/drug therapy/pathology | 3 | 75.0 |
Antigens, Fungal/*immunology | 2 | 12.0 |
Methylprednisolone/pharmacology | 2 | 12.0 |
*Growth Inhibitors | 4 | 7.0 |
Pulmonary Alveoli/*cytology | 6 | 50.0 |
Interferon Type II/immunology/*physiology | 2 | 100.0 |
Anoxia | 2 | 2.0 |
Receptors, Fibronectin | 2 | 16.0 |
Receptors, Immunologic/drug effects/*metabolism | 2 | 25.0 |
Aminophylline/pharmacology | 2 | 40.0 |
RNA, Messenger/drug effects/*genetics | 5 | 41.0 |
*G(M1) Ganglioside | 2 | 40.0 |
Glycosphingolipids/immunology | 2 | 66.0 |
Horses/*blood | 2 | 25.0 |
Liver Neoplasms, Experimental/drug therapy | 2 | 66.0 |
Crystallography | 2 | 6.0 |
Ibuprofen/*pharmacology | 3 | 33.0 |
Immunity, Cellular/*drug effects | 5 | 12.0 |
Parathyroid Hormone/pharmacology | 2 | 7.0 |
Antigens, Surface | 2 | 3.0 |
Body Temperature Regulation/drug effects | 2 | 28.0 |
Cardiac Output/drug effects | 4 | 13.0 |
Pulmonary Circulation/*drug effects | 2 | 18.0 |
Respiration, Artificial/*adverse effects | 4 | 57.0 |
Bone Marrow | 2 | 5.0 |
Arachidonic Acids/*pharmacology | 2 | 11.0 |
Pneumocystis/*immunology | 2 | 25.0 |
Ciprofloxacin/*pharmacology | 2 | 20.0 |
Interferon Type II/metabolism/*pharmacology | 2 | 25.0 |
Skin Physiology | 2 | 5.0 |
Interferon Type I/*blood | 3 | 50.0 |
Heart | 2 | 20.0 |
Interleukin-2/*immunology | 3 | 4.0 |
Plasminogen Inactivators/*metabolism | 4 | 23.0 |
Interleukin-1/biosynthesis/pharmacology | 2 | 40.0 |
*Charcoal | 2 | 33.0 |
Hematopoietic Stem Cells/pathology | 2 | 5.0 |
Hepatocytes/cytology | 2 | 18.0 |
Antigens, Differentiation/*metabolism | 2 | 1.0 |
Mycobacterium tuberculosis/immunology | 6 | 20.0 |
Leukocytes, Mononuclear/chemistry | 2 | 7.0 |
Proto-Oncogenes/*drug effects | 2 | 16.0 |
Chlorpromazine/pharmacology | 2 | 7.0 |
Leukemia, Myelocytic, Acute | 4 | 15.0 |
Receptors, Interferon | 3 | 15.0 |
Cell Degranulation/physiology | 2 | 25.0 |
Macrophages/immunology/secretion | 2 | 33.0 |
Peritoneal Dialysis, Continuous Ambulatory/*adverse effects | 3 | 7.0 |
Receptors, Cell Surface/*analysis/physiology | 2 | 40.0 |
Glucocorticoids/blood | 2 | 28.0 |
Liver Neoplasms/drug therapy/*secondary | 2 | 40.0 |
Ovarian Neoplasms/*drug therapy/pathology | 3 | 12.0 |
Leukocytes, Mononuclear/drug effects/*physiology | 2 | 22.0 |
Nitrogen/urine | 2 | 22.0 |
*Macrophage Activation/drug effects | 2 | 22.0 |
Histocompatibility Antigens Class II/metabolism | 2 | 2.0 |
Hemolytic Plaque Technique | 3 | 5.0 |
Neutrophils/drug effects/immunology/*physiology | 2 | 33.0 |
Oscillometry | 2 | 12.0 |
Lymphocyte Subsets/drug effects | 2 | 10.0 |
Interferons/*therapeutic use | 2 | 9.0 |
Peptide Fragments/isolation & purification | 3 | 5.0 |
Fibroblasts/cytology/drug effects/*metabolism | 3 | 20.0 |
6-Ketoprostaglandin F1 alpha/*metabolism | 2 | 66.0 |
Endothelium, Vascular/*cytology/drug effects/metabolism | 4 | 20.0 |
Liver/*cytology/drug effects/metabolism | 2 | 25.0 |
Lymphotoxin/immunology | 2 | 40.0 |
Shock, Septic/*diagnosis | 2 | 50.0 |
Transforming Growth Factors/*pharmacology | 2 | 8.0 |
Chromium Radioisotopes/diagnostic use | 3 | 15.0 |
Leukemia, Myeloid/metabolism/pathology | 2 | 33.0 |
Receptors, Cell Surface/drug effects/*immunology/metabolism | 2 | 100.0 |
Affinity Labels | 3 | 5.0 |
Light | 2 | 0.0 |
Cyclosporins/*pharmacology | 2 | 5.0 |
Cytokines/immunology/metabolism | 3 | 13.0 |
RNA/blood/genetics/isolation & purification | 2 | 50.0 |
RNA, Neoplasm/genetics/isolation & purification | 2 | 3.0 |
Complement 5a/*pharmacology | 2 | 20.0 |
Interleukin-1/biosynthesis/*genetics/pharmacology | 2 | 100.0 |
Glycoproteins/*genetics | 9 | 4.0 |
Eosinophils/*immunology | 2 | 3.0 |
Methods | 3 | 1.0 |
Ibuprofen/therapeutic use | 2 | 28.0 |
Ascitic Fluid/cytology | 2 | 10.0 |
Hypochlorous Acid/*blood | 2 | 66.0 |
DNA/*genetics/isolation & purification | 2 | 3.0 |
Cyclosporins/therapeutic use | 2 | 5.0 |
Acute-Phase Proteins/analysis/*biosynthesis | 2 | 100.0 |
Lymphokines/*biosynthesis/blood | 2 | 14.0 |
Antigens, Differentiation, T-Lymphocyte/immunology | 2 | 1.0 |
Lymphocyte Function-Associated Antigen-1 | 2 | 2.0 |
Receptors, Antigen, T-Cell/immunology | 2 | 1.0 |
Lipoproteins, LDL/blood | 2 | 0.0 |
Decidua/drug effects/*metabolism | 2 | 100.0 |
Fibroblasts/cytology/immunology | 2 | 18.0 |
Biological Factors/*physiology | 2 | 15.0 |
Antibodies, Monoclonal/diagnostic use/immunology | 2 | 7.0 |
Interleukin-8 | 8 | 44.0 |
Receptors, Leukocyte-Adhesion/immunology | 2 | 16.0 |
Egtazic Acid/pharmacology | 2 | 1.0 |
*Cell Survival/drug effects | 2 | 66.0 |
Hela Cells/cytology/drug effects | 2 | 33.0 |
Receptors, Colony-Stimulating Factor | 2 | 50.0 |
Leucine/metabolism | 2 | 3.0 |
Venae Cavae | 2 | 66.0 |
Azides/pharmacology | 3 | 12.0 |
Sodium Azide | 3 | 23.0 |
Plasmodium berghei/*immunology | 2 | 100.0 |
Biochemistry | 2 | 16.0 |
Interleukin-1/genetics/*physiology | 2 | 50.0 |
*Embolization, Therapeutic | 2 | 8.0 |
Receptors, Cell Surface/drug effects/isolation & purification/*metabolism | 2 | 50.0 |
Leukemia, B-Cell, Chronic/*metabolism | 2 | 16.0 |
Carcinoma/*drug therapy/pathology | 2 | 33.0 |
Biological Factors/*genetics | 2 | 66.0 |
RNA Probes | 3 | 2.0 |
Transforming Growth Factors/genetics | 2 | 28.0 |
Hematopoietic Stem Cells/*metabolism | 2 | 1.0 |
Macrophage-1 Antigen | 2 | 4.0 |
Antigens, T-Independent/*immunology | 2 | 40.0 |
Plasmodium/*immunology | 2 | 50.0 |
Glucagon/metabolism | 2 | 7.0 |
Actins/metabolism | 5 | 0.0 |
Biomechanics | 2 | 1.0 |
Vascular Resistance | 2 | 3.0 |
Receptors, Nerve Growth Factor | 2 | 4.0 |
Caspases/biosynthesis | 2 | 11.0 |
Lung Neoplasms/therapy | 3 | 37.0 |
Aqueous Humor/analysis | 2 | 66.0 |
Interleukin-1/*biosynthesis/genetics/pharmacology | 2 | 100.0 |
Macrophage Colony-Stimulating Factor | 5 | 45.0 |
Biological Factors/*biosynthesis | 3 | 75.0 |
Cyclic AMP/*physiology | 2 | 2.0 |
Interferon-gamma, Recombinant/immunology | 2 | 33.0 |
Interleukin-1/*biosynthesis/immunology | 2 | 66.0 |
Tumor Necrosis Factor-alpha/immunology/pharmacology/*physiology | 2 | 100.0 |
H-2 Antigens/genetics | 3 | 12.0 |
Phorbol 12,13-Dibutyrate | 2 | 14.0 |
Biological Factors/pharmacology | 6 | 31.0 |
Colony-Stimulating Factors/*physiology | 3 | 42.0 |
Receptors, Complement/analysis | 2 | 3.0 |
Receptors, Complement 3b | 3 | 0.0 |
Interferon Type I/physiology | 3 | 37.0 |
Amnion/metabolism | 2 | 12.0 |
Methylcholanthrene | 2 | 22.0 |
Thromboplastin/biosynthesis/*genetics | 2 | 18.0 |
Tumor Cells, Cultured/drug effects/*metabolism | 2 | 8.0 |
Receptors, Cell Surface/*genetics/metabolism | 2 | 2.0 |
Sarcoma, Experimental/*drug therapy/pathology | 2 | 100.0 |
Graft Survival/*drug effects | 3 | 15.0 |
Interleukins/*genetics | 4 | 14.0 |
Interleukins/*genetics/pharmacology | 2 | 100.0 |
Leukocytes, Mononuclear/*analysis | 2 | 50.0 |
Receptors, Cell Surface/*analysis/metabolism | 2 | 22.0 |
Plant Extracts/administration & dosage/*pharmacology/therapeutic use | 2 | 20.0 |
Natriuretic Peptide, Brain/blood | 2 | 15.0 |
Killer Cells, Lymphokine-Activated/metabolism | 2 | 100.0 |
Recombinant Proteins/*therapeutic use | 4 | 18.0 |
Colony-Stimulating Factors/blood | 3 | 75.0 |
Complement Activation/*drug effects | 2 | 2.0 |
Complement Pathway, Alternative/*drug effects | 2 | 9.0 |
Epidermal Growth Factor/*pharmacology | 5 | 0.0 |
Platelet-Derived Growth Factor/*pharmacology | 3 | 3.0 |
Chemistry | 3 | 1.0 |
Cyclosporins/pharmacology | 3 | 7.0 |
Phorbol Esters/*pharmacology | 2 | 5.0 |
Neutrophils/*immunology/metabolism/ultrastructure | 2 | 100.0 |
Muscle, Smooth, Vascular/metabolism | 2 | 3.0 |
Receptors, Immunologic/*analysis | 2 | 3.0 |
Freezing | 3 | 3.0 |
Recombinant Proteins/analysis/pharmacology | 2 | 50.0 |
Lipid A/antagonists & inhibitors | 2 | 50.0 |
Receptors, Complement/metabolism | 2 | 3.0 |
Arachidonic Acids/*blood | 2 | 22.0 |
Melanoma/pathology | 3 | 9.0 |
Interleukin-4/administration & dosage/*pharmacology | 2 | 100.0 |
Receptors, Drug/metabolism | 2 | 10.0 |
Gingivitis/*metabolism | 2 | 33.0 |
Periodontal Index | 2 | 4.0 |
Antibodies, Protozoan | 2 | 28.0 |
Monocytes/immunology/physiology | 2 | 25.0 |
Luminescent Measurements | 7 | 8.0 |
T-Lymphocytes, Cytotoxic/*immunology/secretion | 2 | 50.0 |
Platelet Activating Factor/*administration & dosage/physiology | 2 | 100.0 |
Histocompatibility Antigens Class II/*biosynthesis | 2 | 7.0 |
Collagen/*biosynthesis/genetics | 2 | 11.0 |
RNA, Messenger/genetics/isolation & purification | 2 | 3.0 |
Lymphokines/*physiology | 3 | 2.0 |
Cyclooxygenase Inhibitors | 5 | 31.0 |
Lymphoma/*therapy | 2 | 14.0 |
Complement/*genetics | 2 | 3.0 |
Prednisolone/pharmacology | 2 | 10.0 |
2',5'-Oligoadenylate Synthetase/metabolism | 4 | 33.0 |
Acute-Phase Reaction/*blood | 2 | 7.0 |
Quinolones/*pharmacology | 2 | 11.0 |
Theobromine/*analogs & derivatives | 2 | 66.0 |
Biological Factors/biosynthesis | 2 | 66.0 |
Skin Neoplasms/drug therapy/*therapy | 2 | 100.0 |
Lithium/*pharmacology | 2 | 12.0 |
Lithium Chloride | 2 | 22.0 |
Glycoproteins/*metabolism/pharmacology | 2 | 25.0 |
Cerebral Ventricles/drug effects/*physiology | 2 | 20.0 |
T-Lymphocytes/cytology/*immunology | 2 | 1.0 |
Biological Products/*pharmacology | 8 | 72.0 |
Gene Amplification | 2 | 0.0 |
Tumor Necrosis Factor-alpha/biosynthesis/*therapeutic use | 3 | 100.0 |
Autoimmune Diseases/*drug therapy | 2 | 28.0 |
Methionine/metabolism | 3 | 2.0 |
Tumor Necrosis Factor-alpha/*blood | 8 | 100.0 |
Cytokines/physiology/secretion | 2 | 100.0 |
Thioglycolates/pharmacology | 2 | 25.0 |
Polymers/metabolism | 2 | 4.0 |
Superoxides/biosynthesis | 2 | 20.0 |
Arginine/metabolism | 2 | 3.0 |
Cytochrome P-450 Enzyme System/metabolism | 2 | 0.0 |
Lipopolysaccharides/*physiology | 3 | 60.0 |
Heat/*therapeutic use | 2 | 8.0 |
HLA-D Antigens/immunology | 2 | 5.0 |
Monocytes/*metabolism/ultrastructure | 2 | 33.0 |
Tumor Necrosis Factor-alpha/*biosynthesis/blood | 3 | 100.0 |
Interferon Type I/*physiology | 3 | 30.0 |
Periodontitis/*metabolism | 2 | 20.0 |
*Keratin | 2 | 22.0 |
Macrophages/drug effects/*microbiology | 2 | 33.0 |
Cell Membrane Permeability/*drug effects | 2 | 13.0 |
Tachyphylaxis | 2 | 22.0 |
Interferon Type II/administration & dosage/therapeutic use | 2 | 100.0 |
Picibanil/administration & dosage/therapeutic use | 2 | 100.0 |
Dendritic Cells/immunology/metabolism | 2 | 11.0 |
CD40 Ligand/physiology | 2 | 15.0 |
Collagen/urine | 2 | 11.0 |
Glycoproteins/*toxicity | 4 | 80.0 |
Peptides/urine | 2 | 12.0 |
Receptors, Cytoplasmic and Nuclear | 2 | 16.0 |
Macrophages/metabolism/pathology | 2 | 7.0 |
Hypersensitivity, Delayed/immunology/pathology | 2 | 50.0 |
Immunosuppressive Agents/physiology | 2 | 28.0 |
Interleukin-4 | 3 | 3.0 |
Multiple Organ Failure | 2 | 66.0 |
Receptors, Cell Surface/drug effects | 3 | 16.0 |
Complement Factor H | 2 | 2.0 |
Lymphocytes/*drug effects | 3 | 7.0 |
Pichia/*genetics | 2 | 13.0 |
Saccharomycetales/*genetics | 2 | 33.0 |
Vesicular stomatitis-Indiana virus/*drug effects | 2 | 33.0 |
Glycosaminoglycans/*biosynthesis | 2 | 33.0 |
Tumor Necrosis Factor-alpha/administration & dosage/therapeutic use | 3 | 75.0 |
Crohn Disease/drug therapy/immunology | 2 | 100.0 |
Immunoglobulin G/adverse effects/therapeutic use | 5 | 100.0 |
Adipose Tissue/*enzymology | 2 | 3.0 |
Interleukin-1/*biosynthesis/isolation & purification | 2 | 100.0 |
Tumor Necrosis Factor-alpha/*biosynthesis/isolation & purification | 2 | 100.0 |
Plasminogen Activators/*antagonists & inhibitors | 2 | 28.0 |
*Plasminogen Inactivators | 2 | 22.0 |
Recombinant Proteins/*toxicity | 3 | 37.0 |
Cytopathogenic Effect, Viral | 2 | 1.0 |
Granulocytes/drug effects/*metabolism | 2 | 40.0 |
RNA/biosynthesis | 5 | 5.0 |
Tumor Necrosis Factor-alpha/blood/*pharmacology | 2 | 100.0 |
Macrophages/drug effects/*immunology/metabolism | 2 | 25.0 |
Shock, Septic/immunology | 2 | 20.0 |
Mitomycins/pharmacology | 2 | 6.0 |
Receptors, Tumor Necrosis Factor/chemistry/genetics/immunology | 2 | 100.0 |
*Capillary Permeability | 3 | 10.0 |
Tumor Cells, Cultured/*metabolism | 2 | 6.0 |
Monokines | 8 | 44.0 |
Mortality | 2 | 6.0 |
Superoxides/*biosynthesis | 2 | 50.0 |
Fixatives | 2 | 2.0 |
Formaldehyde | 3 | 3.0 |
*Immunosuppression | 3 | 3.0 |
Neutrophils/*immunology/metabolism | 2 | 11.0 |
Pulmonary Alveoli/cytology/*physiology | 2 | 66.0 |
Antibodies, Monoclonal/physiology | 2 | 2.0 |
Genes, Structural/*drug effects | 2 | 20.0 |
Burkitt Lymphoma/immunology | 2 | 11.0 |
Granulocyte Colony-Stimulating Factor | 2 | 10.0 |
*Antiviral Agents | 2 | 14.0 |
Leukocytes, Mononuclear/*analysis/metabolism | 2 | 100.0 |
Membrane Proteins/immunology/metabolism | 2 | 15.0 |
Bronchoalveolar Lavage Fluid/pathology | 2 | 50.0 |
Erythropoietin/pharmacology | 2 | 1.0 |
Culture Media/analysis | 4 | 20.0 |
*Pregnancy Complications, Infectious | 2 | 7.0 |
Dinoprostone | 5 | 7.0 |
Prostaglandins E/biosynthesis | 4 | 17.0 |
Neoplasms, Experimental/*physiopathology | 2 | 66.0 |
Histamine/*metabolism | 2 | 11.0 |
L Cells (Cell Line)/metabolism | 2 | 18.0 |
Lipoprotein Lipase/*antagonists & inhibitors | 2 | 14.0 |
Mast-Cell Sarcoma/immunology | 3 | 60.0 |
Neoplasms/drug therapy/metabolism | 2 | 11.0 |
Colon/*immunology | 2 | 9.0 |
Transcription Factors/*antagonists & inhibitors/*metabolism/physiology | 3 | 75.0 |
Interferon Type I/immunology | 2 | 33.0 |
Cell Membrane/analysis | 3 | 9.0 |
Interferon Type I/*genetics | 2 | 11.0 |
Acute-Phase Proteins/*genetics | 2 | 15.0 |
Arthritis, Rheumatoid/*drug therapy/epidemiology/immunology | 2 | 100.0 |
Denmark/epidemiology | 2 | 3.0 |
Biological Products/pharmacology | 3 | 60.0 |
Recombinant Proteins/*immunology | 2 | 10.0 |
L Cells (Cell Line)/immunology | 2 | 13.0 |
Radioimmunoassay/methods | 2 | 1.0 |
Leukemia, Myelocytic, Acute/pathology | 3 | 18.0 |
Klebsiella pneumoniae | 3 | 50.0 |
Tumor Necrosis Factor-alpha/adverse effects/pharmacokinetics/*therapeutic | 2 | 100.0 |
Chromatography/methods | 2 | 7.0 |
Colony-Stimulating Factors/*biosynthesis | 2 | 50.0 |
Mitogen-Activated Protein Kinases/metabolism/physiology | 2 | 14.0 |
Glycoproteins/administration & dosage/*therapeutic use | 2 | 66.0 |
Sarcoma, Experimental/physiopathology | 2 | 100.0 |
Glycoproteins/metabolism/*pharmacology | 3 | 37.0 |
Encephalomyocarditis virus/drug effects | 2 | 50.0 |
Glycoproteins/analysis/*immunology | 2 | 40.0 |
Biological Response Modifiers/administration & dosage/therapeutic use | 2 | 66.0 |
Glycoproteins/immunology/*pharmacology | 2 | 50.0 |
Antineoplastic Agents | 3 | 17.0 |
Glycoproteins/pharmacology/*therapeutic use | 2 | 100.0 |
Endothelium/cytology/*drug effects | 2 | 40.0 |
Bone Resorption/*drug effects | 2 | 33.0 |
Prostaglandins E/*biosynthesis | 2 | 12.0 |
Glycoproteins/immunology/*therapeutic use | 2 | 100.0 |
Lipoprotein Lipase/antagonists & inhibitors | 2 | 40.0 |
Glycoproteins/*immunology | 5 | 6.0 |
Glycoproteins/administration & dosage/*pharmacology | 2 | 100.0 |
Glycoproteins/*blood | 2 | 2.0 |
Lipopolysaccharides/analysis | 2 | 20.0 |
Growth Inhibitors/*genetics | 3 | 6.0 |
Glycoproteins/*pharmacology/therapeutic use | 2 | 66.0 |
Commonwealth of Independent States | 2 | 33.0 |
Health Services/*utilization | 2 | 16.0 |
Health Services Research | 2 | 11.0 |
Patient Acceptance of Health Care | 2 | 8.0 |
Biological Products/physiology | 3 | 100.0 |
Immunologic Surveillance | 2 | 7.0 |
*Erythropoiesis | 2 | 2.0 |
Interferons/*immunology/metabolism | 2 | 100.0 |
Glycoproteins/isolation & purification/*pharmacology | 2 | 100.0 |
Monocytes/*analysis | 3 | 37.0 |
Eosinophils/*drug effects/immunology | 2 | 50.0 |
Glycoproteins/*administration & dosage | 2 | 66.0 |
Antioxidants/*administration & dosage | 3 | 18.0 |
*Dietary Supplements | 2 | 3.0 |
Glycoproteins/*isolation & purification/therapeutic use | 2 | 100.0 |
Recombinant Fusion Proteins/genetics/isolation & purification/metabolism | 2 | 5.0 |
Tumor Necrosis Factor-alpha/*analysis/*secretion | 2 | 100.0 |
Growth Inhibitors/*immunology | 2 | 66.0 |
Lipid Peroxidation/drug effects/physiology | 2 | 33.0 |
*Anoxia | 2 | 7.0 |
Thromboxane A2/metabolism | 2 | 20.0 |
Lymphotoxin | 2 | 66.0 |
Receptors, Cytokine/*genetics | 3 | 5.0 |
Receptors, Cell Surface/genetics/physiology | 2 | 11.0 |
Crohn Disease/drug therapy/*immunology | 2 | 66.0 |
17-alpha-Hydroxyprogesterone/blood | 2 | 8.0 |
Sepsis/immunology | 2 | 16.0 |
Drainage/methods | 2 | 40.0 |
United States Food and Drug Administration | 2 | 15.0 |
Inflammation/etiology/*immunology | 2 | 100.0 |
*Aging | 2 | 1.0 |
Prostaglandin D2/analogs & derivatives/*pharmacology | 2 | 25.0 |
Asian Continental Ancestry Group | 2 | 0.0 |
Myocytes, Cardiac/drug effects/metabolism | 2 | 33.0 |
Analgesics, Opioid/*pharmacokinetics/pharmacology | 2 | 28.0 |
Dexmedetomidine/*pharmacokinetics/pharmacology | 2 | 28.0 |
Hypnotics and Sedatives/*pharmacokinetics/pharmacology | 2 | 25.0 |
Respiratory Mechanics/drug effects | 2 | 20.0 |
Immunoglobulin G/*blood | 2 | 3.0 |
Antineoplastic Agents/*analysis | 2 | 100.0 |
Cell Adhesion/drug effects/immunology | 2 | 10.0 |
*Protein Folding | 2 | 1.0 |
Proteins/*chemistry | 2 | 2.0 |
Silicon Dioxide/pharmacology | 2 | 50.0 |
Amyloid beta-Protein Precursor/genetics | 2 | 4.0 |
tau Proteins/genetics | 2 | 28.0 |
Penetrance | 2 | 1.0 |
Apolipoproteins E/genetics | 2 | 0.0 |
Base Sequence/genetics | 2 | 0.0 |
Antineoplastic Agents/chemical synthesis/chemistry/*pharmacology | 2 | 18.0 |
Cell Proliferation/drug effects | 2 | 2.0 |
Flavanones/chemical synthesis/chemistry/*pharmacology | 2 | 40.0 |
Scutellaria baicalensis | 2 | 40.0 |
Protein p53/genetics/*metabolism | 2 | 1.0 |
Liver Diseases, Alcoholic/drug therapy/*metabolism | 2 | 100.0 |
